DocCode - SEQ.TXT

SCORE Placeholder Sheet for IFW Content

Application Number: 17350958

Document Date: 06/17/2021

The presence of this form in the IFW record indicates that the following document type was received in electronic format on the date identified above. This content is stored in the SCORE database.

Since this was an electronic submission, there is no physical artifact folder, no artifact folder is recorded in PALM, and no paper documents or physical media exist. The TIFF images in the IFW record were created from the original documents that are stored in SCORE.

• Sequence Listing

At the time of document entry (noted above):

- USPTO employees may access SCORE content via DAV or via the SCORE web page.
- External customers may access SCORE content via PAIR using the Supplemental Content tab.

	Electronically Flieu		
PRELIMINARY	Attorney Docket No.	REGN-008CIPCON9	
AMENDMENT	Confirmation No.	To Be Assigned	
Under CFR 1.115	First Named Inventor	YANCOPOULOS, GEORGE D.	
	Application Number	To Be Assigned	
Address to:	Filing Date	June 17, 2021	
Mail Stop Patent Application	Group Art Unit	To Be Assigned	
Commissioner for Patents	Examiner Name	To Be Assigned	
P.O. Box 1450	Title: "Use of a VEGF Antagonist to Treat Angiog		
Alexandria, VA 22313-1450	Eye Disorders"		

Electronically Filed

Sir:

Prior to the examination of the above-referenced application on the merits, please enter the amendments below.

Atty Dkt. No.: REGN-008CIPCON9 USSN: To Be Assigned

AMENDMENTS TO THE CLAIMS

1. - 20. (Canceled)

21. (New) A method for treating an angiogenic eye disorder in a patient in need thereof, said method comprising administering by intravitreal injection one or more maintenance doses of 2 mg of a VEGF antagonist comprising amino acids 27-457 of SEQ ID NO:2 at least about 8 weeks after the immediately preceding dose;

wherein said patient has previously received by intravitreal injection an initial dose of 2 mg of the VEGF antagonist followed by one or more secondary doses of 2 mg of the VEGF antagonist;

wherein each secondary dose was administered about 2 to 4 weeks after the immediately preceding dose; and

wherein the patient achieves a gain in visual acuity at 24 weeks following the initial dose compared to baseline.

22. (New) The method of claim 21, wherein the angiogenic eye disorder is age related macular degeneration.

23. (New) The method of claim 21, wherein the angiogenic eye disorder is diabetic retinopathy.

24. (New) The method of claim 21, wherein the angiogenic eye disorder is diabetic macular edema.

25. (New) The method of claim 21, wherein the angiogenic eye disorder is macular edema following retinal vein occlusion.

26. (New) The method of claim 21, wherein the method comprises administering by intravitreal injection two or more maintenance doses of 2 mg of the VEGF antagonist comprising amino acids 27-457 of SEQ ID NO:2 at least about 8 weeks after the immediately preceding dose.

27. (New) The method of claim 26, wherein the patient experiences a gain in visual acuity of at least 7 letters on the ETDRS chart at 24 weeks following the initial dose compared to baseline.

28. (New) The method of claim 21, wherein the method comprises administering by intravitreal injection five or more maintenance doses of 2 mg of the VEGF antagonist comprising amino acids 27-457 of SEQ ID NO:2 at least about 8 weeks after the immediately preceding dose.

29. (New) The method of claim 28, wherein the patient achieves a gain in visual acuity at 52 weeks following the initial dose compared to baseline.

30. (New) The method of claim 29, wherein the patient achieves a gain in visual acuity of at least 8 letters on the ETDRS chart at 52 weeks following the initial dose compared to baseline.

31. (New) The method of claim 21, wherein said patient has previously received by intravitreal injection an initial dose of 2 mg of the VEGF antagonist followed by one or more secondary doses of 2 mg of the VEGF antagonist; followed by one or more tertiary doses of 2 mg of the VEGF antagonist;

wherein each secondary dose was administered about 2 to 4 weeks after the immediately preceding dose;

wherein each tertiary dose was administered at least about 8 weeks after the immediately preceding dose.

32. (New) A method for treating an angiogenic eye disorder in a patient in need thereof, said method comprising administering by intravitreal injection one or more maintenance doses of 2 mg of a VEGF antagonist comprising amino acids 27-457 of SEQ ID NO:2 at least about 8 weeks after the immediately preceding dose;

wherein said patient has previously received by intravitreal injection an initial dose of 2 mg of the VEGF antagonist, followed by one or more secondary doses of 2 mg of the VEGF antagonist;

wherein each secondary dose was administered about 2 to 4 weeks after the immediately preceding dose; and

wherein the patient maintains visual acuity at 24 weeks following the initial dose compared to baseline.

33. (New) The method of claim 32, wherein the angiogenic eye disorder is age related macular degeneration.

34. (**New**) The method of claim 32, wherein the angiogenic eye disorder is diabetic retinopathy.

35. (New) The method of claim 32, wherein the angiogenic eye disorder is diabetic macular edema.

36. (New) The method of claim 32, wherein the angiogenic eye disorder is macular edema following retinal vein occlusion.

37. (New) The method of claim 32, wherein the method comprises administering by intravitreal injection two or more maintenance doses of 2 mg of the VEGF antagonist comprising amino acids 27-457 of SEQ ID NO:2 at least about 8 weeks after the immediately preceding dose.

38. (New) The method of claim 32, wherein the method comprises administering by intravitreal injection five or more maintenance doses of 2 mg of the VEGF antagonist comprising amino acids 27-457 of SEQ ID NO:2 at least about 8 weeks after the immediately preceding dose.

39. (New) The method of claim 32, wherein said patient has previously received by intravitreal injection an initial dose of 2 mg of the VEGF antagonist followed by one or more secondary doses of 2 mg of the VEGF antagonist; followed by one or more tertiary doses of 2 mg of the VEGF antagonist;

wherein each secondary dose was administered about 2 to 4 weeks after the immediately preceding dose;

wherein each tertiary dose was administered at least about 8 weeks after the immediately preceding dose.

40. (New) The method of claim 38, wherein the patient maintains visual acuity at 52 weeks following the initial dose compared to baseline.

41. (New) A method for treating an angiogenic eye disorder in a patient in need thereof, said method comprising administering by intravitreal injection one or more maintenance doses of 2 mg of a first VEGF antagonist comprising amino acids 27-457 of SEQ ID NO:2 at least about 8 weeks after the immediately preceding dose;

wherein the patient has previously received by intravitreal injection an initial dose of a second VEGF antagonist, followed by one or more secondary doses of the second VEGF antagonist;

wherein each secondary dose was administered about 2 to 4 weeks after the immediately preceding dose; and

wherein the treatment with the first VEGF antagonist results in the patient maintaining visual acuity at 24 weeks following the initial dose compared to baseline.

42. (New) The method of claim 41, wherein the angiogenic eye disorder is age related macular degeneration.

43. (New) The method of claim 41, wherein the angiogenic eye disorder is diabetic retinopathy.

44. (New) The method of claim 41, wherein the angiogenic eye disorder is diabetic macular edema.

45. (New) The method of claim 41, wherein the angiogenic eye disorder is macular edema following retinal vein occlusion.

46. (New) The method of claim 41, wherein the method comprises administering by intravitreal injection two or more maintenance doses of 2 mg of a VEGF antagonist comprising amino acids 27-457 of SEQ ID NO:2 at least about 8 weeks after the immediately preceding dose.

47. (New) The method of claim 46, wherein the method comprises administering by intravitreal injection five or more maintenance doses of 2 mg of a VEGF antagonist comprising amino acids 27-457 of SEQ ID NO:2 at least about 8 weeks after the immediately preceding dose.

48. (New) The method of claim 47, wherein the patient maintains visual acuity at 52 weeks following the initial dose compared to baseline.

49. (New) The method of claim 41, wherein said patient has previously received by intravitreal injection an initial dose of 2 mg of the second VEGF antagonist followed by one or more secondary doses of 2 mg of the second VEGF antagonist; followed by one or more tertiary doses of 2 mg of the second VEGF antagonist;

wherein each secondary dose was administered about 2 to 4 weeks after the immediately preceding dose;

wherein each tertiary dose was administered at least about 8 weeks after the immediately preceding dose.

50. (New) A method for treating an angiogenic eye disorder in a patient in need thereof, said method comprising administering by intravitreal injection three or more maintenance doses of 2 mg of a VEGF antagonist comprising amino acids 27-457 of SEQ ID NO:2 about once every 8 or more weeks;

wherein said patient has previously received by intravitreal injection two or more doses of 2 mg of the VEGF antagonist about once every 4 weeks; and

wherein the method results in the patient achieving a gain in visual acuity at 24 weeks after the first maintenance dose.

51. (New) The method of claim 50, wherein the method comprises administering by intravitreal injection four or more maintenance doses of 2 mg of the VEGF antagonist comprising amino acids 27-457 of SEQ ID NO:2 about once every 8 or more weeks.

52. (New) The method of claim 50, wherein the angiogenic eye disorder is age related macular degeneration.

APOTEX V. REGENERON IPR2022-01524 REGENERON EXHIBIT 2012 PAGE 007

53. (New) The method of claim 50, wherein the angiogenic eye disorder is diabetic retinopathy.

54. (New) The method of claim 50, wherein the angiogenic eye disorder is diabetic macular edema.

55. (New) The method of claim 50, wherein the angiogenic eye disorder is macular edema following retinal vein occlusion.

56. (New) The method of claim 50, wherein visual acuity is measured using the Early Treatment Diabetic Retinopathy Study (ETDRS) letter score.

57. (New) A method for treating an angiogenic eye disorder in a patient in need thereof, said method comprising administering by intravitreal injection three or more maintenance doses of 2 mg of a VEGF antagonist comprising amino acids 27-457 of SEQ ID NO:2 about once every 8 or more weeks;

wherein said patient has previously received by intravitreal injection one or more doses of 2 mg of the VEGF antagonist about once every 4 weeks; and

wherein the method results in the patient maintaining visual acuity at 24 weeks after the first maintenance dose.

58. (New) The method of claim 57, wherein the angiogenic eye disorder is age related macular degeneration.

59. (New) The method of claim 57, wherein the angiogenic eye disorder is diabetic retinopathy.

60. (New) The method of claim 57, wherein the angiogenic eye disorder is diabetic macular edema.

61. (New) The method of claim 57, wherein the angiogenic eye disorder is macular edema following retinal vein occlusion.

APOTEX V. REGENERON IPR2022-01524 REGENERON EXHIBIT 2012 PAGE 008

62. (New) The method of claim 57, wherein visual acuity is measured using the Early Treatment Diabetic Retinopathy Study (ETDRS) letter score.

REMARKS UNDER 37 CFR § 1.115

Formal Matters

Claims 21-62 are pending after entry of the amendments set forth herein.

Original claims 1-20 are canceled without prejudice.

Claims 21-62 are added here.

Support for new claims 21-62 can be found in originally pending now canceled claims 1-20, and throughout the specification.

No new matter has been added.

SEQUENCE LISTING

Applicants submit herewith the attached Sequence Listing in .txt format. As set out in MPEP §2422.03(a), the Office has advised that if the sequence listing text file submitted via EFS-Web complies with the requirements of 37 CFR 1.824(a)(2)-(6) and (b) (i.e., is a compliant sequence listing ASCII text file), the text file will serve as both the paper copy required by 37 CFR 1.821(c) and the computer readable form (CRF) required by 37 CFR 1.821(e). Further, per MPEP §2422.03(a), neither (1) a second copy of the sequence listing in a PDF file; nor (2) a statement under 37 CFR 1.821(f) (indicating that the paper copy and CRF copy of the sequence listing are identical) should be submitted.

The Sequence Listing was prepared with the software FASTSEQ for Windows version 4.0, and conforms to the Patent Office guidelines. Applicant respectfully submits that the subject application is in adherence to 37 CFR §§ 1.821-1.825. I hereby certify that the enclosed submission includes no new matter.

Applicants respectfully submit that the present patent application is now in compliance with 37 CFR §§ 1.821-1.825.

STATEMENT UNDER 37 C.F.R. §§1.56 AND 1.2

Applicants hereby advise the Examiner of the status of a co-pending application in compliance with the Applicant's duty to disclose under 37 C.F.R. §§1.56 and 1.2 (see also MPEP §2001.06(b)) as discussed in *McKesson Info. Soln. Inc., v. Bridge Medical Inc.*, 487 F.3d 897; 82 USPQ2d 1865 (Fed. Cir. 2007).

The Applicant wishes to bring to the Examiner's attention U.S. Patent Application No.

13/940,370, filed July 12, 2013 which issued on February 9, 2016 as U.S. Patent 9,254,338.

The Applicant wishes to bring to the Examiner's attention U.S. Patent Application No.

14/972,560, filed December 17, 2015 which issued on June 6, 2017 as U.S. Patent No. 9,669,069.

The Applicant wishes to bring to the Examiner's attention U.S. Patent Application No.

15/471,506, filed March 28, 2017 which issued on November 20, 2018 as U.S. Patent No. 10,130,681. The Applicant wishes to bring to the Examiner's attention U.S. Patent Application No.

16/055,847, filed August 6, 2018 which issued on December 8, 2020 as U.S. Patent No. 10,857,205.

The Applicant wishes to bring to the Examiner's attention U.S. Patent Application No.

16/159,282, filed October 12, 2018 which issued on November 10, 2020 as U.S. Patent No. 10,828,345. The Applicant wishes to bring to the Examiner's attention co-pending U.S. Patent Application

No. 16/397,267, filed April 29, 2019 which issued on January 12, 2021 as U.S. Patent No. 10,888,601.

The Applicant wishes to bring to the Examiner's attention co-pending U.S. Patent Application No. 17/072,417, filed October 16, 2020 for which no actions have been mailed.

The Applicant wishes to bring to the Examiner's attention co-pending U.S. Patent Application No. 17/117,404, filed December 4, 2020 for which no actions have been mailed.

The Applicant wishes to bring to the Examiner's attention co-pending U.S. Patent Application No. 17/112,063, filed December 4, 2020 which was filed concurrently with the above-referenced patent application. No actions have been mailed.

These documents are available on PAIR, and thus are not provided with this communication. Please inform the undersigned if there is any difficulty in obtaining the documents from PAIR.

CONCLUSION

Applicant submits that all of the claims are in condition for allowance, which action is requested. If the Examiner finds that a telephone conference would expedite the prosecution of this application, please telephone the undersigned at the number provided.

Atty Dkt. No.: REGN-008CIPCON9 USSN: To Be Assigned

The Commissioner is hereby authorized to charge any underpayment of fees up to a strict limit of \$3,000.00 beyond that authorized on the credit card, but not more than \$3,000.00 in additional fees due with any communication for the above referenced patent application, including but not limited to any necessary fees for extensions of time, or credit any overpayment of any amount to Deposit Account No. 50-0815, order number REGN-008CIPCON9.

Respectfully submitted, BOZICEVIC, FIELD & FRANCIS LLP

Date: _____ 17 June 2021 _____

By: <u>/Karl Bozicevic, Reg. No. 28,807/</u> Karl Bozicevic, Reg. No. 28,807

Bozicevic, Field & Francis LLP 201 Redwood Shores Parkway, Suite 200 Redwood City, California 94065 Telephone: (650) 327-3400 Direct: (650) 833-7735 Facsimile: (650) 327-3231

Electronic Patent Application Fee Transmittal					
Application Number:					
Filing Date:					
Title of Invention:	USE OF A VEGF ANTAGONIST TO TREAT ANGIOGENIC EYE DISORDERS			E DISORDERS	
First Named Inventor/Applicant Name:	George YANCOPOULOS				
Filer:	Karl Bozicevic/Kimberly Zuehlke				
Attorney Docket Number:	REG	GN-008CIPCON9			
Filed as Large Entity					
Filing Fees for Utility under 35 USC 111(a)					
Description		Fee Code	Quantity	Amount	Sub-Total in USD(\$)
Basic Filing:					
UTILITY APPLICATION FILING		1011	1	320	320
UTILITY SEARCH FEE		1111	1	700	700
UTILITY EXAMINATION FEE		1311	1	800	800
Pages:					
Claims:					
CLAIMS IN EXCESS OF 20		1202	22	100	2200
INDEPENDENT CLAIMS IN EXCESS OF 3		1201	2	480	960
Miscellaneous-Filing:					

Description	Fee Code	Quantity	Amount	Sub-Total in USD(\$)
Petition:				
Patent-Appeals-and-Interference:				
Post-Allowance-and-Post-Issuance:				
Extension-of-Time:				
Miscellaneous:				
	Tot	al in USD	(\$)	4980

Electronic Ac	Electronic Acknowledgement Receipt				
EFS ID:	43021588				
Application Number:	17350958				
International Application Number:					
Confirmation Number:	4833				
Title of Invention:	USE OF A VEGF ANTAGONIST TO TREAT ANGIOGENIC EYE DISORDERS				
First Named Inventor/Applicant Name:	George YANCOPOULOS				
Customer Number:	96387				
Filer:	Karl Bozicevic/Kimberly Zuehlke				
Filer Authorized By:	Karl Bozicevic				
Attorney Docket Number:	REGN-008CIPCON9				
Receipt Date:	17-JUN-2021				
Filing Date:					
Time Stamp:	18:27:39				
Application Type:	Utility under 35 USC 111(a)				

Payment information:

yes
CARD
\$4980
E20216GI27582982

The Director of the USPTO is hereby authorized to charge indicated fees and credit any overpayment as follows:

File Listin	g:				
Document Number	Document Description	File Name	File Size(Bytes)/ Message Digest	Multi Part /.zip	Pages (if appl.)
			154301		
1	Application Data Sheet	WebADS.pdf	cc2494536b29f77dcb976c28961fbf0a5bca 2159	no	9
Warnings:					
Information:		r			
			159371		
2		REGN-008CIPCON9_2021-06-17 _AppIn_as_fld.pdf	f2a5eec92c2ae7b33f2003be2a3065b221a4 a9f9	yes	25
	Multip	bart Description/PDF files in .	zip description		
	Document De	scription	Start	Eı	nd
	Specificat	1	22		
	Claims	23	24		
	Abstrac	t	25	25	
Warnings:					
Information:					
			105393		
3	Drawings-only black and white line drawings	REGN-008CIPCON9_Figure.pdf	2d582f645d0c5d17d717e589b029a393319 91bdb	no	1
Warnings:		•			
	n the PDF is too large. The pages should be pper and may affect subsequent processin		tted, the pages will be re	sized upon en	try into the
Information:					
			173097		
4	Oath or Declaration filed	REGN-008CIPCON9_declaration .pdf	6bda7272374e6af80c8c3d8cf30d012e4657 b588	no	2
Warnings:		•			
	n the PDF is too large. The pages should be pper and may affect subsequent processin		tted, the pages will be re	sized upon en	try into the
Information:		APO	TEX V. REGENERON	PR2022-015	24

5		REGN-008CIPCON9_2021-06-17 _Prelim_Amend.pdf	94035 f1b6b0097f4a68dc8d039ae3eae1ddd3162 304dd	yes	11
	Multip	bart Description/PDF files in .	zip description	·	1
	Document De	scription	Start	E	ind
	Preliminary Am	endment	1		1
	Claims		2		8
	Applicant Arguments/Remarks	Made in an Amendment	9		11
Warnings:					
Information					
			6434		
6	Sequence Listing (Text File)	REGN-008CIPCON9_SeqList.txt		no	-
Warnings:				<u> </u>	1
Information:					
7	Fee Worksheet (SB06)	fee-info.pdf	38698 ec7179c25fa1a922c3c15c2e60acaea46246a b5c	no	2
Warnings:	/arnings:				1
Information:					
		Total Files Size (in bytes)	7	31329	
characterize Post Card, as <u>New Applica</u> If a new appl 1.53(b)-(d) at Acknowledg <u>National Sta</u> If a timely su U.S.C. 371 ar national stag <u>New Internat</u> If a new inter an internatio and of the In	eledgement Receipt evidences receip d by the applicant, and including par- s described in MPEP 503. <u>tions Under 35 U.S.C. 111</u> lication is being filed and the applica nd MPEP 506), a Filing Receipt (37 CF ement Receipt will establish the filin <u>ge of an International Application un</u> bmission to enter the national stage nd other applicable requirements a F ge submission under 35 U.S.C. 371 w tional Application Filed with the USF rnational application is being filed an onal filing date (see PCT Article 11 an ternational Filing Date (Form PCT/Re urity, and the date shown on this Ack on.	ge counts, where applicable. Ition includes the necessary of FR 1.54) will be issued in due og date of the application. <u>Inder 35 U.S.C. 371</u> of an international applicati form PCT/DO/EO/903 indicati ill be issued in addition to the <u>PTO as a Receiving Office</u> and the international applicat of MPEP 1810), a Notification O/105) will be issued in due c	It serves as evidence components for a filir course and the date s on is compliant with ng acceptance of the e Filing Receipt, in du ion includes the nece of the International ourse, subject to pres	of receipt s ng date (see shown on th the condition application e course. essary comp Application scriptions co	a 37 CFR a 37 CFR a 37 cFR a s a bonents for a Number oncerning

Application Dat	a Sheet 37 CFR 1.76	Attorney Docket Number	REGN-008CIPCON9	
	a Sheet S7 CFR 1.70	Application Number		
Title of Invention	USE OF A VEGF ANTAGONIST TO	TO TREAT ANGIOGENIC EYE DISORDERS		
The application data sheet is part of the provisional or nonprovisional application for which it is being submitted. The following form contains the bibliographic data arranged in a format specified by the United States Patent and Trademark Office as outlined in 37 CFR 1.76. This document may be completed electronically and submitted to the Office in electronic format using the Electronic Filing System (EFS) or the document may be printed and included in a paper filed application.				

Secrecy Order 37 CFR 5.2:

Portions or all of the application associated with this Application Data Sheet may fall under a Secrecy Order pursuant to 37 CFR 5.2 (Paper filers only. Applications that fall under Secrecy Order may not be filed electronically.)

Inventor Information:

Invent								
Legal N	lame							
Prefix	Given Name		Middle Name	5		Family Name		Suffix
	George					YANCOPOULOS		
Reside	ence Informati	ion (Select One)	US Residency	() N	on US Resi	dency 🔿 Acti	ve US Military Service	
City	Yorktown Heig	Ihts	State/Province	NY	Country	y of Residence ⁱ	US	
Mailing	Address of Inv	ventor:						
Addre			on Pharmaceuticals, Inc					
Addre	ss 2	777 Old Saw	Mill River Road					
City	Tarryto	wn				rince NY		
Postal	Postal Code 10591			Countr	y i	US		
	All Inventors Must Be Listed - Additional Inventor Information blocks may be generated within this form by selecting the Add button.							

Correspondence Information:

Enter either Customer Number or complete the Correspondence Information section below. For further information see 37 CFR 1.33(a).					
An Address is being provided for the correspondence Information of this application.					
Customer Number	Customer Number 96387				
Email Address	docket@bozpat.com	Add Email Remove Email			

Application Information:

Title of the Invention	USE OF A VEGF ANTAG	JSE OF A VEGF ANTAGONIST TO TREAT ANGIOGENIC EYE DISORDERS			
Attorney Docket Number	REGN-008CIPCON9	REGN-008CIPCON9 Small Entity Status Claimed			
Application Type	Nonprovisional	Nonprovisional			
Subject Matter	Utility	Itility			
Total Number of Drawing S	iheets (if any)	1	Suggested Figure for Publicat	tion (if any)	1

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Application Data Sheet 37 CFR 1.76		Attorney Docket Number	REGN-008CIPCON9	
Application Dat	a Sheet S7 CFR 1.70	Application Number		
Title of Invention	USE OF A VEGF ANTAGONIST TO	A VEGE ANTAGONIST TO TREAT ANGIOGENIC EYE DISORDERS		

Filing By Reference:

Only complete this section when filing an application by reference under 35 U.S.C. 111(c) and 37 CFR 1.57(a). Do not complete this section if application papers including a specification and any drawings are being filed. Any domestic benefit or foreign priority information must be provided in the appropriate section(s) below (i.e., "Domestic Benefit/National Stage Information" and "Foreign Priority Information").

For the purposes of a filing date under 37 CFR 1.53(b), the description and any drawings of the present application are replaced by this reference to the previously filed application, subject to conditions and requirements of 37 CFR 1.57(a).

Application number of the previously filed application	Filing date (YYYY-MM-DD)	Intellectual Property Authority or Country

Publication Information:

Request Early Publication (Fee required at time of Request 37 CFR 1.219)
 Request Not to Publish. I hereby request that the attached application not be published under 35 U.S.C.
 122(b) and certify that the invention disclosed in the attached application has not and will not be the subject of an application filed in another country, or under a multilateral international agreement, that requires publication at eighteen months after filing.

Representative Information:

Representative information should be provided for all practitioners having a power of attorney in the application. Providing this information in the Application Data Sheet does not constitute a power of attorney in the application (see 37 CFR 1.32). Either enter Customer Number or complete the Representative Name section below. If both sections are completed the customer Number will be used for the Representative Information during processing.

Please Select O	201	Customa	r Number		ent Practitioner		on (27 CED 11 0)
Please Select One:			rinumber		entPractitioner	Limited Recognition	on (37 CFR 11.9)
Customer Num	ber	96387					
Prefix	Given Na	ame	Middle Nar	ne	Family Name	Suffix	
						Remove	
Registration N	umber		•			ŀ	
Prefix	Prefix Given Name		Middle Name		Family Name	Suffix	Remove
							hemove
Registration N	umber						
Additional Rep selecting the A		Information bl	ocks may be g	generated v	vithin this form by		

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Application Dat	a Shoot 37 CER 1 76	Attorney Docket Number	REGN-008CIPCON9
Application Data Sheet 37 CFR 1.76		Application Number	
Title of Invention	USE OF A VEGF ANTAGONIST TO TREAT ANGIOGENIC EYE DISORE		ERS

Domestic Benefit/National Stage Information:

This section allows for the applicant to either claim benefit under 35 U.S.C. 119(e), 120, 121, 365(c), or 386(c) or indicate National Stage entry from a PCT application. Providing benefit claim information in the Application Data Sheet constitutes the specific reference required by 35 U.S.C. 119(e) or 120, and 37 CFR 1.78. When referring to the current application, please leave the "Application Number" field blank. Remove **Prior Application Status** Pending Filing or 371(c) Date **Application Number Continuity Type Prior Application Number** (YYYY-MM-DD) Continuation of 17112404 2020-12-04 **Prior Application Status** Pending Remove Filing or 371(c) Date Continuity Type **Prior Application Number** Application Number (YYYY-MM-DD) 17112404 Continuation of 17072417 2020-10-16 **Prior Application Status** Patented Remove Issue Date Application Prior Application Filing Date **Continuity Type** Patent Number (YYYY-MM-DD) Number Number (YYYY-MM-DD) 17072417 16055847 2018-08-06 10857205 2020-12-08 Continuation of **Prior Application Status** Patented Remove Issue Date Application Prior Application Filing Date **Continuity Type** Patent Number (YYYY-MM-DD) Number Number (YYYY-MM-DD) 17072417 Continuation of 16397267 2019-04-29 10888601 2021-01-12 **Prior Application Status** Patented Remove Prior Application Filing Date Issue Date Application **Continuity Type** Patent Number Number Number (YYYY-MM-DD) (YYYY-MM-DD) 16397267 16159282 2018-10-12 10828345 2020-11-10 Continuation of **Prior Application Status** Remove Patented Filing Date Issue Date Application Prior Application **Continuity Type** Patent Number (YYYY-MM-DD) Number Number (YYYY-MM-DD) 15471506 16159282 Continuation of 2017-03-28 10130681 2018-11-20 **Prior Application Status** Patented Remove Issue Date Application Prior Application Filing Date **Continuity Type** Patent Number (YYYY-MM-DD) Number Number (YYYY-MM-DD) 2015-12-17 2017-06-06 15471506 Continuation of 14972560 9669069

PTO/AIA/14 (08-15) Approved for use through 04/30/2017. OMB 0651-0032 U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Application Data Sheet 37 CFR 1.76		Attorney Docket Number	REGN-008CIPCON9
		Application Number	
Title of Invention	USE OF A VEGF ANTAGONIST TO) TREAT ANGIOGENIC EYE DISORD	ERS

Prior Applicat	ion Status	Patented				Remove	
Application Number Continuity Type		inuity Type	Prior Application Number	Filing Date (YYYY-MM-DD)	Pat	tent Number	Issue Date (YYYY-MM-DD)
14972560	Continuat	ion of	13940370	2013-07-12	92543	38	2016-02-09
Prior Applicat	ion Status	Expired				Remove]
Application N	lumber	Cont	inuity Type	Prior Application Nu	ımber		371(c) Date MM-DD)
13940370		Continuation in	n part of	PCT/US2012/020855		2012-01-11	
Prior Applicat	ion Status	Expired				Remove	
Application N	lumber	Cont	inuity Type	Prior Application Nu	ımber		371(c) Date MM-DD)
PCT/US2012/02085	5	Claims benefit	of provisional	61432245		2011-01-13	
Prior Applicat	ion Status	Expired				Remove]
Application N	lumber	Cont	inuity Type	Prior Application Nu	ımber		371(c) Date ·MM-DD)
PCT/US2012/02085	5	Claims benefit	of provisional	61434836		2011-01-21	
Prior Applicat	ion Status	Expired				Remove]
Application N	lumber	Cont	inuity Type	Prior Application Nu	ımber	-	371(c) Date ·MM-DD)
PCT/US2012/020855 Claims benefit of provisional		61561957		2011-11-21			

Foreign Priority Information:

This section allows for the applicant to claim priority to a foreign application. Providing this information in the application data sheet constitutes the claim for priority as required by 35 U.S.C. 119(b) and 37 CFR 1.55. When priority is claimed to a foreign application that is eligible for retrieval under the priority document exchange program (PDX) the information will be used by the Office to automatically attempt retrieval pursuant to 37 CFR 1.55(i)(1) and (2). Under the PDX program, applicant bears the ultimate responsibility for ensuring that a copy of the foreign application is received by the Office from the participating foreign intellectual property office, or a certified copy of the foreign priority application is filed, within the time period specified in 37 CFR 1.55(g)(1).

Application Number	Country ⁱ	Filing Date (YYYY-MM-DD)	Access Code ^l (if applicable)
Additional Foreign Priority D	Data may be generated withir	n this form by selecting the Add	
button.			ENERON IPR2022-01524
		REGENERON	EXHIBIT 2012 PAGE 021

Application Dat	a Sheet 37 CFR 1.76	Attorney Docket Number	REGN-008CIPCON9	
Application Dat	a Sheet S7 CFR 1.70	Application Number		
Title of Invention	USE OF A VEGF ANTAGONIST TO TREAT ANGIOGENIC EYE DISORDERS		ERS	

Statement under 37 CFR 1.55 or 1.78 for AIA (First Inventor to File) Transition Applications

This application (1) claims priority to or the benefit of an application filed before March 16, 2013 and (2) also contains, or contained at any time, a claim to a claimed invention that has an effective filing date on or after March
 16, 2013.

NOTE: By providing this statement under 37 CFR 1.55 or 1.78, this application, with a filing date on or after March 16, 2013, will be examined under the first inventor to file provisions of the AIA.

Application Data Sheet 37 CFR 1.76		Attorney Docket Number	REGN-008CIPCON9
		Application Number	
Title of Invention	USE OF A VEGF ANTAGONIST TO TREAT ANGIOGENIC EYE DISORDERS		ERS

Authorization or Opt-Out of Authorization to Permit Access:

When this Application Data Sheet is properly signed and filed with the application, applicant has provided written authority to permit a participating foreign intellectual property (IP) office access to the instant application-as-filed (see paragraph A in subsection 1 below) and the European Patent Office (EPO) access to any search results from the instant application (see paragraph B in subsection 1 below).

Should applicant choose not to provide an authorization identified in subsection 1 below, applicant **must opt-out** of the authorization by checking the corresponding box A or B or both in subsection 2 below.

NOTE: This section of the Application Data Sheet is **ONLY** reviewed and processed with the **INITIAL** filing of an application. After the initial filing of an application, an Application Data Sheet cannot be used to provide or rescind authorization for access by a foreign IP office(s). Instead, Form PTO/SB/39 or PTO/SB/69 must be used as appropriate.

1. Authorization to Permit Access by a Foreign Intellectual Property Office(s)

A. <u>Priority Document Exchange (PDX)</u> - Unless box A in subsection 2 (opt-out of authorization) is checked, the undersigned hereby grants the USPTO authority to provide the European Patent Office (EPO), the Japan Patent Office (JPO), the Korean Intellectual Property Office (KIPO), the State Intellectual Property Office of the People's Republic of China (SIPO), the World Intellectual Property Organization (WIPO), and any other foreign intellectual property office participating with the USPTO in a bilateral or multilateral priority document exchange agreement in which a foreign application claiming priority to the instant patent application is filed, access to: (1) the instant patent application-as-filed and its related bibliographic data, (2) any foreign or domestic application to which priority or benefit is claimed by the instant application and its related bibliographic data, and (3) the date of filing of this Authorization. See 37 CFR 1.14(h)(1).

B. <u>Search Results from U.S. Application to EPO</u> - Unless box B in subsection 2 (opt-out of authorization) is checked, the undersigned hereby grants the USPTO authority to provide the EPO access to the bibliographic data and search results from the instant patent application when a European patent application claiming priority to the instant patent application is filed. See 37 CFR 1.14(h)(2).

The applicant is reminded that the EPO's Rule 141(1) EPC (European Patent Convention) requires applicants to submit a copy of search results from the instant application without delay in a European patent application that claims priority to the instant application.

2. Opt-Out of Authorizations to Permit Access by a Foreign Intellectual Property Office(s)

A. Applicant **DOES NOT** authorize the USPTO to permit a participating foreign IP office access to the instant application-as-filed. If this box is checked, the USPTO will not be providing a participating foreign IP office with any documents and information identified in subsection 1A above.

B. Applicant **DOES NOT** authorize the USPTO to transmit to the EPO any search results from the instant patent application. If this box is checked, the USPTO will not be providing the EPO with search results from the instant application.

NOTE: Once the application has published or is otherwise publicly available, the USPTO may provide access to the application in accordance with 37 CFR 1.14.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Application Data Sheet 37 CFR 1.76		Attorney Docket Number	REGN-008CIPCON9
		Application Number	
Title of Invention	USE OF A VEGF ANTAGONIST TO TREAT ANGIOGENIC EYE DISORD		ERS

Applicant Information:

Providing assignment information in this section does not substitute for compliance with any requirement of part 3 of Title 37 of CFR to have an assignment recorded by the Office.

information to name and add sufficient prop person to who	t is the inventor be provided in t ress of the assig rietary interest in m the inventor i	this section nee, persor n the matte s obligated	er who is the applicant under 37 C	gal representative who n obligation to assign tl FR 1.46. If the applicant se shows sufficient prop	is the app he inventic is an appli prietary int	licant under 37 CFR 1.43; or the on, or person who otherwise shows icant under 37 CFR 1.46 (assignee, terest) together with one or more
Assignee			C Legal Representative unde	er 35 U.S.C. 117	0	Joint Inventor
Person to	whom the inver	ntor is oblig	jated to assign.	Person who she	ows sufficie	ent proprietary interest
If applicant is	the legal repre	esentative	, indicate the authority to file t	he patent application	n, the inve	entor is:
Name of the	Deceased or L	egally Inca	apacitated Inventor:			
If the Applie	ant is an Orga	nization cl	heck here.			
Organizatio	n Name	REGENERO	N PHARMACEUTICALS, INC.			
Mailing Ad	dress Informa	tion For <i>I</i>	Applicant:			
Address 1		777 OI	d Saw Mill River Road			
Address 2						
City		Tarryto	own	State/Province	NY	
Country ⁱ	US	·		Postal Code	10591	
Phone Num	iber			Fax Number		
Email Addre	ess				·	
Additional A	oplicant Data n	nay be gei	nerated within this form by sel	ecting the Add butto	n.	

Application Dat	a Sheet 37 CFR 1.76	Attorney Docket Number	REGN-008CIPCON9
	a Sheet S7 CFR 1.70	Application Number	
Title of Invention	USE OF A VEGF ANTAGONIST TO TREAT ANGIOGENIC EYE DISORD		ERS

Assignee Information including Non-Applicant Assignee Information:

Providing assignment information in this section does not substitute for compliance with any requirement of part 3 of Title 37 of CFR to have an assignment recorded by the Office.

publication. An a	ssignee-applica	nt identified in the "Applicant	Information" section will appear on	sired to be included on the patent applicatio the patent application publication as an Iso desired on the patent application		
If the Assigned	e or Non-Appl	icant Assignee is an Organiz	ration check here.	\boxtimes		
Organization	Name R	EGENERON PHARMACEUTICAL	.s, INC.			
Mailing Addre	ss Informatio	n For Assignee including I	Non-Applicant Assignee:			
Address 1 777 Old		777 Old Saw Mill River Ro	77 Old Saw Mill River Road			
Address 2						
City		Tarrytown	State/Province	NY		
Country i	US		Postal Code	10591		
Phone Numbe	er		Fax Number			
Email Address	i		I			
Additional Ass selecting the A	•	Applicant Assignee Data ma	ay be generated within this form	by		

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Application Data Sheet 37 CFR 1.76		Attorney Docket Number	REGN-008CIPCON9	
		Application Number		
Title of Invention	USE OF A VEGF ANTAGONIST TO TREAT ANGIOGENIC EYE DISORDERS			

Signature:

NOTE: This Application Data Sheet must be signed in accordance with 37 CFR 1.33(b). **However, if this Application Data Sheet** is submitted with the <u>INITIAL</u> filing of the application <u>and</u> either box A or B is <u>not</u> checked in subsection 2 of the "Authorization or Opt-Out of Authorization to Permit Access" section, then this form must also be signed in accordance with 37 CFR 1.14(c).

This Application Data Sheet **must** be signed by a patent practitioner if one or more of the applicants is a **juristic entity** (e. g., corporation or association). If the applicant is two or more joint inventors, this form must be signed by a patent practitioner, **all** joint inventors who are the applicant, or one or more joint inventor-applicants who have been given power of attorney (e.g., see USPTO Form PTO/AIA/81) on behalf of **all** joint inventor-applicants.

See 37 CFR 1.4(d) for the manner of making signatures and certifications.

Signature	/Karl Bozicevic/			Date (YYYY-MM-DD)			
First Name	Karl	Last Name	Bozicevic	Registration Number	28807		
Additional Signature may be generated within this form by selecting the Add button.							

USE OF A VEGF ANTAGONIST TO TREAT ANGIOGENIC EYE DISORDERS

CROSS-REFERENCE TO RELATED APPLICATIONS

[0001] This application is a continuation of 17/112,404 filed December 4, 2020 which is a continuation of 17/072,417 filed October 16, 2020 which is a continuation of 16/055,847 filed August 6, 2018, now U.S. Patent 10,857,205 issued December 8, 2020 and is a continuation of 16/397,267 filed April 29, 2019, which is a continuation of 16/159,282 filed October 12, 2018, now U.S. Patent No. 10,828,345 issued November 10, 2020, which is a continuation of 15/471,506 filed March 28, 2017, now U.S. Patent No. 10,130,681 issued November 20, 2018, which is a continuation of 14/972,560 filed December 17, 2015, now U.S. Patent No. 9,669,069 issued June 6, 2017, which is a continuation of 13/940,370 filed July 12, 2013, now U.S. Patent No. 9,254,338 issued February 9, 2016, which is a continuation-in-part of International Patent Application No. PCT/US2012/020855, filed on January 11, 2012, which claims the benefit of US Provisional Application Nos. 61/432,245, filed on January 13, 2011, 61/434,836, filed on January 21, 2011, and 61/561,957, filed on November 21, 2011, the contents of which are hereby incorporated by reference in their entireties.

FIELD OF THE INVENTION

[0002] The present invention relates to the field of therapeutic treatments of eye disorders. More specifically, the invention relates to the administration of VEGF antagonists to treat eye disorders caused by or associated with angiogenesis.

BACKGROUND

[0003] Several eye disorders are associated with pathological angiogenesis. For example, the development of age-related macular degeneration (AMD) is associated with a process called choroidal neovascularization (CNV). Leakage from the CNV causes macular edema and collection of fluid beneath the macula resulting in vision loss. Diabetic macular edema (DME) is another eye disorder with an angiogenic component. DME is the most prevalent cause of moderate vision loss in patients with diabetes and is a common complication of diabetic retinopathy, a disease affecting the blood vessels of the retina. Clinically significant DME occurs when fluid leaks into the center of the macula, the light-sensitive part of the retina responsible for sharp, direct vision. Fluid in the macula can cause severe vision loss or blindness. Yet another eye disorder associated with abnormal angiogenesis is central retinal vein occlusion (CRVO). CRVO is caused by obstruction of the central retinal vein that leads to a back-up of blood and fluid in the retina. The retina can also become ischemic, resulting in the growth of new, inappropriate blood vessels that can cause further vision loss and more serious complications. Release of vascular endothelial growth factor (VEGF) contributes to increased vascular permeability in the eye and inappropriate new vessel growth.

Thus, inhibiting the angiogenic-promoting properties of VEGF appears to be an effective strategy for treating angiogenic eye disorders.

[0004] FDA-approved treatments of angiogenic eye disorders such as AMD and CRVO include the administration of an anti-VEGF antibody called ranibizumab (Lucentis®, Genentech, Inc.) on a monthly basis by intravitreal injection.

[0005] Methods for treating eye disorders using VEGF antagonists are mentioned in, *e.g.*, US 7,303,746; US 7,306,799; US 7,300,563; US 7,303,748; and US 2007/0190058. Nonetheless, there remains a need in the art for new administration regimens for angiogenic eye disorders, especially those which allow for less frequent dosing while maintaining a high level of efficacy.

BRIEF SUMMARY OF THE INVENTION

The present invention provides methods for treating angiogenic eye disorders. The [0006] methods of the invention comprise sequentially administering multiple doses of a VEGF antagonist to a patient over time. In particular, the methods of the invention comprise sequentially administering to the patient a single initial dose of a VEGF antagonist, followed by one or more secondary doses of the VEGF antagonist, followed by one or more tertiary doses of the VEGF antagonists. The present inventors have surprisingly discovered that beneficial therapeutic effects can be achieved in patients suffering from angiogenic eye disorders by administering a VEGF antagonist to a patient at a frequency of once every 8 or more weeks, especially when such doses are preceded by about three doses administered to the patient at a frequency of about 2 to 4 weeks. Thus, according to the methods of the present invention, each secondary dose of VEGF antagonist is administered 2 to 4 weeks after the immediately preceding dose, and each tertiary dose is administered at least 8 weeks after the immediately preceding dose. An example of a dosing regimen of the present invention is shown in Figure 1. One advantage of such a dosing regimen is that, for most of the course of treatment (*i.e.*, the tertiary doses), it allows for less frequent dosing (e.g., once every 8 weeks) compared to prior administration regimens for angiogenic eye disorders which require monthly administrations throughout the entire course of treatment. (See, e.g., prescribing information for Lucentis® [ranibizumab], Genentech, Inc.). [0007] The methods of the present invention can be used to treat any angiogenic eye disorder, including, e.g., age related macular degeneration, diabetic retinopathy, diabetic macular edema, central retinal vein occlusion, corneal neovascularization, etc.

[0008] The methods of the present invention comprise administering any VEGF antagonist to the patient. In one embodiment, the VEGF antagonist comprises one or more VEGF receptor-based chimeric molecule(s), (also referred to herein as a "VEGF-Trap" or "VEGFT"). An exemplary VEGF antagonist that can be used in the context of the present invention is a multimeric VEGF-binding

protein comprising two or more VEGF receptor-based chimeric molecules referred to herein as "VEGFR1R2-Fc Δ C1(a)" or "aflibercept."

[0009] Various administration routes are contemplated for use in the methods of the present invention, including, *e.g.*, topical administration or intraocular administration (*e.g.*, intravitreal administration).

[0010] Aflibercept (EYLEA[™], Regeneron Pharmaceuticals, Inc) was approved by the FDA in November 2011, for the treatment of patients with neovascular (wet) age-related macular degeneration, with a recommended dose of 2 mg administered by intravitreal injection every 4 weeks for the first three months, followed by 2 mg administered by intravitreal injection once every 8 weeks.

[0011] Other embodiments of the present invention will become apparent from a review of the ensuing detailed description.

BRIEF DESCRIPTION OF THE FIGURE

[0012] Figure 1 shows an exemplary dosing regimen of the present invention. In this regimen, a single "initial dose" of VEGF antagonist ("VEGFT") is administered at the beginning of the treatment regimen (*i.e.* at "week 0"), two "secondary doses" are administered at weeks 4 and 8, respectively, and at least six "tertiary doses" are administered once every 8 weeks thereafter, *i.e.*, at weeks 16, 24, 32, 40, 48, 56, etc.).

DETAILED DESCRIPTION

[0013] Before the present invention is described, it is to be understood that this invention is not limited to particular methods and experimental conditions described, as such methods and conditions may vary. It is also to be understood that the terminology used herein is for the purpose of describing particular embodiments only, and is not intended to be limiting, since the scope of the present invention will be limited only by the appended claims.

[0014] Unless defined otherwise, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this invention belongs. As used herein, the term "about," when used in reference to a particular recited numerical value, means that the value may vary from the recited value by no more than 1%. For example, as used herein, the expression "about 100" includes 99 and 101 and all values in between (*e.g.*, 99.1, 99.2, 99.3, 99.4, etc.).

[0015] Although any methods and materials similar or equivalent to those described herein can be used in the practice or testing of the present invention, the preferred methods and materials are now described.

DOSING REGIMENS

[0016] The present invention provides methods for treating angiogenic eye disorders. The methods of the invention comprise sequentially administering to a patient multiple doses of a VEGF antagonist. As used herein, "sequentially administering" means that each dose of VEGF antagonist is administered to the patient at a different point in time, *e.g.*, on different days separated by a predetermined interval (*e.g.*, hours, days, weeks or months). The present invention includes methods which comprise sequentially administering to the patient a single initial dose of a VEGF antagonist, followed by one or more secondary doses of the VEGF antagonist, followed by one or more tertiary doses of the VEGF antagonist.

[0017] The terms "initial dose," "secondary doses," and "tertiary doses," refer to the temporal sequence of administration of the VEGF antagonist. Thus, the "initial dose" is the dose which is administered at the beginning of the treatment regimen (also referred to as the "baseline dose"); the "secondary doses" are the doses which are administered after the initial dose; and the "tertiary doses" are the doses which are administered after the secondary doses. The initial, secondary, and tertiary doses may all contain the same amount of VEGF antagonist, but will generally differ from one another in terms of frequency of administration. In certain embodiments, however, the amount of VEGF antagonist contained in the initial, secondary and/or tertiary doses will vary from one another (*e.g.*, adjusted up or down as appropriate) during the course of treatment.

[0018] In one exemplary embodiment of the present invention, each secondary dose is administered 2 to 4 (*e.g.*, 2, 2¹/₂, 3, 3¹/₂, or 4) weeks after the immediately preceding dose, and each tertiary dose is administered at least 8 (*e.g.*, 8, 8¹/₂, 9, 9¹/₂, 10, 10¹/₂, 11, 11¹/₂, 12, 12¹/₂, 13, 13¹/₂, 14, 14¹/₂, or more) weeks after the immediately preceding dose. The phrase "the immediately preceding dose," as used herein, means, in a sequence of multiple administrations, the dose of VEGF antagonist which is administered to a patient prior to the administration of the very next dose in the sequence with no intervening doses.

[0019] In one exemplary embodiment of the present invention, a single initial dose of a VEGF antagonist is administered to a patient on the first day of the treatment regimen (*i.e.*, at week 0), followed by two secondary doses, each administered four weeks after the immediately preceding dose (*i.e.*, at week 4 and at week 8), followed by at least 5 tertiary doses, each administered eight weeks after the immediately preceding dose (*i.e.*, at weeks 16, 24, 32, 40 and 48). The tertiary doses may continue (at intervals of 8 or more weeks) indefinitely during the course of the treatment regimen. This exemplary administration regimen is depicted graphically in Figure 1.

[0020] The methods of the invention may comprise administering to a patient any number of secondary and/or tertiary doses of a VEGF antagonist. For example, in certain embodiments, only

a single secondary dose is administered to the patient. In other embodiments, two or more (e.g., 2, 3, 4, 5, 6, 7, 8, or more) secondary doses are administered to the patient. Likewise, in certain embodiments, only a single tertiary dose is administered to the patient. In other embodiments, two or more (e.g., 2, 3, 4, 5, 6, 7, 8, or more) tertiary doses are administered to the patient. [0021] In embodiments involving multiple secondary doses, each secondary dose may be administered at the same frequency as the other secondary doses. For example, each secondary dose may be administered to the patient 4 weeks after the immediately preceding dose. Similarly, in embodiments involving multiple tertiary doses, each tertiary dose may be administered at the same frequency as the other tertiary doses. For example, each tertiary dose may be administered to the patient 8 weeks after the immediately preceding dose. Alternatively, the frequency at which the secondary and/or tertiary doses are administered to a patient can vary over the course of the treatment regimen. For example, the present invention includes methods which comprise administering to the patient a single initial dose of a VEGF antagonist, followed by one or more secondary doses of the VEGF antagonist, followed by at least 5 tertiary doses of the VEGF antagonist, wherein the first four tertiary doses are administered 8 weeks after the immediately preceding dose, and wherein each subsequent tertiary dose is administered from 8 to 12 (e.g., 8, $8\frac{1}{2}$, 9, $9\frac{1}{2}$, 10, $10\frac{1}{2}$, 11, $11\frac{1}{2}$, 12) weeks after the immediately preceding dose. The frequency of administration may also be adjusted during the course of treatment by a physician depending on the needs of the individual patient following clinical examination.

VEGF ANTAGONISTS

[0022] The methods of the present invention comprise administering to a patient a VEGF antagonist according to specified dosing regimens. As used herein, the expression "VEGF antagonist" means any molecule that blocks, reduces or interferes with the normal biological activity of VEGF.

[0023] VEGF antagonists include molecules which interfere with the interaction between VEGF and a natural VEGF receptor, *e.g.*, molecules which bind to VEGF or a VEGF receptor and prevent or otherwise hinder the interaction between VEGF and a VEGF receptor. Specific exemplary VEGF antagonists include anti-VEGF antibodies, anti-VEGF receptor antibodies, and VEGF receptor-based chimeric molecules (also referred to herein as "VEGF-Traps").

[0024] VEGF receptor-based chimeric molecules include chimeric polypeptides which comprise two or more immunoglobulin (lg)-like domains of a VEGF receptor such as VEGFR1 (also referred to as Flt1) and/or VEGFR2 (also referred to as Flk1 or KDR), and may also contain a multimerizing domain (*e.g.*, an Fc domain which facilitates the multimerization [*e.g.*, dimerization] of two or more chimeric polypeptides). An exemplary VEGF receptor-based chimeric molecule is a molecule

referred to as VEGFR1R2-Fc Δ C1(a) which is encoded by the nucleic acid sequence of SEQ ID NO:1. VEGFR1R2-Fc Δ C1(a) comprises three components: (1) a VEGFR1 component comprising amino acids 27 to 129 of SEQ ID NO:2; (2) a VEGFR2 component comprising amino acids 130 to 231 of SEQ ID NO:2; and (3) a multimerization component ("Fc Δ C1(a)") comprising amino acids 232 to 457 of SEQ ID NO:2 (the C-terminal amino acid of SEQ ID NO:2 [*i.e.*, K458] may or may not be included in the VEGF antagonist used in the methods of the invention; *see e.g.*, US Patent 7,396,664). Amino acids 1-26 of SEQ ID NO:2 are the signal sequence.

[0025] The VEGF antagonist used in the Examples set forth herein below is a dimeric molecule comprising two VEGFR1R2-Fc Δ C1(a) molecules and is referred to herein as "VEGFT." Additional VEGF receptor-based chimeric molecules which can be used in the context of the present invention are disclosed in US 7,396,664, 7,303,746 and WO 00/75319.

ANGIOGENIC EYE DISORDERS

[0026] The methods of the present invention can be used to treat any angiogenic eye disorder. The expression "angiogenic eye disorder," as used herein, means any disease of the eye which is caused by or associated with the growth or proliferation of blood vessels or by blood vessel leakage. Non-limiting examples of angiogenic eye disorders that are treatable using the methods of the present invention include age-related macular degeneration (*e.g.*, wet AMD, exudative AMD, etc.), retinal vein occlusion (RVO), central retinal vein occlusion (CRVO; *e.g.*, macular edema following CRVO), branch retinal vein occlusion (BRVO), diabetic macular edema (DME), choroidal neovascularization (CNV; *e.g.*, myopic CNV), iris neovascularization, neovascular glaucoma, post-surgical fibrosis in glaucoma, proliferative vitreoretinopathy (PVR), optic disc neovascularization, corneal neovascularization, retinal neovascularization, vitreal neovascularization, pannus, pterygium, vascular retinopathy, and diabetic retinopathies.

PHARMACEUTICAL FORMULATIONS

[0027] The present invention includes methods in which the VEGF antagonist that is administered to the patient is contained within a pharmaceutical formulation. The pharmaceutical formulation may comprise the VEGF antagonist along with at least one inactive ingredient such as, *e.g.*, a pharmaceutically acceptable carrier. Other agents may be incorporated into the pharmaceutical composition to provide improved transfer, delivery, tolerance, and the like. The term "pharmaceutically acceptable" means approved by a regulatory agency of the Federal or a state government or listed in the U.S. Pharmacopeia or other generally recognized pharmacopeia for use in animals, and more particularly, in humans. The term "carrier" refers to a diluent, adjuvant, excipient, or vehicle with which the antibody is administered. A multitude of appropriate

formulations can be found in the formulary known to all pharmaceutical chemists: Remington's Pharmaceutical Sciences (15th ed, Mack Publishing Company, Easton, Pa., 1975), particularly Chapter 87 by Blaug, Seymour, therein. These formulations include, for example, powders, pastes, ointments, jellies, waxes, oils, lipids, lipid (cationic or anionic) containing vesicles (such as LIPOFECTIN[™]), DNA conjugates, anhydrous absorption pastes, oil-in-water and water-in-oil emulsions, emulsions carbowax (polyethylene glycols of various molecular weights), semi-solid gels, and semi-solid mixtures containing carbowax. Any of the foregoing mixtures may be appropriate in the context of the methods of the present invention, provided that the VEGF antagonist is not inactivated by the formulation and the formulation is physiologically compatible and tolerable with the route of administration. See also Powell et al. PDA (1998) J Pharm Sci Technol. 52:238-311 and the citations therein for additional information related to excipients and carriers well known to pharmaceutical chemists.

[0028] Pharmaceutical formulations useful for administration by injection in the context of the present invention may be prepared by dissolving, suspending or emulsifying a VEGF antagonist in a sterile aqueous medium or an oily medium conventionally used for injections. As the aqueous medium for injections, there are, for example, physiological saline, an isotonic solution containing glucose and other auxiliary agents, etc., which may be used in combination with an appropriate solubilizing agent such as an alcohol (e.g., ethanol), a polyalcohol (e.g., propylene glycol, polyethylene glycol), a nonionic surfactant [e.g., polysorbate 80, HCO-50 (polyoxyethylene (50 mol) adduct of hydrogenated castor oil)], etc. As the oily medium, there may be employed, e.g., sesame oil, soybean oil, etc., which may be used in combination with a solubilizing agent such as benzyl benzoate, benzyl alcohol, etc. The injection thus prepared can be filled in an appropriate ampoule if desired.

MODES OF ADMINISTRATION

[0029] The VEGF antagonist (or pharmaceutical formulation comprising the VEGF antagonist) may be administered to the patient by any known delivery system and/or administration method. In certain embodiments, the VEGF antagonist is administered to the patient by ocular, intraocular, intravitreal or subconjunctival injection. In other embodiments, the VEGF antagonist can be administered to the patient by topical administration, *e.g.*, via eye drops or other liquid, gel, ointment or fluid which contains the VEGF antagonist and can be applied directly to the eye. Other possible routes of administration include, *e.g.*, intradermal, intramuscular, intraperitoneal, intravenous, subcutaneous, intranasal, epidural, and oral.

AMOUNT OF VEGF ANTAGONIST ADMINISTERED

[0030] Each dose of VEGF antagonist administered to the patient over the course of the treatment regimen may contain the same, or substantially the same, amount of VEGF antagonist. Alternatively, the quantity of VEGF antagonist contained within the individual doses may vary over the course of the treatment regimen. For example, in certain embodiments, a first quantity of VEGF antagonist is administered in the initial dose, a second quantity of VEGF antagonist is administered in the secondary doses, and a third quantity of VEGF antagonist is administered in the tertiary doses. The present invention contemplates dosing schemes in which the quantity of VEGF antagonist contained within the individual doses increases over time (*e.g.*, each subsequent dose contains more VEGF antagonist than the last), decreases over time (*e.g.*, each subsequent dose contains less VEGF antagonist than the last), initially increases then decreases, initially decreases then increases, or remains the same throughout the course of the administration regimen.

The amount of VEGF antagonist administered to the patient in each dose is, in most [0031] cases, a therapeutically effective amount. As used herein, the phrase "therapeutically effective amount" means a dose of VEGF antagonist that results in a detectable improvement in one or more symptoms or indicia of an angiogenic eye disorder, or a dose of VEGF antagonist that inhibits, prevents, lessens, or delays the progression of an angiogenic eye disorder. In the case of an anti-VEGF antibody or a VEGF receptor-based chimeric molecule such as VEGFR1R2-Fc Δ C1(a), a therapeutically effective amount can be from about 0.05 mg to about 5 mg, e.g., about 0.05 mg, about 0.1 mg, about 0.15 mg, about 0.2 mg, about 0.25 mg, about 0.3 mg, about 0.35 mg, about 0.4 mg, about 0.45 mg, about 0.5 mg, about 0.55 mg, about 0.6 mg, about 0.65 mg, about 0.7 mg, about 0.75 mg, about 0.8 mg, about 0.85 mg, about 0.9 mg, about 1.0 mg, about 1.05 mg, about 1.1 mg, about 1.15 mg, about 1.2 mg, about 1.25 mg, about 1.3 mg, about 1.35 mg, about 1.4 mg, about 1.45 mg, about 1.5 mg, about 1.55 mg, about 1.6 mg, about 1.65 mg, about 1.7 mg, about 1.75 mg, about 1.8 mg, about 1.85 mg, about 1.9 mg, about 2.0 mg, about 2.05 mg, about 2.1 mg, about 2.15 mg, about 2.2 mg, about 2.25 mg, about 2.3 mg, about 2.35 mg, about 2.4 mg, about 2.45 mg, about 2.5 mg, about 2.55 mg, about 2.6 mg, about 2.65 mg, about 2.7 mg, about 2.75 mg, about 2.8 mg, about 2.85 mg, about 2.9 mg, about 3.0 mg, about 3.5 mg, about 4.0 mg, about 4.5 mg, or about 5.0 mg of the antibody or receptor-based chimeric molecule.

[0032] The amount of VEGF antagonist contained within the individual doses may be expressed in terms of milligrams of antibody per kilogram of patient body weight (*i.e.*, mg/kg). For example, the VEGF antagonist may be administered to a patient at a dose of about 0.0001 to about 10 mg/kg of patient body weight.

TREATMENT POPULATION AND EFFICACY

[0033] The methods of the present invention are useful for treating angiogenic eye disorders in patients that have been diagnosed with or are at risk of being afflicted with an angiogenic eye disorder. Generally, the methods of the present invention demonstrate efficacy within 104 weeks of the initiation of the treatment regimen (with the initial dose administered at "week 0"), *e.g.*, by the end of week 16, by the end of week 24, by the end of week 32, by the end of week 40, by the end of week 48, by the end of week 56, etc. In the context of methods for treating angiogenic eye disorders such as AMD, CRVO, and DME, "efficacy" means that, from the initiation of treatment, the patient exhibits a loss of 15 or fewer letters on the Early Treatment Diabetic Retinopathy Study (ETDRS) visual acuity chart. In certain embodiments, "efficacy" means a gain of one or more (*e.g.*, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11 or more) letters on the ETDRS chart from the time of initiation of treatment.

EXAMPLES

[0034] The following examples are put forth so as to provide those of ordinary skill in the art with a complete disclosure and description of how to make and use the methods and compositions of the invention, and are not intended to limit the scope of what the inventors regard as their invention. Efforts have been made to ensure accuracy with respect to numbers used (e.g., amounts, temperature, etc.) but some experimental errors and deviations should be accounted for. Unless indicated otherwise, parts are parts by weight, molecular weight is average molecular weight, temperature is in degrees Centigrade, and pressure is at or near atmospheric.

[0035] The exemplary VEGF antagonist used in all Examples set forth below is a dimeric molecule having two functional VEGF binding units. Each functional binding unit is comprised of Ig domain 2 from VEGFR1 fused to Ig domain 3 from VEGFR2, which in turn is fused to the hinge region of a human IgG1 Fc domain (VEGFR1R2-Fc Δ C1(a); encoded by SEQ ID NO:1). This VEGF antagonist is referred to in the examples below as "VEGFT". For purposes of the following Examples, "monthly" dosing is equivalent to dosing once every four weeks.

Example 1: Phase I Clinical Trial of Intravitreally Administered VEGF Receptor-Based Chimeric Molecule (VEGFT) in Subjects with Neovascular AMD

[0036] In this Phase I study, 21 subjects with neovascular AMD received a single intravitreal (IVT) dose of VEGFT. Five groups of three subjects each received either 0.05, 0.15, 0.5, 2 or 4 mg of VEGFT, and a sixth group of six subjects received 1 mg. No serious adverse events related to the study drug, and no identifiable intraocular inflammation was reported. Preliminary results showed that, following injection of VEGFT, a rapid decrease in foveal thickness and macular volume was observed that was maintained through 6 weeks. At Day 43 across all dose groups, mean excess

retinal thickness [excess retinal thickness = (retinal thickness – 179 μ)] on optical coherence tomography (OCT) was reduced from 119 μ to 27 μ as assessed by Fast Macular Scan and from 194 μ to 60 μ as assessed using a single Posterior Pole scan. The mean increase in best corrected visual acuity (BCVA) was 4.75 letters, and BCVA was stable or improved in 95% of subjects. In the 2 highest dose groups (2 and 4 mg), the mean increase in BCVA was 13.5 letters, with 3 of 6 subjects demonstrating improvement of ≥ 3 lines.

Example 2: Phase II Clinical Trial of Repeated Doses of Intravitreally Administered VEGF Receptor-Based Chimeric Molecule (VEGFT) in Subjects with Neovascular AMD

[0037] This study was a double-masked, randomized study of 3 doses (0.5, 2, and 4 mg) of VEGFT tested at 4-week and/or 12-week dosing intervals. There were 5 treatment arms in this study, as follows: 1) 0.5 mg every 4 weeks, 2) 0.5 mg every 12 weeks, 3) 2 mg every 4 weeks, 4) 2 mg every 12 weeks and 5) 4 mg every 12 weeks. Subjects were dosed at a fixed interval for the first 12 weeks, after which they were evaluated every 4 weeks for 9 months, during which additional doses were administered based on pre-specified criteria. All subjects were then followed for one year after their last dose of VEGFT. Preliminary data from a pre-planned interim analysis indicated that VEGFT met its primary endpoint of a statistically significant reduction in retinal thickness after 12 weeks compared with baseline (all groups combined, decrease of 135μ , p < 0.0001). Mean change from baseline in visual acuity, a key secondary endpoint of the study, also demonstrated statistically significant improvement (all groups combined, increase of 5.9 letters, p < 0.0001). Moreover, patients in the dose groups that received only a single dose, on average, demonstrated a decrease in excess retinal thickness (p < 0.0001) and an increase in visual acuity (p = 0.012) at 12 weeks. There were no drug-related serious adverse events, and treatment with the VEGF antagonists was generally well-tolerated. The most common adverse events were those typically associated with intravitreal injections.

Example 3: Phase I Clinical Trial of Systemically Administered VEGF Receptor-Based Chimeric Molecule (VEGFT) in Subjects with Neovascular AMD

[0038] This study was a placebo-controlled, sequential-group, dose-escalating safety, tolerability and bioeffect study of VEGFT by IV infusion in subjects with neovascular AMD. Groups of 8 subjects meeting eligibility criteria for subfoveal choroidal neovascularization (CNV) related to AMD were assigned to receive 4 IV injections of VEGFT or placebo at dose levels of 0.3, 1, or 3 mg/kg over an 8-week period.

[0039] Most adverse events that were attributed to VEGFT were mild to moderate in severity, but 2 of 5 subjects treated with 3 mg/kg experienced dose-limiting toxicity (DLT) (one with Grade 4

hypertension and one with Grade 2 proteinuria); therefore, all subjects in the 3 mg/kg dose group did not enter the study. The mean percent changes in excess retinal thickness were: -12%, -10%, -66%, and -60% for the placebo, 0.3, 1, and 3 mg/kg dose groups at day 15 (ANOVA p< 0.02), and -5.6%, +47.1%, and -63.3% for the placebo, 0.3, and 1 mg/kg dose groups at day 71 (ANOVA p< 0.02). There was a numerical improvement in BCVA in the subjects treated with VEGFT. As would be expected in such a small study, the results were not statistically significant.

Example 4: Phase III Clinical Trials of the Efficacy, Safety, and Tolerability of Repeated Doses of Intravitreal VEGFT in Subjects with Neovascular Age-Related Macular Degeneration

A. Objectives, Hypotheses and Endpoints

[0040] Two parallel Phase III clinical trials were carried out to investigate the use of VEGFT to treat patients with the neovascular form of age-related macular degeneration (Study 1 and Study 2). The primary objective of these studies was to assess the efficacy of IVT administered VEGFT compared to ranibizumab (Lucentis®, Genentech, Inc.), in a non-inferiority paradigm, in preventing moderate vision loss in subjects with all subtypes of neovascular AMD.

[0041] The secondary objectives were (a) to assess the safety and tolerability of repeated IVT administration of VEGFT in subjects with all sub-types of neovascular AMD for periods up to 2 years; and (b) to assess the effect of repeated IVT administration of VEGFT on Vision-Related Quality of Life (QOL) in subjects with all sub-types of neovascular AMD.

[0042] The primary hypothesis of these studies was that the proportion of subjects treated with VEGFT with stable or improved BCVA (<15 letters lost) is similar to the proportion treated with ranibizumab who have stable or improved BCVA, thereby demonstrating non-inferiority.

[0043] The primary endpoint for these studies was the prevention of vision loss of greater than or equal to 15 letters on the ETDRS chart, compared to baseline, at 52 weeks. Secondary endpoints were as follows: (a) change from baseline to Week 52 in letter score on the ETDRS chart; (b) gain from baseline to Week 52 of 15 letters or more on the ETDRS chart; (c) change from baseline to Week 52 in total NEI VFQ-25 score; and (d) change from baseline to Week 52 in CNV area.

B. Study Design

[0044] For each study, subjects were randomly assigned in a 1:1:1:1 ratio to 1 of 4 dosing regimens: (1) 2 mg VEGFT administered every 4 weeks (2Q4); (2) 0.5 mg VEGFT administered every 4 weeks (0.5Q4); (3) 2 mg VEGFT administered every 4 weeks to week 8 and then every 8 weeks (with sham injection at the interim 4-week visits when study drug was not administered (2Q8); and (4) 0.5 mg ranibizumab administered every 4 weeks (RQ4). Subjects assigned to (2Q8) received the 2 mg injection every 4 weeks to week 8 and then a sham injection at interim 4-week

visits (when study drug is not to be administered) during the first 52 weeks of the studies. (No sham injection were given at Week 52).

[0045] The study duration for each subject was scheduled to be 96 weeks plus the recruitment period. For the first 52 weeks (Year 1), subjects received an IVT or sham injection in the study eye every 4 weeks. (No sham injections were given at Week 52). During the second year of the study, subjects will be evaluated every 4 weeks and will receive IVT injection of study drug at intervals determined by specific dosing criteria, but at least every 12 weeks. (During the second year of the study, sham injections will not be given.) During this period, injections may be given as frequently as every 4 weeks, but no less frequently than every 12 weeks, according to the following criteria: (i) increase in central retinal thickness of $\geq 100 \,\mu$ m compared to the lowest previous value as measured by optical coherence tomography (OCT); or (ii) a loss from the best previous letter score of at least 5 ETDRS letters in conjunction with recurrent fluid as indicated by OCT; or (iii) new or persistent fluid as indicated by OCT; or (iv) new onset classic neovascularization, or new or persistent leak on fluorescein angiography (FA); or (v) new macular hemorrhage; or (vi) 12 weeks have elapsed since the previous injection. According to the present protocol, subjects must receive an injection at least every 12 weeks.

[0046] Subjects were evaluated at 4 weeks intervals for safety and best corrected visual acuity (BCVA) using the 4 meter ETDRS protocol. Quality of Life (QOL) was evaluated using the NEI VFQ-25 questionnaire. OCT and FA examinations were conducted periodically.

[0047] Approximately 1200 subjects were enrolled, with a target enrollment of 300 subjects per treatment arm.

[0048] To be eligible for this study, subjects were required to have subfoveal choroidal neovascularization (CNV) secondary to AMD. "Subfoveal" CNV was defined as the presence of subfoveal neovascularization, documented by FA, or presence of a lesion that is juxtafoveal in location angiographically but affects the fovea. Subject eligibility was confirmed based on angiographic criteria prior to randomization.

[0049] Only one eye was designated as the study eye. For subjects who met eligibility criteria in both eyes, the eye with the worse VA was selected as the study eye. If both eyes had equal VA, the eye with the clearest lens and ocular media and least amount of subfoveal scar or geographic atrophy was selected. If there was no objective basis for selecting the study eye, factors such as ocular dominance, other ocular pathology and subject preference were considered in making the selection.

[0050] Inclusion criteria for both studies were as follows: (i) signed Informed consent; (ii) at least 50 years of age; (iii) active primary subfoveal CNV lesions secondary to AMD, including juxtafoveal lesions that affect the fovea as evidenced by FA in the study eye; (iv) CNV at least 50% of total

lesion size; (v) early treatment diabetic retinopathy study (ETDRS) best-corrected visual acuity of: 20/40 to 20/320 (letter score of 73 to 25) in the study eye; (vi) willing, committed, and able to return for all clinic visits and complete all study-related procedures; and (vii) able to read, understand and willing to sign the informed consent form (or, if unable to read due to visual impairment, be read to verbatim by the person administering the informed consent or a family member).

[0051] Exclusion criteria for both studies were as follows: 1. Any prior ocular (in the study eye) or systemic treatment or surgery for neovascular AMD except dietary supplements or vitamins. 2. Any prior or concomitant therapy with another investigational agent to treat neovascular AMD in the study eye, except dietary supplements or vitamins. 3. Prior treatment with anti-VEGF agents as follows: (a) Prior treatment with anti-VEGF therapy in the study eye was not allowed; (b) Prior treatment with anti-VEGF therapy in the fellow eye with an investigational agent (not FDA approved, e.g. bevacizumab) was allowed up to 3 months prior to first dose in the study, and such treatments were not allowed during the study. Prior treatment with an approved anti-VEGF therapy in the fellow eye was allowed; (c) Prior systemic anti-VEGF therapy, investigational or FDA/Health Canada approved, was only allowed up to 3 months prior to first dose, and was not allowed during the study. 4. Total lesion size > 12 disc areas (30.5 mm2, including blood, scars and neovascularization) as assessed by FA in the study eye. 5. Subretinal hemorrhage that is either 50% or more of the total lesion area, or if the blood is under the fovea and is 1 or more disc areas in size in the study eye. (If the blood is under the fovea, then the fovea must be surrounded 270 degrees by visible CNV.) 6. Scar or fibrosis, making up > 50% of total lesion in the study eye. 7. Scar, fibrosis, or atrophy involving the center of the fovea. 8. Presence of retinal pigment epithelial tears or rips involving the macula in the study eye. 9. History of any vitreous hemorrhage within 4 weeks prior to Visit 1 in the study eye. 10. Presence of other causes of CNV, including pathologic myopia (spherical equivalent of -8 diopters or more negative, or axial length of 25 mm or more), ocular histoplasmosis syndrome, angioid streaks, choroidal rupture, or multifocal choroiditis in the study eye. 11. History or clinical evidence of diabetic retinopathy, diabetic macular edema or any other vascular disease affecting the retina, other than AMD, in either eye. 12. Prior vitrectomy in the study eye. 13. History of retinal detachment or treatment or surgery for retinal detachment in the study eye. 14. Any history of macular hole of stage 2 and above in the study eye. 15. Any intraocular or periocular surgery within 3 months of Day 1 on the study eye, except lid surgery, which may not have taken place within 1 month of day 1, as long as it was unlikely to interfere with the injection. 16. Prior trabeculectomy or other filtration surgery in the study eye. 17. Uncontrolled glaucoma (defined as intraocular pressure greater than or equal to 25 mm Hg despite treatment with anti-glaucoma medication) in the study eye. 18. Active intraocular inflammation in either eye. 19. Active ocular or periocular infection in either eye. 20. Any ocular or periocular infection within

the last 2 weeks prior to Screening in either eye. 21. Any history of uveitis in either eye. 22. Active scleritis or episcleritis in either eye. 23. Presence or history of scleromalacia in either eye. 24. Aphakia or pseudophakia with absence of posterior capsule (unless it occurred as a result of a yttrium aluminum garnet [YAG] posterior capsulotomy) in the study eye. 25. Previous therapeutic radiation in the region of the study eye. 26. History of corneal transplant or corneal dystrophy in the study eye. 27. Significant media opacities, including cataract, in the study eye which might interfere with visual acuity, assessment of safety, or fundus photography. 28. Any concurrent intraocular condition in the study eye (e.g. cataract) that, in the opinion of the investigator, could require either medical or surgical intervention during the 96 week study period. 29. Any concurrent ocular condition in the study eye which, in the opinion of the investigator, could either increase the risk to the subject beyond what is to be expected from standard procedures of intraocular injection, or which otherwise may interfere with the injection procedure or with evaluation of efficacy or safety. 30. History of other disease, metabolic dysfunction, physical examination finding, or clinical laboratory finding giving reasonable suspicion of a disease or condition that contraindicates the use of an investigational drug or that might affect interpretation of the results of the study or render the subject at high risk for treatment complications. 31. Participation as a subject in any clinical study within the 12 weeks prior to Day 1. 32. Any systemic or ocular treatment with an investigational agent in the past 3 months prior to Day 1. 33. The use of long acting steroids, either systemically or intraocularly, in the 6 months prior to day 1. 34. Any history of allergy to povidone iodine. 35. Known serious allergy to the fluorescein sodium for injection in angiography. 36. Presence of any contraindications indicated in the FDA Approved label for ranibizumab (Lucentis®). 37. Females who were pregnant, breastfeeding, or of childbearing potential, unwilling to practice adequate contraception throughout the study. Adequate contraceptive measures include oral contraceptives (stable use for 2 or more cycles prior to screening); IUD; Depo-Provera®; Norplant® System implants; bilateral tubal ligation; vasectomy; condom or diaphragm plus either contraceptive sponge, foam or jelly.

[0052] Subjects were not allowed to receive any standard or investigational agents for treatment of their AMD in the study eye other than their assigned study treatment with VEGFT or ranibizumab as specified in the protocol until they completed the Completion/Early Termination visit assessments. This includes medications administered locally (e.g., IVT, topical, juxtascleral or periorbital routes), as well as those administered systemically with the intent of treating the study and/or fellow eye.

[0053] The study procedures are summarized as follows:

[0054] <u>Best Corrected Visual Acuity</u>: Visual function of the study eye and the fellow eye were assessed using the ETDRS protocol (The Early Treatment Diabetic Retinopathy Study Group) at 4

meters. Visual Acuity examiners were certified to ensure consistent measurement of BCVA. The VA examiners were required to remain masked to treatment assignment.

[0055] <u>Optical Coherence Tomography</u>: Retinal and lesion characteristics were evaluated using OCT on the study eye. At the Screen Visit (Visit 1) images were captured and transmitted for both eyes. All OCT images were captured using the Zeiss Stratus OCT[™] with software Version 3 or greater. OCT images were sent to an independent reading center where images were read by masked readers at visits where OCTs were required. All OCTs were electronically archived at the site as part of the source documentation. A subset of OCT images were read. OCT technicians were required to be certified by the reading center to ensure consistency and quality in image acquisition. Adequate efforts were made to ensure that OCT technicians at the site remained masked to treatment assignment.

[0056] <u>Fundus Photography and Fluorescein Angiography (FA)</u>: The anatomical state of the retinal vasculature of the study eye was evaluated by funduscopic examination, fundus photography and FA. At the Screen Visit (Visit 1) funduscopic examination, fundus photography and FA were captured and transmitted for both eyes. Fundus and angiographic images were sent to an independent reading center where images were read by masked readers. The reading center confirmed subject eligibility based on angiographic criteria prior to randomization. All FAs and fundus photographs were archived at the site as part of the source documentation. Photographers were required to be certified by the reading center to ensure consistency and quality in image acquisition. Adequate efforts were made to ensure that all photographers at the site remain masked to treatment assignment.

[0057] <u>Vision-Related Quality of Life</u>: Vision-related QOL was assessed using the National Eye Institute 25-Item Visual Function Questionnaire (NEI VFQ-25) in the interviewer-administered format. NEI VFQ-25 was administered by certified personnel at a contracted call center. At the screening visit, the sites assisted the subject and initiated the first call to the call center to collect all of the subject's contact information and to complete the first NEI VFQ-25 on the phone prior to randomization and IVT injection. For all subsequent visits, the call center called the subject on the phone, prior to IVT injection, to complete the questionnaire.

[0058] <u>Intraocular Pressure</u>: Intraocular pressure (IOP) of the study eye was measured using applanation tonometry or Tonopen. The same method of IOP measurement was used in each subject throughout the study.

[0059]

C. Results Summary (52 Week Data)

[0060] The primary endpoint (prevention of moderate or severe vision loss as defined above) was met for all three VEGFT groups (2Q4, 0.5Q4 and 2Q8) in this study. The results from both studies are summarized in Table 1.

	Ranibizumab 0.5 mg monthly (RQ4)	VEGFT 0.5 mg monthly (0.5Q4)	VEGFT 2 mg monthly (2Q4)	VEGFT 2 mg every 8 weeks ^[a] (2Q8)
Maintenand	ce of vision* (% patient	s losing <15 letters) at	week 52 versus baseli	ne
Study 1	94.4%	95.9%**	95.1%**	95.1%**
Study 2	94.4%	96.3%**	95.6%**	95.6%**
Mean impro	Mean improvement in vision* (letters) at 52 weeks versus bas		s baseline (p-value vs	RQ4)***
Study 1	8.1	6.9 (NS)	10.9 (p<0.01)	7.9 (NS)
Study 2	9.4	9.7 (NS)	7.6 (NS)	8.9 (NS

Table 1

^[a] Following three initial monthly doses

* Visual acuity was measured as the total number of letters read correctly on the Early Treatment Diabetic Retinopathy Study (ETDRS) eye chart.

** Statistically non-inferior based on a non-inferiority margin of 10%, using confidence interval approach (95.1% and 95% for Study 1 and Study 2, respectively)

*** Test for superiority

NS = non-significant

[0061] In Study 1, patients receiving VEGFT 2mg monthly (2Q4) achieved a statistically significant greater mean improvement in visual acuity at week 52 versus baseline (secondary endpoint), compared to ranibizumab 0.5mg monthly (RQ4); patients receiving VEGFT 2mg monthly on average gained 10.9 letters, compared to a mean 8.1 letter gain with ranibizumab 0.5mg dosed every month (p<0.01). All other dose groups of VEGFT in Study 1 and all dose groups in Study 2 were not statistically different from ranibizumab in this secondary endpoint.

[0062] A generally favorable safety profile was observed for both VEGFT and ranibizumab. The incidence of ocular treatment emergent adverse events was balanced across all four treatment groups in both studies, with the most frequent events associated with the injection procedure, the underlying disease, and/or the aging process. The most frequent ocular adverse events were conjunctival hemorrhage, macular degeneration, eye pain, retinal hemorrhage, and vitreous floaters. The most frequent serious non-ocular adverse events were typical of those reported in this elderly population who receive intravitreal treatment for wet AMD; the most frequently reported events were falls, pneumonia, myocardial infarction, atrial fibrillation, breast cancer, and acute coronary syndrome. There were no notable differences among the study arms.

Example 5: Phase II Clinical Trial of VEGFT in Subjects with Diabetic Macular Edema (DME)

[0063] In this study, 221 patients with clinically significant DME with central macular involvement were randomized, and 219 patients were treated with balanced distribution over five groups. The control group received macular laser therapy at baseline, and patients were eligible for repeat laser treatments, but no more frequently than at 16 week intervals. The remaining four groups received VEGFT by intravitreal injection as follows: Two groups received 0.5 or 2 mg of VEGFT once every four weeks throughout the 12-month dosing period (0.5Q4 and 2Q4, respectively). Two groups received three initial doses of 2 mg VEGFT once every four weeks (*i.e.*, at baseline, and weeks 4 and 8), followed through week 52 by either once every 8 weeks dosing (2Q8) or as needed dosing with very strict repeat dosing criteria (PRN). Mean gains in visual acuity versus baseline were as shown in Table 2:

	n	Mean change in visual acuity at week 24 versus baseline (letters)	Mean change in visual acuity at week 52 versus baseline (letters)
Laser	44	2.5	-1.3
VEGFT 0.5 mg monthly (0.5Q4)	44	8.6**	11.0**
VEGFT 2 mg monthly (2Q4)	44	11.4**	13.1**
VEGFT 2 mg every 8 weeks ^[a] (2Q8)	42	8.5**	9.7**
VEGFT 2 mg as needed ^[a] (PRN)	45	10.3**	12.0**

Table 2

^[a] Following three initial monthly doses

** p < 0.01 versus laser

[0064] In this study, the visual acuity gains achieved with VEGFT administration at week 24 were maintained or numerically improved up to completion of the study at week 52 in all VEGFT study groups, including 2 mg dosed every other month

[0065] As demonstrated in the foregoing Examples, the administration of VEGFT to patients suffering from angiogenic eye disorders (*e.g.*, AMD and DME) at a frequency of once every 8 weeks, following a single initial dose and two secondary doses administered four weeks apart, resulted in significant prevention of moderate or severe vision loss or improvements in visual acuity.

Example 6: A Randomized, Multicenter, Double-Masked Trial in Treatment Naïve Patients with Macular Edema Secondary to CRVO

[0066] In this randomized, double-masked, Phase 3 study, patients received 6 monthly injections of either 2 mg intravitreal VEGFT (114 patients) or sham injections (73 patients). From Week 24 to

Week 52, all patients received 2 mg VEGFT as-needed (PRN) according to retreatment criteria. Thus, "sham-treated patients" means patients who received sham injections once every four weeks from Week 0 through Week 20, followed by intravitreal VEGFT as needed from Week 24 through Week 52. "VEGFT-treated patients" means patients who received VEGFT intravitreal injections once every four weeks from Week 0 through Week 20, followed by intravitreal VEGFT as needed from Week 24 through Week 52. The primary endpoint was the proportion of patients who gained ≥15 ETDRS letters from baseline at Week 24. Secondary visual, anatomic, and Quality of Life NEI VFQ-25 outcomes at Weeks 24 and 52 were also evaluated.

[0067] At Week 24, 56.1% of VEGFT-treated patients gained \geq 15 ETDRS letters from baseline vs 12.3% of sham-treated patients (*P*<0.0001). Similarly, at Week 52, 55.3% of VEGFT-treated patients gained \geq 15 letters vs 30.1% of sham-treated patients (*P*<0.01). At Week 52, VEGFT-treated patients gained a mean of 16.2 letters vs 3.8 letters for sham-treated patients (*P*<0.001). Mean number of injections was 2.7 for VEGFT-treated patients vs 3.9 for sham-treated patients. Mean change in central retinal thickness was -413.0 µm for VEGFT-treated patients vs -381.8 µm for sham-treated patients. The proportion of patients with ocular neovascularization at Week 24 were 0% for VEGFT-treated patients and 6.8% for sham-treated patients, respectively; at Week 52 after receiving VEGFT PRN, proportions were 0% and 6.8% for VEGFT-treated and sham-treated. At Week 24, the mean change from baseline in the VFQ-25 total score was 7.2 vs 0.7 for the VEGFT-treated and sham-treated groups; at Week 52, the scores were 7.5 vs 5.1 for the VEGFT-treated and sham-treated groups.

[0068] This Example confirms that dosing monthly with 2 mg intravitreal VEGFT injection resulted in a statistically significant improvement in visual acuity at Week 24 that was maintained through Week 52 with PRN dosing compared with sham PRN treatment. VEGFT was generally well tolerated and had a generally favorable safety profile.

Example 7: Dosing Regimens

[0069] Specific, non-limiting examples of dosing regimens within the scope of the present invention are as follows:

[0070] VEGFT 2 mg (0.05 mL) administered by intravitreal injection once every 4 weeks (monthly).

[0071] VEGFT 2 mg (0.5 mL) administered by intravitreal injection once every 4 weeks for the first 8 weeks, followed by 2 mg (0.05 mL) via intravitreal injection once every 8 weeks.

[0072] VEGFT 2 mg (0.5 mL) administered by intravitreal injection once every 4 weeks for the first 8 weeks, followed by 2 mg (0.05 mL) via intravitreal injection on a less frequent basis based on

visual and/or anatomical outcomes (as assessed by a physician or other qualified medical professional).

[0073] VEGFT 2 mg (0.5 mL) administered by intravitreal injection once every 4 weeks for the first 8 weeks, followed by 2 mg (0.05 mL) via intravitreal injection administered *pro re nata* (PRN) based on visual and/or anatomical outcomes (as assessed by a physician or other qualified medical professional).

[0074] VEGFT 2 mg (0.5 mL) administered by intravitreal injection once every 4 weeks for the first 12 weeks, followed by 2 mg (0.05 mL) via intravitreal injection once every 8 weeks.

[0075] VEGFT 2 mg (0.5 mL) administered by intravitreal injection once every 4 weeks for the first 12 weeks, followed by 2 mg (0.05 mL) via intravitreal injection on a less frequent basis based on visual and/or anatomical outcomes (as assessed by a physician or other qualified medical professional).

[0076] VEGFT 2 mg (0.5 mL) administered by intravitreal injection once every 4 weeks for the first 12 weeks, followed by 2 mg (0.05 mL) via intravitreal injection administered *pro re nata* (PRN) based on visual and/or anatomical outcomes (as assessed by a physician or other qualified medical professional).

[0077] VEGFT 2 mg (0.5 mL) administered by intravitreal injection once every 4 weeks for the first 16 weeks, followed by 2 mg (0.05 mL) via intravitreal injection once every 8 weeks.

[0078] VEGFT 2 mg (0.5 mL) administered by intravitreal injection once every 4 weeks for the first 16 weeks, followed by 2 mg (0.05 mL) via intravitreal injection on a less frequent basis based on visual and/or anatomical outcomes (as assessed by a physician or other qualified medical professional).

[0079] VEGFT 2 mg (0.5 mL) administered by intravitreal injection once every 4 weeks for the first 16 weeks, followed by 2 mg (0.05 mL) via intravitreal injection administered *pro re nata* (PRN) based on visual and/or anatomical outcomes (as assessed by a physician or other qualified medical professional).

[0080] VEGFT 2 mg (0.5 mL) administered by intravitreal injection once every 4 weeks for the first 20 weeks, followed by 2 mg (0.05 mL) via intravitreal injection once every 8 weeks.

[0081] VEGFT 2 mg (0.5 mL) administered by intravitreal injection once every 4 weeks for the first 20 weeks, followed by 2 mg (0.05 mL) via intravitreal injection on a less frequent basis based on visual and/or anatomical outcomes (as assessed by a physician or other qualified medical professional).

[0082] VEGFT 2 mg (0.5 mL) administered by intravitreal injection once every 4 weeks for the first 20 weeks, followed by 2 mg (0.05 mL) via intravitreal injection administered *pro re nata* (PRN)

based on visual and/or anatomical outcomes (as assessed by a physician or other qualified medical professional).

[0083] VEGFT 2 mg (0.5 mL) administered by intravitreal injection once every 4 weeks for the first 24 weeks, followed by 2 mg (0.05 mL) via intravitreal injection once every 8 weeks.

[0084] VEGFT 2 mg (0.5 mL) administered by intravitreal injection once every 4 weeks for the first 24 weeks, followed by 2 mg (0.05 mL) via intravitreal injection on a less frequent basis based on visual and/or anatomical outcomes (as assessed by a physician or other qualified medical professional).

[0085] VEGFT 2 mg (0.5 mL) administered by intravitreal injection once every 4 weeks for the first 24 weeks, followed by 2 mg (0.05 mL) via intravitreal injection administered *pro re nata* (PRN) based on visual and/or anatomical outcomes (as assessed by a physician or other qualified medical professional).

[0086] VEGFT 2 mg (0.5 mL) administered by intravitreal injection once every 4 weeks for the first 28 weeks, followed by 2 mg (0.05 mL) via intravitreal injection once every 8 weeks.

[0087] VEGFT 2 mg (0.5 mL) administered by intravitreal injection once every 4 weeks for the first 28 weeks, followed by 2 mg (0.05 mL) via intravitreal injection on a less frequent basis based on visual and/or anatomical outcomes (as assessed by a physician or other qualified medical professional).

[0088] VEGFT 2 mg (0.5 mL) administered by intravitreal injection once every 4 weeks for the first 28 weeks, followed by 2 mg (0.05 mL) via intravitreal injection administered *pro re nata* (PRN) based on visual and/or anatomical outcomes (as assessed by a physician or other qualified medical professional).

[0089] VEGFT 2 mg (0.05 mL) administered by intravitreal injection as a single initial dose, followed by additional doses administered *pro re nata* (PRN) based on visual and/or anatomical outcomes (as assessed by a physician or other qualified medical professional).

[0090] Variations on the above-described dosing regimens would be appreciated by persons of ordinary skill in the art and are also within the scope of the present invention. For example, the amount of VEGFT and/or volume of formulation administered to a patient may be varied based on patient characteristics, severity of disease, and other diagnostic assessments by a physician or other qualified medical professional.

[0091] Any of the foregoing administration regimens may be used for the treatment of, *e.g.*, agerelated macular degeneration (*e.g.*, wet AMD, exudative AMD, etc.), retinal vein occlusion (RVO), central retinal vein occlusion (CRVO; *e.g.*, macular edema following CRVO), branch retinal vein occlusion (BRVO), diabetic macular edema (DME), choroidal neovascularization (CNV; *e.g.*, myopic CNV), iris neovascularization, neovascular glaucoma, post-surgical fibrosis in glaucoma, proliferative vitreoretinopathy (PVR), optic disc neovascularization, corneal neovascularization, retinal neovascularization, vitreal neovascularization, pannus, pterygium, vascular retinopathy, etc.

SEQUENCES

[0092] SEQ ID NO:1 (DNA sequence having 1377 nucleotides): AGGATCTAGTTCCGGAAGTGATACCGGTAGACCTTTCGTAGAGATGTACAGTGAAATCCCCCGA AATTATACACATGACTGAAGGAAGGGAGCTCGTCATTCCCTGCCGGGTTACGTCACCTAACAT CACTGTTACTTTAAAAAAGTTTCCACTTGACACTTTGATCCCTGATGGAAAACGCATAATCTGG GACAGTAGAAAGGGCTTCATCATATCAAATGCAACGTACAAAGAAATAGGGCTTCTGACCTGT GAAGCAACAGTCAATGGGCATTTGTATAAGACAAACTATCTCACACATCGACAAACCAATACAA TCATAGATGTGGTTCTGAGTCCGTCTCATGGAATTGAACTATCTGTTGGAGAAAAGCTTGTCTT AAATTGTACAGCAAGAACTGAACTAAATGTGGGGATTGACTTCAACTGGGAATACCCTTCTTCG AAGCATCAGCATAAGAAACTTGTAAACCGAGACCTAAAAACCCAGTCTGGGAGTGAGATGAAG AAATTTTTGAGCACCTTAACTATAGATGGTGTAACCCGGAGTGACCAAGGATTGTACACCTGTG CAGCATCCAGTGGGCTGATGACCAAGAAGAACAGCACATTTGTCAGGGTCCATGAAAAGGACA AAACTCACACATGCCCACCGTGCCCAGCACCTGAACTCCTGGGGGGGACCGTCAGTCTTCCTCT TCCCCCCAAAACCCAAGGACACCCTCATGATCTCCCGGACCCCTGAGGTCACATGCGTGGTG GTGGACGTGAGCCACGAAGACCCTGAGGTCAAGTTCAACTGGTACGTGGACGGCGTGGAGGT TCCTCACCGTCCTGCACCAGGACTGGCTGAATGGCAAGGAGTACAAGTGCAAGGTCTCCAAC AAAGCCCTCCCAGCCCCCATCGAGAAAACCATCTCCAAAGCCAAAGGGCAGCCCCGAGAACC ACAGGTGTACACCCTGCCCCCATCCCGGGATGAGCTGACCAAGAACCAGGTCAGCCTGACCT GCCTGGTCAAAGGCTTCTATCCCAGCGACATCGCCGTGGAGTGGGAGAGCAATGGGCAGCCG GAGAACAACTACAAGACCACGCCTCCCGTGCTGGACTCCGACGGCTCCTTCTTCCTCTACAGC AAGCTCACCGTGGACAAGAGCAGGTGGCAGCAGGGGAACGTCTTCTCATGCTCCGTGATGCA TGAGGCTCTGCACAACCACTACACGCAGAAGAGCCTCTCCCTGTCTCCGGGTAAATGA

[0093] <u>SEQ ID NO:2</u> (polypeptide sequence having 458 amino acids):

MVSYWDTGVLLCALLSCLLLTGSSSGSDTGRPFVEMYSEIPEIIHMTEGRELVIPCRVTSPNITVTLK KFPLDTLIPDGKRIIWDSRKGFIISNATYKEIGLLTCEATVNGHLYKTNYLTHRQTNTIIDVVLSPSHGI ELSVGEKLVLNCTARTELNVGIDFNWEYPSSKHQHKKLVNRDLKTQSGSEMKKFLSTLTIDGVTRS DQGLYTCAASSGLMTKKNSTFVRVHEKDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEV TCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKV SNKALPAPIEKTISKAKGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPEN NYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK **[0094]** The present invention is not to be limited in scope by the specific embodiments described herein. Indeed, various modifications of the invention in addition to those described herein will become apparent to those skilled in the art from the foregoing description and the accompanying figures. Such modifications are intended to fall within the scope of the appended claims.

What is claimed is:

1. A method for treating an angiogenic eye disorder in a patient, said method comprising sequentially administering to the patient a single initial dose of a VEGF antagonist, followed by one or more secondary doses of the VEGF antagonist, followed by one or more tertiary doses of the VEGF antagonist;

wherein each secondary dose is administered 2 to 4 weeks after the immediately preceding dose; and

wherein each tertiary dose is administered at least 8 weeks after the immediately preceding dose.

2. The method of claim 1, wherein only a single secondary dose is administered to the patient, and wherein the single secondary dose is administered 4 weeks after the initial dose of the VEGF antagonist.

3. The method of claim 1, wherein only two secondary doses are administered to the patient, and wherein each secondary dose is administered 4 weeks after the immediately preceding dose.

4. The method of claim 3, wherein each tertiary dose is administered 8 weeks after the immediately preceding dose.

5. The method of claim 1, wherein at least 5 tertiary doses of the VEGF antagonist are administered to the patient, and wherein the first four tertiary doses are administered 8 weeks after the immediately preceding dose, and wherein each subsequent tertiary dose is administered 8 or 12 weeks after the immediately preceding dose.

6. The method of claim 1, wherein the angiogenic eye disorder is selected from the group consisting of: age related macular degeneration, diabetic retinopathy, diabetic macular edema, central retinal vein occlusion, branch retinal vein occlusion, and corneal neovascularization.

7. The method of claim 6, wherein the angiogenic eye disorder is age related macular degeneration.

8. The method of claim 1, wherein the VEGF antagonist is an anti-VEGF antibody or fragment thereof, an anti-VEGF receptor antibody or fragment thereof, or a VEGF receptor-based chimeric molecule.

-23-

9. The method of claim 8, wherein the VEGF antagonist is a VEGF receptor-based chimeric molecule.

10. The method of claim 9, wherein the VEGF receptor-based chimeric molecule comprises VEGFR1R2-Fc Δ C1(a) encoded by the nucleic acid sequence of SEQ ID NO:1.

11. The method of claim 9, wherein the VEGF receptor-based chimeric molecule comprises (1) a VEGFR1 component comprising amino acids 27 to 129 of SEQ ID NO:2; (2) a VEGFR2 component comprising amino acids 130-231 of SEQ ID NO:2; and (3) a multimerization component comprising amino acids 232-457 of SEQ ID NO:2.

12. The method of claim 1, wherein all doses of the VEGF antagonist are administered to the patient by topical administration or by intraocular administration.

13. The method of claim 12, wherein all doses of the VEGF antagonist are administered to the patient by intraocular administration.

14. The method of claim 13, wherein the intraocular administration is intravitreal administration.

15. The method of claim 11, wherein all doses of the VEGF antagonist are administered to the patient by topical administration or by intraocular administration.

16. The method of claim 15, wherein all doses of the VEGF antagonist are administered to the patient by intraocular administration.

17. The method of claim 16, wherein the intraocular administration is intravitreal administration.

18. The method of claim 17, wherein all doses of the VEGF antagonist comprise from about 0.5 mg to about 2 mg of the VEGF antagonist.

19. The method of claim 18, wherein all doses of the VEGF antagonist comprise 0.5 mg of the VEGF antagonist.

20. The method of claim 18, wherein all doses of the VEGF antagonist comprise 2 mg of the VEGF antagonist.

ABSTRACT

The present invention provides methods for treating angiogenic eye disorders by sequentially administering multiple doses of a VEGF antagonist to a patient. The methods of the present invention include the administration of multiple doses of a VEGF antagonist to a patient at a frequency of once every 8 or more weeks. The methods of the present invention are useful for the treatment of angiogenic eye disorders such as age related macular degeneration, diabetic retinopathy, diabetic macular edema, central retinal vein occlusion, branch retinal vein occlusion, and corneal neovascularization.




Figure 1

DECLARATION (37 CFR 1.63) FOR UTILITY OR DESIGN APPLICATION USING AN APPLICATION DATA SHEET (37 CFR 1.76)

Title of Invention	USE OF A VEGF ANTAGONIST TO TREAT ANGIOGENIC EYE DISORDERS				
As the below nam	ed inventor, I hereby declare that:				
This declaration is directed to:	The attached application, or				
is alrected to:	United States application or PCT International application number <u>13/940,370</u>				
	filed on <u>July 12, 2013</u> .				
The above-identifi	ed application was made or authorized to be made by me.				
I believe that I am the original inventor or an original joint inventor of a claimed invention in the application.					
I hereby acknowledge that any willful false statement made in this declaration is punishable under 18 U.S.C. 1001 by fine or imprisonment of not more than (5) years, or both.					
	WARNING:				
contribute to identi (other than a check USPTO to support USPTO, petitioners to the USPTO. Pet the application (uni patent. Furthermor in a published appl	t is cautioned to avoid submitting personal information in documents filed in a patent application that may by theft. Personal information such as social security numbers, bank account numbers, or credit card numbers c or credit card authorization form PTO-2038 submitted for payment purposes) is never required by the a petition or an application. If this type of personal information is included in documents submitted to the s/applicants should consider redacting such personal information from the documents before submitting them itioner/applicant is advised that the record of a patent application is available to the public after publication of ess a non-publication request in compliance with 37 CFR 1.213(a) is made in the application) or issuance of a e, the record from an abandoned application may also be available to the public if the application is referenced ication or an issued patent (see 37 CFR 1.14). Checks and credit card authorization forms PTO-2038 tent purposes are not retained in the application file and therefore are not publicly available.				
LEGAL NAME (
Inventor: <u>Y/</u> Signature: <u>¥</u>	ANCOPOULOS, GEORGE D. Date (Optional) : 10/23/13				
Note: An application Use an additional PT	data sheet (PTO/SB/14 of equivalent), including naming the entire inventive entity, must accompany this form. 'O/A1A/01 form for each additional inventor.				

to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the lorm, call 1-800-PTO-9199 and select option 2.

Privacy Act Statement

The Privacy Act of 1974 (P.L. 93-579) requires that you be given certain information in connection with your submission of the attached form related to a patent application or patent. Accordingly, pursuant to the requirements of the Act, please be advised that: (1) the general authority for the collection of this information is 35 U.S.C. 2(b)(2); (2) furnishing of the information solicited is voluntary; and (3) the principal purpose for which the information is used by the U.S. Patent and Trademark Office is to process and/or examine your submission related to a patent application or patent. If you do not furnish the requested information, the U.S. Patent and Trademark Office may not be able to process and/or examine your submission, which may result in termination of proceedings or abandonment of the application or expiration of the patent.

The information provided by you in this form will be subject to the following routine uses:

- The information on this form will be treated confidentially to the extent allowed under the Freedom of information Act (5 U.S.C. 552) and the Privacy Act (5 U.S.C 552a). Records from this system of records may be disclosed to the Department of Justice to determine whether disclosure of these records is required by the Freedom of Information Act.
- 2. A record from this system of records may be disclosed, as a routine use, in the course of presenting evidence to a court, magistrate, or administrative tribunal, including disclosures to opposing counsel in the course of settlement negotiations.
- A record in this system of records may be disclosed, as a routine use, to a Member of Congress submitting a request involving an individual, to whom the record pertains, when the individual has requested assistance from the Member with respect to the subject matter of the record.
- 4. A record in this system of records may be disclosed, as a routine use, to a contractor of the Agency having need for the information in order to perform a contract. Recipients of information shall be required to comply with the requirements of the Privacy Act of 1974, as amended, pursuant to 5 U.S.C. 552a(m).
- 5. A record related to an International Application filed under the Patent Cooperation Treaty in this system of records may be disclosed, as a routine use, to the International Bureau of the World Intellectual Property Organization, pursuant to the Patent Cooperation Treaty.
- A record in this system of records may be disclosed, as a routine use, to another federal agency for purposes of National Security review (35 U.S.C. 181) and for review pursuant to the Atomic Energy Act (42 U.S.C. 218(c)).
- 7. A record from this system of records may be disclosed, as a routine use, to the Administrator, General Services, or his/her designee, during an inspection of records conducted by GSA as part of that agency's responsibility to recommend improvements in records management practices and programs, under authority of 44 U.S.C. 2904 and 2906. Such disclosure shall be made in accordance with the GSA regulations governing inspection of records for this purpose, and any other relevant (*i.e.*, GSA or Commerce) directive. Such disclosure shall not be used to make determinations about individuals.
- 8. A record from this system of records may be disclosed, as a routine use, to the public after either publication of the application pursuant to 35 U.S.C. 122(b) or issuance of a patent pursuant to 35 U.S.C. 151. Further, a record may be disclosed, subject to the limitations of 37 CFR 1.14, as a routine use, to the public if the record was filed in an application which became abandoned or in which the proceedings were terminated and which application is referenced by either a published application, an application open to public inspection or an issued patent.
- 9. A record from this system of records may be disclosed, as a routine use, to a Federal, State, or local law enforcement agency, if the USPTO becomes aware of a violation or potential violation of law or regulation.
- 10.

1

of

18

Sheet

Application Number	17/350,958
Filing Date	2021-06-17
First Named Inventor	George D. Yancopoulos
Art Unit	
Examiner Name	
Attorney Docket Number	REGN-008CIPCON9

	U.S. PATENT DOCUMENTS							
Examiner Initial*	Cite No.	Patent Number Number-Kind Code (<i>if known</i>)	lssue Date YYYY-MM-DD	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear			
	1	7070959	2006-07-04	Papadopoulos				
	2	7303746	2007-12-04	Wiegand				
	3	7303748	2007-12-04	Wiegand				
	4	7306799	2007-12-11	Wiegand				
	5	7396664	2008-07-08	Daly et al.				
	6	8092803	2012-01-10	Furfine et al.				
	7	9254338	2016-02-09	Yancopoulos				
	8	9669069	2017-06-06	Yancopoulos				
	9	10130681	2018-11-20	Yancopoulos				
	10	10406226	2019-09-10	Dix et al.				
	11	10464992	2019-11-05	Furfine et al.				

	U.S. PATENT APPLICATION PUBLICATIONS							
Examiner Initial*	Cite No.	Publication Number Number-Kind Code (if known)	Publication Date YYYY-MM-DD	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear			
	1	2003/0171320	2003-09-11	Guyer				
	2	2005/0163798	2005-07-28	Papadopoulos et al.				
	3	2005/0260203	2005-11-24	Wiegand et al.				
	4	2006/0058234	2006-03-16	Daly et al.				
	5	2006/0172944	2006-08-03	Wiegand et al.				
	6	2007/0190058	2007-08-16	Shams				
	7	2008/0220004	2008-09-11	Wiegand et al.				
	8	2019/0290725	2019-09-26	Vitti et al.				
	9	2019/0388539	2019-12-26	Dix et al.				
	10	2020/0017572	2020-01-16	Furfine et al.				

	FOREIGN PATENT DOCUMENTS								
Examiner Initial*	Cite No.	Foreign Document Number Country Code-Number-Kind Code (<i>if</i> known)	Publication Date YYYY-MM-DD	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	Т			
	1	WO 2006/047325	2006-03-04	Genentech, Inc.					
	2	WO 2000/75319	2000-12-14	Regeneron Pharmaceuitcals, Inc.					
	3	WO 2004/106378 A2	2004-12-09	Regeneron Pharmaceuticals, Inc.					
	4	WO 2005/000895 A2	2005-01-05	Regeneron Pharmaceuticals, Inc.					
	5	WO 2007/022101 A2	2007-02-22	Regeneron Pharmaceuticals, Inc.					

Examiner Signature	Date Considered	
-----------------------	--------------------	--

INFORMATION DISCLOSURE STATEMENT BY APPLICANT						Filing Dat	ed Inventor	17/350,958 2021-06-17 George D. Y	ancopoulos	
Sheet	et 2 of 18		Attorney	Docket Number	REGN-008C	CIPCON9				
					FOREIG		T DOCUMENTS			
Examiner Initial*	Cite No.	Foreign Document Country Code-Number-K known)				Name of Pater Applicant of Cited		Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	т	
	6	WO 2008/0639	32		2008-05	5-29	Genentech, Inc.			

Genentech, Inc.

2010-03-25

7

JP 2010-509369

					for English Equivalent					
	8	WO 2012/097019	2012-07-19	Regeneron Pharmaceuticals, Inc.						
			NON PATENT	LITERATURE DOCUMEN	TS					
Examin er Initials*	Cite Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book,									
	1	1 16/055,847 – Third Party Submissions dated May 1, 2019								
	2	16/159,282 – Third Pa	arty Submissions	dated May 31, 2019						
	3			005, AVE 005, AVE000! ⁻ Trap-Eye." Drugs R D,						
	4	 Regeneron, VEGF Trap (R1R2), VEGF Trap-Eye." Drugs R D, 9(4):261-269 (2008) ANONYMOUS "Lucentis (rangibizymab injection) Intravitreal Injection" pp. 103 (June 2006) 								
	5	ANONYMOUS "Anti-\ August 5, 2019)	'EGF 2019: The S	State of the Art" Review o	f Ophthalmology (published					
	 BARBAZETTO, "Dosing Regimen And The Frequency Of Macular Hemorrhages In Neovascular Age-Related Macular Degeneration Treated With Ranibizumab." Retina, 30(9):1376-85 (2010) 									
	7	Bayer Investor News, "Bayer and Regeneron Start additional Phase 3 Study for VEGE Tran-								
	8	Bayer Investor News, "VECE Trap Eve: New Data Confirm Supposes in the Treatment of								
	9									
	10	BOYER, "A Phase IIIb Study to Evaluate the Safety of Ranibizumab in Subjects with								
	11 BROWN, "Ranibizumab versus Verteporfin for Neovascular Age-Related Macular Degeneration." N Engl J Med, 355(14):1432-44 (October 5, 2006)									
	 BROWN, "Primary Endpoint Results of a Phase II Study of Vascular Endothelial Growth Factor Trap-Eye in Wet Age-related Macular Degeneration." Ophthalmology, 118(6):1089- 97 (June 2011) 									
	13				abetic Macular Edema: The 120(10):2013-22 (October					
	14			-related macular degene phthalmology, 154(2):22	eration: a game-changer or 2-226 (August 2012)					

Examiner Date Signature Considered

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

See WO 2008/063932

for English Equivalent

of

18

3

Sheet

Application Number	17/350,958
Filing Date	2021-06-17
First Named Inventor	George D. Yancopoulos
Art Unit	
Examiner Name	
Attorney Docket Number	REGN-008CIPCON9

NON PATENT LITERATURE DOCUMENTS Examin Т Cite Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, No. magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or Initials* country where published. CAMPOCHIARO et al. "Ranibizumab for Macular Edema Due to Retinal Vein Occlusions 15 Implication of VEGF as a Critical Stimulator" Molecular Therapy, 16(4):791-799 (2008) CAMPOCHIARO. "Ranibizumab for Macular Edema following Branch Retinal Vein Occlusion: six-month primary end point results of a phase III study." Ophthalmology, 16 117(6):1102-1112 (June 2010) CAMPOCHIARO, "Sustained Benefits from Ranibizumab for Macular Edema following Central Retinal Vein Occlusion: Twelve-Month Outcomes of a phase III Study." 17 Ophthalmology, 188(10):2041-49 (October 2011) CAO, "A Subretinal Matrigel Rat Choroidal Neovascularization (CNV) Model and Inhibition 18 of CNV and Associated Inflammation and Fibrosis by VEGF Trap" Investigative Ophthalmology & Visual Science, 51(11):6009-6017 (November 2010) CENTER FOR DRUG EVALUATION AND RESEARCH APPLICATION NUMBER: 21-756 MEDICAL REVIEW(S) (December 17, 2004) 19 <URL:https://www.accessdata.fda.gov/drugsatfda_docs/nda/2004/21-756 Macugen medr.pdf> CENTER FOR DRUG EVALUATION AND RESEARCH BLA APPLICATION NUMBER: REVIEW, MEDICAL 125156 (June 2006) 20 <URL:https://www.accessdata.fda.gov/drugsatfda_docs/nda/2006/125156s000_Lucentis MedR.pdf> CHARLES, Steve (Guest Lecturer) "VEGF Trap Has Positive DME Data" Tenth Annual 21 Retina Fellows Forum Jan 29 and 30, Chicago, (Article Date 03/01/2010) CHATZIRALLI et al. "Intravitreal aflibercept for neovascular age-related macular 22 degeneration in patients aged 90 years or older: 2-year visual acuity outcomes" Eye (2018) 32:1523-1529 CHUNG et al. "Ziv-aflibercept: A novel angiogenesis inhibitor for the treatment of 23 metastatic colorectal cancer" Am J Heath-Syst Pharm (November 1, 2013) 70:1887-1896 COOPER et al., "Increased Renal Expression of Vascular Endothelial Growth Factor (VEGF) and Its Receptor VEGFR-2 in Experimental Diabetes" Diabetes (1999) 48:2229-24 2239 CROLL et al., "VEGF-mediated inflammation precedes angiogenesis in adult brain" 25 Experimental Neurology (2004) 187:388-402 CSAKY, "Safety Implications of Vascular Endothelial Growth Factor Blockade for Subjects Receiving Intravitreal Anti-Vascular Endothelial Growth Factor Therapies." Am. J. 26 Ophthalmology, 148(5):647-56, (November 2009) DeVRIESE et al., "Antibodies against Vascular Endothelial Growth Factor Improve Early 27 Renal Dysfunction in Experimental Diabetes" J. Am. Soc. Nephrol (2001) 12:993-1000 DIXON et al., "VEGF Trap-Eve for the treatment of neovascular age-related macular 28 degeneration" Expert Opin. Investig. Drugs, 18(10):1573-1580 (2009) DO et al., "An exploratory study of the safety, tolerability and bioactivity of a single 29 intravitreal injection of vascular endothelial growth factor Trap-Eye in patients with diabetic macular oedema" Br J Ophthalmol. 93(2):144-1449 (February 2009) DO et al., "The DA VINCI Study: phase 2 primary results of VEGF Trap-Eve in patients 30 with diabetic macular edema" Ophthalmology, 118(9):1819-1826 (September 2011)

Examiner	Date	
Signature	Considered	

4

of

18

Sheet

Application Number	17/350,958
Filing Date	2021-06-17
First Named Inventor	George D. Yancopoulos
Art Unit	
Examiner Name	
Attorney Docket Number	REGN-008CIPCON9

		NON PATENT LITERATURE DO	CUMENTS		
Examin er Initials*	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article magazine, journal, serial, symposium, catalog, etc.), date, page(s), vol country where published.	lume-issue numbe	er(s), publisher, city and/or	Т
	31	DO, "One-Year Outcomes of the DA VINCI Study of VE Macular Edema." Ophthalmology, 119(8):1658-65 (201		in Eyes with Diabetic	
	32	DO et al. "Results of a Phase 1 Study of Intravitreal VE Macular Edema: The CLEAR-IT DME Study" ARVO An			
	33	DO et al. "VEGF Trap-Eye Vision-specific Quality of Life with Neovascular AMD in CLEAR-IT 2: A Phase 2 Clini Abstract (April 2009)			
	34	EICHTEN, "Rapid decrease in tumor perfusion following term tumor growth inhibition in preclinical tumor models	" Angiogenesi	s, 16:429-441 (2013)	
	35	ENGELBERT, "Treat And Extend' Dosing Of Intravitrea Factor Therapy For Type 3 Neovascularization/Retinal 29(10):1424-31 (2009)			
	36	ENGELBERT, "Long-Term Follow-Up For Type 1 (Sub Neovascularization Using A Modified 'Treat And Extend Antivascular Endothelial Growth Factor Therapy." Retir	d' Dosing Regi	ment Of Intravitreal	
	37	ENGELBERT, "The 'Treat and Extend' Dosing Regime Endothelial Growth Factor Therapy for Neovascular Ag Ophthalmology Management, Issue 42, (June 2010) av http://www.visioncareprofessional.com/emails/amdupda	n of Intravitrea e-Related Mac ⁄ailable at	l Anti-Vascular cular Degeneration."	
	38	EREMINA et al., "Glomerular-specific alterations of VE congenital and acquired renal diseases" Journal of Clin 111(5):707-716	GF-A expressi ical Investigati	on lead to distinct on (March 2003)	
	39	ERIKSSON et al., "Structure, Expression and Receptor Vascular Endothelial Growth Factors" Vascular Growth Springer (1999) pp. 41-57			
	40	THE EYETECH STUDY GROUP, "Anti-Vascular Endot Subfoveal Choroidal Neovascularization Secondary to American Academy of Ophthalmology, 110(5):979-986	Age-related Ma	Factor Therapy for acular Degeneration"	
	41 Eylea®, Highlights of Prescribing Information, Revised 08/2018.				
	42	FERRARA, N. "Vascular Endothelial Growth Factor: M Advances in Organ Biology (1999) pp. 1-30		Biological Aspects"	
	43	FERRARA et al., "Clinical applications of angiogenic gr Nature Medicine (December 1999) 5(12):1359-1364	owth factors a	nd their inhibitors"	
	44	FLYVBJERG et al., "Amelioration of Long-Term Renal Mice by a Neutralizing Vascular Endothelial Growth Fac 2002) 51:3090-3094			
	45	FUNG, "An Optical Coherence Tomography-Guided, Va Intravitreal Ranibizumab (Lucentis) for Neovascular Ag Am J Ophthalmology, 143(4):566-83 (April 2007)	e-related Maci	ular Degeneration."	
	46	GALE, "Complementary and Coordinated Roles of the Normal and Pathologic Vascular Formation." Cold Sprir Quantitative Biology, Volume LXVIL, pp. 267-73 (2002)	ng Harbor Sym		
	47	GARCIA-QUINTANILLA, "Pharmacokinetics of Intravitr Related Macular Degeneration." Pharmaceutics, 11:36	eal Anti-VEGF	Drugs in Age-	
Examin Signatu			Date Considered		

of

18

5

Sheet

Application Number	17/350,958
Filing Date	2021-06-17
First Named Inventor	George D. Yancopoulos
Art Unit	
Examiner Name	
Attorney Docket Number	REGN-008CIPCON9

		NON PATENT LITERATURE DOCUMENTS	
Examin er Initials*	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	Т
	48	GOMEZ-MANZANO, "VEGF Trap induces antiglioma effect at different stages of disease." Neuro-Oncology, 10:940-945 (December 2008)	
	49	GRAGOUDAS, "Pegaptanib for Neovascular Age-Related Macular Degeneration." N Engl J Med, 351(27):2805-16, (December 30, 2004)	
	50	GUTIERREZ et al., "Intravitreal bevacizumab (Avastin) in the treatment of macular edema secondary to retinal vein occlusion" Clin. Ophthalmol., 2(4):787,791 (2008)	
	51	HALLER et al., "VEGF Trap-Eye In CRVO: Primary Endpoint Results of the Phase 3 COPERNICUS Study" ARVO Annual Meeting Abstract (April 2011)	
	52	HEIER et al., "CLEAR-IT 2: Phase 2, Randomized Controlled Dose and Interval-Ranging Study of Intravitreal VEFG Trap Eye in Patients with Neovascular Age-Related Macular Degeneration: Predictive Factors for Visual Acuity" ARVO Annual Meeting Abstract (April 2009)	
	53	HEIER, J., "Intravitreal VEGF Trap for AMD: An Update, The CLEAR-IT 2 Extension Study" Presented at the annual meeting of the Association for Research in Vision and Ophthalmology, Retina Today (2009) pp. 44-45	
	54	HEIER et al., " rhuFab V2 (anti-VEGF Antibody) for Treatment of Exudative AMD" Symposium 8:Experimental and Emerging Treatments for Choroidal Neovascularization, 10 pp (2002)	
	55	HEIER et al., "RhuFab V2 in Wet AMD - 6 Month Continued Improvement Following Multiple Intravitreal Injections" Invest Ophthalmol Vis Sci, 44(E-Abstract):972 (2003)	
	56	HEIER et al., "Intravitreal Aflibercept (VEGF Trap-Eye) in Wet Age-related macular Degeneration," Ophthalmology, 119:2537-2548 (2012)	
	57	HEIER, "Intravitreal Aflibercept for Diabetic Macular Edema: 148-Week Results from the VISTA and VIVID Studies." Ophthalmology, 123(11):2376-2385 (November 2016)	
	58	HEIER et al., "The 1-year Results of CLEAR-IT 2, a Phase 2 Study of Vascular Endothelial Growth Factor Trap-Eye Dosed As-needed After 12-week Fixed Dosing" Ophthalmology 2011;118:1098–1106 (June 2011)	
	59	HEIER et al., "The 1-year Results of CLEAR-IT 2, a Phase 2 Study of Vascular Endothelial Growth Factor Trap-Eye Dosed As-needed After 12-week Fixed Dosing: Erratum" Ophthalmology 2011;118:1700 (September 2011)	
	60	HO, "VEGF Trap-Eye in Wet AMD - CLEAR-IT 2: One-Year OCT and FA Outcomes" CLEAR-IT 2 Study Group, pp 1-24 (09/28/2008)	
	61	Ho et al., Slides entitled CLEAR IT 2 One-Year Key Results, Retina Society (2008)	
	62	HOLASH et al., "Vessel Cooption, Regression, and Growth in Tumors Mediated by Angiopoietins and VEGF" Science (June 18, 1999) 284(5422):1994-1998	
	63	HOLASH, "VEGF-Trap: A VEGF blocker with potent antitumor effects" PNAS 99(17)11393-11398 (8/20/2002)	
	64	HOLASH, "Inhibitors of growth factor receptors, signaling pathways and angiogenesis as therapeutic molecular agents." Cancer Metastasis 25:243-252 (2006)	
	65	Information from ClinicalTrials.gov archive History of Changes for Study: NCT00320775 "Safety and Tolerability of Intravitreal Administration of VEGF Trap in Patients With Neovascular Age-Related Macular Degeneration" 70 pages, Latest version submitted June 8, 2011 on ClinicalTrials.gov (NCT00320775_2006-2011)	

Examiner Signature	Date Considered	
-----------------------	--------------------	--

6

of

18

Sheet

Application Number	17/350,958
Filing Date	2021-06-17
First Named Inventor	George D. Yancopoulos
Art Unit	
Examiner Name	
Attorney Docket Number	REGN-008CIPCON9

		NON PATENT LITERATURE DOCUMENTS	
Examin er Initials*	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	Т
	66	Information from ClinicalTrials.gov archive History of Changes for Study: NCT00320775 "Safety and Tolerability of Intravitreal Administration of VEGF Trap in Patients With Neovascular Age-Related Macular Degeneration" 10 pages, Latest version submitted March 16, 2015 on ClinicalTrials.gov (NCT00320775_2015)	
	67	Information from ClinicalTrials.gov archive History of Changes for Study: NCT00320788 "Safety and Efficacy of Repeated Intravitreal Administration of Vascular Endothelial Growth Factor (VEGF) Trap in Patients With Wet Age-Related Macular Degeneration (AMD)" 71 pages, Latest version submitted December 1, 2011 on ClinicalTrials.gov (NCT00320788_2006-2011)	
	68	Information from ClinicalTrials.gov archive History of Changes for Study: NCT00320788 "Safety and Efficacy of Repeated Intravitreal Administration of Vascular Endothelial Growth Factor (VEGF) Trap in Patients With Wet Age-Related Macular Degeneration (AMD)" 31 pages, Latest version submitted January 27, 2012 on ClinicalTrials.gov (NCT00320788_2012)	
	69	Information from ClinicalTrials.gov archive History of Changes for Study: NCT00320814 "Phase 1 Study of VEGF Trap in Patients With Diabetic Macular Edema" 30 pages, Latest version submitted June 8, 2011 on ClinicalTrials.gov (NCT00320814_2006-2011)	
	70	Information from ClinicalTrials.gov archive History of Changes for Study: NCT00509795 "Double-Masked Study of Efficacy and Safety of IVT VEGF Trap-Eye in Subjects With Wet AMD (VIEW 1)" 318 pages, Latest version submitted December 1, 2011 on ClinicalTrials.gov (NCT00509795_2007-2011)	
	71	Information from ClinicalTrials.gov archive History of Changes for Study: NCT00509795 "Double-Masked Study of Efficacy and Safety of IVT VEGF Trap-Eye in Subjects With Wet AMD (VIEW 1)" 200 pages, Latest version submitted December 20, 2012 on ClinicalTrials.gov (NCT00509795_2012)	
	72	Information from ClinicalTrials.gov archive History of Changes for Study: NCT00527423 "Randomized, Single-Masked, Long-Term, Safety and Tolerability Study of VEGF Trap-Eye in AMD" 64 pages, Latest version submitted November 1, 2011 on ClinicalTrials.gov (NCT00527423_2007-2011)	
	73	Information from ClinicalTrials.gov archive History of Changes for Study: NCT00527423 "Randomized, Single-Masked, Long-Term, Safety and Tolerability Study of VEGF Trap-Eye in AMD" 42 pages, Latest version submitted June 10, 2013 on ClinicalTrials.gov (NCT00527423_2012-2013)	
	74	Information from ClinicalTrials.gov archive History of Changes for Study: NCT00637377 "Vascular Endothelial Growth Factor (VEGF) Trap-Eye: Investigation of Efficacy and Safety in Wet Age-Related Macular Degeneration (AMD) (VIEW 2)" 667 pages, Latest version submitted December 16, 2011 on ClinicalTrials.gov (NCT00637377_2008-2011)	

Examiner Date Signature Considered

of

18

7

Sheet

Application Number	17/350,958
Filing Date	2021-06-17
First Named Inventor	George D. Yancopoulos
Art Unit	
Examiner Name	
Attorney Docket Number	REGN-008CIPCON9

	NON PATENT LITERATURE DOCUMENTS				
Examin er Initials*	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.		Т	
	75	Information from ClinicalTrials.gov archive History of Changes for Study: NCT00637377 "Vascular Endothelial Growth Factor (VEGF) Trap-Eye: Investigation of Efficacy and Safety in Wet Age-Related Macular Degeneration (AMD) (VIEW 2)" 289 pages, Latest version submitted November 28, 2014 on ClinicalTrials.gov (NCT00637377_2012-2014)			
	76	Information from ClinicalTrials.gov archive History of Changes for Study: NCT00789477 "DME And VEGF Trap-Eye [Intravitreal Aflibercept Injection (IAI;EYLEA®;BAY86-5321)] INvestigation of Clinical Impact (DA VINCI)" 135 pages, Latest version submitted May 2, 2011 on ClinicalTrials.gov (NCT00789477_2008-2011)			
	77	Information from ClinicalTrials.gov archive History of Changes for Study: NCT00789477 "DME And VEGF Trap-Eye [Intravitreal Aflibercept Injection (IAI;EYLEA®;BAY86-5321)] INvestigation of Clinical Impact (DA VINCI)" 53 pages, Latest version submitted August 28, 2014 on ClinicalTrials.gov (NCT00789477_2013-2014)			
	78	Information from ClinicalTrials.gov archive History of Changes for Study: NCT00943072 "Vascular Endothelial Growth Factor (VEGF) Trap-Eye: Investigation of Efficacy and Safety in Central Retinal Vein Occlusion (CRVO)" 98 pages, Latest version submitted May 9, 2011 on ClinicalTrials.gov (NCT00943072_2009-2011)			
	79	Information from ClinicalTrials.gov archive History of Changes for Study: NCT00943072 "Vascular Endothelial Growth Factor (VEGF) Trap-Eye: Investigation of Efficacy and Safety in Central Retinal Vein Occlusion (CRVO)" 64 pages, Latest version submitted April 16, 2013 on ClinicalTrials.gov (NCT00943072_2012-2013)			
	80	Information from ClinicalTrials.gov archive View of NCT00637377 "Vascular Endothelial Growth Factor (VEGF) Trap-Eye: Investigation of Efficacy and Safety in Wet Age-Related Macular Degeneration (AMD) (VIEW 2)" <i>ClinicalTrials.gov.</i> Web. (2010-11-30).			
	81	Information from ClinicalTrials.gov archive on the VIEW 2 study (NCT00637377) "VEGF Trap-Eye: Investigation of Efficacy and Safety in Wet AMD (VIEW 2)" version available (updated on 17 March 2008)			
	82	Information from ClinicalTrials.gov archive on the view of NCT00509795 "Vascular Endothelial Growth Factor (VEGF) Trap-Eye: Investigation of Efficacy and Safety in Wet Age-Related Macular Degeneration (AMD)" (12-01-2009)			
	83	Information from Clinical Trials.gov archive on the view of NCT00789477 "DME and VEGF Trap-Eye: Investigation of Clinical Impact" (11-18-2010)			
	84	Information from ClinicalTrials.gov archive on the view of NCT00509795 "Vascular Endothelial Growth Factor (VEGF) Trap-Eye: Investigation of Efficacy and Safety in Wet Age-Related Macular Degeneration (AMD)" (01-07-2011)			

Signature	Γ	Examiner Signature		Date Considered	
-----------	---	-----------------------	--	--------------------	--

8

of

18

Sheet

Application Number	17/350,958
Filing Date	2021-06-17
First Named Inventor	George D. Yancopoulos
Art Unit	
Examiner Name	
Attorney Docket Number	REGN-008CIPCON9

		NON PATENT LITERATURE DOCUMENTS	
Examin er Initials*	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	Т
	85	Information from ClinicalTrials.gov archive on the view of NCT01012973 "Vascular Endothelial Growth Factor (VEGF) Trap-Eye: Investigation of Efficacy and Safety in Central Retinal Vein Occlusion (CRVO)(GALILEO) 7 pages, first posted 11/13/2009; results first posted 11/22/2012; last update posted 11/3/14; printed 12/4/19 (https://clinicaltrials.gov/ct2/show/study/NCT01012973) (NOTE: May correspond to "Vascular Endothelial Growth Factor Trap‐ Eye Investigation of Efficacy and Safety in Central Retinal Vein Occlusion title, 8 pages, 11/12/2009, US [Cited in Third Party Observations filed in parent application USSN 16/055,847 for which a copy is unavailable on PAIR]" which was cited in the Third Party Observations dated 05/01/19)	
	86	KAISER, "Vascular endothelial growth factor Trap-Eye for diabetic macular oedema." Br. J. Ophthalmol, 93(2):135-36 (February 2009)	
	87	KARIA, Niral, "Retinal vein occlusion: pathophysiology and treatment options" Clinical Ophthalmology, 4:809-816 (2010)	
	88	KOROBELNIK et al., "Intravitreal Aflibercept Injection for Macular Edema Resulting from Central Retinal Vein Occlusion" American Academy of Ophthalmology (2014) 121(1):202- 208	
	89	KOROBELNIK, "Intravitreal Aflibercept for Diabetic Macular Edema." Ophthalmology, 121(11):2247-54 (November 2014)	
	90	KUO, "Comparative evaluation of the antitumor activity of antiangiogenic proteins delivered by gene transfer" PNAS 98(8):4605-4610 (04/10/2001)	
	91	KRZYSTOLIK et al., "Prevention of Experimental Choroidal NEovascularization With Intravitreal Anti-Vascular Endothelial Growth Factor Antibody Fragment" Arch Ophthamol., 120:338-346 (Mar. 2002)	
	92	LALWANI, "All About PrONTO: Study Yielded Good Results in AMD With Treatment Guided by OCT." Retina Today (May 2007)	
	93	LALWANI, 'A Variable-dosing Regimen with Intravitreal Ranibizumab for Neovascular Age-related Macular Degeneration: Year 2 of the PrONTO Study." Am J Ophthalmology, 148(1):43-58 (July 2009)	
	94	LEVINE, "Macular Hemorrhage In Neovascular Age-Related Macular Degeneration After Stabilization With Antiangiogenic Therapy." Retina, 29(8):1074-79 (2009)	
	95	Lucentis Label Title, 7 pages, 30/06/2010 [Cited in Third Party Observations filed in parent application USSN 16/055,847 for which a copy is unavailable on PAIR]	
	96	MAJOR et al., "DA VINCI: DME and VEGF Trap-Eye: Investigation of Clinical Impact: Phase 2 Study in Patients with Diabetic Macular Edema (DME)" ARVO Annual Meeting Abstract (April 2010)	
	97	MARGOLIS, "Hemorrhagic Recurrence Of Neovascular Age-Related Macular Degeneration Not Predicted By Spectral Domain Optical Coherence Tomography." Retinal Cases & Brief Reports, 4:1-4 (2010)	
	98	MASSIN, "Safety and Efficacy of Ranibizumab in Diabetic Macular Edema (RESOLVE Study*)." Diabetes Care, 33(11):2399-405 (November 2010)	
	99	MITCHELL, "The RESTORE Study, Ranibizumab Monotherapy or Combined with Laser versus Laser Monotherapy for Diabetic Macular Edema." Ophthalmology, 188(4):615-25 (April 2011)	

Examiner Signature	Date Considered	
-----------------------	--------------------	--

9

of

18

Sheet

Application Number	17/350,958
Filing Date	2021-06-17
First Named Inventor	George D. Yancopoulos
Art Unit	
Examiner Name	
Attorney Docket Number	REGN-008CIPCON9

		NON PATENT LITERATURE DOCUMENTS					
Examin er Initials*	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.					
	100	100MITCHELL, Edith P. "Targeted Therapy for Metastatic Colorectal Cancer: Role of Aflibercept" Clinical Colorectal Cancer (2013) 12(2):73-85					
	101	MITRA et al., "Review of anti-vascular endothelial growth factor therapy in macular edema secondary to central retinal vein occlusions" Expert Review in Ophthalmol, Taylor & Francis, GB 6(6):623-629 (January 2011)					
	102	MOUSA AND MOUSA, "Current Status of Vascular Endothelial Growth Factor Inhibition in Age-Related Macular Degeneration" Biodrugs; 24(3); 183-194 (2010)					
	103 N/A "Materials from June 2011 FDA Committee Mtg" (06/17/2011)						
	104 N/A "Materials from Dec 2011 FDA Committee Mtg"(12/01/2011)						
	105	NGUYEN et al., "A Phase I Study of Intravitreal Vascular Endothelial Growth Factor Trap- Eye in Patients with Neovascular Age-Related Macular Degeneration" Opthamology, J.B. Lippincott Co., Philadelphia, PA, US, 116(11):2141-2148 (November 1, 2009)					
	106	NGUYEN et al., "A phase I trial of an IV-administered vascular endothelial growth factor trap for treatment in patients with choroidal neovascularization due to age-related macular degeneration" Ophthalmology, 113(9):1522e1-1522e14 (Sept 2006) (epub July 28,2006)					
	107	NGUYEN et al., "Randomized, Double-masked, Active-controlled Phase 3 Trial of the Efficacy and Safety of Intravitreal VEGF Trap-Eye in Wet AMD: One-year Results of the VIEW 1 Study" ARVO Annual Meeting Abstract (April 2011)					
	108	NGUYEN, "Ranibizumab for Diabetic Macular Edema, Results from 2 Phase III Randomized Trials: RISE and RIDE." Ophthalmology, 119(4):789-801 (April 2012)					
	109	NGUYEN et al., "Results of a Phase I, Dose-Escalation, Safety, Tolerability, and Bioactivity Study of Intravitreous VEGF Trap in Patients with Neovascular Age-Related Macular Degeneration" ARVO Annual Meeting Abstract (May 2006)					
	110	NICHOLS, EARL R., "AAO: Ranibizumab (rhuRab) May Improve Vision in Age-Related Macular Degeneration" Doctor's Guide Global Edition, www.pslgroup.com/dg/23f2aa.htm, pp. 1-2 (November 24, 2003)					
	111	NOGUERA-TROISE et al., "Blockade of D114 inhibits tumour growth by promoting non- productive angiogenesis" Nature (December 2006) 444:1032-1037					
	112	OHR, "Aflibercept in wet age-related macular degeneration: a perspective review" Ther. Adv. Chronic Dis., 3(4):153-161 (2012)					
	113	OLIVERA et al., "VEGF Trap R1R2 suppresses experimental corneal angiogenesis" European Journal of Ophthalmology, 20(1):48-54 (January 1, 2010)					
	114	PAI et al., "Current concepts in intravitreal drug therapy for diabetic retinopathy" Saudi Journal of Ophthalmology 24(4):143-149 (June 30, 2010)					
	115	15:171-185 (2012)					
	116	Regeneron SEC Form 10-K (February 27, 2008)					
	117						
	118	Regeneron SEC Form 10-K (February 17, 2011)					
	119	Regeneron SEC Form 10-Q (May 8, 2006)					
	120	Regeneron SEC Form 10-Q (August 8, 2006)					
Examin Signatu		Date Considered					

INFORMATION DISCLOSURE STATEMENT BY APPLICANT			Application Number Filing Date First Named Inventor Art Unit Examiner Name	17/350,958 2021-06-17 George D. Yancopoulos			
Sheet		10 of 18	Attorney Docket Number	REGN-008CIPCON9	-		
	NON PATENT LITERATURE DOCUMENTS						
Examin er Initials*	Ute Include name of the author (in CAPITAL LETIERS), title of the article (when appropriate), title of the item (book,				Т		
	121	Regeneron SEC Form 10-Q	(November 6, 2006)				
	122	Regeneron SEC Form 10-Q	(May 4, 2007)				
	123	Regeneron SEC Form 10-Q	(August 3, 2007)				
	124	Regeneron SEC Form 10-Q	(April 30, 2009)				
	125	Regeneron SEC Form 10-Q					
	126	Regeneron SEC Form 10-Q	(April 29, 2010)				
	127	Regeneron SEC Form 10-Q	(July 28, 2010)				
	128	Regeneron SEC Form 10-Q	(October 28, 2010)				
	129	Regeneron SEC Form 10-Q	(May 3, 2011)				
	130	Regeneron SEC Form 10-Q	(July 28, 2011)				
131 Regeneron SEC Form 10-Q (October 27, 2011)							
	132	Regeneron SEC Form 8-K E dated May 1, 2006" (May 2, 2		egeneron Pharmaceuticals, Inc.			
	133	Regeneron SEC Form 8-K E dated May 3, 2006" (May 5, 2		egeneron Pharmaceuticals, Inc.			
	134	Regeneron SEC Form 8-K E Meeting of Shareholders held					
	135	Regeneron SEC Form 8-K E	xhibit: "Press Release date	d May 2, 2007" (May 3, 2007)			
	136	Regeneron SEC Form 8-K E Meeting of Shareholders to b		entation at Regeneron's Annual une 8, 2007)			
	137	Regeneron SEC Form 8-K E 2007)	xhibit: "Press Release dated	d October 1, 2007" (October 1,			
	138	Regeneron SEC Form 8-K E 6, 2007)	xhibit: "Press Release date	d November 6, 2007" (November			
	139			d May 1, 2008" (May 2, 2008)			
	140	Regeneron SEC Form 8-K E: 4, 2008)	xhibit: "Press Release date	d November 4, 2008" (November			
	141	intends to use in conjunction	with meetings with investor	generon Pharmaceuticals, Inc. 's at the J.P. Morgan 27th Annual -15, 2009." (January 9, 2009)			
	142	Regeneron SEC Form 8-K E	xhibit: "Press Release date	d April 30, 2009" (May 1, 2009)			
	143	Regeneron SEC Form 8-K E 4, 2009)	xhibit: "Press Release date	d November 3, 2009." (November			
	144		Central Retinal Vein Occlu	orting Positive Results for VEGF usion (CRVO) and in Phase 2 er 20, 2010." (December 20,			

Signature Considered	Examiner	Date	
	Signature	Considered	

18

of

11

Sheet

Application Number	17/350,958
Filing Date	2021-06-17
First Named Inventor	George D. Yancopoulos
Art Unit	
Examiner Name	
Attorney Docket Number	REGN-008CIPCON9

NON PATENT LITERATURE DOCUMENTS Examin Т Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or Cite No. Initials* country where published. Regeneron SEC Form 8-K Exhibit: "Press Release dated February 17, 2011" (February 145 18.2011) Regeneron SEC Form 8-K Exhibit: "Press Release Reporting Positive Results for VEGF 146 Trap-Eye in Second Phase 3 Study in Central Retinal Vein Occlusion, dated April 27, 2011" (April 27, 2011) Regeneron SEC Form 8-K Exhibit: "Press Release dated May 3, 2011." (May 3, 2011) 147 Regeneron SEC Form 8-K Exhibit: "Press Release, dated June 17, 2011, Announcing that 148 EYLEA™ (aflibercept ophthalmic solution) Received Unanimous Recommendation for Approval for Treatment of Wet AMD from FDA Advisory Committee." (June 21, 2011) Regeneron SEC Form 8-K Exhibit: "Presentation entitled VEGF Trap-Eye in CRVO: 1-149 year Results of the Phase 3 COPERNICUS Study" (August 22, 2011) Regeneron SEC Form 8-K Exhibit: "Press Release Announcing FDA Approval of EYLEATM 150 (aflibercept) Injection for the Treatment of Wet Age-Related Macular Degeneration, dated November 18, 2011" (November 21, 2011) Regeneron Press Release "Positive Interim Phase 2 Data Reported For VEGF Trap-Eve 151 In Age-Related Macular Degeneration" (March 27, 2007) Regeneron Press Release "VEGF TRAP-Eye Phase 2 Wet AMD Results Reported At 152 Arvo Annual Meeting" (May 9, 2007) Regeneron Press Release "Regeneron Reports Second Quarter Financial And Operating 153 Results" (August 1, 2007) Regeneron Pharmaceuticals, Inc., "Regeneron and Bayer Healthcare Initiate Phase 3 154 Global Development Program for VEGF Trap-Eye In Wet Age-Related Macular Degeneration (AMD)" (August 2, 2007) Regeneron Pharmaceuticals, Inc. FORM 10-Q, published on 7 November 2007 for the 155 period ending 30 September 2007 Regeneron Press Release "Regeneron Announces Positive Primary Endpoint Results 156 From A Phase 2 Study Of VEGF Trap-Eye In Age-Related Macular Degeneration" (October 1, 2007) Regeneron Press Release "Regeneron Reports Fourth Quarter And Full Year 2007 157 Financial And Operating Results" (February 27, 2008) Regeneron Pharmaceuticals, Inc., "Regeneron and Bayer HealthCare Announce Encouraging 32-Week Follow-up Results from a Phase 2 Study of VEGF Trap-Eye in 158 Age-Related Macular Degeneration" (April 28, 2008) Regeneron, Press release "Regeneron Reports First Quarter 2008 Financial and 159 Operating Results", May 1, 2008. Regeneron Press Release, "Bayer and Regeneron Dose First Patient in Second Phase 3 160 Study for VEGF Trap-Eye in Wet Age-Related Macular Degeneration." May 8, 2008 Regeneron Pharmaceuticals Inc., "CLEAR-IT-2: Interim Results Of The Phase II, Randomized, Controlled Dose-and Interval-ranging Study Of Repeated Intravitreal VEGF Trap Administration In Patients With Neovascular Age-related Macular Degeneration 161 (AMD)" poster presented at the 2007 Association for Research in Vision and Ophthalmology meeting in Ft. Lauderdale, Florida (May 2007)

Examiner	Date	
Signature	Considered	

of

18

12

Sheet

Application Number	17/350,958
Filing Date	2021-06-17
First Named Inventor	George D. Yancopoulos
Art Unit	
Examiner Name	
Attorney Docket Number	REGN-008CIPCON9

		NON PATENT LITERATURE DOCUMENTS	
Examin er Initials*	Cite Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.		Т
	162	Regeneron Pharmaceuticals Inc., "An Exploratory Study of the Safety, Tolerability and Biological Effect of a Single Intravitreal Administration of VEGF Trap in Patients with Diabetic Macular Edema" poster presented at the 2007 Association for Research in Vision and Ophthalmology meeting in Ft. Lauderdale, Florida (May 2007)	
	163	Regeneron Pharmaceuticals Inc., "Optical Coherence Tomography Outcomes of a Phase 1, Dose-Escalation, Safety, Tolerability, and Bioactivity Study of Intravitreal VEGF Trap in Patients with Neovascular Age-Related Macular Degeneration: The CLEAR-IT 1 Study" poster presented at the 2007 Association for Research in Vision and Ophthalmology meeting in Ft. Lauderdale, Florida (May 2007)	
	164	Regeneron Pharmaceuticals, Inc., "Regeneron and Bayer HealthCare Announce VEGF Trap-Eye Achieved Durable Improvement in Vision over 52 Weeks in a Phase 2 Study in Patients with Age-related Macular Degeneration" (August 19, 2008)	
	165	Regeneron Pharmaceuticals Inc., "VIEW 1 Vascular Endothelial Growth Factor (VEGF) Trap-Eye 1-Year Results: Investigation of Efficacy and Safety in Wet Age-Related Macular Degeneration (AMD) " presented at Bascom Palmer Eye Institute's Angiogenesis, Exudation and Degeneration 2011 meeting in Miami, Florida (February 12, 2011)	
	166	Regeneron Pharmaceuticals Inc., "VIEW 2 Vascular Endothelial Growth Factor (VEGF) Trap-Eye 1-Year Results: Investigation of Efficacy and Safety in Wet Age-Related Macular Degeneration (AMD) " presented at Bascom Palmer Eye Institute's Angiogenesis, Exudation and Degeneration 2011 meeting in Miami, Florida (February 12, 2011)	
	167	Regeneron Pharmaceuticals Inc., "VEGF Trap-Eye CLEAR-IT 2 Final Primary Endpoint Results" presented at the 2007 Retina Society Conference in Boston, Massachusetts (September 30, 2007)	
	168	Regeneron Pharmaceuticals Inc., "VEGF Trap-Eye Final Phase 2 Results in Age-related Macular Degeneration Presented at 2008 Retina Society Meeting" (September 28, 2008) (XP-002770952)	
	169	Regeneron 2008 Annual Report	
	170	Regeneron Pharmaceuticals, Inc. "Regeneron Reports Full Year and Fourth Quarter 2008 Financial and Operating Results" (February 26, 2009)	
	171	Regeneron Pharmaceuticals, Inc. "Bayer and Regeneron Extend Development Program for VEGF Trap-Eye to Include Central Retinal Vein Occlusion" (April 30, 2009)	
	172	Regeneron Press Release "First Patient Enrolled In Regeneron And Bayer Healthcare VEGF Trap-Eye Phase 3 Program In Central Retinal Vein Occlusion" (July 23, 2009)	
	173	Regeneron Press Release "Enrollment Completed in Regeneron and Bayer HealthCare Phase 3 Studies of VEGF Trap-Eye in Neovascular Age-Related Macular Degeneration (Wet AMD)" September 14, 2009	
	174	Regeneron 2009 Annual Report and 10-K	
	175	Regeneron Press Release, "VEGF Trap-Eye Shows Positive Results in a Phase 2 Study in Patients With Diabetic Macular Edema." February 18, 2010	
	176	Regeneron Press Release "Regeneron Schedules November 22, 2010 Teleconference And Webcast To Discuss Results Of Two Phase 3 Studies With VEGF Trap-Eye In Wet Age-Related Macular Degeneration" (November 19, 2010)	

Examiner	Date	
Signature	Considered	

of

18

13

Sheet

Signature

Application Number	17/350,958
Filing Date	2021-06-17
First Named Inventor	George D. Yancopoulos
Art Unit	
Examiner Name	
Attorney Docket Number	REGN-008CIPCON9

NON PATENT LITERATURE DOCUMENTS Examin Т Cite Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, No. magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or Initials* country where published. Regeneron Press Release "Bayer and Regeneron Report Positive Top-Line Results of 177 Two Phase 3 Studies with VEGF Trap-Eve in Wet Age-related Macular Degeneration" November 22, 2010 Regeneron Press Release "Regeneron and Bayer Report Positive Results for VEGF Trap-Eye in Phase 3 Study in Central Retinal Vein Occlusion (CRVO) and in Phase 2 178 Study in Diabetic Macular Edema (DME)" December 20, 2010 179 Regeneron 2010 Annual Report and 10-K Regeneron Press Release "Regeneron And Bayer Start Phase 3 Trial To Extend Ophthalmology Research & Development Program For VEGF Trap-Eye In Asia" (January 180 18.2011) Regeneron Press Release "Regeneron To Webcast Investor Briefing On VEGF Trap-Eve 181 Clinical Program On Sunday, February 13th At 9 Am Et" (February 9, 2011) Regeneron Press Release "Regeneron Submits Biologics License Application To FDA For 182 VEGF Trap-Eye For Treatment Of Wet Age-Related Macular Degeneration" (February 22, 2011) Regeneron Press Release "Regeneron And Bayer Announce Start Of Phase 3 Clinical 183 Program In Diabetic Macular Edema" (April 8, 2011) Regeneron Pharmaceuticals, Inc., "FDA Grants Priority Review for VEGF Trap-Eye for the 184 Treatment of Wet Age-Related Macular Degeneration" (April 18, 2011) Regeneron Press Release "VEGF Trap-Eye Submitted for EU Marketing Authorization for 185 Treatment of Wet Age-Related Macular Degeneration (June 7, 2011) Regeneron Pharmaceuticals, Inc., "Regeneron Announces EYLEA™ (aflibercept ophthalmic solution) Receives Unanimous Recommendation for Approval for Treatment of 186 Wet AMD from FDA Advisory Committee" (June 17, 2011) Regeneron Press Release "Regeneron Announces Clinical Presentations at ASRS 2011 187 Annual Meeting" (August 17, 2011) Regeneron Pharmaceuticals, Inc., "Regeneron Announces FDA Approval of EYLEA™ (aflibercept) Injection for the Treatment of Wet Age-Related Macular 188 Degeneration: CORRECTED (November 18, 2011) Regeneron Pharmaceuticals, Inc., "Regeneron and Bayer Initiate Phase 3 Clinical 189 Program for the Treatment of Wet Age-Related Macular Degeneration in China" (November 28, 2011) Regeneron Pharmaceuticals, Inc., "Two Year Results of Phase 3 Studies with EYLEA™ 190 (aflibercept) Injection in wet AMD Show Sustained Improvement in Visual Acuity" (December 5, 2011) REGILLO et al., "Randomized, Double-Masked, Sham-Controlled Trial of Ranibizumab for 191 Neovascular Age-related Macular Degeneration: OIER Study Year 1" American Journal of Ophthalmology, 145(2):239-248 (2008) ROSENFELD, "Ranibizumab for Neovascular Age-Related Macular Degeneration." N 192 Engl J Med, 355(14):1419-31 (October 5, 2006) ROSENFELD, "Lessons Learned From Avastin and OCT-The Great, the Good, the Bad, 193 and the Ugly: The LXXV Edward Jackson Memorial Lecture." Am. J. Ophthalmology, 204:26-45 (August 2019) Examiner Date

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Considered

of

18

14

Sheet

Application Number	17/350,958
Filing Date	2021-06-17
First Named Inventor	George D. Yancopoulos
Art Unit	
Examiner Name	
Attorney Docket Number	REGN-008CIPCON9

NON PATENT LITERATURE DOCUMENTS Examin Т Cite Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, No. magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or Initials* country where published. RUDGE et al., "VEGF Trap complex formation measures production rates of VEGF, providing a biomarker for predicting efficacious angiogenic blockade" PNAS (November 194 20, 2007) 104(47):18363-18370 RUDGE et al. "Clinical Development of VEGF Trap" In: Figg W.D., Folkman J. (eds) 195 Angiogenesis (2008) SCHMIDT-ERFURTH, "Efficacy and Safety of Monthly versus Quarterly Ranibizumab Treatment in Neovascular Age-related Macular Degeneration: The EXCIE Study" 196 Ophthalmology, 118(5)831-839 (2010) SCHMIDT-ERFURTH et al. "Primary Results of an International Phase III Study Using 197 Intravitreal VEGF Trap-Eye Compared to Ranibizumab in Patients with Wet AMD (VIEW 2)" ARVO Annual Meeting Abstract (April 2011) SCHMIDT-ERFURTH. "Three-Year Outcomes of Individualized Ranibizumab Treatment 198 in Patients with Diabetic Macular Edema." Ophthalmology, 121(5):1045-53, (May 2014) SCHMIDT-ERFURTH et al., "Intravitreal Aflibercept Injection for Neovascular Age-related 199 Macular Degeneration" Ophthalmology (2014) 121:193-201 SCHNICHELS, "Comparative toxicity and proliferation testing of aflibercept, bevacizumab 200 and ranibizumab on different ocular cells." Br. J. Ophthalmol., 97:917-923 (2013) SEMERARO et al., "Aflibercept in wet AMD: specific role and optimal use" Drug Design, 201 Development and Therapy (August 2, 2013) 7:711-722 SHARMA and S. AND KAISER, P. K., Update on VEGF TRAP-Eye Clinical Trials and Retinal. Physician, pp. 1-6 (Nov/Dec 2010) <URL: 202 https://www.retinalphysician.com/issues/2010/nov-dec/update-on-vegf-trap-eye-clinicaltrials> SIMO AND HERNANDEZ, "Advances in Medical Treatment of Diabetic Retinopathy" 203 Diabetes Care, 32(8):1556-1562 (August 2009) SLAKTER et al., "Influence of Baseline Angiographic Classification on Outcomes in the 204 CLEAR-IT 2 Phase 2 Study of Intravitreal VEGF Trap-Eye in Neovascular Age-Related Macular Degeneration" ARVO Annual Meeting Abstract (April 2010) SLAKTER et al., "A Phase 2, Randomized, Controlled Dose-and Interval-Ranging Study of Intravitreal VEGF Trap-Eye in Patients with Neovascular Age-Related Macular 205 Degeneration: Optical Coherence Tomography (OCT) and Fluorescein Angiography (FA) Outcomes at 1 Year" ARVO Annual Meeting Abstract (April 2009) Slides for the 2008 Retina Society Meeting "VEGF Trap-Eye in Wet AMD CLEAR-IT 2: 206 Summary of One-Year Key Results", September 28, 2008. SPAIDE, "Ranibizumab According to Need: A Treatment for Age-related Macular 207 Degeneration." Am J Ophthalmology, 143(4):679-680 (April 2007) STEWART, "The expanding role of vascular endothelial growth factor inhibitors in 208 opthamology" Mayo Clin Proc. 87(1):77-88 (January 2012) STEWART et al., "Predicted biological activity of intravitreal VEGF Trap" British Journal of 209 Ophthalmology, 92(5):667-668 (2008) STEWART, "Aflibercept" Nature Reviews: Drug Discovery 11:269-270 (04/01/2012) 210

Signature Considered			
----------------------	--	--	--

of

18

15

Sheet

Application Number	17/350,958
Filing Date	2021-06-17
First Named Inventor	George D. Yancopoulos
Art Unit	
Examiner Name	
Attorney Docket Number	REGN-008CIPCON9

NON PATENT LITERATURE DOCUMENTS Examin Т Cite Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, No. magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or Initials* country where published. TANNOCK et al., "Aflibercept versus placebo in combination with docetaxel and prednisone for treatment of men with metastatic castration-resistant prostate cancer 211 (VENICE): a phase 3, double-blind randomized trial" Lancet Oncol (2013) 14:760-768 THOMAS REUTERS INTEGRITY "VEGF Trap-Eye final phase II results in age-related 212 macular degeneration presented at 2008 Retina Society Meeting" (September 28, 2008) THURSTON, Gavin "Complementary actions of VEGF and Angiopoietin-1 on blood vessel 213 growth and leakage" J. Anat. (2002) 200:575-580 THURSTON, "Vascular endothelial growth factor and other signaling pathways in 214 developmental and pathologic angiogenesis." International Journal of Hematology, 80:7-20 (2004) Updated Information from ClinicalTrials.gov archive History of Changes for Study: NCT01012973 "Vascular Endothelial Growth Factor (VEGF) Trap-Eve: Investigation of 215 Efficacy and Safety in Central Retinal Vein Occlusion (CRVO)(GALILEO) 38 pages, Latest version submitted October 27, 2014 on Clinical Trials.gov (NCT01012973 01182013 27424.1) Updated Information from ClinicalTrials.gov archive History of Changes for Study: NCT01012973 "Vascular Endothelial Growth Factor (VEGF) Trap-Eye: Investigation of 216 Efficacy and Safety in Central Retinal Vein Occlusion (CRVO)(GALILEO) 10 pages, Latest version submitted October 27, 2014 on Clinical Trials.gov (NCT01012973_01252011_27433.1) Updated Information from ClinicalTrials.gov archive History of Changes for Study: NCT01012973 "Vascular Endothelial Growth Factor (VEGF) Trap-Eye: Investigation of 217 Efficacy and Safety in Central Retinal Vein Occlusion (CRVO)(GALILEO) 11 pages, Latest version submitted October 27, 2014 on Clinical Trials.gov (NCT01012973 01262012 27428.1) Updated Information from ClinicalTrials.gov archive History of Changes for Study: NCT01012973 "Vascular Endothelial Growth Factor (VEGF) Trap-Eve: Investigation of 218 Efficacy and Safety in Central Retinal Vein Occlusion (CRVO)(GALILEO) 38 pages, Latest version submitted October 27, 2014 on ClinicalTrials.gov (NCT01012973 01302013 27423.1) Updated Information from ClinicalTrials.gov archive History of Changes for Study: NCT01012973 "Vascular Endothelial Growth Factor (VEGF) Trap-Eye: Investigation of Efficacy and Safety in Central Retinal Vein Occlusion (CRVO)(GALILEO) 12 pages, 219 Latest version submitted October 27, 2014 on ClinicalTrials.gov (NCT01012973 02092010 27442.1) Updated Information from ClinicalTrials.gov archive History of Changes for Study: NCT01012973 "Vascular Endothelial Growth Factor (VEGF) Trap-Eye: Investigation of 220 Efficacy and Safety in Central Retinal Vein Occlusion (CRVO)(GALILEO) 11 pages. Latest version submitted October 27, 2014 on Clinical Trials.gov (NCT01012973 02202012 27427.1) Updated Information from ClinicalTrials.gov archive History of Changes for Study: NCT01012973 "Vascular Endothelial Growth Factor (VEGF) Trap-Eye: Investigation of 221 Efficacy and Safety in Central Retinal Vein Occlusion (CRVO)(GALILEO) 12 pages, Latest version submitted October 27, 2014 on Clinical Trials.gov (NCT01012973 03162010 27441.1) Examiner Date Signature Considered

16

18

of

Sheet

Application Number	17/350,958
Filing Date	2021-06-17
First Named Inventor	George D. Yancopoulos
Art Unit	
Examiner Name	
Attorney Docket Number	REGN-008CIPCON9

	NON PATENT LITERATURE DO	CUMENTS					
Examin er Initials*	magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.						
222	Updated Information from ClinicalTrials.gov archive His NCT01012973 "Vascular Endothelial Growth Factor (VI Efficacy and Safety in Central Retinal Vein Occlusion (Latest version submitted October 27, 2014 on ClinicalT (NCT01012973_04082011_27432.1)	EGF) Trap-Eye CRVO)(GALIL	e: Investigation of				
223	Updated Information from ClinicalTrials.gov archive His NCT01012973 "Vascular Endothelial Growth Factor (VI Efficacy and Safety in Central Retinal Vein Occlusion (Latest version submitted October 27, 2014 on ClinicalT (NCT01012973_04162010_27440.1)	EGF) Trap-Eye CRVO)(GALIL	e: Investigation of				
 Updated Information from ClinicalTrials.gov archive History of Changes for Study: NCT01012973 "Vascular Endothelial Growth Factor (VEGF) Trap-Eye: Investigation of Efficacy and Safety in Central Retinal Vein Occlusion (CRVO)(GALILEO) 10 pages, Latest version submitted October 27, 2014 on ClinicalTrials.gov (NCT01012973_06232011_27431.1) 							
 Updated Information from ClinicalTrials.gov archive History of Changes for Study: NCT01012973 "Vascular Endothelial Growth Factor (VEGF) Trap-Eye: Investigation of Efficacy and Safety in Central Retinal Vein Occlusion (CRVO)(GALILEO) 12 pages, Latest version submitted October 27, 2014 on ClinicalTrials.gov (NCT01012973_07222010_27439.1) 							
226	Latest version submitted October 27, 2014 on Clinical Trials.gov (NCT01012973_08252010_27438.1)						
Updated Information from ClinicalTrials.gov archive History of Changes for Study: NCT01012973 "Vascular Endothelial Growth Factor (VEGF) Trap-Eye: Investigation of Efficacy and Safety in Central Retinal Vein Occlusion (CRVO)(GALILEO) 10 pages, Latest version submitted October 27, 2014 on ClinicalTrials.gov (NCT01012973_08262010_27437.1)							
 Updated Information from ClinicalTrials.gov archive History of Changes for Study: NCT01012973 "Vascular Endothelial Growth Factor (VEGF) Trap-Eye: Investigation of Efficacy and Safety in Central Retinal Vein Occlusion (CRVO)(GALILEO) 10 pages, Latest version submitted October 27, 2014 on ClinicalTrials.gov (NCT01012973_09082010_27436.1) 							
229	Updated Information from ClinicalTrials.gov archive History of Changes for Study: NCT01012973 "Vascular Endothelial Growth Factor (VEGF) Trap-Eye: Investigation of						
230	Updated Information from ClinicalTrials.gov archive History of Changes for Study: NCT01012973 "Vascular Endothelial Growth Factor (VEGF) Trap-Eye: Investigation of						
Examiner Signature		Date Considered					

of

18

17

Sheet

Application Number	17/350,958
Filing Date	2021-06-17
First Named Inventor	George D. Yancopoulos
Art Unit	
Examiner Name	
Attorney Docket Number	REGN-008CIPCON9

NON PATENT LITERATURE DOCUMENTS Examin Т Cite Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, No. magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or Initials* country where published. Updated Information from ClinicalTrials.gov archive History of Changes for Study: NCT01012973 "Vascular Endothelial Growth Factor (VEGF) Trap-Eve: Investigation of Efficacy and Safety in Central Retinal Vein Occlusion (CRVO)(GALILEO) 38 pages, 231 Latest version submitted October 27, 2014 on Clinical Trials.gov (NCT01012973 10232012 27426.1) Updated Information from ClinicalTrials.gov archive History of Changes for Study: NCT01012973 "Vascular Endothelial Growth Factor (VEGF) Trap-Eye: Investigation of 232 Efficacy and Safety in Central Retinal Vein Occlusion (CRVO)(GALILEO) 38 pages, Latest version submitted October 27, 2014 on Clinical Trials.gov (NCT01012973 10272013 27422.1) Updated Information from ClinicalTrials.gov archive History of Changes for Study: NCT01012973 "Vascular Endothelial Growth Factor (VEGF) Trap-Eye: Investigation of 233 Efficacy and Safety in Central Retinal Vein Occlusion (CRVO)(GALILEO) 10 pages, Latest version submitted October 27, 2014 on Clinical Trials.gov (NCT01012973 11012010 27434.1) Updated Information from ClinicalTrials.gov archive History of Changes for Study: NCT01012973 "Vascular Endothelial Growth Factor (VEGF) Trap-Eye: Investigation of 234 Efficacy and Safety in Central Retinal Vein Occlusion (CRVO)(GALILEO) 12 pages, Latest version submitted October 27, 2014 on Clinical Trials.gov (NCT01012973 11132009 27444.1) Updated Information from ClinicalTrials.gov archive History of Changes for Study: NCT01012973 "Vascular Endothelial Growth Factor (VEGF) Trap-Eye: Investigation of Efficacy and Safety in Central Retinal Vein Occlusion (CRVO)(GALILEO) 10 pages. 235 Latest version submitted October 27, 2014 on Clinical Trials.gov (NCT01012973 11292011 27429.1) Updated Information from ClinicalTrials.gov archive History of Changes for Study: NCT01012973 "Vascular Endothelial Growth Factor (VEGF) Trap-Eye: Investigation of 236 Efficacy and Safety in Central Retinal Vein Occlusion (CRVO)(GALILEO) 38 pages. Latest version submitted October 27, 2014 on Clinical Trials.gov (NCT01012973 12182012 27425.1) Updated Information from ClinicalTrials.gov archive History of Changes for Study: NCT01012973 "Vascular Endothelial Growth Factor (VEGF) Trap-Eye: Investigation of 237 Efficacy and Safety in Central Retinal Vein Occlusion (CRVO)(GALILEO) 12 pages, Latest version submitted October 27, 2014 on Clinical Trials.gov (NCT01012973 12212010 27443.1) Vascular Endothelial Growth Factor Trap‐ Eye Investigation of Efficacy and Safety in Central Retinal Vein Occlusion title, 8 pages, 11/12/2009, US [Cited in Third Party Observations filed in parent application USSN 16/055,847 for which a copy is unavailable on PAIR] NOTE: May correspond to "Information from ClinicalTrials.gov archive on the view of NCT01012973 "Vascular Endothelial Growth Factor (VEGF) Trap-238 Eye: Investigation of Efficacy and Safety in Central Retinal Vein Occlusion (CRVO)(GALILEO) 7 pages, first posted 11/13/2009; results first posted 11/22/2012; last update posted 11/3/14; printed 12/4/19 (https://clinicaltrials.gov/ct2/show/study/NCT01012973)" cited by the Examiner in the Office Action dated 12/10/19 in USSN 16/055.847 Examiner Date Signature Considered

INFORMATION DISCLOSURE STATEMENT BY APPLICANT		Application Number17/350,958Filing Date2021-06-17First Named InventorGeorge D. YancopoulosArt UnitExaminer Name					
Sheet	neet 18 of 18			18	Attorney Docket Number	REGN-008CIPCON9	
				NON	I PATENT LITERATURE DO	CUMENTS	
Examin er Initials*	Cite Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book,				т		
	239 WACHSBERGER, "VEGF trap in combination with radiotherapy improves tumor control in u87 glioblastoma." Int. J. Radiation Oncology Biol Phys. 67(5):1526-1537 (2007)						
	240 WHO Drug Information, "International Nonproprietary Names for Pharmaceutical Substances (INN)" 20(2):115-119 (2006)						
	241 WOLFSON, "Regeneron Focuses on Age-Related Macular Degeneration." Chemistry & Biology 15:303-304 (April 2008)						
	242 XIA et al., "Transgenic delivery of VEGF to mouse skin leads to an inflammatory condition resembling human psoriasis" Blood (July 1, 2003) 102(1):161-168						
	243 YANCOPOULOS, "Vascular-specific growth factors and blood vessel formation." Nature 407:242-48 (September 14, 2000)						
	244	YANCOPOUL (October 1, 20		"Clinical A	pplication of Therapies Tar	rgeting VEGF." Cell 143:13-16	
	245	YUNG, "Movi Oncology, 10			Next Steps in Angiogenesis	s Therapy?" Society for Neuro-	

Examiner	Date	
Signature	Considered	

Electronic Acknowledgement Receipt					
EFS ID:	43039798				
Application Number:	17350958				
International Application Number:					
Confirmation Number:	4833				
Title of Invention:	USE OF A VEGF ANTAGONIST TO TREAT ANGIOGENIC EYE DISORDERS				
First Named Inventor/Applicant Name:	George YANCOPOULOS				
Customer Number:	96387				
Filer:	Karl Bozicevic/Kimberly Zuehlke				
Filer Authorized By:	Karl Bozicevic				
Attorney Docket Number:	REGN-008CIPCON9				
Receipt Date:	21-JUN-2021				
Filing Date:					
Time Stamp:	14:19:15				
Application Type:	Utility under 35 USC 111(a)				

Payment information:

Submitted with Payment no							
File Listing:	:						
Document Number	Document Description		File Name	File Size(Bytes)/ Message Digest	Multi Part /.zip	Pages (if appl.)	
				53665			
1	Transmittal Letter	REC	GN-008CIPCON9_2021-06-21 _IDS_Trans.pdf	bc273e0aa078a7e8b37f04204ae165bbf70c 172e	no	3	
Warnings:	Arnings: APOTEX V. REGENERON IPR2022-01524						

Information	:				
2	Information Disclosure Statement (IDS) Form (SB08)	REGN-008CIPCON9_2021-06-17 _IDS_SB08A.pdf	196336 , 8391badc7f4d6fa9f1c26ae537abab16f49a 281e	no	18
Warnings:			<u> </u>		
Information	:				
This is not an l	JSPTO supplied IDS fillable form				
		Total Files Size (in bytes)	: 25	50001	
characterize	vledgement Receipt evidences receip ed by the applicant, and including pag s described in MPEP 503.	•			
characterize Post Card, a <u>New Applica</u> If a new app	ed by the applicant, and including pages s described in MPEP 503. In <u>ations Under 35 U.S.C. 111</u> lication is being filed and the applica	ge counts, where applicable. tion includes the necessary o	It serves as evidence components for a filin	of receipt s g date (see	imilar to 37 CFR
characterize Post Card, a <u>New Applica</u> If a new app 1.53(b)-(d) a	ed by the applicant, and including pages s described in MPEP 503. <u>ations Under 35 U.S.C. 111</u> lication is being filed and the applica and MPEP 506), a Filing Receipt (37 CF	ge counts, where applicable. tion includes the necessary o R 1.54) will be issued in due	It serves as evidence components for a filin	of receipt s g date (see	imilar to 37 CFR
characterize Post Card, as <u>New Applica</u> If a new app 1.53(b)-(d) a Acknowledg <u>National Sta</u> If a timely su U.S.C. 371 an	ed by the applicant, and including pay s described in MPEP 503. Itions Under 35 U.S.C. 111 lication is being filed and the applica and MPEP 506), a Filing Receipt (37 CF gement Receipt will establish the filin age of an International Application ur ubmission to enter the national stage and other applicable requirements a F	ge counts, where applicable. tion includes the necessary of R 1.54) will be issued in due g date of the application. <u>Inder 35 U.S.C. 371</u> of an international applicati orm PCT/DO/EO/903 indicati	It serves as evidence components for a filin course and the date s ion is compliant with ing acceptance of the	of receipt s g date (see hown on th the conditi application	imilar to 37 CFR his ons of 35
characterize Post Card, as <u>New Applica</u> If a new app 1.53(b)-(d) a Acknowledg <u>National Sta</u> If a timely su U.S.C. 371 an national sta	ed by the applicant, and including pay s described in MPEP 503. <u>Ations Under 35 U.S.C. 111</u> lication is being filed and the applica and MPEP 506), a Filing Receipt (37 CF gement Receipt will establish the filin age of an International Application ur ubmission to enter the national stage and other applicable requirements a F ge submission under 35 U.S.C. 371 wi	ge counts, where applicable. tion includes the necessary of R 1.54) will be issued in due g date of the application. <u>Ider 35 U.S.C. 371</u> of an international applicati orm PCT/DO/EO/903 indicati ill be issued in addition to the	It serves as evidence components for a filin course and the date s ion is compliant with ing acceptance of the	of receipt s g date (see hown on th the conditi application	imilar to 37 CFR his ons of 35
characterize Post Card, as <u>New Applica</u> If a new app 1.53(b)-(d) a Acknowledg <u>National Sta</u> If a timely su U.S.C. 371 an national sta <u>New Interna</u> If a new inte	ed by the applicant, and including pay s described in MPEP 503. Itions Under 35 U.S.C. 111 lication is being filed and the applica and MPEP 506), a Filing Receipt (37 CF gement Receipt will establish the filin age of an International Application ur ubmission to enter the national stage and other applicable requirements a F	ge counts, where applicable. tion includes the necessary of R 1.54) will be issued in due g date of the application. <u>Inder 35 U.S.C. 371</u> of an international applicati orm PCT/DO/EO/903 indicati ill be issued in addition to the <u>TO as a Receiving Office</u> and the international applicat	It serves as evidence components for a filin course and the date s ion is compliant with ing acceptance of the e Filing Receipt, in du ion includes the nece	of receipt s g date (see hown on th the conditi application e course. ssary comp	imilar to 37 CFR iis ons of 35 n as a oonents f

the application.

	Attorney Docket No.	REGN-008CIPCON9	
	Confirmation No.	4833	
INFORMATION	First Named Inventor	George D. Yancopoulos	
DISCLOSURE STATEMENT	Application Number	17/350,958	
	Filing Date	June 17, 2021	
	Group Art Unit		
Address to:	Examiner Name		
Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450	Title: "Use of a VEGF Antagonist to Treat Angiog Eye Disorders"		

Electronically Filed 6/21/2021

Sir:

Applicant submits herewith documents which may be material to the examination of this application and in respect of which there may be a duty to disclose in accordance with 37 C.F.R. § 1.56. This submission is not intended to constitute an admission that any document referred to therein is "prior art" for this invention unless specifically designated as such. A listing of the documents is shown on enclosed Form PTO/SB/08A.

The publications discussed herein are provided to comply with the duty to disclose in accordance with 37 C.F.R. § 1.56. However, nothing herein is to be construed as an admission that the present invention is not entitled to antedate such publication by virtue of prior invention. Further, the dates of publication provided may be different from the actual publication dates which may need to be independently confirmed

The Examiner is requested to make the documents listed on the enclosed PTO/SB/08A of record in this application. Applicants would appreciate the Examiner initialing and returning the initialed copy of form PTO/SB/08A, indicating the documents cited therein have been considered and made of record herein.

All of the references identified herein were disclosed in parent application serial number 17/112,404, and as such, copies thereof are not included pursuant to the provisions of 37 CFR § 1.98(d).

Statements

No statement

PTA Statement under 37 CFR § 1.704(d)(1): Each item of information contained in the information disclosure statement filed herewith:

(i) Was first cited in any communication from a patent office in a counterpart foreign or international application or from the Office, and this communication was not received by any individual designated in § 1.56(c) more than thirty days prior to the filing of the information disclosure statement; or

(ii) Is a communication that was issued by a patent office in a counterpart foreign or international application or by the Office, and this communication was not received by any individual designated in § 1.56(c) more than thirty days prior to the filing of the information disclosure statement.

IDS Statement under 37 CFR § 1.97(e)(1): Each item of information contained in the information disclosure statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of the information disclosure statement; or

IDS Statement under 37 CFR § 1.97(e)(2): No item of information contained in the information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the person signing the certification after making reasonable inquiry, no item of information contained in the information disclosure statement was known to any individual designated in § 1.56(c) more than three months prior to the filing of the information disclosure statement.

Fees

 \square

 \boxtimes No fee is believed to be due.

The appropriate fee set forth in 37 C.F.R. §1.17(p) accompanies this information disclosure statement.

The Commissioner is hereby authorized to charge any underpayment of fees up to a strict limit of \$3,000.00 beyond that authorized on the credit card, but not more than \$3,000.00 in additional fees due with any communication for the above-referenced patent application, including but not limited to any necessary fees for extensions of time, or credit any overpayment of any amount to Deposit Account No. 50-0815, order number REGN-008CIPCON9.

Respectfully submitted, BOZICEVIC, FIELD & FRANCIS LLP

Date: June 21, 2021

By: /Karl Bozicevic, Reg. No. 28,807/ Karl Bozicevic Reg. No. 28,807

BOZICEVIC, FIELD & FRANCIS LLP 201 Redwood Shores Parkway, Suite 200 Redwood City, CA 94065 Telephone: (650) 327-3400 Facsimile: (650) 327-3231 Sequence Listing was accepted. See attached Validation Report. If you need help call the Patent Electronic Business Center at (866) 217-9197 (toll free). Reviewer: Zhang, Yizhu (ASRC) Timestamp: [year=2021; month=6; day=21; hr=22; min=20; sec=47; ms=94;]

Validated By CRFValidator v 1.0.5

Application No:	17350958		Version No:	1.0
	Input Set:			
	Output Set:			
	Started:	2021-06-17	18:46:16.26	0
	Finished:	2021-06-17	18:46:16.35	2
	Elapsed:	0 hr(s) 0 i	min(s) 0 sec	(s) 92 ms
Tot	al Warnings:	2		
3	otal Errors:	1		
No. of Sec	qIDs Defined:	2		
Actual	SeqID Count:	2		
Error code Erro	r Description			
E 287 Inv	alid WIPO ST.2	date format	; Use (YYYY-	-MM-DD) in <141>
W 213 Art	ificial or Unk	nown found i	n <213> in	SEQ ID (1)
W 213 Art	ificial or Unk	nown found i	.n <213> in	SEQ ID (2)

SEQUENCE LISTING

<110> George D. Yancopoulos <120> Use of a VEGF Antagonist to Treat Angiogenic Eye Disorders <130> REGN-008CIPCON9 <140> US 17/350,958 <141> 2021-06-17 <150> 17/112,404 <151> 2020-12-04 <150> 17/072,417 <151> 2020-10-16 <150> 16/055,847 <151> 2018-08-06 <150> 16/397,267 <151> 2019-04-29 <150> 16/159,272 <151> 2018-10-12 <150> 15/471,506 <151> 2017-03-28 <150> 14/972,560 <151> 2015-12-17 <150> 13/940,370 <151> 2013-07-12 <150> PCT/US2012/020855 <151> 2012-01-11 <150> 61/432,245 <151> 2011-01-13 <150> 61/434,836 <151> 2011-01-21 <150> 61/561,957 <151> 2011-11-21 <160> 2 <170> FastSEQ for Windows Version 4.0 <210> 1 <211> 1377 <212> DNA

<213> Artificial Sequence

<223> Synthetic

<220>

<400>1atggtcaget actgggacae eggggteetg etgtgegege tgeteagetg tetgettete 60 acaggateta gtteeggaag tgataceggt agaeettteg tagagatgta eagtgaaate 120 cccgaaatta tacacatgac tgaaggaagg gagctcgtca ttccctgccg ggttacgtca 180 cctaacatca ctgttacttt aaaaaagttt ccacttgaca ctttgatccc tgatggaaaa 240 cgcataatct gggacagtag aaagggcttc atcatatcaa atgcaacgta caaagaaata 300 gggcttctga cctgtgaagc aacagtcaat gggcatttgt ataagacaaa ctatctcaca 360 catcgacaaa ccaatacaat catagatgtg gttctgagtc cgtctcatgg aattgaacta 420 tctgttggag aaaagcttgt cttaaattgt acagcaagaa ctgaactaaa tgtggggatt 480 gacttcaact gggaataccc ttcttcgaag catcagcata agaaacttgt aaaccgagac 540 ctaaaaaccc agtctgggag tgagatgaag aaatttttga gcaccttaac tatagatggt 600 gtaacccgga gtgaccaagg attgtacacc tgtgcagcat ccagtgggct gatgaccaag 660 aagaacagca catttgtcag ggtccatgaa aaggacaaaa ctcacacatg cccaccgtgc 720 ccagcacctg aacteetggg gggaccgtea gtetteetet teeececaaa acceaaggae 780 acceteatga teteeeggae eeetgaggte acatgegtgg tggtggaegt gageeaegaa 840 gaccctgagg tcaagttcaa ctggtacgtg gacggcgtgg aggtgcataa tgccaagaca 900 aageegeggg aggageagta caacageaeg taeegtgtgg teagegteet eacegteetg 960 caccaggact ggctgaatgg caaggagtac aagtgcaagg tctccaacaa agccctccca 1020 gececeateg agaaaaceat etecaaagee aaagggeage eeegagaaee acaggtgtae 1080 accetgeece cateeeggga tgagetgaee aagaaceagg teageetgae etgeetggte 1140 aaaggettet ateccagega categeegtg gagtggggaga geaatgggea geeggagaae 1200 aactacaaga ccacgcctcc cgtgctggac tccgacggct ccttcttcct ctacagcaag 1260 ctcaccgtgg acaagagcag gtggcagcag gggaacgtct tctcatgctc cgtgatgcat 1320 gaggetetge acaaceaeta caegeagaag ageeteteee tgteteeggg taaatga 1377 <210> 2 <211> 458 <212> PRT <213> Artificial Sequence <220> <223> Synthetic <400>2Met Val Ser Tyr Trp Asp Thr Gly Val Leu Leu Cys Ala Leu Leu Ser 1 5 10 15 Cys Leu Leu Thr Gly Ser Ser Gly Ser Asp Thr Gly Arg Pro 20 25 30 Phe Val Glu Met Tyr Ser Glu Ile Pro Glu Ile Ile His Met Thr Glu 35 45 40 Gly Arg Glu Leu Val Ile Pro Cys Arg Val Thr Ser Pro Asn Ile Thr 50 55 60 Val Thr Leu Lys Lys Phe Pro Leu Asp Thr Leu Ile Pro Asp Gly Lys 70 75 65 80 Arg Ile Ile Trp Asp Ser Arg Lys Gly Phe Ile Ile Ser Asn Ala Thr 85 90 95 Tyr Lys Glu Ile Gly Leu Leu Thr Cys Glu Ala Thr Val Asn Gly His 100 105 110

Leu Tyr Lys Thr Asn Tyr Leu Thr His Arg Gln Thr Asn Thr Ile Ile

Asp Val Val Leu Ser Pro Ser His Gly Ile Glu Leu Ser Val Gly Glu

Lys Leu Val Leu Asn Cys Thr Ala Arg Thr Glu Leu Asn Val Gly Ile

125

140

155

120

135

150

115

130

145

Asp Phe Asn Trp Glu Tyr Pro Ser Ser Lys His Gln His Lys Lys Leu 165 170 Val Asn Arg Asp Leu Lys Thr Gln Ser Gly Ser Glu Met Lys Lys Phe Leu Ser Thr Leu Thr Ile Asp Gly Val Thr Arg Ser Asp Gln Gly Leu 195 200 Tyr Thr Cys Ala Ala Ser Ser Gly Leu Met Thr Lys Lys Asn Ser Thr 215 220 Phe Val Arg Val His Glu Lys Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu Leu Leu Gly Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys 260 265 Val Val Asp Val Ser His Glu Asp Pro Glu Val Lys Phe Asn Trp 275 280 Tyr Val Asp Gly Val Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala Pro Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly 340 345 350 Gln Pro Arg Glu Pro Gln Val Tyr Thr Leu Pro Pro Ser Arg Asp Glu Leu Thr Lys Asn Gln Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu Thr Val Asp Lys Ser Arg Trp Gln Gln Gly Asn 420 425 430 Val Phe Ser Cys Ser Val Met His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu Ser Pro Gly Lys

	United State	<u>s Patent</u>	and Tradema	UNITED STATES United States Pa Address: COMMISSIC P.O. Box 1450	S DEPARTMENT OF COMMERCE tent and Trademark Office DNER FOR PATENTS ginia 22313-1450
APPLICATION NUMBER	FILING or 371(c) DATE	GRP ART UNIT	FIL FEE REC'D	ATTY.DOCKET.NO	TOT CLAIMS IND CLAIMS
17/350,958	06/17/2021		4980	REGN-008CIPCON9	42 5
96387				C FILING REC	ONFIRMATION NO. 4833
Regeneron - B 201 REDWOC SUITE 200		ARKWAY		· · •	

Date Mailed: 07/01/2021

Receipt is acknowledged of this non-provisional utility patent application. The application will be taken up for examination in due course. Applicant will be notified as to the results of the examination. Any correspondence concerning the application must include the following identification information: the U.S. APPLICATION NUMBER, FILING DATE, NAME OF FIRST INVENTOR, and TITLE OF INVENTION. Fees transmitted by check or draft are subject to collection.

Please verify the accuracy of the data presented on this receipt. If an error is noted on this Filing Receipt, please submit a written request for a corrected Filing Receipt, including a properly marked-up ADS showing the changes with strike-through for deletions and underlining for additions. If you received a "Notice to File Missing Parts" or other Notice requiring a response for this application, please submit any request for correction to this Filing Receipt with your reply to the Notice. When the USPTO processes the reply to the Notice, the USPTO will generate another Filing Receipt incorporating the requested corrections provided that the request is grantable.

Inventor(s)

George YANCOPOULOS, Yorktown Heights, NY;

Applicant(s)

REGENERON PHARMACEUTICALS, INC., Tarrytown, NY

Assignment For Published Patent Application

REGENERON PHARMACEUTICALS, INC., Tarrytown, NY

Power of Attorney: None

Domestic Priority data as claimed by applicant

This application is a CON of 17/112,404 12/04/2020which is a CON of 17/072,417 10/16/2020which is a CON of 16/055,847 08/06/2018 PAT 10857205and is a CON of 16/397,267 04/29/2019 PAT 10888601which is a CON of 16/159,282 10/12/2018 PAT 10828345which is a CON of 15/471,506 03/28/2017 PAT 10130681which is a CON of 14/972,560 12/17/2015 PAT 9669069which is a CON of 13/940,370 07/12/2013 PAT 9254338which is a CIP of PCT/US2012/020855 01/11/2012 which claims benefit of 61/432,245 01/13/2011and claims benefit of 61/561,957 11/21/2011 **Foreign Applications** for which priority is claimed (You may be eligible to benefit from the **Patent Prosecution Highway** program at the USPTO. Please see <u>http://www.uspto.gov</u> for more information.) - None. Foreign application information must be provided in an Application Data Sheet in order to constitute a claim to foreign priority. See 37 CFR 1.55 and 1.76.

Permission to Access Application via Priority Document Exchange: Yes

Permission to Access Search Results: Yes

Applicant may provide or rescind an authorization for access using Form PTO/SB/39 or Form PTO/SB/69 as appropriate.

If Required, Foreign Filing License Granted: 06/30/2021

The country code and number of your priority application, to be used for filing abroad under the Paris Convention, is **US 17/350,958 Projected Publication Date:** 10/07/2021 **Non-Publication Request:** No **Early Publication Request:** No **Title**

USE OF A VEGF ANTAGONIST TO TREAT ANGIOGENIC EYE DISORDERS

Preliminary Class

Statement under 37 CFR 1.55 or 1.78 for AIA (First Inventor to File) Transition Applications: No

PROTECTING YOUR INVENTION OUTSIDE THE UNITED STATES

Since the rights granted by a U.S. patent extend only throughout the territory of the United States and have no effect in a foreign country, an inventor who wishes patent protection in another country must apply for a patent in a specific country or in regional patent offices. Applicants may wish to consider the filing of an international application under the Patent Cooperation Treaty (PCT). An international (PCT) application generally has the same effect as a regular national patent application in each PCT-member country. The PCT process **simplifies** the filing of patent applications on the same invention in member countries, but **does not result** in a grant of "an international patent" and does not eliminate the need of applicants to file additional documents and fees in countries where patent protection is desired.

Almost every country has its own patent law, and a person desiring a patent in a particular country must make an application for patent in that country in accordance with its particular laws. Since the laws of many countries differ in various respects from the patent law of the United States, applicants are advised to seek guidance from specific foreign countries to ensure that patent rights are not lost prematurely.

Applicants also are advised that in the case of inventions made in the United States, the Director of the USPTO must issue a license before applicants can apply for a patent in a foreign country. The filing of a U.S. patent application serves as a request for a foreign filing license. The application's filing receipt contains further information and guidance as to the status of applicant's license for foreign filing.

Applicants may wish to consult the USPTO booklet, "General Information Concerning Patents" (specifically, the section entitled "Treaties and Foreign Patents") for more information on timeframes and deadlines for filing foreign page 2 of 4

patent applications. The guide is available either by contacting the USPTO Contact Center at 800-786-9199, or it can be viewed on the USPTO website at http://www.uspto.gov/web/offices/pac/doc/general/index.html.

For information on preventing theft of your intellectual property (patents, trademarks and copyrights), you may wish to consult the U.S. Government website, http://www.stopfakes.gov. Part of a Department of Commerce initiative, this website includes self-help "toolkits" giving innovators guidance on how to protect intellectual property in specific countries such as China, Korea and Mexico. For questions regarding patent enforcement issues, applicants may call the U.S. Government hotline at 1-866-999-HALT (1-866-999-4258).

LICENSE FOR FOREIGN FILING UNDER

Title 35, United States Code, Section 184

Title 37, Code of Federal Regulations, 5.11 & 5.15

GRANTED

The applicant has been granted a license under 35 U.S.C. 184, if the phrase "IF REQUIRED, FOREIGN FILING LICENSE GRANTED" followed by a date appears on this form. Such licenses are issued in all applications where the conditions for issuance of a license have been met, regardless of whether or not a license may be required as set forth in 37 CFR 5.15. The scope and limitations of this license are set forth in 37 CFR 5.15(a) unless an earlier license has been issued under 37 CFR 5.15(b). The license is subject to revocation upon written notification. The date indicated is the effective date of the license, unless an earlier license of similar scope has been granted under 37 CFR 5.13 or 5.14.

This license is to be retained by the licensee and may be used at any time on or after the effective date thereof unless it is revoked. This license is automatically transferred to any related applications(s) filed under 37 CFR 1.53(d). This license is not retroactive.

The grant of a license does not in any way lessen the responsibility of a licensee for the security of the subject matter as imposed by any Government contract or the provisions of existing laws relating to espionage and the national security or the export of technical data. Licensees should apprise themselves of current regulations especially with respect to certain countries, of other agencies, particularly the Office of Defense Trade Controls, Department of State (with respect to Arms, Munitions and Implements of War (22 CFR 121-128)); the Bureau of Industry and Security, Department of Commerce (15 CFR parts 730-774); the Office of Foreign AssetsControl, Department of Treasury (31 CFR Parts 500+) and the Department of Energy.

NOT GRANTED

No license under 35 U.S.C. 184 has been granted at this time, if the phrase "IF REQUIRED, FOREIGN FILING LICENSE GRANTED" DOES NOT appear on this form. Applicant may still petition for a license under 37 CFR 5.12, if a license is desired before the expiration of 6 months from the filing date of the application. If 6 months has lapsed from the filing date of this application and the licensee has not received any indication of a secrecy order under 35 U.S.C. 181, the licensee may foreign file the application pursuant to 37 CFR 5.15(b).

SelectUSA

The United States represents the largest, most dynamic marketplace in the world and is an unparalleled location for business investment, innovation, and commercialization of new technologies. The U.S. offers tremendous resources and advantages for those who invest and manufacture goods here. Through SelectUSA, our nation works to promote and facilitate business investment. SelectUSA provides information assistance to the international investor community; serves as an ombudsman for existing and potential investors; advocates on behalf of U.S. cities, states, and regions competing for global investment; and counsels U.S. economic development organizations on investment attraction best practices. To learn more about why the United States is the best country in the world to develop technology, manufacture products, deliver services, and grow your business, visit http://www.SelectUSA.gov or call +1-202-482-6800.

PATENT APPLICATION FEE DETERMINATION RECORD Substitute for Form PTO-875							Application or Docket Number 17/350,958				
APPLICATION AS FILED - PART I (Column 1) (Column 2) SMALL ENTITY								OR	OTHER THAN OR SMALL ENTITY		
	FOR	NUMBE	RFILE	D NUMBE	R EXTRA		RATE(\$)	FEE(\$)		RATE(\$)	FEE(\$)
	SIC FEE FR 1.16(a), (b), or (c))	N	/A	М	J/A		N/A			N/A	320
	RCH FEE FR 1.16(k), (i), or (m))	N	/A	N	J/A		N/A			N/A	700
	MINATION FEE FR 1.16(o), (p), or (q))	N	/A	N	J/A		N/A			N/A	800
TOT	AL CLAIMS	42	minus	20=	22				OR	× 100 =	2200
IND	EPENDENT CLAI	^{NS} 5	minus	3 = *	2				1	× 480 =	960
APF FEE	PLICATION SIZ	E sheets of p \$310 (\$15 50 sheets	oaper, th 5 for sma or fractic	and drawings e e application siz all entity) for ea In thereof. See CFR 1.16(s).	ze fee due is ch additional						0.00
MUL	TIPLE DEPENDE	ENT CLAIM PRE	SENT (37	7 CFR 1.16(j))							0.00
*lft	he difference in co	olumn 1 is less th	an zero,	enter "0" in colur	nn 2.		TOTAL		1	TOTAL	4980
	APPLIC	CATION AS A	MEND	ED - PART I	I				-		
		(Column 1)	_	(Column 2)	(Column 3)	. –	SMALL	ENTITY	OR	OTHEF SMALL	
NT A		CLAIMS REMAINING AFTER AMENDMENT		HIGHEST NUMBER PREVIOUSLY PAID FOR	PRESENT EXTRA		RATE(\$)	ADDITIONAL FEE(\$)		RATE(\$)	ADDITIONAL FEE(\$)
ME	Total (37 CFR 1.16(i))	*	Minus	**	=	x	=		OR	X =	
AMENDMENT	Independent (37 CFR 1.16(h))	*	Minus	***	=	×	=		OR	x =	
AM	Application Size Fe	e (37 CFR 1.16(s))]		
	FIRST PRESENT	TION OF MULTIPL	E DEPEN	DENT CLAIM (37 C	FR 1.16(j))				OR		
							TOTAL ADD'L FEE		OR	TOTAL ADD'L FEE	
		(Column 1)		(Column 2)	(Column 3)	. –		-	-		
NT B		CLAIMS REMAINING AFTER AMENDMENT		HIGHEST NUMBER PREVIOUSLY PAID FOR	PRESENT EXTRA		RATE(\$)	ADDITIONAL FEE(\$)		RATE(\$)	ADDITIONAL FEE(\$)
ΜË	Total (37 CFR 1.16(i))	*	Minus	**	=	×	=		OR	x =	
AMENDMENT	Independent (37 CFR 1.16(h))	*	Minus	***	=	×	=		OR	x =	
AM		e (37 CFR 1.16(s))									
	FIRST PRESENT	TION OF MULTIPL	E DEPEN	DENT CLAIM (37 C	FR 1.16(j))				OR		
							TOTAL ADD'L FEE		OR	TOTAL ADD'L FEE	
*	 If the entry in cc If the "Highest N If the "Highest Nu The "Highest Num 	Jumber Previous	ly Paid Fo Paid For"	Dr [®] IN THIS SPA	CE is less thar s less than 3, er	n 20, hter "מ	enter "20". 3".	in column 1.			

Page 1 of 8

	ATTY. DOCKET NO.	APPLICATION NO.
	REGN-008CIPCON9	17/350,958
SUBSTITUTE 1449	APPLICANT	
INFORMATION DISCLOSURE STATEMENT	Regeneron Pharmaceuticals, Inc.	
	FILING DATE	GROUP
	June 17, 2021	

U.S. PATENT DOCUMENTS							
	DOCUMENT NUMBER	DATE	NAME	REFERENCE PROVIDED*			
1	6,171,586	1/9/2001	Lam et al.	not required per 69 Fed. Reg. 56481			
2	7,303,747	12/4/2007	Wiegand <i>et al</i> .	not required per 69 Fed. Reg. 56481			
3	7,374,757	5/20/2008	Papadopoulos <i>et al</i> .	not required per 69 Fed. Reg. 56481			
4	7,374,758	5/20/2008	Papadopoulos et al.	not required per 69 Fed. Reg. 56481			
5	7,378,095	5/27/2008	Cao et al.	not required per 69 Fed. Reg. 56481			
6	7,521,049	4/21/2009	Wiegand et al.	not required per 69 Fed. Reg. 56481			
7	7,531,173	5/12/2009	Wiegand <i>et al.</i>	not required per 69 Fed. Reg. 56481			
8	10,828,345	11/10/2020	Yancopoulos	not required per 69 Fed. Reg. 56481			
9	2003/0113316	6/19/2003	Kaisheva <i>et al</i> .	not required per 69 Fed. Reg. 56481			
10	2003/0138417	7/24/2003	Kaisheva <i>et al</i> .	not required per 69 Fed. Reg. 56481			
11	2004/0197324	10/7/2004	Liu <i>et al</i> .	not required per 69 Fed. Reg. 56481			
12	2006/0217311	9/28/2006	Dix <i>et al.</i>	not required per 69 Fed. Reg. 56481			
13	2016/0130337	5/12/2016	Gekkieva et al.	not required per 69 Fed. Reg. 56481			

FOREIGN PATENT DOCUMENTS							
DOCUMENT NUMBER DATE COUNTRY TRANSLATION REFERENCE PROVIDED*							
	14	2663325	11/20/2013	EP	n/a	Herewith	
	15	97/04801	2/13/1997	WO	n/a	Herewith	

NON-PATENT LITERATURE DOCUMENTS						
	DOCUMENT (Including Author, Title, Date, Pertinent Pages, etc.)	REFERENCE PROVIDED*				
16	7,374,758 – Patent Term Extension Application submitted December 22, 2011	Herewith				
17	ADIS R&D Profile "Aflibercept: AVE 0005, AVE 005, AVE0005, VEGF Trap - Regeneron, VEGF Trap (R1R2), VEGF Trap-Eye." Drugs R D, 9(4):261-269 (2008)	Herewith				

EXAMINER	DATE CONSIDERED
EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line three considered. Include copy of this form with next communication to Applicant.	ough citation if not in conformance and not
*Copies of the listed references are either submitted herewith or were previously cited by or submitted to, the Office in a	a prior application. Pursuant to 37 C.F.R. §

1.97(d) and MPEP §609, the indicated reference may have been previously cited by or submitted to, the Office in a prior application, where the prior application is identified by its U.S. Application Number in this Information Disclosure Statement.

SUBSTITUTE 1449 INFORMATION DISCLOSURE STATEMENT	ATTY. DOCKET NO.	APPLICATION NO.
	REGN-008CIPCON9	17/350,958
	APPLICANT	
	Regeneron Pharmaceuticals, Inc.	
	FILING DATE	GROUP
	June 17, 2021	

	NON-PATENT LITERATURE DOCUMENTS		
	DOCUMENT (Including Author, Title, Date, Pertinent Pages, etc.)	REFERENCE PROVIDED*	
18	Andersen & Krummen, "Recombinant protein expression for therapeutic applications" Current Opinion in Biotechnology 13:117-123 (2002)	Herewith	
19	Anderson <i>et al.</i> , "Delivery of Anti-Angiogenic Molecular Therapies for Retinal Disease" Drug Discovery Today 15: 272 (2010)	Herewith	
20	Article in Retinal Physician, "Subspecialty News", available online at http://www.retinalphysician.com/printarticle.aspx?articleID=104007 (March 2010)	Herewith	
21	Ass'n for Res. Vision & Ophthalmology, ARVO® News (Summer 2007)	Herewith	
22	Ass'n for Res. Vision & Ophthalmology, ARVO® News (Winter/Spring 2008)	Herewith	
23	AVASTIN® label	Herewith	
24	Avery, R. L., D. J. Pieramici, M. D. Rabena, A. A. Castellarin, M. A. Nasir and M. J. Giust, "Intravitreal bevacizumab (Avastin) for neovascular age-related macular degeneration" Ophthalmology 113(3): 363-372 e365 (2006)	Herewith	
25	Bashshur <i>et al.</i> , "Intravitreal Bevacizumab for the Management of Choroidal Neovascularization in Age-Related Macular Degeneration" Am J. Ophthalmology 142: 1 (2006)	Herewith	
26	Bayer Press Release, "Bayer and Regeneron Dose First Patient in Second Phase 3 Study for VEGF Trap-Eye in Wet Age-Related Macular Degeneration." May 8, 2008	Herewith	
27	Bayer Press Release, "VEGF Trap-Eye Shows Positive Results in Phase II Study in Patients with Diabetic Macular Edema" February 18, 2010	Herewith	
28	Bayer Press Release, "Bayer HealthCare and Regeneron Announce Encouraging 32-Week Follow Up Results From A Phase 2 Study of VEGF Trap-Eye in Age- Related Macular Degeneration" April 28, 2008	Herewith	
29	Bayer Press Release "Bayer HealthCare and Regeneron Announce VEGF Trap- Eye Achieved Durable Improvement in Vision Over 52 Weeks in a Phase 2 Study in Patients with Age-Related Macular Degeneration" August 19, 2008	Herewith	

EXAMINER	DATE CONSIDERED
	billi considerad
EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line three considered. Include copy of this form with next communication to Applicant.	ough citation if not in conformance and not
*Copies of the listed references are either submitted herewith or were previously cited by or submitted to, the Office in a 1.97(d) and MPEP §609, the indicated reference may have been previously cited by or submitted to, the Office in a prior identified by its U.S. Application Number in this Information Disclosure Statement.	

SUBSTITUTE 1449 <u>INFORMATION DISCLOSURE STATEMENT</u>	ATTY. DOCKET NO.	APPLICATION NO.
	REGN-008CIPCON9	17/350,958
	APPLICANT	
	Regeneron Pharmaceuticals, Inc.	
	FILING DATE	GROUP
	June 17, 2021	

NON-PATENT LITERATURE DOCUMENTS		
	DOCUMENT (Including Author, Title, Date, Pertinent Pages, etc.)	REFERENCE PROVIDED*
30	BMJ Publishing Group Ltd., "Review: Ranibizumab (Lucentis) In NeovascularAge-Related Macular Degeneration: Evidence From Clinical Trials" British J.Ophthalmology (December 2020), https://bjo.bmj.com/content/94/1/2.altmetrics	Herewith
31	Bontempo, "Preformulation Development of Parenteral Biopharmaceuticals" Drugs and the Pharmaceutical Sciences 85:91-108 (1997)	Herewith
32	Bressler, N. M. and G. Treatment of Age-Related Macular Degeneration with Photodynamic Therapy Study, "Photodynamic therapy of subfoveal choroidal neovascularization in age-related macular degeneration with verteporfin: two- year results of 2 randomized clinical trials-tap report 2." Arch Ophthalmol 119(2): 198-207 (2001)	Herewith
33	Brown & Regillo, "Anti-VEGF Agents in the Treatment of Neovascular Age- Related Macular Degeneration: Applying Clinical Trial Results to the Treatment of Everyday Patients" Am J. Ophthalmology 144: 627 (2007)	Herewith
34	Chi <i>et al.</i> , "Physical Stability of Proteins in Aqueous Solution: Mechanism and Driving Forces in Nonnative Protein Aggregation" Pharmaceutical Research Vol. 20, No. 9, 1325-1336 (September 2003)	Herewith
35	Ciulla & Rosenfeld, "Antivascular Endothelial Growth Factor Therapy For Neovascular Age-Related Macular Degeneration" Current Opinion Ophthalmology 20: 158 (2009)	Herewith
36	Clinicaltrials.gov. I-SPY 2 TRIAL: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breast Cancer, Accessed 2010; http://clinical trials.gov/ct2/show/NCT01042379?term-NCT01042379&rank=1	Herewith
37	CMS, Local Coverage Determination (LCD) for Ranibizumab (Lucentis) (L29266, First Coast Service Options, Inc June 14, 2011)	Herewith
38	Controls in SCI experiments, RegenBase. Retrieved January 6, 2021, from http://regenbase.org/control-groups.html	Herewith
39	Department of Health and Human Services, Office of Inspector General, "Questionable Billing for Medicare Ophthalmology Services" September 2015 OEI-04-12-00280	Herewith
40	Drug Vehicle (Code C927), National Cancer Institute (NCI). Retrieved January 6, 2021, from https://ncithesaurus.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary =NCI_Thesaurus&code=C927&ns=ncit	Herewith

EXAMINER	DATE CONSIDERED
EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line thr considered. Include copy of this form with next communication to Applicant.	ough citation if not in conformance and not
*Copies of the listed references are either submitted herewith or were previously cited by or submitted to, the Office in a 1.97(d) and MPEP §609, the indicated reference may have been previously cited by or submitted to, the Office in a prior identified by its U.S. Application Number in this Information Disclosure Statement.	

SUBSTITUTE 1449 INFORMATION DISCLOSURE STATEMENT	ATTY. DOCKET NO.	APPLICATION NO.
	REGN-008CIPCON9	17/350,958
	APPLICANT	
	Regeneron Pharmaceuticals, Inc.	
	FILING DATE	GROUP
	June 17, 2021	

NON-PATENT LITERATURE DOCUMENTS		
	DOCUMENT (Including Author, Title, Date, Pertinent Pages, etc.)	REFERENCE PROVIDED*
41	EP 2 663 325 File History	Herewith
42	Eylea® Prescribing Information, Revised 05/2019	Herewith
43	Ferrara, N. & Kerbel, R., "Angiogenesis as a Therapeutic Target" Nature 438: 967 (2005)	Herewith
44	Fraser <i>et al.</i> , "Single Injections of Vascular Endothelial Growth Factor Trap Block Ovulation in the Macaque and Produce a Prolonged, Dose-Related Suppression of Ovarian Function." J. Clin. Endocrinol & Metab. 90(2): 1114- 1122 (February 2005)	Herewith
45	Genentech, "FDA Approves Lucentis for the Treatment of Wet Age-Related Macular Degeneration," News Release dated June 30, 2006 (June 30, 2006)	Herewith
46	Gupta, O. P., G. Shienbaum, A. H. Patel, C. Fecarotta, R. S. Kaiser and C. D. Regillo, "A treat and extend regimen using ranibizumab for neovascular age- related macular degeneration clinical and economic impact" Ophthalmology 117(11): 2134-2140 (2010)	Herewith
47	Heier, "Intravitreal VEGF Trap for AMD: An Update" Retina Today 44 (October 2009)	Herewith
48	Heier, J. S., P. A. Campochiaro, L. Yau, Z. Li, N. Saroj, R. G. Rubio and P. Lai "Ranibizumab for macular edema due to retinal vein occlusions: long-term follow-up in the HORIZON trial" Ophthalmology 119(4): 802-809 (2012)	Herewith
49	HERCEPTIN® label	Herewith
50	Holz <i>et al.</i> , "VEGF Trap-Eye for Macular Oedema Secondary to Central Retinal Vein Occlusion: 6-Month Results of the Phase III GALILEO Study" British J. Ophthalmology 97: 278 (2013)	Herewith

EXAMINER	DATE CONSIDERED
EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line three considered. Include copy of this form with next communication to Applicant.	ough citation if not in conformance and not
*Copies of the listed references are either submitted herewith or were previously cited by or submitted to, the Office in a prior application. Pursuant to 37 C.F.R. § 1.97(d) and MPEP §609, the indicated reference may have been previously cited by or submitted to, the Office in a prior application, where the prior application is identified by its U.S. Application Number in this Information Disclosure Statement.	

SUBSTITUTE 1449 <u>INFORMATION DISCLOSURE STATEMENT</u>	ATTY. DOCKET NO.	APPLICATION NO.
	REGN-008CIPCON9	17/350,958
	APPLICANT	
	Regeneron Pharmaceuticals, Inc.	
	FILING DATE	GROUP
	June 17, 2021	

NON-PATENT LITERATURE DOCUMENTS		
	DOCUMENT (Including Author, Title, Date, Pertinent Pages, etc.)	REFERENCE PROVIDED*
51	Ip, M. S., I. U. Scott, P. C. VanVeldhuisen, N. L. Oden, B. A. Blodi, M. Fisher, L. J. Singerman, M. Tolentino, C. K. Chan, V. H. Gonzalez and S. S. R. Group "A randomized trial comparing the efficacy and safety of intravitreal triamcinolone with observation to treat vision loss associated with macular edema secondary to central retinal vein occlusion: the Standard Care vs Corticosteroid for Retinal Vein Occlusion (SCORE) study report 5" Arch Ophthalmol 127(9): 1101-1114 (2009)	Herewith
52	Janeway <i>et al.</i> , "The structure of a typical antibody molecule" Immunobiology: The Immune System in Health and Disease. 5th edition. New York: Garland Science (2001)	Herewith
53	Keane <i>et al.</i> , "Effect of Ranibizumab Retreatment Frequency on Neurosensory Retinal Volume in Neovascular AMD" Retina 29: 592 (2009)	Herewith
54	Kim <i>et al.</i> , "Potent VEGF Blockade Causes Regression of Coopted Vessels in a Model of Neuroblastoma" Proc. Nat'l Acad. Sci. 99: 11399 (2002)	Herewith
55	LUCENTIS Approval (2006)	Herewith
56	LUCENTIS® Label (14 pages)	Herewith
57	LUCENTIS® Prescribing Information (2006)	Herewith
58	Macular Photocoagulation Study, G., "Laser photocoagulation of subfoveal neovascular lesions in age-related macular degeneration. Results of a randomized clinical trial. Macular Photocoagulation Study Group" Arch Ophthalmol 109(9): 1220-1231 (1991)	Herewith
59	Massin, "Anti-VEGF Therapy for Diabetic Macular Edema: An Update" Retina Today 54 (Sept./Oct. 2008)	Herewith
60	Michels, S., P. J. Rosenfeld, C. A. Puliafito, E. N. Marcus and A. S. Venkatraman, "Systemic bevacizumab (Avastin) therapy for neovascular age- related macular degeneration twelve-week results of an uncontrolled open-label clinical study" Ophthalmology 112(6): 1035-1047 (2005)	Herewith

EXAMINER	DATE CONSIDERED
EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line thro considered. Include copy of this form with next communication to Applicant.	ugh citation if not in conformance and not
*Copies of the listed references are either submitted herewith or were previously cited by or submitted to, the Office in a 1.97(d) and MPEP §609, the indicated reference may have been previously cited by or submitted to, the Office in a prior identified by its U.S. Application Number in this Information Disclosure Statement.	

	ATTY. DOCKET NO.	APPLICATION NO.
	REGN-008CIPCON9	17/350,958
SUBSTITUTE 1449	APPLICANT	
INFORMATION DISCLOSURE STATEMENT	Regeneron Pharmaceuticals, Inc.	
	FILING DATE	GROUP
	June 17, 2021	

	NON-PATENT LITERATURE DOCUMENTS	
	DOCUMENT (Including Author, Title, Date, Pertinent Pages, etc.)	REFERENCE PROVIDED*
61	Mitchell <i>et al.</i> , "Ranibizumab (Lucentis) in Neovascular Age-Related Macular Degeneration: Evidence from Clinical Trials" Brit. J. Ophthalmology 94: 2 (2009)	Herewith
62	Ni & Hui, "Emerging Pharmacologic Therapies for Wet Age-Related Macular Degeneration" Ophthalmologica 223: 401 (2009)	Herewith
63	Parkins & Lashmar, "The formulation of biopharmaceutical products" Pharmaceutical Science & Technology Today Vol. 3, No. 4: 129-137 (April 4, 2000)	Herewith
64	Phosphate buffer. Cold Spring Harbor Protocols 2006: pdb.rec8543 (2006)	Herewith
65	Randolph & Jones, "Surfactant-Protein Interactions" Rational Design of Stable Protein Formulations pp. 159-175, Springer, Boston, MA (2002)	Herewith
66	RAPTIVA® label	Herewith
67	Regeneron Pharmaceuticals Inc. Regeneron Receives \$20 Million Milestone Payment for Initiation of Phase 3 Study of VEGF Trap-Eye in Wet AMD. Media Release: 14 Aug 2007. Available from URL: http://www.regeneron.com	Herewith
68	Regeneron Pharmaceuticals Inc. Regeneron Reports Fourth Quarter and Full Year 2004 Financial and Operating Results. Media Release: 22 Feb 2005. Available from URL: http://www.regeneron.com	Herewith
69	Regeneron Pharmaceuticals Inc. Regeneron Reports Fourth Quarter and Full Year 2005 Financial and Operating Results. Media Release: 24 Feb 2006. Available from URL: http://regeneron.com	Herewith
70	Regeneron Pharmaceuticals Inc. Regeneron Reports Positive Phase Data for the VEGF Trap in Age-Related Macular Degeneration; Preliminary Results Show Improvements in Vision and Reginal Swelling; VEGF Trap Was Well Tolerated at All Dose Levels. Media Release: 1 May 2006. Available from URL: http://www.regeneron.com	Herewith
71	Regeneron SEC Form 10-Q (September 30, 2009)	Herewith
72	Reichert, "Antibody-Based Therapeutics To Watch In 2011" MABS 3: 76 (2011)	Herewith

EXAMINER	DATE CONSIDERED
EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line t considered. Include copy of this form with next communication to Applicant.	rough citation if not in conformance and not

*Copies of the listed references are either submitted herewith or were previously cited by or submitted to, the Office in a prior application. Pursuant to 37 C.F.R. § 1.97(d) and MPEP §609, the indicated reference may have been previously cited by or submitted to, the Office in a prior application, where the prior application is identified by its U.S. Application Number in this Information Disclosure Statement.

	ATTY. DOCKET NO.	APPLICATION NO.
	REGN-008CIPCON9	17/350,958
SUBSTITUTE 1449	APPLICANT	
INFORMATION DISCLOSURE STATEMENT	Regeneron Pharmaceuticals, Inc.	
	FILING DATE	GROUP
	June 17, 2021	

	NON-PATENT LITERATURE DOCUMENTS	
	DOCUMENT (Including Author, Title, Date, Pertinent Pages, etc.)	REFERENCE PROVIDED*
73	REMICADE® label	Herewith
74	Retina Coding Q & A, Retinal Physician, 16: 18, 54 (July/August 2019)	Herewith
75	Rogers <i>et al.</i> , "The prevalence of retinal vein occlusion: pooled data from population studies from the United States, Europe, Asia, and Australia" Ophthalmology 117(2): 313-319 e311 (2010)	Herewith
76	Rosenfeld, P. J., A. A. Moshfeghi and C. A. Puliafito, "Optical coherence tomography findings after an intravitreal injection of bevacizumab (avastin) for neovascular age-related macular degeneration" Ophthalmic Surg Lasers Imaging 36(4): 331-335 (2005)	Herewith
77	Rudge <i>et al.</i> , "VEGF Trap as a Novel Antiangiogenic Treatment Currently in Clinical Trials for Cancer and Eye Diseases, and VelociGene®-based Discovery of the Next Generation of Angiogenesis Targets," Cold Spring Harbor Symposia on Quantitative Biology 70: 411-418 (2005)	Herewith
78	Schmidt-Erfurth "Current Concepts in the Management of Diabetic Macular Edema" Proceedings 7:52 (2010)	Herewith
79	Scott <i>et al.</i> , "A randomized trial comparing the efficacy and safety of intravitreal triamcinolone with standard care to treat vision loss associated with macular Edema secondary to branch retinal vein occlusion: the Standard Care vs Corticosteroid for Retinal Vein Occlusion (SCORE) study report 6" Arch Ophthalmol 127(9): 1115-1128 (2009)	Herewith
80	SIMULECT® label	Herewith
81	Spaide <i>et al.</i> , "Prospective Study of Intravitreal Ranibizumab as a Treatment for Decreased Visual Acuity Secondary to Central Retinal Vein Occlusion" Am J. Ophthalmology 147: 298 (2009)	Herewith
82	Spielberg, L. & Leys, A., "Intravitreal Bevacizumab for Myopic Choroidal Neovascularization: Short-Term and 1-Year Results" Bulletin Societe Belge D'Ophtalmologie 312: 17 (2009)	Herewith
83	Steinbrook, "The Price of Sight — Ranibizumab, Bevacizumab, and the Treatment of Macular Degeneration" N. Eng. J. Med. 355:1409 (2006)	Herewith

EXAMINER	DATE CONSIDERED
EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line three considered. Include copy of this form with next communication to Applicant.	ough citation if not in conformance and not
*Copies of the listed references are either submitted herewith or were previously cited by or submitted to, the Office in a 1.97(d) and MPEP §609, the indicated reference may have been previously cited by or submitted to, the Office in a prior identified by its U.S. Application Number in this Information Disclosure Statement.	

APOTEX V. REGENERON IPR2022-01524 REGENERON EXHIBIT 2012 PAGE 094

	ATTY. DOCKET NO.	APPLICATION NO.
	REGN-008CIPCON9	17/350,958
SUBSTITUTE 1449	APPLICANT	
INFORMATION DISCLOSURE STATEMENT	Regeneron Pharmaceuticals, Inc.	
	FILING DATE	GROUP
	June 17, 2021	

1	NON-PATENT LITERATURE DOCUMENTS	
	DOCUMENT (Including Author, Title, Date, Pertinent Pages, etc.)	REFERENCE PROVIDED*
84	The Branch Vein Occlusion Study, G., "Argon laser photocoagulation for macular edema in branch vein occlusion" Am J Ophthalmol 98(3): 271-282 (1984)	Herewith
85	The Central Vein Occlusion Study, G., "Evaluation of grid pattern photocoagulation for macular edema in central vein occlusion. The Central Vein Occlusion Study Group M report" Ophthalmology 102(10): 1425-1433 (1995)	Herewith
86	U.S. DEP'T HEALTH & HUMAN SERVS., NAT'L INST. HEALTH, NAT'L EYE INST., "Age-Related Macular Degeneration: What You Should Know" (Sept. 2015) https://www.nei.nih.gov/sites/default/files/healthpdfs/WYSK_AMD_English_Se pt2015_PRINT.pdf	Herewith
87	U.S. DEP'T HEALTH & HUMAN SERVS., NAT'L INST. HEALTH, NAT'L EYE INST., "Diabetic Retinopathy: What You Should Know" (Sept. 2015), https://www.nei.nih.gov/sites/default/files/2019-06/Diabetic-Retinopathy-What- You-Should-Know-508.pdf	Herewith
88	U.S. Department of Health and Human Services Food and Drug Administration, "Guidance for industry Q1A(R2) stability testing of new drug substances and products" Rockville, MD (November 2003)	Herewith
89	Vascular Endothelial Growth Factor (VEGF) Trap-Eye: Investigation of Efficacy and Safety in Wet Age-Related Macular Degeneration (AMD) (VIEW1), NCT00509795, ClinicalTrials.gov (Apr. 28, 2009), https://clinicaltrials.gov/ct2/show/NCT00509795 ("NCT-795")	Herewith
90	Wall Street Journal, "Genentech's Big Drug for Eyes Faces a Rival" (2007)	Herewith
91	Wulff et al., "Prevention of Thecal Angiogenesis, Antral Follicular Growth, and Ovulation in the Primate by Treatment with Vascular Endothelial Growth Factor Trap R1R2" Endocrinology 143(7): 2797-2807 (July 2002)	Herewith
92	XOLAIR® label	Herewith
93	Zarbin & Rosenfeld, "Pathway-Based Therapies for Age-Related Macular Degeneration: An Integrated Survey of Emerging Treatment Alternatives" Retina 30: 1350 (2010)	Herewith

EXAMINER	DATE CONSIDERED
EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line three considered. Include copy of this form with next communication to Applicant.	ough citation if not in conformance and not
*Copies of the listed references are either submitted herewith or were previously cited by or submitted to, the Office in a 1.97(d) and MPEP §609, the indicated reference may have been previously cited by or submitted to, the Office in a prior identified by its U.S. Application Number in this Information Disclosure Statement.	

Electronic A	cknowledgement Receipt
EFS ID:	43207875
Application Number:	17350958
International Application Number:	
Confirmation Number:	4833
Title of Invention:	USE OF A VEGF ANTAGONIST TO TREAT ANGIOGENIC EYE DISORDERS
First Named Inventor/Applicant Name:	George YANCOPOULOS
Customer Number:	96387
Filer:	Karl Bozicevic/Kimberly Zuehlke
Filer Authorized By:	Karl Bozicevic
Attorney Docket Number:	REGN-008CIPCON9
Receipt Date:	09-JUL-2021
Filing Date:	17-JUN-2021
Time Stamp:	11:35:42
Application Type:	Utility under 35 USC 111(a)

Payment information:

Submitted with	Payment		no			
File Listing:						
Document Number	Document Description		File Name	File Size(Bytes)/ Message Digest	Multi Part /.zip	Pages (if appl.)
				53488		
1	Transmittal Letter	REG	GN-008CIPCON9_2021-07-09 _SuppIDS_trans.pdf	f3581abc37d7eb6a3d0e0d9c8a3bf66b241 Seeee	no	3
Warnings:		-	APO	TEX V. REGENERON	IPR2022-015	24

Information	:				
2	Information Disclosure Statement (IDS) Form (SB08)	Substitute_1449_17350958_20 21-07-09_REGN-008CIPCON9. pdf	78563 5252a0dd1edf1cf3c617c15ba356f0dc7ea6 0789	no	8
Warnings:			1		I
Information	:				
This is not an	JSPTO supplied IDS fillable form				
		Total Files Size (in bytes)	13	32051	
characterize	vledgement Receipt evidences receip ed by the applicant, and including pag s described in MPEP 503.				-
characterize Post Card, a <u>New Applica</u> If a new app	ed by the applicant, and including pages s described in MPEP 503. An <u>ations Under 35 U.S.C. 111</u> lication is being filed and the applica	ge counts, where applicable. tion includes the necessary o	It serves as evidence components for a filin	of receipt s g date (see	imilar to 37 CFR
characterize Post Card, a <u>New Applica</u> If a new app 1.53(b)-(d) a	ed by the applicant, and including pages s described in MPEP 503. <u>ations Under 35 U.S.C. 111</u> lication is being filed and the applica and MPEP 506), a Filing Receipt (37 CF	ge counts, where applicable. tion includes the necessary o R 1.54) will be issued in due	It serves as evidence components for a filin	of receipt s g date (see	imilar to 37 CFR
characterize Post Card, a <u>New Applica</u> If a new app 1.53(b)-(d) a Acknowledg	ed by the applicant, and including pages s described in MPEP 503. An <u>ations Under 35 U.S.C. 111</u> lication is being filed and the applica	ge counts, where applicable. tion includes the necessary o R 1.54) will be issued in due g date of the application.	It serves as evidence components for a filin	of receipt s g date (see	imilar to 37 CFR
characterize Post Card, a <u>New Applica</u> If a new app 1.53(b)-(d) a Acknowledg <u>National Sta</u> If a timely so	ed by the applicant, and including pages s described in MPEP 503. Ations Under 35 U.S.C. 111 lication is being filed and the applica and MPEP 506), a Filing Receipt (37 CF gement Receipt will establish the filin age of an International Application un ubmission to enter the national stage	ge counts, where applicable. tion includes the necessary of R 1.54) will be issued in due g date of the application. <u>Inder 35 U.S.C. 371</u> of an international applicati	It serves as evidence components for a filin course and the date s ion is compliant with t	of receipt s g date (see hown on th the conditi	imilar to 37 CFR iis ons of 35
characterize Post Card, a <u>New Applica</u> If a new app 1.53(b)-(d) a Acknowledg <u>National Sta</u> If a timely so U.S.C. 371 a	ed by the applicant, and including pages s described in MPEP 503. Ations Under 35 U.S.C. 111 lication is being filed and the applica and MPEP 506), a Filing Receipt (37 CF gement Receipt will establish the filin age of an International Application un	ge counts, where applicable. tion includes the necessary of R 1.54) will be issued in due g date of the application. <u>Inder 35 U.S.C. 371</u> of an international application orm PCT/DO/EO/903 indication	It serves as evidence components for a filin course and the date s ion is compliant with t ing acceptance of the	of receipt s g date (see hown on th the conditi application	imilar to 37 CFR iis ons of 35
characterize Post Card, a <u>New Applica</u> If a new app 1.53(b)-(d) a Acknowledg <u>National Sta</u> If a timely se U.S.C. 371 a national sta <u>New Interna</u>	ed by the applicant, and including pages s described in MPEP 503. <u>Ations Under 35 U.S.C. 111</u> lication is being filed and the applica and MPEP 506), a Filing Receipt (37 CF gement Receipt will establish the filin age of an International Application un ubmission to enter the national stage and other applicable requirements a F ge submission under 35 U.S.C. 371 wi ational Application Filed with the USP	ge counts, where applicable. tion includes the necessary of R 1.54) will be issued in due g date of the application. <u>Inder 35 U.S.C. 371</u> of an international applicati orm PCT/DO/EO/903 indicati ill be issued in addition to the <u>PTO as a Receiving Office</u>	It serves as evidence components for a filin course and the date s ion is compliant with t ing acceptance of the e Filing Receipt, in du	of receipt s g date (see hown on th the conditi application e course.	imilar to 37 CFR is ons of 35 n as a
characterize Post Card, a <u>New Applica</u> If a new app 1.53(b)-(d) a Acknowledg <u>National Sta</u> If a timely so U.S.C. 371 a national sta <u>New Interna</u> If a new inter	ed by the applicant, and including pages s described in MPEP 503. Ations Under 35 U.S.C. 111 lication is being filed and the applica and MPEP 506), a Filing Receipt (37 CF gement Receipt will establish the filin age of an International Application un ubmission to enter the national stage and other applicable requirements a F ge submission under 35 U.S.C. 371 wi ational Application Filed with the USP ornational application is being filed an	ge counts, where applicable. tion includes the necessary of R 1.54) will be issued in due g date of the application. <u>Inder 35 U.S.C. 371</u> of an international applicati orm PCT/DO/EO/903 indicati ill be issued in addition to the <u>TO as a Receiving Office</u> and the international applicat	It serves as evidence components for a filin course and the date s ion is compliant with t ing acceptance of the e Filing Receipt, in du ion includes the nece	of receipt s g date (see hown on th the conditi application e course. ssary comp	imilar to 37 CFR is ons of 38 n as a
characterize Post Card, a <u>New Applica</u> If a new app 1.53(b)-(d) a Acknowledg <u>National Sta</u> If a timely so U.S.C. 371 a national sta <u>New Interna</u> If a new internati	ed by the applicant, and including pages s described in MPEP 503. <u>Ations Under 35 U.S.C. 111</u> lication is being filed and the applica and MPEP 506), a Filing Receipt (37 CF gement Receipt will establish the filin age of an International Application un ubmission to enter the national stage and other applicable requirements a F ge submission under 35 U.S.C. 371 wi ational Application Filed with the USP	ge counts, where applicable. tion includes the necessary of R 1.54) will be issued in due g date of the application. <u>Inder 35 U.S.C. 371</u> of an international applicati orm PCT/DO/EO/903 indicati ill be issued in addition to the <u>TO as a Receiving Office</u> and the international application	It serves as evidence components for a filin course and the date s ing acceptance of the e Filing Receipt, in du ion includes the nece of the International A	of receipt s g date (see hown on th the conditi application e course. ssary comp Application	imilar to 37 CFR is ons of 35 n as a oonents f

the application.

	Attorney Docket No.	REGN-008CIPCON9	
N/DODI (A TION	Confirmation No.	4833	
INFORMATION	First Named Inventor	George D. Yancopoulos	
DISCLOSURE STATEMENT	Application Number	17/350,958	
	Filing Date	June 17, 2021	
	Group Art Unit		
Address to:	Examiner Name		
Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450	Title: "Use of a VEGF Antagonist to Treat Angiogenic Eye Disorders"		

Electronically Filed 7/9/2021

Sir:

Applicant submits herewith documents which may be material to the examination of this application and in respect of which there may be a duty to disclose in accordance with 37 C.F.R. § 1.56. This submission is not intended to constitute an admission that any document referred to therein is "prior art" for this invention unless specifically designated as such. A listing of the documents is shown on enclosed Form PTO/SB/08A.

The publications discussed herein are provided to comply with the duty to disclose in accordance with 37 C.F.R. § 1.56. However, nothing herein is to be construed as an admission that the present invention is not entitled to antedate such publication by virtue of prior invention. Further, the dates of publication provided may be different from the actual publication dates which may need to be independently confirmed.

The Examiner is requested to make the documents listed on the enclosed PTO/SB/08A of record in this application. Applicants would appreciate the Examiner initialing and returning the initialed copy of form PTO/SB/08A, indicating the documents cited therein have been considered and made of record herein.

All of the references identified herein were disclosed in parent application serial number 17/112,404, and as such, copies thereof are not included pursuant to the provisions of 37 CFR § 1.98(d).

Statements

No statement

PTA Statement under 37 CFR § 1.704(d)(1): Each item of information contained in the information disclosure statement filed herewith:

(i) Was first cited in any communication from a patent office in a counterpart foreign or international application or from the Office, and this communication was not received by any individual designated in § 1.56(c) more than thirty days prior to the filing of the information disclosure statement; or

(ii) Is a communication that was issued by a patent office in a counterpart foreign or international application or by the Office, and this communication was not received by any individual designated in § 1.56(c) more than thirty days prior to the filing of the information disclosure statement.

IDS Statement under 37 CFR § 1.97(e)(1): Each item of information contained in the information disclosure statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of the information disclosure statement; or

IDS Statement under 37 CFR § 1.97(e)(2): No item of information contained in the information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the person signing the certification after making reasonable inquiry, no item of information contained in the information disclosure statement was known to any individual designated in § 1.56(c) more than three months prior to the filing of the information disclosure statement.

Fees

No fee is believed to be due.

The appropriate fee set forth in 37 C.F.R. §1.17(p) accompanies this information disclosure statement.

The Commissioner is hereby authorized to charge any underpayment of fees up to a strict limit of \$3,000.00 beyond that authorized on the credit card, but not more than \$3,000.00 in additional fees due with any communication for the above-referenced patent application, including but not limited to any necessary fees for extensions of time, or credit any overpayment of any amount to Deposit Account No. 50-0815, order number REGN-008CIPCON9.

Respectfully submitted, BOZICEVIC, FIELD & FRANCIS LLP

Date: July 9, 2021

By: /Karl Bozicevic, Reg. No. 28,807/ Karl Bozicevic Reg. No. 28,807

BOZICEVIC, FIELD & FRANCIS LLP 201 Redwood Shores Parkway, Suite 200 Redwood City, CA 94065 Telephone: (650) 327-3400 Facsimile: (650) 327-3231

					Applicatio	on Number	17/350),958
	INFORMATION DISCLOSURE				Filing Dat	te	2021-0	06-17
			First Nam	First Named Inventor Art Unit		e D. YANCOPOULOS		
STATEMENT BY APPLICANT		Art Unit	Assigned					
					Examiner	⁻ Name	To Be	Assigned
Sheet	Sheet 1 of 2		2	Attorney Docket Number		REGN-008CIPCON9		
				U.S. F	PATENT C	DOCUMENTS		
Examiner	Cite	Patent Numb	er		e Date	Name of Patentee	e or Pages, Columns, Lines, Where	
Initial*	No.	Number-Kind Code (if kn	num)	YYYY-	-MM-DD	Applicant of Cited Document		Relevant Passages or Relevant
			00000					Figures Appear
	1							

	U.S. PATENT APPLICATION PUBLICATIONS									
Examiner	Cite	Publication Number	Publication Date	Name of Patentee or	Pages, Columns, Lines, Where					
Initial*	No.		YYYY-MM-DD	Applicant of Cited Document	Relevant Passages or Relevant					
		Number-Kind Code (if known)			Figures Appear					
	1									

	FOREIGN PATENT DOCUMENTS							
Examiner Initial*	Cite No.	Foreign Document Number Country Code-Number-Kind Code (<i>if</i> known)	Publication Date YYYY-MM-DD	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	т		
	1							

		NON PATENT LITERATURE DOCUMENTS				
Examin er Initials*	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	Т			
	1	Eylea®, Highlights of Prescribing Information, Revised 11/2011				
	2	IPR2021-00880, Paper 1, Petition for IPR (May 5, 2021)				
	3	IPR2021-00880, Exhibit 1002, Albini Declaration (May 4, 2021)				
	4	IPR2021-00880, Exhibit 1003, Gerritsen Declaration (April 30, 2021)				
	5 IPR2021-00880, Paper 10, Preliminary Response of Patent Owner (August 16, 2021)					
	6	IPR2021-00881, Paper 1, Petition for IPR (May 5, 2021)				
	7	IPR2021-00881, Exhibit 1002, Albini Declaration (May 4, 2021)				
	8	IPR2021-00881, Exhibit 1003, Gerritsen Declaration (April 26, 2021)				
	9	IPR2021-00881, Paper 10, Preliminary Response of Patent Owner (August 16, 2021)				
	10	IPR2021-00881, Exhibit 2001, Do Declaration (August 13, 2021)				
	11	Mitchell <i>et al.</i> , "Evaluating the Impact of Intravitreal Aflibercept on Diabetic Retinopathy Progression in the VIVID-DME and VISTA-DME Studies" Ophthalmol Retina 2(10):988-96 (2018)				
	12	PGR2021-00035, Paper 2, Petition for PGR (January 7, 2021)				
	13	PGR2021-00035, Paper 6, Preliminary Response of Patent Owner (April 15, 2021)				
	14	PGR2021-00035, Exhibit 1003 Wu Declaration (January 7, 2021)				
	15	PGR2021-00035, Exhibit 2001 Do Declaration (April 14, 2021)				
	16	PGR2021-00035, Exhibit 2002 D. Brown Declaration (April 14, 2021)				
	17	CAO, J. R., R.; Wang, Q.; Yancopoulos, G.D.; Wiegand, S.J. (2002). Inhibition of Corneal Neovascularization and Inflammation by VEGF Trap. In "ARVO", Invest. Ophthalmol. Vis. Sci. Vol. 43. E-Abstract 1863				
Exami	ner	Date				

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Signature

Considered

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

of

2

2

Sheet

Т

Application Number	17/350,958
Filing Date	2021-06-17
First Named Inventor	George D. YANCOPOULOS
Art Unit	To Be Assigned
Examiner Name	To Be Assigned
Attorney Docket Number	REGN-008CIPCON9

T

NON PATENT LITERATURE DOCUMENTS

		NON PATENT LITERATORE DOCOMENTS	
Examin er Initials*	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	Т
	18	WANG, Q. R., R.; Cao, J.; Yancopoulos, G.D.; and Wiegand, S.J. (2002). Anti- Angiogenic Properties of a New VEGF Antagonist, VEGF Trap, in a Mouse Model of Retinal Neovascularization. In "ARVO", Invest. Ophthalmol. Vis. Sci., Vol. 43. E-Abstract. 3714	
	19	SAISHIN, Y., Saishin, Y., Takahashi, K., Lima e Silva, R., <i>et al.</i> (2003). VEGF- TRAP(R1R2) suppresses choroidal neovascularization and VEGF-induced breakdown of the blood-retinal barrier. J Cell Physiol 195:241-48	
	20	CURSIEFEN, C., Cao, J., Chen, L., Liu, Y., Maruyama, K., <i>et al.</i> (2004). Inhibition of hemangiogenesis and lymphangiogenesis after normal-risk corneal transplantation by neutralizing VEGF promotes graft survival. Invest Ophthalmol Vis Sci 45(8):2666-73	
	21	CURSIEFEN, C., Chen, L., Borges, L. P., Jackson, D., Cao, J., <i>et al.</i> (2004). VEGF-A stimulates lymphangiogenesis and hemangiogenesis in inflammatory neovascularization via macrophage recruitment. J Clin Invest 113(7):1040-50	
	22	CAO, J.; Song, H.; Renard, R.A.; Liu, Y.; Yancopolous, G.D.; Wiegand, S.J. (2005). Systemic Administration of VEGF Trap Suppresses Vascular Leak and Leukostasis in the Retinas of Diabetic Rats. In "ARVO", Vol. 46. Invest. Ophthalmol. Vis. Sci. E-Abstract 446	
	23	NORK, T. M., Dubielzig, R. R., Christian, B. J., Miller, P. E., Miller, J. M., <i>et al.</i> (2011). Prevention of experimental choroidal neovascularization and resolution of active lesions by VEGF trap in nonhuman primates. Arch Ophthalmol 129(8):1042-52	

Examiner	Date	
Signature	Considered	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Electronic A	cknowledgement Receipt
EFS ID:	43680346
Application Number:	17350958
International Application Number:	
Confirmation Number:	4833
Title of Invention:	USE OF A VEGF ANTAGONIST TO TREAT ANGIOGENIC EYE DISORDERS
First Named Inventor/Applicant Name:	George YANCOPOULOS
Customer Number:	96387
Filer:	Karl Bozicevic/Kimberly Zuehlke
Filer Authorized By:	Karl Bozicevic
Attorney Docket Number:	REGN-008CIPCON9
Receipt Date:	03-SEP-2021
Filing Date:	17-JUN-2021
Time Stamp:	11:27:30
Application Type:	Utility under 35 USC 111(a)

Payment information:

Submitted with Payment no						
File Listing:						
Document Number	Document Description		File Name	File Size(Bytes)/ Message Digest	Multi Part /.zip	Pages (if appl.)
			51693			
1	Transmittal Letter	REC	GN-008CIPCON9_2021-09-03 _SuppIDS_trans.pdf	5acbf4aa247e185b8b9acdb438a6d70ec59 b22c0	no	2
Warnings:	APOTEX V. REGENERON IPR2022-01524					

Information:					
			36160		
2	Information Disclosure Statement (IDS) Form (SB08)	REGN-008CIPCON9_2021-09-03 _SuppIDS_SB08A.pdf	2b545a90ee475b7037fee14d33356c38e47 d7263	no	2
Warnings:			ļI		
Information:					
This is not an U	SPTO supplied IDS fillable form				
			793050		
3	Non Patent Literature	125387lbl-20111118.pdf	5c03734e77f1148b0d55d3ab6349462c3e7 a5b62	no	15
Warnings:			ļI		
Information:					
			36299		
4	Non Patent Literature	Cao_2002.pdf	e693fe75b60971f6ca8e1d8e35b729fc75be 93b8	no	2
Warnings:			•		
Information:					
		Cao_2005.pdf	43551	no	2
5	Non Patent Literature		eb7955ce21b031deb532a5f38d0a738efc0 b1925		
Warnings:			· · · · ·	•	
Information:					
			1178915		
6	Non Patent Literature	Cursiefen_2004_Inhibition_of_ hema.pdf	c20e10253dcf5992806ef217c653c91af9a5 6cfd	no	8
Warnings:			μμ		
Information:					
		Cursiefen_2004_VEGF-	4515931		
7	Non Patent Literature	A_stimulates_lymphangiogene sis.pdf	d5cb6606895155d33ba1c3d3c5de790490 47e84c	no	12
Warnings:			μ		
Information:					
		IPR2021-00880-2021-05-05_01	1454636		
8	Non Patent Literature	_Petition_for_Review_of_US96 69069_880.pdf	3eb7d60c61a299ac49257bbaa2f37a6efb84 0229	no	91
Warnings:			L L		
Information:		APO	TEX V. REGENERON I	PR2022-015	524

9	Non Patent Literature	IPR2021-00880-2021-08-16_10 _POPR_Mylan_069_Patent.pdf	767215 62b60957cb794ccdcc7ab77457f5d4c185c 699af	no	70
Warnings:					
Information:					
10	Non Patent Literature	IPR2021-00880- Ex_1002_Albini_Decl_880.pdf	1100357	no	119
Warnings:			4c924cf26f34134fb38f62959de15dc3aff6a 641		
Information:					
		IPR2021-00880-	6081340		
11	Non Patent Literature	Ex_1003_Gerritsen_Decl_880. pdf	ae519137a3b230b16a8818485f1e3c6284c e8a00	no	59
Warnings:					
Information:					
		IPR2021-00881-2021-05-05_01	1239630		
12	Non Patent Literature	_Petition_for_IPR_of_9254338_ 881.pdf	6977365612a1c5c91994d47caf135b11523 38c64	no	89
Warnings:					
Information:					
			801029		
13	Non Patent Literature	IPR2021-00881-2021-08-16_10 _POPR_Mylan_338_Patent.pdf	3c8b306e28ac79c6dc86d9d327013014abf a8136	no	76
Warnings:		•			
Information:					
		IPR2021-00881-	23233259		
14	Non Patent Literature	Ex_1002_Albini_Decl_881.pdf	309bc9a75b5ef775299bfa0ff7de17df378af 1a3	no	152
Warnings:		ł	I	I	
Information:					
		IPR2021-00881-	5491742		
	Non Patent Literature	Ex_1003_Gerritsen_Decl_881. pdf		no	53
15	Non Patent Literature		61cd4ed4ce04aa2bf5a9e9147c0ffeee6a69 585d		55
15 Warnings:	Non Patent Literature				

16	Non Patent Literature	IPR2021-00881- Ex2001_Do_Declaration.pdf	306073 9f39940c757a122c755015fb7978e3caf54af 627	no	19
Warnings:					
		Ι			
17	Non Patent Literature	Mitchell_2018.pdf	6781952 dbf07aca9b56716a91c66dedab29d1b8e2b 03cde	no	9
Warnings:					
Information:					
	Non Patent Literature	Nork_2011.pdf	2073112		11
18			0422baa35069c8a843f2285a00830fdd7464 6fe9	no	
Warnings:		•			
Information:					
	Non Patent Literature	PGR2021-00035-2021-01-07_02 _Petition_for_PGR_of_US10828 345.pdf	2787300	no	92
19					
Warnings:		•			
Information:					
			726423		Γ
20	Non Patent Literature	PGR2021-00035-2021-04-15_06 _POPR.pdf		no	96
Warnings:		-	<u> </u>		<u> </u>
Information:					
	Non Patent Literature	PGR2021-00035- Ex_1003_Wu_Declaration.pdf	2852812	no	81
21			674123a21173ad450aac4a919ea02c7fdc99 587d		
Warnings:					
Information:					
			389537		
		PGR2021-00035-		no	35
22	Non Patent Literature	Ex_2001_Do_Declaration.pdf	aa9eefe29251b69326733d5b6e23289687d 9eddd		
22 Warnings:	Non Patent Literature	Ex_2001_Do_Declaration.pdf			

23	Non Patent Literature	PGR2021-00035- Ex_2002_D_Brown_Declaration .pdf	2704458	no	22			
			ffb2b452babea1bd305e93c4d4257b7124a 4c2dd					
Warnings:								
Information:								
			582298					
24	Non Patent Literature	Saishin_2003.pdf	2194d1ea1d4df56a20264398ec00939c017 df130	no	8			
Warnings:								
Information:								
	Non Patent Literature	Wang_2002.pdf	41117					
25			ba3f92115f8ff1f74d748cf92929101bf40fc9 bc	no	2			
Warnings:		•	•					
Information:								
		Total Files Size (in bytes)	: 66	069889				
This Acknowledgement Receipt evidences receipt on the noted date by the USPTO of the indicated documents, characterized by the applicant, and including page counts, where applicable. It serves as evidence of receipt similar to a Post Card, as described in MPEP 503. New Applications Under 35 U.S.C. 111 If a new application is being filed and the application includes the necessary components for a filing date (see 37 CFR 1.53(b)-(d) and MPEP 506), a Filing Receipt (37 CFR 1.54) will be issued in due course and the date shown on this Acknowledgement Receipt will establish the filing date of the application. National Stage of an International Application under 35 U.S.C. 371 If a timely submission to enter the national stage of an international application is compliant with the conditions of 35 U.S.C. 371 and other applicable requirements a Form PCT/DO/EO/903 indicating acceptance of the application as a national stage submission under 35 U.S.C. 371 will be issued in addition to the Filing Receipt, in due course. New International Application Filed with the USPTO as a Receiving Office If a new international application is being filed and the international application of the International Application Number and of the International Filing Date (Form PCT/RO/105) will be issued in due course, subject to prescriptions concerning national security, and the date shown on this Acknowledgement Receipt will establish the international filing date of the application.								

Exect officially 1 field					
	Attorney Docket No.	REGN-008CIPCON9			
	Confirmation No.	4833			
SUPPLEMENTAL INFORMATION	First Named Inventor	George D. Yancopoulos			
DISCLOSURE STATEMENT	Application Number	17/350,958			
	Filing Date	June 17, 2021			
	Group Art Unit	To Be Assigned			
Address to:	Examiner Name	To Be Assigned			
Commissioner for Patents	Title: <i>"Use of a VEGF Antagonist to Treat Angiogenic Eye Disorders"</i>				
P.O. Box 1450 Alexandria, VA 22313-1450					
Alexandria, VA 22515-1430					

Electronically Filed

Sir:

Applicant submits herewith documents which may be material to the examination of this application and in respect of which there may be a duty to disclose in accordance with 37 C.F.R. § 1.56. This submission is not intended to constitute an admission that any document referred to therein is "prior art" for this invention unless specifically designated as such. A listing of the documents is shown on enclosed Form PTO/SB/08A and copies of the foreign patents and non-patent literature are also enclosed.

The publications discussed herein are provided to comply with the duty to disclose in accordance with 37 C.F.R. § 1.56. However, nothing herein is to be construed as an admission that the present invention is not entitled to antedate such publication by virtue of prior invention. Further, the dates of publication provided may be different from the actual publication dates which may need to be independently confirmed.

The Examiner is requested to make the documents listed on the enclosed PTO/SB/08A of record in this application. Applicants would appreciate the Examiner initialing and returning the initialed copy of form PTO/SB/08A, indicating the documents cited therein have been considered and made of record herein.

Statements

 \square

No statement

PTA Statement under 37 CFR § 1.704(d)(1): Each item of information contained in the information disclosure statement filed herewith:

(i) Was first cited in any communication from a patent office in a counterpart foreign or international application or from the Office, and this communication was not received by any individual designated in § 1.56(c) more than thirty days prior to the filing of the information disclosure statement; or

(ii) Is a communication that was issued by a patent office in a counterpart foreign or international application or by the Office, and this communication was not received by any individual designated in § 1.56(c) more than thirty days prior to the filing of the information disclosure statement.

- **IDS Statement under 37 CFR § 1.97(e)(1):** Each item of information contained in the information disclosure statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of the information disclosure statement; or
- **IDS Statement under 37 CFR § 1.97(e)(2):** No item of information contained in the information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the person signing the certification after making reasonable inquiry, no item of information contained in the information disclosure statement was known to any individual designated in § 1.56(c) more than three months prior to the filing of the information disclosure statement.

<u>Fees</u>

 \boxtimes No fee is believed to be due.

The appropriate fee set forth in 37 C.F.R. §1.17(p) accompanies this information disclosure statement.

The Commissioner is hereby authorized to charge any underpayment of fees up to a strict limit of \$3,000.00 beyond that authorized on the credit card, but not more than \$3,000.00 in additional fees due with any communication for the above-referenced patent application, including but not limited to any necessary fees for extensions of time, or credit any overpayment of any amount to Deposit Account No. 50-0815, order number REGN-008CIPCON9.

Respectfully submitted, BOZICEVIC, FIELD & FRANCIS LLP

By: <u>/Karl Bozicevic, Reg. No. 28,807/</u> Karl Bozicevic Reg. No. 28,807

Date: <u>3 September 2021</u>

BOZICEVIC, FIELD & FRANCIS LLP 201 Redwood Shores Parkway, Suite 200 Redwood City, CA 94065 Telephone: (650) 327-3400 Facsimile: (650) 327-3231

UNITED ST	ates Patent and Tradem	UNITED STA' United States Address: COMMIS P.O. Box I	a, Virginia 22313-1450
APPLICATION NUMBER	FILING OR 371(C) DATE	FIRST NAMED APPLICANT	ATTY. DOCKET NO./TITLE
17/350,958	06/17/2021	George YANCOPOULOS	REGN-008CIPCON9
			CONFIRMATION NO. 4833
96387		PUBLICAT	
Regeneron - Bozicevic, Fi	eld & Francis		
201 REDWOOD SHORES PARKWAY			CC000000128958841*
SUITE 200		^(JC000000128958841*
REDWOOD CITY, CA 940	065		

Title: USE OF A VEGF ANTAGONIST TO TREAT ANGIOGENIC EYE DISORDERS

Publication No.US-2021-0308216-A1 Publication Date:10/07/2021

NOTICE OF PUBLICATION OF APPLICATION

The above-identified application will be electronically published as a patent application publication pursuant to 37 CFR 1.211, et seq. The patent application publication number and publication date are set forth above.

The publication may be accessed through the USPTO's publically available Searchable Databases via the Internet at www.uspto.gov. The direct link to access the publication is currently http://www.uspto.gov/patft/.

The publication process established by the Office does not provide for mailing a copy of the publication to applicant. A copy of the publication may be obtained from the Office upon payment of the appropriate fee set forth in 37 CFR 1.19(a)(1). Orders for copies of patent application publications are handled by the USPTO's Public Records Division. The Public Records Division can be reached by telephone at (571) 272-3150 or (800) 972-6382, by facsimile at (571) 273-3250, by mail addressed to the United States Patent and Trademark Office, Public Records Division, Alexandria, VA 22313-1450 or via the Internet.

In addition, information on the status of the application, including the mailing date of Office actions and the dates of receipt of correspondence filed in the Office, may also be accessed via the Internet through the Patent Electronic Business Center at www.uspto.gov using the public side of the Patent Application Information and Retrieval (PAIR) system. The direct link to access this status information is currently https://portal.uspto.gov/pair/PublicPair. Prior to publication, such status information is confidential and may only be obtained by applicant using the private side of PAIR.

Further assistance in electronically accessing the publication, or about PAIR, is available by calling the Patent Electronic Business Center at 1-866-217-9197.

Office of Data Managment, Application Assistance Unit (571) 272-4000, or (571) 272-4200, or 1-888-786-0101

SUBSTITUTE 1449	ATTY. DOCKET NO.	APPLICATION NO.
	REGN-008CIPCON9	17/350,958
	APPLICANT	
INFORMATION DISCLOSURE STATEMENT	REGENERON PHARMACEUTICALS	, INC.
	FILING DATE	GROUP
	June 17, 2021	To be assigned

	U.S. PATENT DOCUMENTS			
	DOCUMENT NUMBER	DATE	NAME	REFERENCE PROVIDED*
1.	US 2004/0213787 A1	2004-10-28	Sleeman <i>et al.</i>	not required per 69 Fed. Reg. 56481
2.	US 6,833,349 B2	2004-12-21	Xia et al.	not required per 69 Fed. Reg. 56481
3.	US 2004/0266688 A1	2004-12-30	Nayak	not required per 69 Fed. Reg. 56481
4.	US 2005/0032699 A1	2005-02-10	Holash et al.	not required per 69 Fed. Reg. 56481
5.	US 6,879,294 B2	2005-05-24	Davis-Smyth et al.	not required per 69 Fed. Reg. 56481
6.	US 2005/0281822 A1	2005-12-22	Cedarbaum <i>et al</i> .	not required per 69 Fed. Reg. 56481
7.	US 2006/0030000 A1	2006-02-09	Alitalo <i>et al.</i>	not required per 69 Fed. Reg. 56481
8.	US 7,378,095 B2	2008-05-27	Cao et al.	not required per 69 Fed. Reg. 56481
9.	US 7,482,002 B2	2009-01-27	Cedarbaum	not required per 69 Fed. Reg. 56481
10). US 2009/0264358 A1	2009-10-22	Yu	not required per 69 Fed. Reg. 56481
11	US 7,750,138 B2	2010-07-06	Fang <i>et al.</i>	not required per 69 Fed. Reg. 56481
12	2. US 7,951,585 B2	2011-05-31	Ke	not required per 69 Fed. Reg. 56481
13	3. US 8,216,575 B2	2012-07-10	Yu	not required per 69 Fed. Reg. 56481
14	US 2013/0295094 A1	2013-11-07	Yancopoulos	not required per 69 Fed. Reg. 56481
15	5. US 9,657,084 B2	2017-05-23	Ke et al.	not required per 69 Fed. Reg. 56481

FOREIGN PATENT DOCUMENTS					
	DOCUMENT NUMBER	DATE	COUNTRY	TRANSLATION	REFERENCE PROVIDED*
16.	CN 1304427C	2007-03-14	China	Machine translation	Previously in US Application 17/072,417
17.	CN 100502945C	2009-06-24	China	Corresponds to US 2009/0264358 A1	Previously in US Application 17/072,417
18.	CN 100567325C	2009-12-09	China	Machine translation	Previously in US Application 17/072,417
19.	WO 2012/097019	2012-07-19	WIPO	N/A	Previously in US Application 17/072,417
20.	CN 102233132 B	2013-10-23	China	Machine translation	Previously in US Application 17/072,417
21.	CN 102380096 B	2014-04-30	China	Machine translation	Previously in US Application 17/072,417

EXAMINER	DATE CONSIDERED	
EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.		
*Copies of the listed references are either submitted herewith or were previously cited by or submitted to, the Office in a prior application. Pursuant to 37 C.F.R. § 1.97(d) and MPEP §609, the indicated reference may have been previously cited by or submitted to, the Office in a prior application, where the prior application is identified by its U.S. Application Number in this Information Disclosure Statement.		

	ATTY. DOCKET NO.	APPLICATION NO.
	REGN-008CIPCON9	17/350,958
SUBSTITUTE 1449	APPLICANT	
SUBSTITUTE 1449 INFORMATION DISCLOSURE STATEMENT	REGENERON PHARMACEUTICALS	, INC.
	FILING DATE	GROUP
	June 17, 2021	To be assigned

FOREIGN PATENT DOCUMENTS						
		DOCUMENT NUMBER	DATE	COUNTRY	TRANSLATION	REFERENCE PROVIDED*
22	2.	CN 103212075 B	2017-06-27	China	Machine translation	Previously in US Application 17/072,417
23	3.	CN 107115294 A	2017-09-01	China	Machine translation	Previously in US Application 17/072,417

	NON-PATENT LITERATURE DOCUMENTS	
	DOCUMENT (Including Author, Title, Date, Pertinent Pages, etc.)	REFERENCE PROVIDED*
24.	Anonymous, Meeting Archive Titled "PA003 Eighteen-Month Results From an Extension Study of a Phase 2, Dose- and Interval-Ranging Study of VEGF Trap- Eye in Wet AMD," presented by David S Boyer, MD at Moscone Center (October 2009)	Previously in US Application 17/072,417
25.	Anonymous, Meeting Archive Titled "PA040 One-Year Results of the DA VINCI Study of VEGF Trap-Eye in Diabetic Macular Edema," presented by Diana V Do, MD at Orange County Convention Center (October 2011)	Previously in US Application 17/072,417
26.	Anonymous, Meeting Archive Titled "PA080 One-Year Results of a Phase 2 Study of Intravitreal VEGF Trap-Eye in Patients with Neovascular Age-Related Macular Degeneration," presented by David S Boyer, MD at Georgia World Congress Center (November 2008)	Previously in US Application 17/072,417
27.	Anonymous, Meeting Archive Titled "PO259 OCT and Fluorescein Angiography Outcomes Through 1 Year for a Phase 2 Study of Intravitreal VEGF Trap-Eye in Neovascular AMD," presented by Peter K Kaiser, MD at Moscone Center (October 2009)	Previously in US Application 17/072,417
28.	Anonymous, Meeting Archive Titled "PO260 VEGF Trap-Eye Vision-Specific Quality of Life Through 52 Weeks in Patients with Neovascular AMD in CLEAR-IT 2: A Phase 2 Clinical Trial," presented by Allen C Ho, MD at Moscone Center (October 2009)	Previously in US Application 17/072,417
29.	Anonymous, Meeting Archive Titled "PO492 One-Year Results of the VIEW 1 and VIEW 2 Studies: VEGF Trap-Eye in Wet AMD," presented by David M Brown MD at Orange County Center (October 2011)	Previously in US Application 17/072,417
30.	Anonymous, Meeting Archive Titled "PO549 The 6-Month (Primary Endpoint) Results of the Phase 3 GALILEO Study: VEGF Trap-Eye in Central Retinal Vein Occlusion," presented by Jean-Francois Korobelnik, MD at Orange County Convention Center (October 2011)	Previously in US Application 17/072,417
31.	Anonymous, Meeting Archive Titled "PO571 OCT and Fluorescein Angiographic Outcomes Through 1 Year for the Phase 2 Study of Intravitreal VEGF Trap-Eye in Neovascular AMD," presented by Quan Dong Nguyen, MD at Georgia World Congress Center (November 2008)	Previously in US Application 17/072,417

EXAMINER	DATE CONSIDERED
EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line thr considered. Include copy of this form with next communication to Applicant.	ough citation if not in conformance and not
*Copies of the listed references are either submitted herewith or were previously cited by or submitted to, the Office in a	a prior application. Pursuant to 37 C.F.R. §

1.97(d) and MPEP §609, the indicated reference may have been previously cited by or submitted to, the Office in a prior application, where the prior application is identified by its U.S. Application Number in this Information Disclosure Statement.

	ATTY. DOCKET NO.	APPLICATION NO.
	REGN-008CIPCON9	17/350,958
SUBSTITUTE 1449	APPLICANT	
INFORMATION DISCLOSURE STATEMENT	REGENERON PHARMACEUTICALS	, INC.
	FILING DATE	GROUP
	June 17, 2021	To be assigned

	NON-PATENT LITERATURE DOCUMENTS	
	DOCUMENT (Including Author, Title, Date, Pertinent Pages, etc.)	REFERENCE PROVIDED*
32.	Bontempo, "Preformulation Development of Parenteral Biopharmaceuticals," Drugs and the Pharmaceutical Sciences, 85:91-108 (1997)	Previously in US Application 17/072,417
33.	Bressler, N. M. Treatment of Age-Related Macular Degeneration with Photodynamic Therapy Study Group, "Photodynamic therapy of subfoveal choroidal neovascularization in age-related macular degeneration with verteporfin: two-year results of 2 randomized clinical trials-tap report 2," <i>Arch.</i> <i>Ophthalmol.</i> , 119(2):198-207 (2001)	Previously in US Application 17/072,417
34.	Brown <i>et al.</i> , "Ranibizumab for Diabetic Macular Edema (DME): 24-Month Efficacy and Safety Results of RISE - a Phase 3 Randomized Controlled Trial," ARVO Annual Meeting Abstract, <i>Investigative Ophthalmology & Visual</i> <i>Science</i> , 52:6647 (April 2011)	Previously in US Application 17/072,417
35.	Brown <i>et al.</i> , "Sustained benefits from ranibizumab for macular edema following branch retinal vein occlusion: 12-month outcomes of a phase III study," <i>Ophthalmology</i> , 118(8):1594-2049 (2011)	Previously in US Application 17/072,417
36.	Cao <i>et al.</i> , "VEGF Trap Promotes Regression of Choroidal Neovascularization (CNV) and Inhibits Fibrosis and Inflammation in the Subretinal Matrigel CNV Model," ARVO Annual Meeting Abstract, <i>Investigative Ophthalmology & Visual Science</i> , 50:2979 (April 2009)	Previously in US Application 17/072,417
37.	Center for Drug Evaluation and Research Application Number: 21-756 Medical Review(s) (December 17, 2004) <url:https: 2004="" 21-<br="" drugsatfda_docs="" nda="" www.accessdata.fda.gov="">756_Macugen_medr.pdf></url:https:>	Previously in US Application 17/072,417
38.	Center for Drug Evaluation and Research BLA Application Number: 125156 Medical Review, (June 2006) <url:https: 125156s0000_<br="" 2006="" drugsatfda_docs="" nda="" www.accessdata.fda.gov="">Lucentis_MedR.pdf></url:https:>	Previously in US Application 17/072,417
39.	Cheung <i>et al.</i> , "Combined anti-PIGF and anti-VEGF Therapy Ameliorates Pathological Neovascularization and Improves Retinal Revascularization in the Murine Model of Oxygen Induced Ischemic Retinopathy," ARVO Annual Meeting Abstract, <i>Investigative Ophthalmology & Visual Science</i> , 52:6064 (April 2011)	Previously in US Application 17/072,417
40.	Dixon <i>et al.</i> , "VEGF Trap-Eye for the treatment of neovascular age-related macular degeneration," <i>Expert Opin. Investig. Drugs</i> , 18(10):1573-1580 (2009)	Previously in US Application 17/072,417
41.	The Eyetech Study Group, "Anti-Vascular Endothelial Growth Factor Therapy for Subfoveal Choroidal Neovascularization Secondary to Age-related Macular Degeneration," <i>Ophthalmology</i> , 110(5):979-986 (May 2003)	Previously in US Application 17/072,417
42.	Heier <i>et al.</i> , "Ranibizumab for Choroidal Neovascularization Secondary to Causes Other Than Age-Related Macular Degeneration: A Phase I Clinical Trial," <i>Ophthalmology</i> , 118(1):111-118 (January 2011)	Previously in US Application 17/072,417

EXAMINER	DATE CONSIDERED
EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line thr	ough citation if not in conformance and not
considered. Include copy of this form with next communication to Applicant.	
	' I' ' D ' ATOED ?

SUBSTITUTE 1449 <u>INFORMATION DISCLOSURE STATEMENT</u>	ATTY. DOCKET NO.	APPLICATION NO.
	REGN-008CIPCON9	17/350,958
	APPLICANT	
	REGENERON PHARMACEUTICALS	, INC.
	FILING DATE	GROUP
	June 17, 2021	To be assigned

NON-PATENT LITERATURE DOCUMENTS		
	DOCUMENT (Including Author, Title, Date, Pertinent Pages, etc.)	REFERENCE PROVIDED*
43.	Heier, "Intravitreal Aflibercept for Diabetic Macular Edema: 148-Week Results from the VISTA and VIVID Studies," <i>Ophthalmology</i> , 123(11):2376-2385 (2016)	Previously in US Application 17/072,417
44.	Herceptin label, September 1998	Previously in US Application 17/072,417
45.	Information from ClinicalTrials.gov archive on the VIEW 2 study (NCT00637377) "VEGF Trap-Eye: Investigation of Efficacy and Safety in Wet AMD (VIEW 2)," v1 (March 17, 2008)	Previously in US Application 17/072,417
46.	Ip <i>et al.</i> , "A randomized trial comparing the efficacy and safety of intravitreal triamcinolone with observation to treat vision loss associated with macular edema secondary to central retinal vein occlusion: the Standard Care vs Corticosteroid for Retinal Vein Occlusion (SCORE) study report 5," <i>Arch. Ophthalmol.</i> , 127(9):1101-1114 (2009)	Previously in US Application 17/072,417
47.	Kaiser, "Vascular endothelial growth factor Trap-Eye for diabetic macular oedema," <i>Br. J. Ophthalmol.</i> , 93(2):135-36 (February 2009)	Previously in US Application 17/072,417
48.	Korobelnik <i>et al.</i> , "Intravitreal Aflibercept Injection for Macular Edema Resulting from Central Retinal Vein Occlusion," <i>Ophthalmology</i> , 121(1):202- 208 (2014)	Previously in US Application 17/072,417
49.	Krzystolik <i>et al.</i> , "Prevention of Experimental Choroidal Neovascularization With Intravitreal Anti-Vascular Endothelial Growth Factor Antibody Fragment," <i>Arch. Ophthalmol.</i> , 120(3):338-346 (Mar. 2002)	Previously in US Application 17/072,417
50.	Lalwani, "All About PrONTO: Study Yielded Good Results in AMD With Treatment Guided by OCT," <i>Retina Today</i> (May 2007)	Previously in US Application 17/072,417
51.	Lobov <i>et al.</i> , "VEGF Trap Treatment Regresses Pathological Neovessels, Improves Revascularization and Reduces Retinal Ischemia in the Murine Oxygen-Induced Retinopathy (OIR) Model," ARVO Annual Meeting Abstract, <i>Investigative Ophthalmology & Visual Science</i> , 52:3128 (April 2011)	Previously in US Application 17/072,417
52.	Lucentis Approval (June 30, 2006)	Previously in US Application 17/072,417
53.	Lucentis Label Title, 7 pages, 06/2010 [Cited in Third Party Observations filed in parent application USSN 16/055,847 for which a copy is unavailable on PAIR]	Previously in US Application 17/072,417
54.	Macular Photocoagulation Study Group, "Laser photocoagulation of subfoveal neovascular lesions in age-related macular degeneration. Results of a randomized clinical trial," <i>Arch. Ophthalmol.</i> , 109(9):1220-1231 (1991)	Previously in US Application 17/072,417
55.	Mitchell <i>et al.</i> , "Ranibizumab (Lucentis) in Neovascular Age-Related Macular Degeneration: Evidence from Clinical Trials," <i>Brit. J. Ophthalmology</i> , 94:2-13 (2010) (first online publication on May 20, 2009)	Previously in US Application 17/072,417
56.	Mitra <i>et al.</i> , "Review of anti-vascular endothelial growth factor therapy in macular edema secondary to central retinal vein occlusions," <i>Expert Review in Ophthalmol.</i> , Taylor & Francis, GB 6(6):623-629 (January 2011)	Previously in US Application 17/072,417

EXAMINER	DATE CONSIDERED
EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line thr considered. Include copy of this form with next communication to Applicant.	ough citation if not in conformance and not

SUBSTITUTE 1449 INFORMATION DISCLOSURE STATEMENT	ATTY. DOCKET NO.	APPLICATION NO.
	REGN-008CIPCON9	17/350,958
	APPLICANT	
	REGENERON PHARMACEUTICALS	, INC.
	FILING DATE	GROUP
	June 17, 2021	To be assigned

NON-PATENT LITERATURE DOCUMENTS		
	DOCUMENT (Including Author, Title, Date, Pertinent Pages, etc.)	REFERENCE PROVIDED*
57.	Mousa and Mousa, "Current Status of Vascular Endothelial Growth Factor Inhibition in Age-Related Macular Degeneration," <i>Biodrugs</i> , 24(3):183-194 (2010)	Previously in US Application 17/072,417
58.	Nguyen <i>et al.</i> , "A phase I trial of an IV-administered vascular endothelial growth factor trap for treatment in patients with choroidal neovascularization due to age- related macular degeneration," <i>Ophthalmology</i> , 113(9):1522e1-1522e14 (Sept 2006) (epub July 28, 2006)	Previously in US Application 17/072,417
59.	Regeneron Pharmaceuticals Inc., "Regeneron Receives \$20 Million MilestonePayment for Initiation of Phase 3 Study of VEGF Trap-Eye in Wet AMD,"Media Release: 13 Aug 2007. Available from URL: http://www.regeneron.com	Previously in US Application 17/072,417
60.	Regeneron Pharmaceuticals Inc., "An Exploratory Study of the Safety,Tolerability and Biological Effect of a Single Intravitreal Administration ofVEGF Trap in Patients with Diabetic Macular Edema," poster presented at the2007 Association for Research in Vision and Ophthalmology meeting in Ft.Lauderdale, Florida (May 2007)	Previously in US Application 17/072,417
61.	Regeneron Pharmaceuticals Inc., "CLEAR-IT-2: Interim Results Of The Phase II, Randomized, Controlled Dose-and Interval-ranging Study Of Repeated Intravitreal VEGF Trap Administration In Patients With Neovascular Age- related Macular Degeneration (AMD)," poster presented at the 2007 Association for Research in Vision and Ophthalmology meeting in Ft. Lauderdale, Florida (May 2007)	Previously in US Application 17/072,417
62.	Regeneron Pharmaceuticals Inc., "Optical Coherence Tomography Outcomes of a Phase 1, Dose-Escalation, Safety, Tolerability, and Bioactivity Study of Intravitreal VEGF Trap in Patients with Neovascular Age-Related Macular Degeneration: The CLEAR-IT 1 Study," poster presented at the 2007 Association for Research in Vision and Ophthalmology meeting in Ft. Lauderdale, Florida (May 2007)	Previously in US Application 17/072,417
63.	Regeneron Pharmaceuticals Inc., "Regeneron Reports First Quarter 2008 Financial and Operating Results," Press release May 1, 2008.	Previously in US Application 17/072,417
64.	Regeneron Pharmaceuticals Inc., Form 10-Q, published November 7, 2007, for the period ending September 30, 2007.	Previously in US Application 17/072,417
65.	Regillo <i>et al.</i> , "Randomized, Double-Masked, Sham-Controlled Trial of Ranibizumab for Neovascular Age-related Macular Degeneration: OIER Study Year 1," <i>American Journal of Ophthalmology</i> , 145(2):239-248 (2008)	Previously in US Application 17/072,417
66.	Rosenfeld <i>et al.</i> , "Optical coherence tomography findings after an intravitreal injection of bevacizumab (avastin) for neovascular age-related macular degeneration," <i>Ophthalmic. Surg. Lasers Imaging</i> , 36(4):331-335 (2005)	Previously in US Application 17/072,417

EXAMINER	DATE CONSIDERED
EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line throu considered. Include copy of this form with next communication to Applicant.	ugh citation if not in conformance and not
*Copies of the listed references are either submitted herewith or were previously cited by or submitted to, the Office in a prior application. Pursuant to 37 C.F.I 1.97(d) and MPEP §609, the indicated reference may have been previously cited by or submitted to, the Office in a prior application, where the prior application identified by its U.S. Application Number in this Information Disclosure Statement.	

Page 6 of 12

SUBSTITUTE 1449 INFORMATION DISCLOSURE STATEMENT	ATTY. DOCKET NO.	APPLICATION NO.
	REGN-008CIPCON9	17/350,958
	APPLICANT	
	REGENERON PHARMACEUTICALS	, INC.
	FILING DATE	GROUP
	June 17, 2021	To be assigned

NON-PATENT LITERATURE DOCUMENTS		
	DOCUMENT (Including Author, Title, Date, Pertinent Pages, etc.)	REFERENCE PROVIDED*
67.	Scott <i>et al.</i> , "A randomized trial comparing the efficacy and safety of intravitreal triamcinolone with standard care to treat vision loss associated with macular Edema secondary to branch retinal vein occlusion: the Standard Care vs Corticosteroid for Retinal Vein Occlusion (SCORE) study report 6," <i>Arch. Ophthalmol.</i> , 127(9):1115-1128 & 127(12):1653 (2009)	Previously in US Application 17/072,417
68.	Simo and Hernandez, "Advances in Medical Treatment of Diabetic Retinopathy," <i>Diabetes Care</i> , 32(8):1556-1562 (August 2009)	Previously in US Application 17/072,417
69.	Slides for the 2008 Retina Society Meeting "VEGF Trap-Eye in Wet AMD CLEAR-IT 2: Summary of One-Year Key Results," September 28, 2008.	Previously in US Application 17/072,417
70.	Tolentino <i>et al.</i> , "One-year Results Of The Da Vinci Study of VEGF Trap-Eye In DME," ARVO Annual Meeting Abstract, <i>Investigative Ophthalmology & Visual Science</i> , 52:6646 (April 2011)	Previously in US Application 17/072,417
71.	van Bruggen <i>et al.</i> , "VEGF antagonism reduces edema formation and tissue damage after ischemia/reperfusion injury in the mouse brain," <i>The Journal of clinical investigation</i> , 104(11):1613-1620 (1999)	Previously in US Application 17/072,417
72.	WHO Drug Information, "International Nonproprietary Names for Pharmaceutical Substances (INN)," 20(2):115-119 (2006)	Previously in US Application 17/072,417

EXAMINER	DATE CONSIDERED
EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line three considered. Include copy of this form with next communication to Applicant.	ough citation if not in conformance and not
1.97(d) and MPEP §609, the indicated reference may have been previously cited by or submitted to, the Office in a prior	
	EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through

Page 7 of 12

SUBSTITUTE 1449 INFORMATION DISCLOSURE STATEMENT	ATTY. DOCKET NO.	APPLICATION NO.
	REGN-008CIPCON9	17/350,958
	APPLICANT	
	REGENERON PHARMACEUTICALS, INC.	
	FILING DATE	GROUP
	June 17, 2021	To be assigned

NON-PATENT LITERATURE DOCUMENTS - INSTITUTION DECISIONS		
	DOCUMENT (Including Author, Title, Date, Pertinent Pages, etc.)	REFERENCE PROVIDED*
73.	IPR2021-00880 dated November 10, 2021, for US 9,669,069 B2	Previously in US Application 17/072,417
74.	IPR2021-00881 dated November 10, 2021, for US 9,254,338 B2	Previously in US Application 17/072,417

EXAMINER	DATE CONSIDERED
EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line three considered. Include copy of this form with next communication to Applicant.	ough citation if not in conformance and not
*Copies of the listed references are either submitted herewith or were previously cited by or submitted to, the Office in a 1.97(d) and MPEP §609, the indicated reference may have been previously cited by or submitted to, the Office in a prior identified by its U.S. Application Number in this Information Disclosure Statement.	1 11 -

	ATTY. DOCKET NO.	APPLICATION NO.
	REGN-008CIPCON9	17/350,958
SUBSTITUTE 1449	APPLICANT	
INFORMATION DISCLOSURE STATEMENT	REGENERON PHARMACEUTICALS	, INC.
	FILING DATE	GROUP
	June 17, 2021	To be assigned

FOREIGN PATENT DOCUMENTS - UPDATES TO PREVIOUS IDS CITATIONS					
	DOCUMENT NUMBER	DATE	COUNTRY	TRANSLATION	REFERENCE PROVIDED*
75.	WO 97/04801	1997-02-13	WIPO	N/A	Previously in US Application 17/072,417
76.	EP 2663325	2013-11-20	EPO	N/A	Previously in US Application 17/072,417

1	NON-PATENT LITERATURE DOCUMENTS - UPDATES TO PREVIOUS IDS CITAT	IONS
	DOCUMENT (Including Author, Title, Date, Pertinent Pages, etc.)	REFERENCE PROVIDED*
77.	7,374,758 – Patent Term Extension Application submitted December 22, 2011	Previously in US Application 17/072,417
78.	ADIS R&D Profile, "Aflibercept: AVE 0005, AVE 005, AVE0005, VEGF Trap - Regeneron, VEGF Trap (R1R2), VEGF Trap-Eye," <i>Drugs R. D.</i> , 9(4):261-269 (2008)	Previously in US Application 17/072,417
79.	Andersen & Krummen, "Recombinant protein expression for therapeutic applications," <i>Current Opinion in Biotechnology</i> , 13:117-123 (2002)	Previously in US Application 17/072,417
80.	Anderson <i>et al.</i> , "Delivery of Anti-Angiogenic Molecular Therapies for Retinal Disease," <i>Drug Discovery Today</i> , 15(7/8):272-282 (2010)	Previously in US Application 17/072,417
81.	Article in Retinal Physician, "Subspecialty News," available online at http://www.retinalphysician.com/printarticle.aspx?articleID=104007 (March 2010)	Previously in US Application 17/072,417
82.	Ass'n for Res. Vision & Ophthalmology, ARVO News (Summer 2007)	Previously in US Application 17/072,417
83.	Ass'n for Res. Vision & Ophthalmology, ARVO News (Winter/Spring 2008)	Previously in US Application 17/072,417
84.	Avastin Label (Revised 12/2017)	Previously in US Application 17/072,417
85.	Avery, R. L., D. J. Pieramici, M. D. Rabena, A. A. Castellarin, M. A. Nasir and M. J. Giust, "Intravitreal bevacizumab (Avastin) for neovascular age-related macular degeneration," <i>Ophthalmology</i> , 113(3):363-372e5 (2006)	Previously in US Application 17/072,417
86.	Bashshur <i>et al.</i> , "Intravitreal Bevacizumab for the Management of Choroidal Neovascularization in Age-Related Macular Degeneration," <i>Am. J.</i> <i>Ophthalmology</i> , 142(1):1-9 (2006)	Previously in US Application 17/072,417
87.	 Bayer Press Release, "Bayer and Regeneron Dose First Patient in Second Phase 3 Study for VEGF Trap-Eye in Wet Age-Related Macular Degeneration," May 8, 2008 	Previously in US Application 17/072,417
88.	Bayer Press Release, "Bayer HealthCare and Regeneron Announce Encouraging 32-Week Follow Up Results From A Phase 2 Study of VEGF Trap-Eye in Age-Related Macular Degeneration," April 28, 2008	Previously in US Application 17/072,417

EXAMINER	DATE CONSIDERED
EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line three considered. Include copy of this form with next communication to Applicant.	ough citation if not in conformance and not
*Copies of the listed references are either submitted herewith or were previously cited by or submitted to, the Office in a 1.97(d) and MPEP §609, the indicated reference may have been previously cited by or submitted to, the Office in a prior identified by its U.S. Application Number in this Information Disclosure Statement.	

		1480 / 01 12
	ATTY. DOCKET NO.	APPLICATION NO.
	REGN-008CIPCON9	17/350,958
SUBSTITUTE 1449	APPLICANT	
INFORMATION DISCLOSURE STATEMENT	REGENERON PHARMACEUTICALS	, INC.
	FILING DATE	GROUP
	June 17, 2021	To be assigned

	NON-PATENT LITERATURE DOCUMENTS - UPDATES TO PREVIOUS IDS CITATI	ONS
	DOCUMENT (Including Author, Title, Date, Pertinent Pages, etc.)	REFERENCE PROVIDED*
89.	Bayer Press Release, "Bayer HealthCare and Regeneron Announce VEGF Trap- Eye Achieved Durable Improvement in Vision Over 52 Weeks in a Phase 2 Study in Patients with Age-Related Macular Degeneration," August 19, 2008	Previously in US Application 17/072,417
90.	Bayer Press Release, "VEGF Trap-Eye Shows Positive Results in Phase II Study in Patients with Diabetic Macular Edema," February 18, 2010	Previously in US Application 17/072,417
91.	BMJ Publishing Group Ltd., "Review: Ranibizumab (Lucentis) In Neovascular Age-Related Macular Degeneration: Evidence From Clinical Trials," <i>British J.</i> <i>Ophthalmology</i> , (December 2020), https://bjo.bmj.com/content/94/1/2.altmetrics	Previously in US Application 17/072,417
92.	Brown & Regillo, "Anti-VEGF Agents in the Treatment of Neovascular Age- Related Macular Degeneration: Applying Clinical Trial Results to the Treatment of Everyday Patients," <i>Am J. Ophthalmology</i> , 144(4)627-637e2 (2007)	Previously in US Application 17/072,417
93.	Chi <i>et al.</i> , "Physical Stability of Proteins in Aqueous Solution: Mechanism and Driving Forces in Nonnative Protein Aggregation" <i>Pharmaceutical Research</i> , 20(9):1325-1336 (September 2003)	Previously in US Application 17/072,417
94.	Ciulla & Rosenfeld, "Antivascular Endothelial Growth Factor Therapy For Neovascular Age-Related Macular Degeneration," <i>Current Opinion</i> <i>Ophthalmology</i> , 20:158-165 (2009)	Previously in US Application 17/072,417
95.	Clinicaltrials.gov. I-SPY 2 TRIAL: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breast Cancer, Accessed 2010; http://clinical trials.gov/ct2/show/NCT01042379?term-NCT01042379&rank=1	Previously in US Application 17/072,417
96.	CMS, Local Coverage Determination (LCD) for Ranibizumab (Lucentis) (L29266, First Coast Service Options, Inc June 14, 2011)	Previously in US Application 17/072,417
97.	Controls in SCI experiments, RegenBase. Retrieved January 6, 2021, from http://regenbase.org/control-groups.html	Previously in US Application 17/072,417
98.	Drug Vehicle (Code C927), National Cancer Institute (NCI). Retrieved January 6, 2021, from https://ncithesaurus.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary =NCI_Thesaurus&code=C927&ns=ncit	Previously in US Application 17/072,417
99.	EP 2 663 325 File History	Previously in US Application 17/072,417
100.	Eylea Prescribing Information, Revised 05/2019	Previously in US Application 17/072,417
101.	Ferrara, N. & Kerbel, R., "Angiogenesis as a Therapeutic Target," <i>Nature</i> , 438:967-974 (2005)	Previously in US Application 17/072,417
102.	Fraser <i>et al.</i> , "Single Injections of Vascular Endothelial Growth Factor Trap Block Ovulation in the Macaque and Produce a Prolonged, Dose-Related Suppression of Ovarian Function." J. Clin. Endocrinol & Metab. 90(2): 1114- 1122 (February 2005)	Previously in US Application 17/072,417

EXAMINER	DATE CONSIDERED
EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line th considered. Include copy of this form with next communication to Applicant.	rough citation if not in conformance and not

Page 10 of 12

	ATTY. DOCKET NO.	APPLICATION NO.
	REGN-008CIPCON9	17/350,958
SUBSTITUTE 1449	APPLICANT	
INFORMATION DISCLOSURE STATEMENT	REGENERON PHARMACEUTICALS	, INC.
	FILING DATE	GROUP
	June 17, 2021	To be assigned

	NON-PATENT LITERATURE DOCUMENTS - UPDATES TO PREVIOUS IDS CITATIO	
	DOCUMENT (Including Author, Title, Date, Pertinent Pages, etc.)	REFERENCE PROVIDED*
103.	Genentech, "FDA Approves Lucentis for the Treatment of Wet Age-Related Macular Degeneration," News Release dated June 30, 2006 (June 30, 2006)	Previously in US Application 17/072,417
104.	Gupta, O. P., G. Shienbaum, A. H. Patel, C. Fecarotta, R. S. Kaiser and C. D. Regillo, "A treat and extend regimen using ranibizumab for neovascular age- related macular degeneration clinical and economic impact," <i>Ophthalmology</i> , 117(11): 2134-2140 (2010)	Previously in US Application 17/072,417
105.	Heier <i>et al.</i> , "Ranibizumab for macular edema due to retinal vein occlusions: long-term follow-up in the HORIZON trial," <i>Ophthalmology</i> , 119(4):802-809 (2012)	Previously in US Application 17/072,417
106.	Heier, "Intravitreal VEGF Trap for AMD: An Update," Retina Today 44 (October 2009)	Previously in US Application 17/072,417
107.	Holz <i>et al.</i> , "VEGF Trap-Eye for Macular Oedema Secondary to Central Retinal Vein Occlusion: 6-Month Results of the Phase III GALILEO Study," <i>British J.</i> <i>Ophthalmology</i> , 97:278-284 (2013)	Previously in US Application 17/072,417
108.	Information from ClinicalTrials.gov archive on the VIEW 1 study (NCT00509795) "Vascular Endothelial Growth Factor (VEGF) Trap-Eye: Investigation of Efficacy and Safety in Wet Age-Related Macular Degeneration (AMD) (VIEW1)," changes from v8 (March 3, 2009) to v9 (April 28, 2009)	Previously in US Application 17/072,417
109.	Janeway <i>et al.</i> , "The structure of a typical antibody molecule" Immunobiology: The Immune System in Health and Disease. 5th edition. New York: Garland Science (2001)	Previously in US Application 17/072,417
110.	Keane <i>et al.</i> , "Effect of Ranibizumab Retreatment Frequency on NeurosensoryRetinal Volume in Neovascular AMD," <i>Retina</i> , 29(5):592-600 (2009)	Previously in US Application 17/072,417
111.	Kim <i>et al.</i> , "Potent VEGF Blockade Causes Regression of Coopted Vessels in a Model of Neuroblastoma," <i>Proc. Nat'l Acad. Sci.</i> , 99(17):11399-11404 (2002)	Previously in US Application 17/072,417
112.	Lucentis Label (Revised 2006)	Previously in US Application 17/072,417
113.	Lucentis Label (Revised 2014)	Previously in US Application 17/072,417
114.	Massin, "Anti-VEGF Therapy for Diabetic Macular Edema: An Update," Retina Today 54 (Sept./Oct. 2008)	Previously in US Application 17/072,417
115.	Michels, S., P. J. Rosenfeld, C. A. Puliafito, E. N. Marcus and A. S. Venkatraman, "Systemic bevacizumab (Avastin) therapy for neovascular age- related macular degeneration twelve-week results of an uncontrolled open-label clinical study," <i>Ophthalmology</i> , 112(6):1035-1047 (2005)	Previously in US Application 17/072,417
116.	Ni & Hui, "Emerging Pharmacologic Therapies for Wet Age-Related Macular Degeneration," <i>Ophthalmologica</i> , 223:401-410 (Published Online First 20 May 2009)	Previously in US Application 17/072,417
117.	Parkins & Lashmar, "The formulation of biopharmaceutical products," <i>Pharmaceutical Science & Technology Today</i> , 3(4):129-137 (April 4, 2000)	Previously in US Application 17/072,417

EXAMINER	DATE CONSIDERED
EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line three considered. Include copy of this form with next communication to Applicant.	ough citation if not in conformance and not

Page 11 of 12

	ATTY. DOCKET NO.	APPLICATION NO.
SUBSTITUTE 1449	REGN-008CIPCON9	17/350,958
SUBSTITUTE 1449	APPLICANT	
INFORMATION DISCLOSURE STATEMENT	REGENERON PHARMACEUTICALS	, INC.
	FILING DATE	GROUP
	June 17, 2021	To be assigned

	NON-PATENT LITERATURE DOCUMENTS - UPDATES TO PREVIOUS IDS CITATIO	ONS
	DOCUMENT (Including Author, Title, Date, Pertinent Pages, etc.)	REFERENCE PROVIDED*
118.	Phosphate buffer. Cold Spring Harbor Protocols 2006: pdb.rec8543 (2006)	Previously in US Application 17/072,417
119.	Randolph & Jones, "Surfactant-Protein Interactions" <i>Rational Design of Stable</i> <i>Protein Formulations</i> pp. 159-175, Springer, Boston, MA (2002)	Previously in US Application 17/072,417
120.	Raptiva Label (Final Labelling 03-13-2009)	Previously in US Application 17/072,417
121.	Regeneron Pharmaceuticals Inc., Regeneron Reports Fourth Quarter and FullYear 2004 Financial and Operating Results. Media Release: 22 Feb 2005.	Previously in US Application 17/072,417
122.	Regeneron Pharmaceuticals Inc., Regeneron Reports Fourth Quarter and Full Year 2005 Financial and Operating Results. Media Release: 24 Feb 2006.	Previously in US Application 17/072,417
123.	Regeneron Pharmaceuticals Inc., Regeneron Reports Positive Phase 1 Data for the VEGF Trap in Age-Related Macular Degeneration; Preliminary Results Show Improvements in Vision and Reginal Swelling; VEGF Trap Was Well Tolerated at All Dose Levels. Media Release: 1 May 2006.	Previously in US Application 17/072,417
124.	Regeneron SEC Form 10-Q (September 30, 2009)	Previously in US Application 17/072,417
125.	Reichert, "Antibody-Based Therapeutics To Watch In 2011," <i>MABS</i> , 3(1):76-99 (2011)	Previously in US Application 17/072,417
126.	Remicade Label (Revised November 2013)	Previously in US Application 17/072,417
127.	Retina Coding Q & A, Retinal Physician, 16: 18, 54 (July/August 2019)	Previously in US Application 17/072,417
128.	Rogers <i>et al.</i> , "The prevalence of retinal vein occlusion: pooled data from population studies from the United States, Europe, Asia, and Australia," <i>Ophthalmology</i> , 117(2):313-319e1 (2010)	Previously in US Application 17/072,417
129.	Rudge <i>et al.</i> , "VEGF Trap as a Novel Antiangiogenic Treatment Currently in Clinical Trials for Cancer and Eye Diseases, and VelociGene-based Discovery of the Next Generation of Angiogenesis Targets," <i>Cold Spring Harbor</i> <i>Symposia on Quantitative Biology</i> , 70:411-418 (2005)	Previously in US Application 17/072,417
130.	Schmidt-Erfurth, "Current Concepts in the Management of Diabetic Macular Edema," <i>Johns Hopkins Advanced Studies in Ophthalmology</i> , 7(2):52-59 (2010)	Previously in US Application 17/072,417
131.	Simulect Label (May 1998)	Previously in US Application 17/072,417
132.	Spaide <i>et al.</i> , "Prospective Study of Intravitreal Ranibizumab as a Treatment for Decreased Visual Acuity Secondary to Central Retinal Vein Occlusion," <i>Am. J.</i> <i>Ophthalmology</i> , 147(2):298-306 (2009)	Previously in US Application 17/072,417
133.	Spielberg, L. & Leys, A., "Intravitreal Bevacizumab for Myopic Choroidal Neovascularization: Short-Term and 1-Year Results," <i>Bulletin Societe Belge</i> <i>D'Ophtalmologie</i> , 312:17-27 (2009)	Previously in US Application 17/072,417

EXAMINER	DATE CONSIDERED
EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through the second seco	ough citation if not in conformance and not
considered. Include copy of this form with next communication to Applicant.	•
*Copies of the listed references are either submitted herewith or were previously cited by or submitted to, the Office in a	a prior application. Pursuant to 37 C.F.R. §
1.97(d) and MPEP §609, the indicated reference may have been previously cited by or submitted to, the Office in a prior	application, where the prior application is
identified by its U.S. Application Number in this Information Disclosure Statement.	

	ATTY. DOCKET NO.	APPLICATION NO.
SUBSTITUTE 1449 INFORMATION DISCLOSURE STATEMENT	REGN-008CIPCON9	17/350,958
	APPLICANT	
	REGENERON PHARMACEUTICALS	, INC.
	FILING DATE	GROUP
	June 17, 2021	To be assigned

	NON-PATENT LITERATURE DOCUMENTS - UPDATES TO PREVIOUS IDS CITATI	ONS
	DOCUMENT (Including Author, Title, Date, Pertinent Pages, etc.)	REFERENCE PROVIDED*
134.	Steinbrook, "The Price of Sight — Ranibizumab, Bevacizumab, and the Treatment of Macular Degeneration," <i>N. Eng. J. Med.</i> , 355(14):1409-1412 (2006)	Previously in US Application 17/072,417
135.	The Branch Vein Occlusion Study, G., "Argon laser photocoagulation for macular edema in branch vein occlusion," <i>Am. J. Ophthalmology</i> , 98(3):271- 282 (1984)	Previously in US Application 17/072,417
136.	The Central Vein Occlusion Study, G., "Evaluation of grid pattern photocoagulation for macular edema in central vein occlusion. The Central Vein Occlusion Study Group M report," <i>Ophthalmology</i> , 102(10):1425-1433 (1995)	Previously in US Application 17/072,417
137.	U.S. Department of Health and Human Services, Food and Drug Administration, "Guidance for industry Q1A(R2) stability testing of new drug substances and products," Rockville, MD (November 2003)	Previously in US Application 17/072,417
138.	U.S. Department of Health and Human Services, National Institute of Health, National Eye Institute, "Age-Related Macular Degeneration: What You Should Know," (Sept. 2015) https://www.nei.nih.gov/sites/default/files/healthpdfs/WYSK_AMD_English_S ept2015_PRINT.pdf	Previously in US Application 17/072,417
139.	U.S. Department of Health and Human Services, National Institute of Health, National Eye Institute, "Diabetic Retinopathy: What You Should Know," (Sept. 2015) https://www.nei.nih.gov/sites/default/files/2019-06/Diabetic-Retinopathy- What-You-Should-Know-508.pdf	Previously in US Application 17/072,417
140.	U.S. Department of Health and Human Services, Office of Inspector General, "Questionable Billing for Medicare Ophthalmology Services" September 2015 OEI-04-12-00280	Previously in US Application 17/072,417
141.	Wall Street Journal, "Genentech's Big Drug for Eyes Faces a Rival" (2007)	Previously in US Application 17/072,417
142.	Wulff et al., "Prevention of Thecal Angiogenesis, Antral Follicular Growth, and Ovulation in the Primate by Treatment with Vascular Endothelial Growth Factor Trap R1R2" Endocrinology 143(7): 2797-2807 (July 2002)	Previously in US Application 17/072,417
143.	Xolair Label (2003)	Previously in US Application 17/072,417
144.	Zarbin & Rosenfeld, "Pathway-Based Therapies for Age-Related Macular Degeneration: An Integrated Survey of Emerging Treatment Alternatives" Retina 30: 1350 (2010)	Previously in US Application 17/072,417

EXAMINER	DATE CONSIDERED
EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line throconsidered. Include copy of this form with next communication to Applicant.	ough citation if not in conformance and not
*Copies of the listed references are either submitted herewith or were previously cited by or submitted to, the Office in a 1.97(d) and MPEP §609, the indicated reference may have been previously cited by or submitted to, the Office in a prior identified by its U.S. Application Number in this Information Disclosure Statement.	

Electronic A	cknowledgement Receipt
EFS ID:	44366474
Application Number:	17350958
International Application Number:	
Confirmation Number:	4833
Title of Invention:	USE OF A VEGF ANTAGONIST TO TREAT ANGIOGENIC EYE DISORDERS
First Named Inventor/Applicant Name:	George YANCOPOULOS
Customer Number:	96387
Filer:	Karl Bozicevic/Kimberly Zuehlke
Filer Authorized By:	Karl Bozicevic
Attorney Docket Number:	REGN-008CIPCON9
Receipt Date:	24-NOV-2021
Filing Date:	17-JUN-2021
Time Stamp:	14:52:21
Application Type:	Utility under 35 USC 111(a)

Payment information:

Submitted with Payment no			no			
File Listing:						
Document Number	Document Description		File Name	File Size(Bytes)/ Message Digest	Multi Part /.zip	Pages (if appl.)
			53432			
1	Transmittal Letter	REG	GN-008CIPCON9_2021-11-24 _SuppIDS_trans.pdf	8f103c143482994f0e2a9ee2a7c97900abf3 4b97	no	3
Warnings:	rnings: APOTEX V. REGENERON IPR2022-01524					

	:				
2	Information Disclosure Statement (IDS) Form (SB08)	REGN-008CIPCON9_2021-11-24 _SuppIDS_1449.pdf	127437 71b95e4b299b9b0679a004f443be9d4fc46 \$0537	no	12
Warnings:			<u> </u>		<u> </u>
Information	:				
This is not an l	ISPTO supplied IDS fillable form				
		Total Files Size (in bytes)	: 18	80869	
lf a new app	tions Under 35 U.S.C. 111 lication is being filed and the applica	•	-		
lf a new app 1.53(b)-(d) a	lication is being filed and the applica nd MPEP 506), a Filing Receipt (37 CF	R 1.54) will be issued in due	-		
If a new app 1.53(b)-(d) a Acknowledg <u>National Sta</u> If a timely su U.S.C. 371 a	lication is being filed and the applica	FR 1.54) will be issued in due og date of the application. <u>oder 35 U.S.C. 371</u> of an international applicati form PCT/DO/EO/903 indicati	course and the date s on is compliant with ng acceptance of the	hown on th the conditional states application	iis ons of 35
If a new app 1.53(b)-(d) a Acknowledg <u>National Sta</u> If a timely su U.S.C. 371 an national sta <u>New Interna</u> If a new inte	lication is being filed and the applica nd MPEP 506), a Filing Receipt (37 CF ement Receipt will establish the filin ge of an International Application ur obmission to enter the national stage nd other applicable requirements a F ge submission under 35 U.S.C. 371 wi tional Application Filed with the USP rnational application is being filed an	R 1.54) will be issued in due og date of the application. <u>Inder 35 U.S.C. 371</u> of an international applicati form PCT/DO/EO/903 indicati ill be issued in addition to the <u>PTO as a Receiving Office</u> nd the international applicat	course and the date s on is compliant with ing acceptance of the e Filing Receipt, in du ion includes the nece	the conditional the conditional the conditional the conditional termination of the course.	iis ons of 35 1 as a onents f
If a new app 1.53(b)-(d) a Acknowledg <u>National Sta</u> If a timely su U.S.C. 371 an national sta <u>New Interna</u> If a new inte an international of the Im	lication is being filed and the applica nd MPEP 506), a Filing Receipt (37 CF ement Receipt will establish the filin ge of an International Application ur obmission to enter the national stage nd other applicable requirements a F ge submission under 35 U.S.C. 371 wi tional Application Filed with the USP	R 1.54) will be issued in due og date of the application. <u>oder 35 U.S.C. 371</u> of an international applicati form PCT/DO/EO/903 indicati ill be issued in addition to the <u>PTO as a Receiving Office</u> nd the international applicat of MPEP 1810), a Notification O/105) will be issued in due c	course and the date s on is compliant with ng acceptance of the e Filing Receipt, in du ion includes the nece of the International ourse, subject to pres	the condition application the course. The course comp application scriptions c	iis ons of 35 n as a onents f Number oncernin

the application.

Licet offenny Theu					
SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT	Attorney Docket No.	REGN-008CIPCON9			
	Confirmation No.	4833			
	First Named Inventor	George D. Yancopoulos			
	Application Number	17/350,958			
	Filing Date	June 17, 2021			
	Group Art Unit	To Be Assigned			
Address to:	Examiner Name	To Be Assigned			
Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450	Title: "Use of a VEGF Eye Disorders"	Antagonist to Treat Angiogenic			

Electronically Filed

Sir:

The attention of the Examiner is invited to the documents listed on the attached Substitute 1449.

Copies of the U.S. patents and published applications listed on the attached Substitute 1449 are not submitted herewith, in accordance with the Strategic Plan Final Rule, 69 Fed. Reg. 56481-56547 (September 21, 2004), effective October 21, 2004.

Copies of the foreign publications and non-patent literature documents listed on the attached Substitute 1449 are submitted in parent U.S. Application No. 17/072,417. Applicant respectfully submits that a subset of references submitted herein were previously submitted in this or a priority application. Nonetheless, Applicant is submitting these previously submitted references to provide an accurate reference citation or to provide a clearer copy of the reference.

Applicant notes that the transmittal letter accompanying the Information Disclosure Statement submitted for this application on July 9, 2021, incorrectly recited that "[a]ll of the references identified herein were disclosed in parent application serial number 17/112,404." Accordingly, the citations previously submitted in the July 9, 2021 Information Disclosure Statement are resubmitted here as Ref. Nos. 75 to 143 in order to correct the record. Applicant notes that this group of resubmitted citations accounts for part of the citations provided herein.

Applicant would also like to bring to the Examiner's attention that the PTAB has instituted *inter partes* reviews for related U.S. Patent Nos. 9,254,338 and 9,669,069.

It is respectfully requested that the information above be expressly considered during the prosecution of this application, and that the documents be made of record therein and appear among the "References Cited" on any patent to issue therefrom.

No aspect of these submissions constitute admission of prior art status or a disclaimer of claim scope.

Statements

No statement. Because this Information Disclosure Statement is being submitted prior to issuance of the first action on the merits of the above-captioned application, no certification or fee is required.

PTA Statement under 37 CFR § 1.704(d)(1): Each item of information contained in the information disclosure statement filed herewith:

(i) Was first cited in any communication from a patent office in a counterpart foreign or international application or from the Office, and this communication was not received by any individual designated in § 1.56(c) more than thirty days prior to the filing of the information disclosure statement; or

(ii) Is a communication that was issued by a patent office in a counterpart foreign or international application or by the Office, and this communication was not received by any individual designated in § 1.56(c) more than thirty days prior to the filing of the information disclosure statement.

- **IDS Statement under 37 CFR § 1.97(e)(1):** Each item of information contained in the information disclosure statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of the information disclosure statement; or
- **IDS Statement under 37 CFR § 1.97(e)(2):** No item of information contained in the information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the person signing the certification after making reasonable inquiry, no item of information contained in the information disclosure statement was known to any individual designated in § 1.56(c) more than three months prior to the filing of the information disclosure statement.

<u>Fees</u>

 \boxtimes No fee is believed to be due.

The appropriate fee set forth in 37 C.F.R. §1.17(p) accompanies this information disclosure statement.

The Commissioner is hereby authorized to charge any underpayment of fees up to a strict limit of \$3,000.00 beyond that authorized on the credit card, but not more than \$3,000.00 in additional fees due with any communication for the above-referenced patent application, including but not limited to any necessary fees for extensions of time, or credit any overpayment of any amount to Deposit Account No. 50-0815, order number REGN-008CIPCON9.

Respectfully submitted, BOZICEVIC, FIELD & FRANCIS LLP

Date: 24 November 2021

BOZICEVIC, FIELD & FRANCIS LLP 201 Redwood Shores Parkway, Suite 200 Redwood City, CA 94065 Telephone: (650) 327-3400 Facsimile: (650) 327-3231 By: /Karl Bozicevic, Reg. No. 28,807/ Karl Bozicevic Reg. No. 28,807

INFORMATION DISCLOSURE STATEMENT BY APPLICANT		Filing Dat	ed Inventor	George To Be	,958 7, 2021 9 D. YANCOPOULOS Assigned Assigned		
Sheet	et 1 of 1		Attorney I	Docket Number	REGN-008CIPCON9		
U.S. F Examiner Cite Patent Number Issue				PATENT D Date MM-DD	OCUMENTS Name of Patente Applicant of Cited Do		Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear

	U.S. PATENT APPLICATION PUBLICATIONS							
Examiner Initial*	Cite No.	Publication Number	Publication Date YYYY-MM-DD	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant			
		Number-Kind Code (if known)			Figures Appear			
	1							

Davis-Smyth et al.

2005-05-24

1

6897294

	FOREIGN PATENT DOCUMENTS						
Examiner Initial*	Cite No.	Foreign Document Number Country Code-Number-Kind Code (<i>if</i> known)	Publication Date YYYY-MM-DD	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	Т	
	1						

		NON PATENT LITERATURE DOCUMENTS	
Examin er Initials*	No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	Т
	1		

Examiner	Date	
Signature	Considered	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Electronic A	Electronic Acknowledgement Receipt				
EFS ID:	44540119				
Application Number:	17350958				
International Application Number:					
Confirmation Number:	4833				
Title of Invention:	USE OF A VEGF ANTAGONIST TO TREAT ANGIOGENIC EYE DISORDERS				
First Named Inventor/Applicant Name:	George YANCOPOULOS				
Customer Number:	96387				
Filer:	Karl Bozicevic/Kimberly Zuehlke				
Filer Authorized By:	Karl Bozicevic				
Attorney Docket Number:	REGN-008CIPCON9				
Receipt Date:	16-DEC-2021				
Filing Date:	17-JUN-2021				
Time Stamp:	17:26:23				
Application Type:	Utility under 35 USC 111(a)				

Payment information:

Submitted with Payment			no			
File Listing	:					
Document Number	Document Description		File Name	File Size(Bytes)/ Message Digest	Multi Part /.zip	Pages (if appl.)
				51517		
1	Transmittal Letter	REGN-008CIPCON9_2021-12-16		e986418a58734a24122b75c108ed362e1e7 b8342	no	2
Warnings:	APOTEX V. REGENERON IPR2022-01524					

rmation Disclosure Statement (IDS) Form (SB08) upplied IDS fillable form ment Receipt evidences receip he applicant, and including pag ibed in MPEP 503.		386bfdab0963dd1d972318d7ab02206db8 4cfb57 7 SPTO of the indicated	73821 d document	
ment Receipt evidences receip ne applicant, and including pag	t on the noted date by the U	SPTO of the indicated	d document	
ment Receipt evidences receip ne applicant, and including pag	t on the noted date by the U	SPTO of the indicated	d document	
ment Receipt evidences receip ne applicant, and including pag	t on the noted date by the U	SPTO of the indicated	d document	
ne applicant, and including pag	t on the noted date by the U	SPTO of the indicated	d document	
ne applicant, and including pag	t on the noted date by the U	SPTO of the indicated		
<u>Jnder 35 U.S.C. 111</u> n is being filed and the applica EP 506), a Filing Receipt (37 CF	R 1.54) will be issued in due			
•				
ion to enter the national stage er applicable requirements a F	of an international applicati orm PCT/DO/EO/903 indicati	ing acceptance of the	application	
Application Filed with the USP	TO as a Receiving Office			
ing date (see PCT Article 11 an	d MPEP 1810), a Notification	of the International	Application	n Numbei
	Receipt will establish the film n International Application un ion to enter the national stage er applicable requirements a F mission under 35 U.S.C. 371 wi Application Filed with the USP nal application is being filed ar ing date (see PCT Article 11 an	Receipt will establish the filing date of the application. <u>n International Application under 35 U.S.C. 371</u> ion to enter the national stage of an international applicat er applicable requirements a Form PCT/DO/EO/903 indicat mission under 35 U.S.C. 371 will be issued in addition to th <u>Application Filed with the USPTO as a Receiving Office</u> nal application is being filed and the international applicat ing date (see PCT Article 11 and MPEP 1810), a Notification	Receipt will establish the filing date of the application. <u>n International Application under 35 U.S.C. 371</u> ion to enter the national stage of an international application is compliant with er applicable requirements a Form PCT/DO/EO/903 indicating acceptance of the mission under 35 U.S.C. 371 will be issued in addition to the Filing Receipt, in du <u>Application Filed with the USPTO as a Receiving Office</u> nal application is being filed and the international application includes the nece	Receipt will establish the filing date of the application. <u>n International Application under 35 U.S.C. 371</u> ion to enter the national stage of an international application is compliant with the conditi er applicable requirements a Form PCT/DO/EO/903 indicating acceptance of the application mission under 35 U.S.C. 371 will be issued in addition to the Filing Receipt, in due course. <u>Application Filed with the USPTO as a Receiving Office</u> nal application is being filed and the international application includes the necessary comp ing date (see PCT Article 11 and MPEP 1810), a Notification of the International Application

the application.

Electronically Filed

	•	
	Attorney Docket No.	REGN-008CIPCON9
	Confirmation No.	4833
SUPPLEMENTAL INFORMATION	First Named Inventor	George D. Yancopoulos
DISCLOSURE STATEMENT	Application Number	17/350,958
	Filing Date	June 17, 2021
	Group Art Unit	To Be Assigned
Address to:	Examiner Name	To Be Assigned
Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450	Title: "Use of a VEGF Eye Disorders"	Antagonist to Treat Angiogenic

Sir:

Applicant submits herewith documents which may be material to the examination of this application and in respect of which there may be a duty to disclose in accordance with 37 C.F.R. § 1.56. This submission is not intended to constitute an admission that any document referred to therein is "prior art" for this invention unless specifically designated as such. A listing of the documents is shown on enclosed Form PTO/SB/08A.

The publications discussed herein are provided to comply with the duty to disclose in accordance with 37 C.F.R. § 1.56. However, nothing herein is to be construed as an admission that the present invention is not entitled to antedate such publication by virtue of prior invention. Further, the dates of publication provided may be different from the actual publication dates which may need to be independently confirmed

The Examiner is requested to make the documents listed on the enclosed PTO/SB/08A of record in this application. Applicants would appreciate the Examiner initialing and returning the initialed copy of form PTO/SB/08A, indicating the documents cited therein have been considered and made of record herein.

Statements

- No statement
- **PTA Statement under 37 CFR § 1.704(d)(1):** Each item of information contained in the information disclosure statement filed herewith:

(i) Was first cited in any communication from a patent office in a counterpart foreign or international application or from the Office, and this communication was not received by any individual designated in § 1.56(c) more than thirty days prior to the filing of the information disclosure statement; or

(ii) Is a communication that was issued by a patent office in a counterpart foreign or international application or by the Office, and this communication was not received by any individual designated in § 1.56(c) more than thirty days prior to the filing of the information disclosure statement.

IDS Statement under 37 CFR § 1.97(e)(1): Each item of information contained in the information disclosure statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of the information disclosure statement; or

IDS Statement under 37 CFR § 1.97(e)(2): No item of information contained in the information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the person signing the certification after making reasonable inquiry, no item of information contained in the information disclosure statement was known to any individual designated in § 1.56(c) more than three months prior to the filing of the information disclosure statement.

<u>Fees</u>

 \square

 \square No fee is believed to be due.

The appropriate fee set forth in 37 C.F.R. §1.17(p) accompanies this information disclosure statement.

The Commissioner is hereby authorized to charge any underpayment of fees up to a strict limit of \$3,000.00 beyond that authorized on the credit card, but not more than \$3,000.00 in additional fees due with any communication for the above-referenced patent application, including but not limited to any necessary fees for extensions of time, or credit any overpayment of any amount to Deposit Account No. 50-0815, order number REGN-008CIPCON9.

Respectfully submitted, BOZICEVIC, FIELD & FRANCIS LLP

Date: <u>16 December 2021</u>

By: /Karl Bozicevic, Reg. No. 28,807/ Karl Bozicevic Reg. No. 28,807

BOZICEVIC, FIELD & FRANCIS LLP 201 Redwood Shores Parkway, Suite 200 Redwood City, CA 94065 Telephone: (650) 327-3400 Facsimile: (650) 327-3231

	ATTY. DOCKET NO.	APPLICATION NO.
SUBSTITUTE 1449 INFORMATION DISCLOSURE STATEMENT	REGN-008CIPCON9	17/350,958
	APPLICANT	
	REGENERON PHARMACEUTICALS	, INC.
	FILING DATE	GROUP
	June 17, 2021	To be assigned

	U.S. PATENT DOCUMENTS				
		DOCUMENT NUMBER	DATE	NAME	REFERENCE PROVIDED*
1.		US 7,300,563 B2	2007-11-27	Diaddario, Jr.	not required per 69 Fed. Reg. 56481
2.	2.	US 7,300,653 B2	2007-11-27	Wiegand et al.	not required per 69 Fed. Reg. 56481
3.	5.	US 7,608,261 B2	2009-10-27	Furfine <i>et al</i> .	not required per 69 Fed. Reg. 56481
4.	ŀ.	US 2010/0160,233 A1	2010-06-24	Bissery et al.	not required per 69 Fed. Reg. 56481
5.	5.	US 7,972,598 B2	2011-07-05	Daly <i>et al</i> .	not required per 69 Fed. Reg. 56481
6.	5.	US 8,029,791 B2	2011-10-04	Papadopoulos et al.	not required per 69 Fed. Reg. 56481
7.	<i>'</i> .	US 8,343,737 B2	2013-01-01	Papadopoulos <i>et al</i> .	not required per 69 Fed. Reg. 56481
8.	3.	US 8,647,842 B2	2014-02-11	Papadopoulos <i>et al.</i>	not required per 69 Fed. Reg. 56481
9.).	US 10,857,205 B2	2020-12-08	Yancopoulos	not required per 69 Fed. Reg. 56481
10	.0.	US 10,888,601 B2	2021-01-12	Yancopoulos	not required per 69 Fed. Reg. 56481
1	1.	US 11,066,458 B2	2021-07-20	Furfine et al.	not required per 69 Fed. Reg. 56481
12	2.	US 11,084,865 B2	2021-08-10	Furfine et al.	not required per 69 Fed. Reg. 56481
11	.3.	US 11,253,572 B2	2022-02-22	Yancopoulos	not required per 69 Fed. Reg. 56481

FOREIGN PATENT DOCUMENTS					
	DOCUMENT NUMBER	DATE	COUNTRY	TRANSLATION	REFERENCE PROVIDED*
14.	EP 3222285 A1	2017-09-27	EPO	N/A	Previously in US Application 17/072,417

NON-PATENT LITERATURE DOCUMENTS				
	DOCUMENT (Including Author, Title, Date, Pertinent Pages, etc.)	REFERENCE PROVIDED*		
15.	Abraham <i>et al.</i> , "Randomized, Double-Masked, Sham-Controlled Trial of Ranibizumab for Neovascular Age-Related Macular Degeneration: PIER Study Year 2," <i>Am. J. Ophthalmology</i> , 150(3), pp. 315-324.e1 (September 2010)	Previously in US Application 17/072,417		
16.	Adamis, "Ocular Angiogenesis: Vascular Endothelial Growth Factor and Other Factors," in <i>Retinal Pharmacotherapy 23</i> , Nguyen <i>et al.</i> , eds., (2010)	Previously in US Application 17/072,417		
17.	American Academy of Ophthalmology, "Anti-VEGF Treatments," https://www.aao.org/eye-health/drugs/anti-vegf-treatments (accessed November 8, 2021)	Previously in US Application 17/072,417		

EXAMINER	DATE CONSIDERED
EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line thr	ough citation if not in conformance and not
considered. Include copy of this form with next communication to Applicant.	

	ATTY. DOCKET NO.	APPLICATION NO.
SUBSTITUTE 1449 INFORMATION DISCLOSURE STATEMENT	REGN-008CIPCON9	17/350,958
	APPLICANT	
	REGENERON PHARMACEUTICALS	, INC.
	FILING DATE	GROUP
	June 17, 2021	To be assigned

	NON-PATENT LITERATURE DOCUMENTS	
	DOCUMENT (Including Author, Title, Date, Pertinent Pages, etc.)	REFERENCE PROVIDED*
18.	American Academy of Ophthalmology, "Bevacizumab," https://eyewiki.aao.org/Bevacizumab (accessed November 2, 2021)	Previously in US Application 17/072,417
19.	American Academy of Ophthalmology, "Ophthalmology Subspecialists," June 6, 2016, https://www.aao.org/eye-health/tips-prevention/ophthalmology-subspecialists (accessed September 26, 2022)	Previously in US Application 17/072,417
20.	American Academy of Ophthalmology, "Retinal Vasculitis," https://eyewiki.aao.org/Retinal_Vasculitis (accessed January 13, 2022)	Previously in US Application 17/072,417
21.	American Academy of Ophthalmology, "What is Avastin," https://www.aao.org/eye-health/drugs/avastin (accessed November 9, 2021)	Previously in US Application 17/072,417
22.	American Academy of Ophthalmology, "What is Eylea," https://www.aao.org/eye-health/drugs/what-is-eylea (accessed November 9, 2021)	Previously in US Application 17/072,417
23.	American Academy of Ophthalmology, "What is Lucentis," https://www.aao.org/eye-health/drugs/lucentis (accessed November 9, 2021)	Previously in US Application 17/072,417
24.	American Society of Retina Specialists, "About Us," https://www.asrs.org/about (accessed December 6, 2021)	Previously in US Application 17/072,417
25.	American Society of Retina Specialists, "Age-Related Macular Degeneration," https://www.asrs.org/patients/retinal-diseases/2/agerelated-macular- degeneration (accessed December 30, 2021)	Previously in US Application 17/072,417
26.	American Society of Retina Specialists, "Branch Retinal Vein Occlusion," https://www.asrs.org/patients/retinal-diseases/24/branch-retinal-vein-occlusion (accessed December 30, 2021)	Previously in US Application 17/072,417
27.	American Society of Retina Specialists, "Central Retinal Vein Occlusion," https://www.asrs.org/patients/retinal-diseases/22/central-retinal-vein-occlusion (accessed December 30, 2021)	Previously in US Application 17/072,417
28.	American Society of Retina Specialists, "Diabetic Retinopathy," https://www.asrs.org/patients/retinal-diseases/3/diabetic-retinopathy (accessed December 30, 2021)	Previously in US Application 17/072,417
29.	American Speech-Language-Hearing Association, "Calculating Medicare Fee Schedule Rates," https://www.asha.org/practice/reimbursement/medicare/calculating-medicare- fee-schedule-rates/ (accessed November 22, 2021)	Previously in US Application 17/072,417
30.	 Amgen v. F. Hoffman-La Roche, Ltd., Case No. 05-cv-12237 (D. Mass.), ECF 610-3, Declaration of Alexander M. Klibanov, Ph.D. in Support of Defendants' Opposition to Amgen's Motion for Summary Judgment of Infringement of '422 Claim 1, '933 Claim 3, and '698 Claim 6 (June 28, 2007), cited in Deposition of Dr. Alexander M. Klibanov, Ph.D., on March 24, 2022 	Previously in US Application 17/072,417
31.	Amgen, "Fusion Protein," https://www.amgen.com/stories/2018/08/the-shape- of-drugs-to-come/fusion-protein (accessed January 7, 2022)	Previously in US Application 17/072,417

EXAMINER	DATE CONSIDERED
EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line thro considered. Include copy of this form with next communication to Applicant.	ugh citation if not in conformance and not

SUBSTITUTE 1449 INFORMATION DISCLOSURE STATEMENT	ATTY. DOCKET NO.	APPLICATION NO.
	REGN-008CIPCON9	17/350,958
	APPLICANT	
	REGENERON PHARMACEUTICALS	, INC.
	FILING DATE	GROUP
	June 17, 2021	To be assigned

	NON-PATENT LITERATURE DOCUMENTS	
	DOCUMENT (Including Author, Title, Date, Pertinent Pages, etc.)	REFERENCE PROVIDED*
32.	Amino acid sequence alignment of SEQ ID NO:2 of the '338 and '069 patents with aflibercept amino acid sequence from WHO 2006, SEQ ID NO:16 of the '758 patent, and SEQ ID NO:16 of the '959 patent, submitted on May 27, 2022, in IPR2021-00881 as Exhibit 1122	Previously in US Application 17/072,417
33.	Amino acid sequence alignment of SEQ ID NO:2 of the '338 patent with SEQ ID NO:16 of the '758 patent and SEQ ID NO:4 of Dix, submitted in IPR2022-00881 as Exhibit 1093	Previously in US Application 17/072,417
34.	Amino acid sequence alignment of SEQ ID NO:2 of the '338 patent, aflibercept amino acid sequence from WHO 2006, and SEQ ID NO:2 of the '173 patent, cited in Deposition of Dr. Alexander M. Klibanov, Ph.D., on March 24, 2022, submitted in IPR2021-00881 as Exhibit 1117	Previously in US Application 17/072,417
35.	Amino acid sequence alignment of SEQ ID NO:2 of the '681 and '601 patents with aflibercept amino acid sequence from WHO 2006, SEQ ID NO:16 of the '758 patent, and SEQ ID NO:16 of the '959 patent, submitted in IPR2022- 01226 as Exhibit 1087	Previously in US Application 17/072,417
36.	Amino acid sequence alignment of SEQ ID NO:2 of the '681 and '601 patents with SEQ ID NO:16 of the '758 patent and SEQ ID NO:2 of the '173 patent, submitted in IPR2022-01226 as Exhibit 1092	Previously in US Application 17/072,417
37.	Annotated version of '338 patent claim 1, cited in Deposition of Dr. Diana V. Do, M.D., on April 21, 2022	Previously in US Application 17/072,417
38.	ASRS Clinical Updates, "ASRS Fights Novitas [sic] Decision to Interpret Eylea Usage More Frequently than q8 as 'Off Label'," (May 24, 2016) (accessed April 7, 2022), cited in Deposition of Dr. David M. Brown, M.D., on April 26, 2022	Previously in US Application 17/072,417
39.	Avastin Label (revised 2004), https://www.accessdata.fda.gov/drugsatfda_docs/label/2004/125085lbl.pdf (accessed September 26, 2022)	Previously in US Application 17/072,417
40.	BasePair Biotechnologies, "What is an Aptamer? – Aptamers and SELEX," https://www.basepairbio.com/what-is-an-aptamer/ (accessed December 30, 2021)	Previously in US Application 17/072,417
41.	Batta <i>et al.</i> , "Trends in FDA Drug Approvals Over Last 2 Decades: An Observational Study," <i>J. FAMILY MEDICINE & PRIMARY CARE</i> , 9, pp. 105- 114 (2020)	Previously in US Application 17/072,417
42.	Bausch and Lomb, "Help Your Patients Obtain Access to Visudyne," https://www.bauschretinarx.com/visudyne/ecp/ordering/ (accessed January 12, 2022)	Previously in US Application 17/072,417
43.	Bausch and Lomb, "Visudyne," https://www.bauschretinarx.com/visudyne/ecp/about/ (accessed December 2, 2021)	Previously in US Application 17/072,417
44.	Bausch Health Companies, Form 10-K, 2020	Previously in US Application 17/072,417

EXAMINER	DATE CONSIDERED
EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line thr considered. Include copy of this form with next communication to Applicant.	ough citation if not in conformance and not
*Comies of the listed references are either submitted berewith or were previously cited by or submitted to the Office in	prior application Pursuant to 37 C E R &

	ATTY. DOCKET NO.	APPLICATION NO.
	REGN-008CIPCON9	17/350,958
SUBSTITUTE 1449	APPLICANT	
INFORMATION DISCLOSURE STATEMENT	REGENERON PHARMACEUTICALS	, INC.
	FILING DATE	GROUP
	June 17, 2021	To be assigned

	NON-PATENT LITERATURE DOCUMENTS	
	DOCUMENT (Including Author, Title, Date, Pertinent Pages, etc.)	REFERENCE PROVIDED*
45.	BCBS Florida, "Vascular Endothelial Growth Factor Inhibitors for Ocular Neovascularization," revised April 1, 2022	Previously in US Application 17/072,417
46.	Beovu Label (revised June 2020), https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/761125s004lbl.pdf (accessed September 26, 2022)	Previously in US Application 17/072,417
47.	Beovu Label (revised October 2019), https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/761125s000lbl.pdf (accessed September 26, 2022)	Previously in US Application 17/072,417
48.	Bhisitkul <i>et al.</i> , "Alternative anti-VEGF treatment regimens in exudative age- related macular degeneration," <i>Expert Rev. Ophthalmol.</i> , 5(6) (January 2010)	Previously in US Application 17/072,417
49.	BIOSPACE, "Bayer HealthCare AG and Regeneron Pharmaceuticals, Inc. to Collaborate on VEGF Trap for the Treatment Of Eye Diseases; Regeneron Retains U.S. Commercialization Rights, Receives \$75 Million Upfront, and Eligible for up to \$245 Million of Milestone Payments," (October 19, 2006), https://www.biospace.com/article/releases/bayer-healthcare-ag-and-regeneron- pharmaceuticals-inc-to-collaborate-on-vegf-trap-for-the-treatment-of-eye- diseases-b-regeneron-b-retains-u-s-c/ (accessed September 26, 2022)	Previously in US Application 17/072,417
50.	Bork <i>et al.</i> , "Increasing the Sialylation of Therapeutic Glycoproteins: The Potential of the Sialic Acid Biosynthetic Pathway," <i>J. Pharm. Sci.</i> , 98(10), pp. 3499-3508 (October 2009)	Previously in US Application 17/072,417
51.	Bright Focus Foundation, "Age-Related Macular Degeneration: Facts & Figures," https://www.brightfocus.org/macular/article/age-related-macular- facts-figures (accessed November 5, 2021)	Previously in US Application 17/072,417
52.	Brown <i>et al.</i> , "Intravitreal Aflibercept Injection for Macular Edema Secondary to Central Retinal Vein Occlusion: 1-Year Results from the Phase 3 COPERNICUS Study", <i>Am. J. Ophthalmol.</i> , 155, pp. 329-437 (March 2013)	Previously in US Application 17/072,417
53.	Brown <i>et al.</i> , "Ranibizumab Versus Verteporfin Photodynamic Therapy for Neovascular Age-Related Macular Degeneration: Two-Year Results of the ANCHOR Study," <i>Ophthalmology</i> , 116(1), pp. 57-65.e5 (January 2009)	Previously in US Application 17/072,417
54.	Calculator.net, "Sample Size Calculator," https://www.calculator.net/sample- size-calculator.html?type=2&cl2=95&ss2=200&pc2=50&ps2=3000&x= 68&y=18#findci (accessed January 25, 2022)	Previously in US Application 17/072,417
55.	Campochiaro <i>et al.</i> , "Antagonism of Vascular Endothelial Growth Factor for Macular Edema Caused by Retinal Vein Occlusions: Two-Year Outcomes," <i>Ophthalmology</i> , 117(12), pp. 2387-2394.e5 (December 2010) (online publication)	Previously in US Application 17/072,417
56.	Cantu <i>et al.</i> , "Thioesterases: A New Perspective Based on Their Primary and Tertiary Structures," <i>Protein Science</i> , 19(17), pp. 1281-1295 (July 2010)	Previously in US Application 17/072,417
57.	CAS registry for No. 862111-32-8, cited in Deposition of Dr. Alexander M. Klibanov, Ph.D., on March 24, 2022	Previously in US Application 17/072,417

EXAMINER	DATE CONSIDERED
EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line three considered. Include copy of this form with next communication to Applicant.	ough citation if not in conformance and not

	ATTY. DOCKET NO.	APPLICATION NO.
	REGN-008CIPCON9	17/350,958
SUBSTITUTE 1449	APPLICANT	
INFORMATION DISCLOSURE STATEMENT	REGENERON PHARMACEUTICALS	, INC.
	FILING DATE	GROUP
	June 17, 2021	To be assigned

	NON-PATENT LITERATURE DOCUMENTS	
	DOCUMENT (Including Author, Title, Date, Pertinent Pages, etc.)	REFERENCE PROVIDED*
58.	Center for Drug Evaluation and Research, Approved Labeling for BLA Application No. 125156 (Lucentis) (2006)	Previously in US Application 17/072,417
59.	Center for Drug Evaluation and Research, Medical Review for BLA Application No. 125387 (November 18, 2011)	Previously in US Application 17/072,417
60.	Center for Drug Evaluation and Research, Statistical Review for BLA Application No. 125387 (November 18, 2011)	Previously in US Application 17/072,417
61.	Centers for Disease Control and Prevention, "Vision Loss: A Public Health Problem," https://www.cdc.gov/visionhealth/basic_information/vision_loss.htm (accessed June 12, 2020)	Previously in US Application 17/072,417
62.	Centers for Medicare & Medicaid Services, "Medicare Physician & Other Practitioners - by Provider and Service," https://data.cms.gov/provider- summary-by-type-of-service/medicare-physician-other-practitioners/medicare- physician-other-practitioners-by-provider-and-service (accessed November 19, 2021)	Previously in US Application 17/072,417
63.	Centers for Medicare & Medicaid Services, "Payment Allowance Limits for Medicare Part B Drugs: Effective October 1, 2012, through December 31, 2012," (October 2012), https://www.cms.gov/Medicare/Medicare-Fee-for- Service-Part-B-Drugs/McrPartBDrugAvgSalesPrice/2012ASPFiles (accessed September 26, 2022)	Previously in US Application 17/072,417
64.	Centers for Medicare & Medicaid Services, "Payment Allowance Limits for Medicare Part B Drugs: Effective October 1, 2013, through December 31, 2013," (October 2013), https://www.cms.gov/Medicare/Medicare-Fee-for- Service-Part-B-Drugs/McrPartBDrugAvgSalesPrice/2013ASPFiles (accessed September 26, 2022)	Previously in US Application 17/072,417
65.	Centers for Medicare & Medicaid Services, "Payment Allowance Limits for Medicare Part B Drugs: Effective October 1, 2014, through December 31, 2014," (October 2014), https://www.cms.gov/Medicare/Medicare-Fee-for- Service-Part-B-Drugs/McrPartBDrugAvgSalesPrice/2014ASPFiles (accessed September 26, 2022)	Previously in US Application 17/072,417
66.	Centers for Medicare & Medicaid Services, "Payment Allowance Limits for Medicare Part B Drugs: Effective October 1, 2015, through December 31, 2015," (October 2015), https://www.cms.gov/Medicare/Medicare-Fee-for- Service-Part-B-Drugs/McrPartBDrugAvgSalesPrice/2015ASPFiles (accessed September 26, 2022)	Previously in US Application 17/072,417
67.	Centers for Medicare & Medicaid Services, "Payment Allowance Limits for Medicare Part B Drugs: Effective October 1, 2016, through December 31, 2016," (October 2016), https://www.cms.gov/Medicare/Medicare-Fee-for- Service-Part-B-Drugs/McrPartBDrugAvgSalesPrice/2016ASPFiles (accessed September 26, 2022)	Previously in US Application 17/072,417

EXAMINER	DATE CONSIDERED
EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line three considered. Include copy of this form with next communication to Applicant.	ough citation if not in conformance and not
*Copies of the listed references are either submitted herewith or were previously cited by or submitted to, the Office in a	a prior application Pursuant to 37 C F R &

	ATTY. DOCKET NO.	APPLICATION NO.
	REGN-008CIPCON9	17/350,958
SUBSTITUTE 1449	APPLICANT	
INFORMATION DISCLOSURE STATEMENT	REGENERON PHARMACEUTICALS	, INC.
	FILING DATE	GROUP
	June 17, 2021	To be assigned

	NON-PATENT LITERATURE DOCUMENTS	
	DOCUMENT (Including Author, Title, Date, Pertinent Pages, etc.)	REFERENCE PROVIDED*
68.	Centers for Medicare & Medicaid Services, "Payment Allowance Limits for Medicare Part B Drugs: Effective October 1, 2017, through December 31, 2017," (October 2017), https://www.cms.gov/Medicare/Medicare-Fee-for- Service-Part-B-Drugs/McrPartBDrugAvgSalesPrice/2017ASPFiles (accessed September 26, 2022)	Previously in US Application 17/072,417
69.	Centers for Medicare & Medicaid Services, "Payment Allowance Limits for Medicare Part B Drugs: Effective October 1, 2018, through December 31, 2018," (October 2018), https://www.cms.gov/Medicare/Medicare-Fee-for- Service-Part-B-Drugs/McrPartBDrugAvgSalesPrice/2018ASPFiles (accessed September 26, 2022)	Previously in US Application 17/072,417
70.	Centers for Medicare & Medicaid Services, "Payment Allowance Limits for Medicare Part B Drugs: Effective October 1, 2019, through December 31, 2019," (October 2019), https://www.cms.gov/Medicare/Medicare-Fee-for- Service-Part-B-Drugs/McrPartBDrugAvgSalesPrice/2019ASPFiles (accessed September 26, 2022)	Previously in US Application 17/072,417
71.	Centers for Medicare & Medicaid Services, "Payment Allowance Limits for Medicare Part B Drugs: Effective October 1, 2020, through December 31, 2020," (October 2020), https://www.cms.gov/medicare/medicare-part-b-drug- average-sales-price/2020-asp-drug-pricing-files (accessed September 26, 2022)	Previously in US Application 17/072,417
72.	Centers for Medicare & Medicaid Services, "Payment Allowance Limits for Medicare Part B Drugs: Effective October 1, 2021, through December 31, 2021," (October 2021), https://www.cms.gov/medicare/medicare-part-b-drug- average-sales-price/2021-asp-drug-pricing-files (accessed September 26, 2022)	Previously in US Application 17/072,417
73.	Centers for Medicare & Medicaid Services, "Physician Fee Schedule," https://www.cms.gov/Medicare/Medicare-Fee-for-Service- Payment/PhysicianFeeSched (accessed November 22, 2021)	Previously in US Application 17/072,417
74.	Centers for Medicare & Medicare Services, "2021 ASP Drug Pricing Files," https://www.cms.gov/medicare/medicare-part-b-drug-average-sales-price/2021- asp-drug-pricing-files (accessed November 22, 2021)	Previously in US Application 17/072,417
75.	Centers for Medicare & Medicare Services, "Medicare Part B Drug Average Sales Price," https://www.cms.gov/Medicare/Medicare-Fee-for-Service-Part-B- Drugs/McrPartBDrugAvgSalesPrice (accessed December 8, 2021)	Previously in US Application 17/072,417
76.	Chen <i>et al.</i> , "Carboxylic ester hydrolases: Classification and database derived from their primary, secondary, and tertiary structures," <i>Protein Science</i> , 25(11), pp. 1942-1953 (November 2016)	Previously in US Application 17/072,417
77.	Christensen, "Methodology of Superiority vs. Equivalence Trials and Non- Inferiority Trials," <i>J. HEPATOLOGY</i> , 46(5), pp. 947-954 (May 2007) (online publication)	Previously in US Application 17/072,417

EXAMINER	DATE CONSIDERED
EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line thro considered. Include copy of this form with next communication to Applicant.	ough citation if not in conformance and not

SUBSTITUTE 1449 <u>INFORMATION DISCLOSURE STATEMENT</u>	ATTY. DOCKET NO.	APPLICATION NO.
	REGN-008CIPCON9	17/350,958
	APPLICANT	
	REGENERON PHARMACEUTICALS	, INC.
	FILING DATE	GROUP
	June 17, 2021	To be assigned

	NON-PATENT LITERATURE DOCUMENTS		
	DOCUMENT (Including Author, Title, Date, Pertinent Pages, etc.)	REFERENCE PROVIDED*	
78.	Clark <i>et al.</i> , "Treatment Paradigms in AMD Management: Assessing Consistent Long-Term Dosing," <i>RETINA TODAY SUPP.</i> , pp. 1-16 (September 2017), cited in Deposition of Dr. David M. Brown, M.D., on April 26, 2022	Previously in US Application 17/072,417	
79.	ClinicalTrials.gov Archive, History of Changes for Study: NCT00473330, "A Study of Ranibizumab Injection in Subjects With Clinically Significant Macular Edema (ME) With Center Involvement Secondary to Diabetes Mellitus (RISE)," Version 13, dated March 21, 2017, submitted in IPR2021-00881 as Exhibit 2122	Previously in US Application 17/072,417	
80.	ClinicalTrials.gov Archive, History of Changes for Study: NCT00473382, "A Study of Ranibizumab Injection in Subjects With Clinically Significant Macular Edema (ME) With Center Involvement Secondary to Diabetes Mellitus (RIDE)," Version 13, dated March 21, 2017, submitted in IPR2021-00881 as Exhibit 2123	Previously in US Application 17/072,417	
81.	ClinicalTrials.gov Archive, History of Changes for Study: NCT00485836, "A Study of the Efficacy and Safety of Ranibizumab Injection in Patients With Macular Edema Secondary to Central Retinal Vein Occlusion (CRUISE)," Version 10, dated June 29, 2017, submitted in IPR2021-00881 as Exhibit 2125	Previously in US Application 17/072,417	
82.	ClinicalTrials.gov Archive, History of Changes for Study: NCT00486018, "A Study of the Efficacy and Safety of Ranibizumab Injection in Patients With Macular Edema Secondary to Branch Retinal Vein Occlusion (BRAVO)," Version 12, dated April 4, 2017, submitted in IPR2021-00881 as Exhibit 2124	Previously in US Application 17/072,417	
83.	ClinicalTrials.gov Archive, History of Changes for Study: NCT00519285, "Aflibercept in Combination With Docetaxel in Metastatic Androgen Independent Prostate Cancer (VENICE)," Version 01, dated August 21, 2007, submitted in IPR2021-00881 as Exhibit 2078	Previously in US Application 17/072,417	
84.	ClinicalTrials.gov Archive, History of Changes for Study: NCT00644124, "Aflibercept and Standard Chemotherapy (R-CHOP) in First Line of Non Hodgkin B-Cell Lymphoma," Version 01, dated March 21, 2008, submitted in IPR2021-00881 as Exhibit 2079	Previously in US Application 17/072,417	
85.	ClinicalTrials.gov Archive, History of Changes for Study: NCT00794417, "A Study of Aflibercept Administered in Combination With Pemetrexed and Cisplatin in Patients With Advanced Carcinoma," Version 01, dated November 19, 2008, submitted in IPR2021-00881 as Exhibit 2053	Previously in US Application 17/072,417	
86.	ClinicalTrials.gov Archive, History of Changes for Study: NCT01148615, "A Study of Intravenous Aflibercept With Docetaxel in Chinese Patients With Solid Tumors," Version 01, dated June 21, 2010, submitted in IPR2021-00881 as Exhibit 2054	Previously in US Application 17/072,417	

EXAMINER	DATE CONSIDERED
EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line thr considered. Include copy of this form with next communication to Applicant.	ough citation if not in conformance and not
*Copies of the listed references are either submitted herewith or were previously cited by or submitted to, the Office in a	a prior application. Pursuant to 37 C.F.R. §

SUBSTITUTE 1449 INFORMATION DISCLOSURE STATEMENT	ATTY. DOCKET NO.	APPLICATION NO.
	REGN-008CIPCON9	17/350,958
	APPLICANT	
	REGENERON PHARMACEUTICALS	, INC.
	FILING DATE	GROUP
	June 17, 2021	To be assigned

NON-PATENT LITERATURE DOCUMENTS		
	DOCUMENT (Including Author, Title, Date, Pertinent Pages, etc.)	REFERENCE PROVIDED*
87.	ClinicalTrials.gov Archive, History of Changes for Study: NCT01486771, "Macugen for Proliferative Diabetic Retinopathy Study With Extended Dosing (M-PDRS ED)," Version 01, dated December 5, 2011, submitted in IPR2021- 00881 as Exhibit 2109	Previously in US Application 17/072,417
88.	ClinicalTrials.gov Archive, History of Changes for Study: NCT01940900, "A Phase 3 Safety and Efficacy Study of Fovista (E10030) Intravitreous Administration in Combination With Lucentis Compared to Lucentis Monotherapy," Version 21, dated August 13, 2018, submitted in IPR2021- 00881 as Exhibit 2025	Previously in US Application 17/072,417
89.	ClinicalTrials.gov Archive, History of Changes for Study: NCT01944839, "A Phase 3 Safety and Efficacy Study of Fovista (E10030) Intravitreous Administration in Combination With Lucentis Compared to Lucentis Monotherapy," Version 27, dated August 8, 2018, submitted in IPR2021-00881 as Exhibit 2024	Previously in US Application 17/072,417
90.	ClinicalTrials.gov Archive, History of Changes for Study: NCT02247479, "A Study Investigating the Efficacy and Safety of Lampalizumab Intravitreal Injections in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration (CHROMA)," Version 60, dated June 17, 2019, submitted in IPR2021-00881 as Exhibit 2021	Previously in US Application 17/072,417
91.	ClinicalTrials.gov Archive, History of Changes for Study: NCT02247531, "A Study Investigating the Safety and Efficacy of Lampalizumab Intravitreal Injections in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration (SPECTRI)," Version 60, dated October 14, 2019, submitted in IPR2021-00881 as Exhibit 2020	Previously in US Application 17/072,417
92.	ClinicalTrials.gov Archive, History of Changes for Study: NCT03577899, "Efficacy and Safety Trial of Conbercept Intravitreal Injection for Neovascular AMD(PANDA-1)," Version 06, dated June 23, 2021, submitted in IPR2021- 00881 as Exhibit 2023	Previously in US Application 17/072,417
93.	ClinicalTrials.gov Archive, History of Changes for Study: NCT03630952, "Efficacy and Safety Trial of Conbercept Intravitreal Injection for Neovascular AMD(PANDA-2)," Version 07, dated June 22, 2021, submitted in IPR2021- 00881 as Exhibit 2022	Previously in US Application 17/072,417
94.	ClinicalTrials.gov, "1997: Congress Passes Law (FDAMA) Requiring Trial Registration," https://clinicaltrials.gov/ct2/about-site/history (accessed April 26, 2021)	Previously in US Application 17/072,417
95.	ClinicalTrials.gov, "What Is ClinicalTrials.gov?" https://www.clinicaltrials.gov/ct2/about-site/background (accessed January 20, 2021)	Previously in US Application 17/072,417

EXAMINER	DATE CONSIDERED	
EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.		
*Conjes of the listed references are either submitted berewith or were previously cited by or submitted to the Office in s	prior application Pursuant to 37 C E R &	

SUBSTITUTE 1449 INFORMATION DISCLOSURE STATEMENT	ATTY. DOCKET NO.	APPLICATION NO.
	REGN-008CIPCON9	17/350,958
	APPLICANT	
	REGENERON PHARMACEUTICALS	, INC.
	FILING DATE	GROUP
	June 17, 2021	To be assigned

	NON-PATENT LITERATURE DOCUMENTS	
	DOCUMENT (Including Author, Title, Date, Pertinent Pages, etc.)	REFERENCE PROVIDED*
96.	CloudResearch, "Determining Sample Size: How Many Survey Participants Do You Need?" https://www.cloudresearch.com/resources/guides/statistical- significance/determine-sample-size/ (accessed January 25, 2022)	Previously in US Application 17/072,417
97.	CMS.gov Medicare Coverage Database, "Billing and Coding: Aflibercept (Eylea)," https://www.cms.gov/medicare-coverage- database/view/article.aspx?articleid=53387&ver=28&keyword=&keywordType =starts&areaId=all&docType=6,3,5,1,F,P&contractOption=all&hcpcsOption=c ode&hcpcsStartCode=J0178&hcpcsEndCode=J0178&sortBy=title&bc=1 (accessed April 22, 2021)	Previously in US Application 17/072,417
98.	Cobo <i>et al.</i> , "The Clearance of Intravitreal Gentamicin," <i>Am. J. Ophthalmology</i> , 92(1), pp. 59-62 (1981)	Previously in US Application 17/072,417
99.	Complaint, <i>Horizon Healthcare Servs., Inc. v. Regeneron Pharms., Inc.</i> , No. 1:22-cv-10493-FDS (D. Mass. April 4, 2022), ECF Nos. 1 – 1-18	Previously in US Application 17/072,417
100.	Complaint, United States v. Regeneron Pharms., Inc., No. 1:20-cv-11217-FDS (D. Mass. June 24, 2020), ECF Nos. 1 — 1-39	Previously in US Application 17/072,417
101.	Corporate Finance Institute, "SEC Filings - Requirements for Public Companies & Where to Find Them," https://corporatefinanceinstitute.com/resources/data/public-filings/sec-filings/ (accessed January 20, 2021)	Previously in US Application 17/072,417
102.	Cousins, "Controversies in the Long-term Management of Neovascular AMD: The Role of Imaging in Clinical Decision Making," <i>Retinal Physician</i> (January 1, 2010), https://www.retinalphysician.com/issues/2010/jan-feb/controversies- in-the-long-term-management-of-neova (accessed September 26, 2022)	Previously in US Application 17/072,417
103.	Cruz, "PIER Data Suggest a Need for Tailored Injection Schedule," <i>Ocular Surgery News</i> , (September 1, 2006), https://www.healio.com/news/ophthalmology/20120331/pier-data-suggest-a-need-for-tailored-injection-schedule (accessed February 10, 2022)	Previously in US Application 17/072,417
104.	Dadgostar <i>et al.</i> , "Evaluation of Injection Frequency and Visual Acuity Outcomes for Ranibizumab Monotherapy in Exudative Age-related Macular Degeneration," <i>Ophthalmology</i> , 116, pp. 1740-1747 (2009)	Previously in US Application 17/072,417
105.	Declaration of Doris Weber dated March 7, 2022, in IPR2021-00881	Previously in US Application 17/072,417
106.	Demarest <i>et al.</i> , "Optimization of the Antibody C _H 3 Domain by Residue Frequency Analysis of IgG Sequences," <i>J. Mol. Biol.</i> , 335(1), pp. 41-48 (January 2004)	Previously in US Application 17/072,417
107.	Do <i>et al.</i> , "Pharmacokinetic Study of Intravitreal Aflibercept In Humans with Neovascular Age-Related Macular Degeneration," <i>RETINA</i> , 00, pp. 1-5 (2019), also available as <i>RETINA</i> , 40(4), pp. 643-647 (April 2020)	Previously in US Application 17/072,417
108.	Donohue <i>et al.</i> , "A Decade of Direct-to-Consumer Advertising of Prescription Drugs," <i>The New England Journal of Medicine</i> , 35(7), pp. 673-681 (August 2007)	Previously in US Application 17/072,417

EXAMINER DATE CONSIDERED
EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

Page 10 of 25

SUBSTITUTE 1449 INFORMATION DISCLOSURE STATEMENT	ATTY. DOCKET NO.	APPLICATION NO.
	REGN-008CIPCON9	17/350,958
	APPLICANT	
	REGENERON PHARMACEUTICALS	, INC.
	FILING DATE	GROUP
	June 17, 2021	To be assigned

	NON-PATENT LITERATURE DOCUMENTS	
	DOCUMENT (Including Author, Title, Date, Pertinent Pages, etc.)	REFERENCE PROVIDED*
109.	Donohue <i>et al.</i> , "Effect of Direct-to-Consumer Advertising on Medication Choice: The Case of Antidepressants," Journal of Public Policy & Marketing, 23(2), pp. 115-127 (September 2004)	Previously in US Application 17/072,417
110.	Dreyfuss <i>et al.</i> , "Ocular Angiogenesis," <i>Journal of Ophthalmology</i> , 2015, pp. Article ID 892043 (September 2015)	Previously in US Application 17/072,417
111.	Drugs.com, "Eylea FDA Approval History," https://www.drugs.com/history/eylea.html (accessed November 16, 2021)	Previously in US Application 17/072,417
112.	Drugs.com, "FDA Approves Eylea for Wet Age-Related Macular Degeneration," (November 18, 2011), https://www.drugs.com/newdrugs/fda- approves-eylea-wet-age-related-macular-degeneration-2955.html (accessed February 4, 2022)	Previously in US Application 17/072,417
113.	Duncan <i>et al.</i> , "Inhibition of Vascular Endothelial Growth Factor in the Primate Ovary Up-Regulates Hypoxia-Inducible Factor-1α in the Follicle and Corpus Luteum," <i>ENDOCRINOLOGY</i> , 149, pp. 3313-3320 (April 2008) (online publication), cited in Deposition of Dr. Alexander M. Klibanov, Ph.D., on March 24, 2022	Previously in US Application 17/072,417
114.	Elvidge, "Opthotech's Fovista crashes out in wet AMD," <i>BIOPHARMADIVE</i> (August 14, 2017), available at https://www.biopharmadive.com/news/opthotech-fovista-phase-3-failure- setback-novartis/449248/ (accessed August 2, 2021)	Previously in US Application 17/072,417
115.	Elyasi <i>et al.</i> , "Diabetic Macular Edema: Diagnosis and Management," EyeNet Magazine, May 2021: 35-37 (May 2021)	Previously in US Application 17/072,417
116.	EP Patent Application No. 3 222 285 File History	Previously in US Application 17/072,417
117.	Ex. (a)(1)(a) to Tender Offer Statement to Momenta, filed with SEC on September 2, 2020	Previously in US Application 17/072,417
118.	Excerpts from J.M. Berg et al., Biochemistry (5th Ed. 2002)	Previously in US Application 17/072,417
119.	Expert Declaration of Angelo P. Tanna, M.D., dated September 6, 2022, in IPR2022-01524	Previously in US Application 17/072,417
120.	Expert Declaration of David M. Brown, M.D., dated February 10, 2022, in IPR2021-00880 and IPR2021-00881	Previously in US Application 17/072,417
121.	Expert Declaration of Dr. Alexander M. Klibanov, Ph.D., dated February 8, 2022, in IPR2021-00880 and IPR2021-00881 - [[REDACTED]]	Previously in US Application 17/072,417
122.	Expert Declaration of Dr. Diana V. Do, M.D., dated February 10, 2022, in IPR2021-00881	Previously in US Application 17/072,417
123.	Expert Declaration of Dr. Lucian V. Del Priore, M.D., Ph.D., dated February 9, 2022, in IPR2021-00880 and IPR2021-00881 - [[REDACTED]]	Previously in US Application 17/072,417
124.	Expert Declaration of Dr. Thomas A. Albini in Support of Petition for Inter Partes Review of Patent No. 10,130,681 B2, dated June 30, 2022, in IPR2022- 01225	Previously in US Application 17/072,417

 EXAMINER
 DATE CONSIDERED

 EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

SUBSTITUTE 1449 INFORMATION DISCLOSURE STATEMENT	ATTY. DOCKET NO.	APPLICATION NO.
	REGN-008CIPCON9	17/350,958
	APPLICANT	
	REGENERON PHARMACEUTICALS	, INC.
	FILING DATE	GROUP
	June 17, 2021	To be assigned

NON-PATENT LITERATURE DOCUMENTS		
	DOCUMENT (Including Author, Title, Date, Pertinent Pages, etc.)	REFERENCE PROVIDED*
125.	Expert Declaration of Dr. Thomas A. Albini in Support of Petition for Inter Partes Review of Patent No. 10,888,601 B2, dated June 30, 2022, in IPR2022- 01226	Previously in US Application 17/072,417
126.	Expert Declaration of Dr. Thomas A. Albini in Support of Petitioner's Reply, dated May 27, 2022, in IPR2021-00881	Previously in US Application 17/072,417
127.	Expert Declaration of Ivan T. Hofmann Support of Petitioner's Reply, dated May 27, 2022, in IPR2021-00881 - [[REDACTED]]	Previously in US Application 17/072,417
128.	Expert Declaration of Mary Gerritsen, Ph.D. in Support of Petition for Inter Partes Review of U.S. Patent No. 10,130,681 B2, dated June 30, 2022, in IPR2022-01225	Previously in US Application 17/072,417
129.	Expert Declaration of Mary Gerritsen, Ph.D. in Support of Petition for Inter Partes Review of U.S. Patent No. 10,888,601 B2, dated June 30, 2022, in IPR2022-01226	Previously in US Application 17/072,417
130.	Expert Declaration of Mary Gerritsen, Ph.D. in Support of Petitioner's Reply, dated May 26, 2022, in IPR2021-00881	Previously in US Application 17/072,417
131.	Expert Declaration of Richard Manning, Ph.D., dated February 11, 2022, in IPR2021-00881 - [[REDACTED]]	Previously in US Application 17/072,417
132.	Eye Care Surgery Center, "Macular Degeneration," https://www.eyecaresurgerycenterbr.com/diabetes-retina/macular-degeneration/ (accessed November 18, 2021)	Previously in US Application 17/072,417
133.	EyeGuru.org, "Intravitreal Injection Standard Dosing Table," https://eyeguru.org/blog/intravitreal-injection-dosing/ (accessed December 6, 2021)	Previously in US Application 17/072,417
134.	Eylea Label (revised March 2021), https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/125387s069lbl.pdf (accessed September 26, 2022)	Previously in US Application 17/072,417
135.	Eylea Label (revised May 2016), https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/125387s051lbl.pdf (accessed September 26, 2022)	Previously in US Application 17/072,417
136.	Eylea Label (revised October 2014), https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/125387s043lbl.pdf (accessed September 26, 2022)	Previously in US Application 17/072,417
137.	Eylea Label (revised September 2012), https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/125387s004lbl.pdf (accessed September 26, 2022)	Previously in US Application 17/072,417
138.	Eylea, "Wet AMD: Dosing Flexibility," https://hcp.eylea.us/about/wet-amd- dosing/ (accessed January 5, 2022)	Previously in US Application 17/072,417
139.	Eylea Approval Letter (November 18, 2011)	Previously in US Application 17/072,417

EXAMINER	DATE CONSIDERED	
EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.		
*Copies of the listed references are either submitted herewith or were previously cited by or submitted to, the Office in a	a prior application. Pursuant to 37 C.F.R. §	

SUBSTITUTE 1449	ATTY. DOCKET NO.	APPLICATION NO.
	REGN-008CIPCON9	17/350,958
	APPLICANT	
INFORMATION DISCLOSURE STATEMENT	REGENERON PHARMACEUTICALS, INC.	
	FILING DATE	GROUP
	June 17, 2021	To be assigned

NON-PATENT LITERATURE DOCUMENTS			
	DOCUMENT (Including Author, Title, Date, Pertinent Pages, etc.)	REFERENCE PROVIDED*	
140.	Fauser <i>et al.</i> , "Suppression of Intraocular Vascular Endothelial Growth Factor During Aflibercept Treatment of Age-Related Macular Degeneration," <i>Am. J.</i> <i>Ophthalmology</i> , 158, pp. 532-536 (2014)	Previously in US Application 17/072,417	
141.	FDA Center for Drug Evaluation and Research, "Application Number: 125387Orig1s000 [EYLEA] Summary Review," https://www.accessdata.fda.gov/drugsatfda_docs/nda/2011/125387Orig1s000Su mR.pdf (accessed May 20, 2022)	Previously in US Application 17/072,417	
142.	FDA, "Drugs@FDA: FDA-Approved Drugs, BLA 125387," https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.pro cess&ApplNo=125387 (accessed May 18, 2022)	Previously in US Application 17/072,417	
143.	FDA, "22 Case Studies Where Phase 2 and Phase 3 Trials Had Divergent Results" (January 2017), submitted in IPR2021-00881 as Exhibit 1146	Previously in US Application 17/072,417	
144.	FDA, "Guidance for Industry: Expedited Programs for Serious Conditions— Drugs and Biologics" (May 2014), https://www.fda.gov/media/86377/download (accessed September 26, 2022)	Previously in US Application 17/072,417	
145.	FDA, "Macugen Drug Approval Package Page," March 23, 2005, https://www.accessdata.fda.gov/drugsatfda_docs/nda/2004/21- 756_Macugen.cfm (accessed January 12, 2022)	Previously in US Application 17/072,417	
146.	FDA, "Non-Inferiority Clinical Trials to Establish Effectiveness: Guidance for Industry" (November 2016), submitted in IPR2021-00881 as Exhibit 2097	Previously in US Application 17/072,417	
147.	FDA, "Purple Book Database of Licensed Biological Products," https://purplebooksearch.fda.gov/patent-list (accessed May 13, 2022)	Previously in US Application 17/072,417	
148.	Fernández-Ferreiro <i>et al.</i> , "Preclinical PET Study of Intravitreal Injections," <i>Investigative Ophthalmology & Visual Science</i> , 58(7), pp. 2843-2851 (June 2017)	Previously in US Application 17/072,417	
149.	Ferrara <i>et al.</i> , "Development of ranibizumab, an anti-vascular endothelial growth factor antigen binding fragment, as therapy for neovascular age-related macular degeneration," <i>Retina</i> , 26(8), pp. 859-870 (October 2006)	Previously in US Application 17/072,417	
150.	FiercePharma, "Beovu, Novartis," (October 25, 2021), https://www.fiercepharma.com/special-report/beovu-novartis-top-10-drug- launch-disasters (accessed December 30, 2021)	Previously in US Application 17/072,417	
151.	FiercePharma, "Novartis' Hot New Eye Drug Beovu Tied to Potential Vision Loss: Experts," (February 24, 2020), https://www.fiercepharma.com/pharma/retinal-society-flags-serious-side-effect- for-novartis-beovu (accessed December 30, 2021)	Previously in US Application 17/072,417	
152.	FiercePharma, "The Top 20 Drugs by Worldwide sales in 2020," (May 3, 2021), https://www.fiercepharma.com/special-report/top-20-drugs-by-2020-sales (accessed September 26, 2022)	Previously in US Application 17/072,417	

EXAMINER	DATE CONSIDERED	
EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.		
*Conjes of the listed references are either submitted herewith or were previously cited by or submitted to the Office in a	prior application Dursuant to 27 C E P &	

SUBSTITUTE 1449 INFORMATION DISCLOSURE STATEMENT	ATTY. DOCKET NO.	APPLICATION NO.
	REGN-008CIPCON9	17/350,958
	APPLICANT	
	REGENERON PHARMACEUTICALS	, INC.
	FILING DATE	GROUP
	June 17, 2021	To be assigned

	NON-PATENT LITERATURE DOCUMENTS	
	DOCUMENT (Including Author, Title, Date, Pertinent Pages, etc.)	REFERENCE PROVIDED*
153.	FocusVision, "Survey Sample Size: How Much Do I Need?" (April,11, 2019), https://www.focusvision.com/blog/survey-sample-size-how-much-do-i-need/ (accessed January 25, 2022)	Previously in US Application 17/072,417
154.	Fraser <i>et al.</i> , "The Role of Vascular Endothelial Growth Factor and Estradiol in the Regulation of Endometrial Angiogenesis and Cell Proliferation in the Marmoset," <i>Endocrinology</i> , 149(9), pp. 4413-4420 (May 2008) (electronic publication)	Previously in US Application 17/072,417
155.	Gagnon <i>et al.</i> , "The Cost of Pushing Pills: A New Estimate of Pharmaceutical Promotion Expenditures in the United States," PLoS Medicine, 5(1), pp. 29-33 (January 2008)	Previously in US Application 17/072,417
156.	Gallemore <i>et al.</i> , "When Anti-VEGF Treatment Fails: Retina Specialists Are Charting New Territory and Learning How to Spot and React to Failed Anti- VEGF Therapy," <i>Rev. Ophthalmology</i> , (March 2008)	Previously in US Application 17/072,417
157.	Genentech, Inc., "FDA Green-Lights Genentech's Lucentis for Macular Edema following Retinal Vein Occlusion," Press Release, (June 23, 2010), https://www.genengnews.com/news/fda-green-lights-genentechs-lucentis-for- macular-edema-following-retinal-vein-occlusion/ (accessed January 12, 2022)	Previously in US Application 17/072,417
158.	Genentech, Inc., "Genentech, Inc. Submits Biologics License Application For FDA Review Of Lucentis [™] In Wet Age-Related Macular Degeneration," Press Release, (Dec. 30, 2005), https://www.biospace.com/article/releases/genentech- inc-submitsbiologics-license-application-for-fda-review-of-lucentis-tm-in- wetage- related-macular-degeneration-/ (accessed February 3, 2022)	Previously in US Application 17/072,417
159.	Gomez-Manzano <i>et al.</i> , "VEGF Trap Induces Antiglioma Effect at Different Stages of Disease," <i>NEURO-ONCOLOGY</i> , 10, pp. 940-945 (December 2008), cited in Deposition of Dr. Alexander M. Klibanov, Ph.D., on March 24, 2022	Previously in US Application 17/072,417
160.	GOOD DAYS, https://www.mygooddays.org/ (accessed May 18, 2022)	Previously in US Application 17/072,417
161.	Guha <i>et al.</i> , "The Economics of Commercial Success in Pharmaceutical Patent Litigation," <i>Landslide</i> 1(5) (2009)	Previously in US Application 17/072,417
162.	Hachiya <i>et al.</i> , "Increase in respiratory cost at high growth temperature is attributed to high protein turnover cost in Petunia x hybrida petals," <i>Plant, Cell, and Environment</i> , 30(10), pp. 1269-1283 (October 2007)	Previously in US Application 17/072,417
163.	Hanhart <i>et al.</i> , Correspondence regarding "Fellow Eye Effect of Unilateral Intravitreal Anti-VEGF Injections in Eyes with Diabetic Macular Edema," <i>EYE</i> , 29, pp. 292-293 (November 2014) (online publication), cited in Deposition of Dr. Alexander M. Klibanov, Ph.D., on March 24, 2022	Previously in US Application 17/072,417
164.	Hayes, "SEC Filings: Forms You Need To Know," <i>INVESTOPEDIA</i> , https://www.investopedia.com/articles/fundamental-analysis/08/sec-forms.asp (accessed January 20, 2021)	Previously in US Application 17/072,417
165.	HCPCS Codes, "HCPCS Codes," https://hcpcs.codes/ (accessed January 6, 2022)	Previously in US Application 17/072,417

 EXAMINER
 DATE CONSIDERED

 EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

SUBSTITUTE 1449 INFORMATION DISCLOSURE STATEMENT	ATTY. DOCKET NO.	APPLICATION NO.
	REGN-008CIPCON9	17/350,958
	APPLICANT	
	REGENERON PHARMACEUTICALS	, INC.
	FILING DATE	GROUP
	June 17, 2021	To be assigned

NON-PATENT LITERATURE DOCUMENTS		
	DOCUMENT (Including Author, Title, Date, Pertinent Pages, etc.)	REFERENCE PROVIDED*
166.	Healio, "Access to Retina Providers Shows No Geographic Bias in U.S.," (March 12, 2019), https://www.healio.com/news/ophthalmology/20190312/access-to-retina- providers-shows-no-geographic-bias-in-us (accessed December 6, 2021)	Previously in US Application 17/072,417
167.	Hecht, "Ophthalmic Preparations," <i>Remington: The Science and Practice of Pharmacy</i> , Volume II, 19th edition, Chapter 89, pp. 1563-1576 (1995) (Easton, PA)	Previously in US Application 17/072,417
168.	Heier & FOCUS Study Group, Abstract: Intravitreal Ranibizumab (Lucentis [™]) with Verteporfin Photodynamic Therapy for Neovascular Age-Related Macular Degeneration: Year One Results, Am. Soc'y Retina Specialists Ann. Meeting 94 (2005)	Previously in US Application 17/072,417
169.	Heier <i>et al.</i> , "Intravitreal Aflibercept (VEGF Trap-Eye) in Wet Age-related Macular Degeneration," <i>Ophthalmology</i> , 119, Appendices 2-8, pp. 1-34 (December 2012), submitted in IPR2022-01524 as Exhibit 1030	Previously in US Application 17/072,417
170.	Heier, "VEGF Trap-Eye for Exudative AMD," Retinal Physician, (April 2009)	Previously in US Application 17/072,417
171.	Heimann, "Intravitreal Injections: Techniques and Sequelae," in <i>Medical Retina</i> , Holz & Spaide, eds., (2007) (New York, NY)	Previously in US Application 17/072,417
172.	Helzner, "Lucentis After 1 Year: Doctors praise this practice-transforming therapy — but find drawbacks," <i>Retinal Physician</i> (July 1, 2007), https://www.retinalphysician.com/issues/2007/july-aug/lucentis-after-1-year (accessed September 26, 2022)	Previously in US Application 17/072,417
173.	Highlights of Prescribing Information for Eylea (Revised: June 2021), cited in Deposition of Dr. Richard Manning, Ph.D., on May 4, 2022, submitted in IPR2021-00881 as Exhibit 1152	Previously in US Application 17/072,417
174.	Hirokawa <i>et al.</i> , "Tau Proteins: The Molecular Structure and Mode of Binding on Microtubules," <i>J. Cell Biol.</i> , 107(4), pp. 1449-1459 (October 1988)	Previously in US Application 17/072,417
175.	Hopkins Medicine, "Photodynamic Therapy for Age-Related Macular Degeneration," https://www.hopkinsmedicine.org/health/treatment-tests-and- therapies/photodynamic-therapy-for-agerelated-macular-degeneration (accessed December 1, 2021)	Previously in US Application 17/072,417
176.	Iacono <i>et al.</i> , "Antivascular Endothelial Growth Factor in Diabetic Retinopathy," <i>Dev. Ophthalmol.</i> , 46, pp. 39-53 (2010)	Previously in US Application 17/072,417
177.	IPR2021-00880, Corrected Patent Owner Response (February 11, 2022)	Previously in US Application 17/072,417
178.	IPR2021-00880, Patent Owner Sur-Reply (July 6, 2022)	Previously in US Application 17/072,417
179.	IPR2021-00880, Petitioner Reply (May 27, 2022) - [[REDACTED]]	Previously in US Application 17/072,417
180.	IPR2021-00881, Corrected Patent Owner Response (February 11, 2022) - [[REDACTED]]	Previously in US Application 17/072,417

EXAMINER	DATE CONSIDERED
EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line three considered. Include copy of this form with next communication to Applicant.	ough citation if not in conformance and not

Page 15 of 25

SUBSTITUTE 1449 INFORMATION DISCLOSURE STATEMENT	ATTY. DOCKET NO.	APPLICATION NO.
	REGN-008CIPCON9	17/350,958
	APPLICANT	
	REGENERON PHARMACEUTICALS	, INC.
	FILING DATE	GROUP
	June 17, 2021	To be assigned

	NON-PATENT LITERATURE DOCUMENTS	
	DOCUMENT (Including Author, Title, Date, Pertinent Pages, etc.)	REFERENCE PROVIDED*
181.	IPR2021-00881, Patent Owner Sur-Reply (July 6, 2022)	Previously in US Application 17/072,417
182.	IPR2021-00881, Petitioner Reply (May 27, 2022) - [[REDACTED]]	Previously in US Application 17/072,417
183.	IPR2022-01225, Paper 1, Petition for IPR (July 1, 2022)	Previously in US Application 17/072,417
184.	IPR2022-01226, Paper 1, Petition for IPR (July 1, 2022)	Previously in US Application 17/072,417
185.	IPR2022-01524, Paper 1, Petition for IPR (September 9, 2022)	Previously in US Application 17/072,417
186.	IQVIA, "Available IQVIA Data," https://www.iqvia.com/insights/the-iqvia- institute/available-iqvia-data (accessed January 18, 2022)	Previously in US Application 17/072,417
187.	IQVIA, Form 10-K, 2020	Previously in US Application 17/072,417
188.	Jaffe <i>et al.</i> , "Differential Response to Anti-VEGF Regimens in Age-Related Macular Degeneration Patients with Early Persistent Retinal Fluid," <i>Ophthalmology</i> , 123(9), pp. 1856-1864 (September 2016)	Previously in US Application 17/072,417
189.	Jager <i>et al.</i> , "Risks of Intravitreous Injection: A Comprehensive Review," <i>RETINA</i> , 24(5), pp. 676-698 (October 2004) (Philadelphia, PA)	Previously in US Application 17/072,417
190.	Johnson & Johnson Services, Inc., "Johnson & Johnson Completes Acquisition of Momenta Pharmaceuticals, Inc.," Press Release, (October 1, 2020), https://www.jnj.com/johnson-johnson-completes-acquisition-of-momenta- pharmaceuticals-inc (accessed August 2, 2021)	Previously in US Application 17/072,417
191.	Johnson & Johnson Services, Inc., "Johnson & Johnson to Acquire Momenta Pharmaceuticals, Inc., Expanding Janssen's Leadership in Novel Treatments for Autoimmune Diseases," Press Release, (August 19, 2020) https://www.jnj.com/johnson-johnson-to-acquire-momenta-pharmaceuticals- inc-expanding-janssens-leadership-in-novel-treatments-for-autoimmune- diseases (accessed August 2, 2021)	Previously in US Application 17/072,417
192.	Kaiser Family Foundation, "A Snapshot of Sources of Coverage Among Medicare Beneficiaries in 2018," available at: https://www.kff.org/medicare/issue-brief/a-snapshot-of-sources-of-coverage- among-medicare-beneficiaries-in-2018/ (accessed March 23, 2021)	Previously in US Application 17/072,417
193.	Kaiser Family Foundation, "Medicare Advantage in 2021: Enrollment Update and Key Trends," https://www.kff.org/medicare/issue-brief/medicare- advantage-in-2021-enrollment-update-and-key-trends/ (accessed June 21, 2021)	Previously in US Application 17/072,417
194.	Kanghong Pharmaceutical, "Announcement of Chengdu Kanghong Pharmaceutical Group Co., Ltd. on Stopping the Global Multi-center Clinical Trial of Conbercept Ophthalmic Injection," Press Release, http://epaper.zqrb.cn/html/2021-04/10/content_716426.htm?div=-1 (with English translation) (accessed September 26, 2022)	Previously in US Application 17/072,417

EXAMINER	DATE CONSIDERED	
EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.		
*Copies of the listed references are either submitted herewith or were previously cited by or submitted to, the Office in a	a prior application. Pursuant to 37 C.F.R. §	

Page 16 of 25

SUBSTITUTE 1449 INFORMATION DISCLOSURE STATEMENT	ATTY. DOCKET NO.	APPLICATION NO.
	REGN-008CIPCON9	17/350,958
	APPLICANT	
	REGENERON PHARMACEUTICALS	, INC.
	FILING DATE	GROUP
	June 17, 2021	To be assigned

NON-PATENT LITERATURE DOCUMENTS		
	DOCUMENT (Including Author, Title, Date, Pertinent Pages, etc.)	REFERENCE PROVIDED*
195.	Kim <i>et al.</i> , "A Brief History of Anti-VEGF for the Treatment of Ocular Angiogenesis," <i>The American Journal of Pathology</i> , 181(2), pp. 376-379 (August 2012)	Previously in US Application 17/072,417
196.	Kim <i>et al.</i> , "Eyes that Do Not Meet the Eligibility Criteria of Clinical Trials on Age-Related Macular Degeneration: Proportions of the Real-World Patient Population and Reasons for Exclusion," <i>Journal of Ophthalmology</i> , 2021: Article ID 6635467, 8 pages (April 2021)	Previously in US Application 17/072,417
197.	Kleiger <i>et al.</i> , "The 1.7 Å Crystal Structure of BOI: A Study of How Two Dissimilar Amino Acid Sequences Can Adopt the Same Fold," <i>J. Mol. Biol.</i> , 299(4), pp. 1019-1034 (June 2000)	Previously in US Application 17/072,417
198.	Kuepper, "The Best Investment Information Sources: Using SEC Filings, Analyst Reports, and Company Websites," <i>The Balance</i> , https://www.thebalance.com/top-best-sources-of-investor-information-1979207 (accessed January 20, 2021)	Previously in US Application 17/072,417
199.	Kuhlmann <i>et al.</i> , "Lessons Learned from Biosimilar Epoetins and Insulins," <i>The</i> <i>British Journal of Diabetes & Vascular Disease</i> , 10(2), pp. 90-99 (April 2010)	Previously in US Application 17/072,417
200.	L36962: Medicare Part AB Local Coverage Determination (LCD) Comment Summary (May 2, 2014), cited in Deposition of Dr. David M. Brown, M.D., on April 26, 2022, submitted in IPR2021-00881 as Exhibit 1140	Previously in US Application 17/072,417
201.	Li <i>et al.</i> , "Safety and Efficacy of Conbercept in Neovascular Age-Related Macular Degeneration: Results from a 12-Month Randomized Phase 2 Study: AURORA Study," <i>Ophthalmology</i> , 121(9), pp. 1740-1747 (2014)	Previously in US Application 17/072,417
202.	Ling <i>et al.</i> , "Deregulating Direct-to-Consumer Marketing of Prescription Drugs: Effects on Prescription and Over-the-Counter Product Sales," <i>Journal of Law</i> <i>and Economics</i> , 45, pp. 691-723 (2002)	Previously in US Application 17/072,417
203.	Liu <i>et al.</i> , "A Novel Engineered VEGF Blocker with an Excellent Pharmacokinetic Profile and Robust Anti-Tumor Activity," <i>BMC CANCER</i> , 15(170), pp. 1-14 (March 2015) (online publication), cited in Deposition of Dr. Alexander M. Klibanov, Ph.D., on March 24, 2022	Previously in US Application 17/072,417
204.	Lucentis Label (revised April 2017), https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/125156s114lbl.pdf (accessed September 26, 2022)	Previously in US Application 17/072,417
205.	Lucentis Label (revised August 2012), https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/125156s0069s0076 lbl.pdf (accessed September 26, 2022)	Previously in US Application 17/072,417
206.	Lucentis Label (revised June 2010), https://www.accessdata.fda.gov/drugsatfda_docs/label/2010/125156s053lbl.pdf (accessed September 26, 2022)	Previously in US Application 17/072,417

EXAMINER	DATE CONSIDERED
EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line three considered. Include copy of this form with next communication to Applicant.	bugh citation if not in conformance and not
*Copies of the listed references are either submitted herewith or were previously cited by or submitted to, the Office in a	prior application. Pursuant to 37 C.F.R. §

SUBSTITUTE 1449 INFORMATION DISCLOSURE STATEMENT	ATTY. DOCKET NO.	APPLICATION NO.
	REGN-008CIPCON9	17/350,958
	APPLICANT	
	REGENERON PHARMACEUTICALS	, INC.
	FILING DATE	GROUP
	June 17, 2021	To be assigned

	NON-PATENT LITERATURE DOCUMENTS	
	DOCUMENT (Including Author, Title, Date, Pertinent Pages, etc.)	REFERENCE PROVIDED*
207.	Lucentis Label (revised March 2018), https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/125156s117lbl.pdf (accessed September 26, 2022)	Previously in US Application 17/072,417
208.	Macugen Approval Letter (December 17, 2004)	Previously in US Application 17/072,417
209.	Macugen Label (revised December 2004), https://www.accessdata.fda.gov/drugsatfda_docs/label/2004/021756lbl.pdf (accessed September 26, 2022)	Previously in US Application 17/072,417
210.	Macugen Label (submitted with NDA 21-756), submitted in IPR2021-00881 as Exhibit 2038	Previously in US Application 17/072,417
211.	Mankiw, <i>Principles of Microeconomics</i> , 5th ed., South-Western Cengage Learning (Mason, OH) (September 2009)	Previously in US Application 17/072,417
212.	Manning <i>et al.</i> , "Similar Products at Different Prices: Can Biopharmaceutical Companies Segment Markets?" <i>International Journal of the Economics of</i> <i>Business</i> , 22(2), pp. 231-243 (June 2015)	Previously in US Application 17/072,417
213.	Mathis, "Fine-Tuning Your Anti-VEGF Injection Protocols: The Second Article in Our Series Recapping Research and Analysis Presented at Our Annual Meeting," <i>Retinal Physician</i> (October 1, 2009), https://www.retinalphysician.com/issues/2009/october-2009/fine-tuning-your- anti-vegf-injection-protocols (accessed February 4, 2022)	Previously in US Application 17/072,417
214.	Mayo Clinic, "Wet Macular Degeneration Symptoms and Causes," https://www.mayoclinic.org/diseases-conditions/wet-macular- degeneration/symptoms-causes/syc-20351107 (accessed November 11, 2021)	Previously in US Application 17/072,417
215.	Mayo Clinic, "Wet Macular Degeneration," https://www.mayoclinic.org/diseases-conditions/wet-macular- degeneration/diagnosis-treatment/drc-20351113 (accessed November 11, 2021)	Previously in US Application 17/072,417
216.	Medicare Interactive, "Medicare Part B Covered Services," https://www.medicareinteractive.org/get-answers/medicare-covered- services/medicare-coverage-overview/summary-of-part-b-covered-services (accessed November 22, 2021)	Previously in US Application 17/072,417
217.	Medicare Interactive, "The Parts of Medicare (A, B, C, D)," https://www.medicareinteractive.org/get-answers/medicare-basics/medicare- coverage-overview/original-medicare (accessed November 30, 2021)	Previously in US Application 17/072,417
218.	Medicare.gov, "Macular Degeneration Tests & Treatment," https://www.medicare.gov/coverage/macular-degeneration-tests-treatment (accessed November 22, 2021)	Previously in US Application 17/072,417
219.	Medicare.gov, "Medicare Advantage Plans," https://www.medicare.gov/sign- up-change-plans/types-of-medicare-health-plans/medicare-advantage-plans (accessed December 31, 2021)	Previously in US Application 17/072,417

EXAMINER	DATE CONSIDERED	
EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.		
*Conjes of the listed references are either submitted herewith or were previously cited by or submitted to the Office in a	prior application Dyrayout to 27 C E D \$	

	ATTY. DOCKET NO.	APPLICATION NO.
	REGN-008CIPCON9	17/350,958
SUBSTITUTE 1449	APPLICANT	
INFORMATION DISCLOSURE STATEMENT	REGENERON PHARMACEUTICALS	, INC.
	FILING DATE	GROUP
	June 17, 2021	To be assigned

	NON-PATENT LITERATURE DOCUMENTS	
	DOCUMENT (Including Author, Title, Date, Pertinent Pages, etc.)	REFERENCE PROVIDED*
220.	Medicare.gov, "When Does Medicare Coverage Start?" https://www.medicare.gov/basics/get-started-with-medicare/sign-up/when-does- medicare-coverage-start (accessed December 15, 2021)	Previously in US Application 17/072,417
221.	Medline Plus, "Laser Photocoagulation – Eye," https://medlineplus.gov/ency/article/007664.htm (accessed December 2, 2021)	Previously in US Application 17/072,417
222.	Miller & Zois, LLC, "Novartis Looking to Repurpose its Dangerous Beovu Drug," November 28, 2020, https://www.drugrecalllawyerblog.com/novartis- repurpose-beovu.html (accessed September 23, 2021)	Previously in US Application 17/072,417
223.	Miller, "Taking Advantage of the New Purple Book Patent Requirements for Biologics," (April 26, 2021), https://www.morganlewis.com/pubs/2021/04/taking-advantage-of-the-new- purple-book-patent-requirements-for-biologics (accessed September 26, 2022)	Previously in US Application 17/072,417
224.	Moroney <i>et al.</i> , "Aflibercept in Epithelial Ovarian Carcinoma," <i>Future</i> <i>Oncology</i> , 5(5), pp. 591-600 (June 2009)	Previously in US Application 17/072,417
225.	Mueller <i>et al.</i> , "Ocular Infection and Inflammation," EMERGENCY MED. CLINICS N. AM., 26(1), pp. 57-72 (February 2008) (Philadelphia, PA)	Previously in US Application 17/072,417
226.	Murphy <i>et al.</i> , "Protein Folding, Misfolding, Stability and Aggregation: An Overview," in <i>Misbehaving Proteins - Protein (Mis)Folding, Aggregation, and</i> <i>Stability</i> ; Murphy <i>et al.</i> , eds., Springer, (2006) (New York, NY)	Previously in US Application 17/072,417
227.	Nieto <i>et al.</i> , "Ocular silicon distribution and clearance following intravitreal injection of porous silicon microparticles," <i>Exp. Eye Res.</i> , 116, pp. 161-168 (November 2013)	Previously in US Application 17/072,417
228.	Novartis Press Release, "Novartis Receives FDA Approval for Beovu, Offering Wet AMD Patients Vision Gains and Greater Fluid Reductions vs Aflibercept," (October 8, 2019), https://www.novartis.com/news/media-releases/novartis- receives-fda-approval-beovu-offering-wet-amd-patients-vision-gains-and- greater-fluid-reductions-vs-aflibercept (accessed September 26, 2022)	Previously in US Application 17/072,417
229.	Novartis Press Release, "US FDA Approves Updated Novartis Beovu Label, to Include Additional Safety Information," (June 11, 2020), https://www.novartis.com/news/media-releases/us-fda-approves-updated- novartis-beovu-label-include-additional-safety-information (accessed September 26, 2022)	Previously in US Application 17/072,417
230.	Novartis, Annual Report, 2020, submitted in IPR2021-00881 as Exhibit 2230	Previously in US Application 17/072,417
231.	Nucleic acid sequence alignment of SEQ ID NO:1 of the '338 and '069 patents with SEQ ID NO:15 of the '758 patent and SEQ ID NO:15 of the '959 patent, submitted in IPR2021-00881 as Exhibit 1124	Previously in US Application 17/072,417
232.	Nucleotide sequence alignment of SEQ ID NO:1 of the '338 patent with SEQ ID NO:15 of the '758 patent and SEQ ID NO:3 of Dix, submitted in IPR2022- 00881 as Exhibit 1094	Previously in US Application 17/072,417

EXAMINER	DATE CONSIDERED		
EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.			

SUBSTITUTE 1449 INFORMATION DISCLOSURE STATEMENT	ATTY. DOCKET NO.	APPLICATION NO.
	REGN-008CIPCON9	17/350,958
	APPLICANT	
	REGENERON PHARMACEUTICALS	, INC.
	FILING DATE	GROUP
	June 17, 2021	To be assigned

	NON-PATENT LITERATURE DOCUMENTS	
	DOCUMENT (Including Author, Title, Date, Pertinent Pages, etc.)	REFERENCE PROVIDED*
233.	Nucleotide sequence alignment of SEQ ID NO:1 of the '681 and '601 patents with SEQ ID NO:15 of the '758 patent and SEQ ID NO:1 of the '173 patent, submitted in IPR2022-01226 as Exhibit 1093	Previously in US Application 17/072,417
234.	Park <i>et al.</i> , "New Approach to Anti-VEGF Agents for Age-Related Macular Degeneration," <i>Journal of Ophthalmology</i> , 2012:Article ID 637316 (February 2012)	Previously in US Application 17/072,417
237.	Pflugfelder <i>et al.</i> , "Intravitreal Vancomycin: Retinal Toxicity, Clearance, and Interaction with Gentamicin," <i>Arch. Ophthalmol.</i> , 105(6), pp. 831-837 (June 1987)	Previously in US Application 17/072,417
238.	Pindyck et al., Microeconomics, Upper Saddle River: Prentice Hall (2013)	Previously in US Application 17/072,417
239.	Piques <i>et al.</i> , "Ribosome and transcript copy numbers, polysome occupancy and enzyme dynamics in Arabidopsis," <i>Molecular Systems Biology</i> , 5(1), pp. 314 (January 2009)	Previously in US Application 17/072,417
240.	Prangé <i>et al.</i> , "Exploring Hydrophobic Sites in Proteins with Xenon or Krypton," <i>Proteins: Structure, Function, and Genetics</i> , 30(1), pp. 61-73 (January 1998)	Previously in US Application 17/072,417
241.	Publication of OIG Special Fraud Alerts, 59 Fed. Reg. 242, (December 19, 1994), https://oig.hhs.gov/documents/physicians-resources/980/121994.pdf (accessed September 26, 2022)	Previously in US Application 17/072,417
242.	Quiram <i>et al.</i> , "Exudative Age-Related Macular Degeneration: Current Therapies and Potential Treatments," <i>CLINICAL MEDICINE:</i> <i>THERAPEUTICS</i> , 1, pp. 1003-1011 (2009) (online publication)	Previously in US Application 17/072,417
243.	Ramazi <i>et al.</i> , "Post-translational modifications in proteins: resources, tools and prediction methods," <i>Database</i> , 2021(1):baab012 (April 2021)	Previously in US Application 17/072,417
244.	Regeneron Form 10-K for the year ended December 31, 2005, submitted in IPR2021-00881 as Exhibit 1147	Previously in US Application 17/072,417
245.	Regeneron Form 10-K for the year ended December 31, 2011, submitted in IPR2021-00881 as Exhibit 1149	Previously in US Application 17/072,417
246.	Regeneron Pharmaceuticals, Inc., "About," https://www.regeneron.com/about (accessed November 3, 2021)	Previously in US Application 17/072,417
247.	Regeneron Pharmaceuticals, Inc., "Eylea (aflibercept) Injection: Components of Reimbursement," 2015 - [[REDACTED]]	Previously in US Application 17/072,417
248.	Regeneron Pharmaceuticals, Inc., "Eylea Injection Receives FDA Approval for Macular Edema Following Retinal Vein Occlusion (RVO)," Press Release, (October 6, 2014) https://investor.regeneron.com/news-releases/news-release- details/eylear-aflibercept-injection-receives-fda-approval-macular-edema (accessed September 26, 2022)	Previously in US Application 17/072,417

EXAMINER	DATE CONSIDERED	
EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.		
*Copies of the listed references are either submitted herewith or were previously cited by or submitted to, the Office in a	a prior application. Pursuant to 37 C.F.R. §	

Page 20 of 25

	ATTY. DOCKET NO.	APPLICATION NO.
	REGN-008CIPCON9	17/350,958
SUBSTITUTE 1449	APPLICANT	
INFORMATION DISCLOSURE STATEMENT	REGENERON PHARMACEUTICALS	, INC.
	FILING DATE	GROUP
	June 17, 2021	To be assigned

	NON-PATENT LITERATURE DOCUMENTS	
	DOCUMENT (Including Author, Title, Date, Pertinent Pages, etc.)	REFERENCE PROVIDED*
249.	Regeneron Pharmaceuticals, Inc., "Eylea Injection Receives FDA Approval for the Treatment of Diabetic Macular Edema (DME)," Press Release, (July 29, 2014) https://investor.regeneron.com/news-releases/news-release-details/eylear- aflibercept-injection-receives-fda-approval-treatment (accessed September 26, 2022)	Previously in US Application 17/072,417
250.	Regeneron Pharmaceuticals, Inc., "EYLEA," https://eylea.us/ (accessed May 18, 2022)	Previously in US Application 17/072,417
251.	Regeneron Pharmaceuticals, Inc., "FDA Approves Eylea Injection for Diabetic Retinopathy," (May 13, 2019) https://investor.regeneron.com/news- releases/news-release-details/fda-approves-eylear-aflibercept-injection-diabetic- retinopathy (accessed September 26, 2022)	Previously in US Application 17/072,417
252.	Regeneron Pharmaceuticals, Inc., "For the Treatment of Wet Age-Related Macular Degeneration," 2012	Previously in US Application 17/072,417
253.	Regeneron Pharmaceuticals, Inc., "History," https://www.regeneron.com/about/history (accessed December 15, 2021)	Previously in US Application 17/072,417
254.	Regeneron Pharmaceuticals, Inc., "Regeneron Announces FDA Approval of Eylea (Aflibercept) Injection for Macular Edema Following Central Retinal Vein Occlusion," Press Release, (September 21, 2012) https://investor.regeneron.com/news-releases/news-release-details/regeneron- announces-fda-approval-eylear-aflibercept-injection (accessed September 26, 2022)	Previously in US Application 17/072,417
255.	Regeneron Pharmaceuticals, Inc., "Regeneron Reports Fourth Quarter and Full Year 2012 Financial and Operating Results," Press Release (February 14, 2013), https://investor.regeneron.com/news-releases/news-release- details/regeneron-reports-fourth-quarter-and-full-year-2012-financial (accessed August 2, 2021)	Previously in US Application 17/072,417
256.	Regeneron Pharmaceuticals, Inc., "Regeneron Reports Fourth Quarter and Full Year 2019 Financial and Operating Results," Press Release, (February 6, 2020), https://investor.regeneron.com/news-releases/news-release-details/regeneron- reports-fourth-quarter-and-full-year-2019-financial (accessed August 2, 2021)	Previously in US Application 17/072,417
257.	Regeneron Pharmaceuticals, Inc., "Regeneron's Yancopoulos Receives Columbia College's Alexander Hamilton Award," Press Release, (November 22, 2019) https://www.prnewswire.com/news-releases/regenerons-yancopoulos- receives-columbia-colleges-alexander-hamilton-award-300963506.html (accessed September 26, 2022), cited in Deposition of Dr. Diana V. Do, M.D., on April 21, 2022	Previously in US Application 17/072,417

EXAMINER	DATE CONSIDERED	
EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.		
*Copies of the listed references are either submitted herewith or were previously cited by or submitted to, the Office in a prior application. Pursuant to 37 C.F.R. §		

1.97(d) and MPEP §609, the indicated reference may have been previously cited by or submitted to, the Office in a prior application, where the prior application is identified by its U.S. Application Number in this Information Disclosure Statement.

	ATTY. DOCKET NO.	APPLICATION NO.
	REGN-008CIPCON9	17/350,958
SUBSTITUTE 1449	APPLICANT	
INFORMATION DISCLOSURE STATEMENT	REGENERON PHARMACEUTICALS	, INC.
	FILING DATE	GROUP
	June 17, 2021	To be assigned

NON-PATENT LITERATURE DOCUMENTS		
	DOCUMENT (Including Author, Title, Date, Pertinent Pages, etc.)	REFERENCE PROVIDED*
258.	Regeneron Pharmaceuticals, Inc., "Representative Regeneron U.S. Product Related Patents, EYLEA (aflibercept) Injection," (January 2022), https://www.regeneron.com/downloads/us-patent-products.pdf (accessed September 26, 2022), cited in Deposition of Dr. Richard Manning, Ph.D., on May 4, 2022	Previously in US Application 17/072,417
259.	Regeneron Pharmaceuticals, Inc., "Research Areas," https://www.regeneron.com/science/research-areas (accessed November 3, 2021)	Previously in US Application 17/072,417
260.	Regeneron Pharmaceuticals, Inc., "U.S. Eylea Historical Brand P&L," May 2021, submitted in IPR2021-00881 as Exhibit 2200 - [[REDACTED]]	Previously in US Application 17/072,417
261.	Regeneron Pharmaceuticals, Inc., "US Eylea P&L LTD," December 2021, submitted in IPR2021-00881 as Exhibit 2170 - [[REDACTED]]	Previously in US Application 17/072,417
262.	Regeneron Pharmaceuticals, Inc., ATU Sales Share Data: All Indications, 2021, submitted in IPR2021-00881 as Exhibit 2279	Previously in US Application 17/072,417
263.	Regeneron Pharmaceuticals, Inc., ATU Sales Share Data: BRVO, 2021, submitted in IPR2021-00881 as Exhibit 2283	Previously in US Application 17/072,417
264.	Regeneron Pharmaceuticals, Inc., ATU Sales Share Data: CRVO, 2021, submitted in IPR2021-00881 as Exhibit 2282	Previously in US Application 17/072,417
265.	Regeneron Pharmaceuticals, Inc., ATU Sales Share Data: DME, 2021, submitted in IPR2021-00881 as Exhibit 2281	Previously in US Application 17/072,417
266.	Regeneron Pharmaceuticals, Inc., ATU Sales Share Data: DR w/o DME, 2021, submitted in IPR2021-00881 as Exhibit 2284	Previously in US Application 17/072,417
267.	Regeneron Pharmaceuticals, Inc., ATU Sales Share Data: Wet AMD, 2021, submitted in IPR2021-00881 as Exhibit 2280	Previously in US Application 17/072,417
268.	Regeneron Pharmaceuticals, Inc., Earnings Call Transcript, April 26, 2012, submitted in IPR2021-00881 as Exhibit 2134	Previously in US Application 17/072,417
269.	Regeneron Pharmaceuticals, Inc., Earnings Call Transcript, February 13, 2012, submitted in IPR2021-00881 as Exhibit 2133	Previously in US Application 17/072,417
270.	Regeneron Pharmaceuticals, Inc., Earnings Call Transcript, July 25, 2012, submitted in IPR2021-00881 as Exhibit 2135	Previously in US Application 17/072,417
271.	Regeneron Pharmaceuticals, Inc., Eylea Gross & Net Sales P&L YTD, 2021, submitted in IPR2021-00881 as Exhibit 2285 - [[REDACTED]]	Previously in US Application 17/072,417
272.	Regeneron Pharmaceuticals, Inc., Eylea Marketing Material, 2013, submitted in IPR2021-00881 as Exhibit 2136	Previously in US Application 17/072,417
273.	Regeneron Pharmaceuticals, Inc., Eylea Marketing Material, November 2013, submitted in IPR2021-00881 as Exhibit 2137	Previously in US Application 17/072,417
274.	Regeneron Pharmaceuticals, Inc., Form 10-K, 2020, submitted in IPR2021- 00881 as Exhibit 2254	Previously in US Application 17/072,417

EXAMINER	DATE CONSIDERED
EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line three considered. Include copy of this form with next communication to Applicant.	ough citation if not in conformance and not

SUBSTITUTE 1449 INFORMATION DISCLOSURE STATEMENT	ATTY. DOCKET NO.	APPLICATION NO.
	REGN-008CIPCON9	17/350,958
	APPLICANT	
	REGENERON PHARMACEUTICALS	, INC.
	FILING DATE	GROUP
	June 17, 2021	To be assigned

NON-PATENT LITERATURE DOCUMENTS		
	DOCUMENT (Including Author, Title, Date, Pertinent Pages, etc.)	REFERENCE PROVIDED*
275.	Retinal Physician, "Ongoing Treatment for Patients with Neovascular AMD," (October 1, 2007), https://www.retinalphysician.com/issues/2007/october- 2007/ongoing-treatment-for-patients-with-neovascular-am (accessed September 26, 2022)	Previously in US Application 17/072,417
276.	Retinal Physician, "Retinal Physician Symposium Covers Broad Range of Topics," (September 1, 2006), https://www.retinalphysician.com/issues/2006/september-2006/retinal- physician-symposium-covers-broad-range-of (accessed February 4, 2022)	Previously in US Application 17/072,417
277.	Retinal Physician, "Revisiting an Early Treatment for Wet AMD: Is There a Role for Thermal Laser in the Era of Anti-VEGF Therapy?" Press Release, (September 1, 2011) https://www.retinalphysician.com/issues/2011/september- 2011/revisiting-an-early-treatment-for-wet-amd (accessed September 26, 2022)	Previously in US Application 17/072,417
278.	Roche, "FDA Approves Lucentis for Treatment of Diabetic Macular Edema," Press Release, (August 13, 2012) https://www.roche.com/investors/updates/inv- update-2012-08-13.htm (accessed September 26, 2022)	Previously in US Application 17/072,417
279.	Roche, "FDA Approves Roche's Lucentis for Diabetic Retinopathy, the Leading Cause of Blindness Among Working Age Adults in the United States," Press Release, (April 18, 2017) https://www.roche.com/media/releases/med- cor-2017-04-18b.htm (accessed September 26, 2022)	Previously in US Application 17/072,417
280.	Roche, Finance Report, 2020, submitted in IPR2021-00881 as Exhibit 2256	Previously in US Application 17/072,417
281.	Rowe <i>et al.</i> , <i>Handbook of Pharmaceutical Excipients</i> , Cover to Preface (5th ed. 2006) (London, UK)	Previously in US Application 17/072,417
282.	Schneider, "Nits, Grits, and Soft Information in SEC Filings," <i>U. PA. L. REV.</i> , 121(2), pp. 254-305 (1972) (Philadelphia, PA)	Previously in US Application 17/072,417
283.	Schweitzer, <i>Pharmaceutical Economics and Policy: Second Edition</i> , Oxford University Press (2007) (New York, NY)	Previously in US Application 17/072,417
284.	ScienceDaily, "FDA Approves First Angiogenesis Inhibitor to Treat Colorectal Cancer," Press Release, (February 27, 2004) https://www.sciencedaily.com/releases/2004/02/040227071334.htm (accessed September 26, 2022)	Previously in US Application 17/072,417
285.	Shen <i>et al.</i> , "Clearance of Intravitreal Voriconazole," <i>Invest. Ophthalmology & Visual Sci.</i> , 45(5), pp. 2238-2241 (May 2007)	Previously in US Application 17/072,417
286.	Sivaprasad, "Sustained-Release Steroid Options For DME Therapy," <i>Retina</i> <i>Today</i> , pp. 34-36 (September 2021)	Previously in US Application 17/072,417
287.	Solá <i>et al.</i> , "Effects of Glycosylation on the Stability of Protein Pharmaceuticals," <i>Journal of Pharmaceutical Sciences</i> , 98(4), pp. 1223-1245 (April 2009)	Previously in US Application 17/072,417

EXAMINER	DATE CONSIDERED
EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through	ough citation if not in conformance and not
considered. Include copy of this form with next communication to Applicant.	

SUBSTITUTE 1449 INFORMATION DISCLOSURE STATEMENT	ATTY. DOCKET NO.	APPLICATION NO.
	REGN-008CIPCON9	17/350,958
	APPLICANT	
	REGENERON PHARMACEUTICALS	, INC.
	FILING DATE	GROUP
	June 17, 2021	To be assigned

	NON-PATENT LITERATURE DOCUMENTS	
	DOCUMENT (Including Author, Title, Date, Pertinent Pages, etc.)	REFERENCE PROVIDED*
288.	Stefanini <i>et al.</i> , "Increase of Plasma VEGF after Intravenous Administration of Bevacizumab Is Predicted by a Pharmacokinetic Model," <i>CANCER</i> <i>RESEARCH</i> , 70(23), pp. 9886-9894 (December 2010), cited in Deposition of Dr. Alexander M. Klibanov, Ph.D., on March 24, 2022	Previously in US Application 17/072,417
289.	Thomas <i>et al.</i> , "Comparative Effectiveness of Aflibercept for the Treatment of Patients with Neovascular Age-related Macular Degeneration," <i>Clinical Ophthalmology</i> , 7, pp. 495-501 (March 2013)	Previously in US Application 17/072,417
290.	Thomson Reuters, "Thomson Reuters Links Discovery and Literature Citation Databases," Press Release (January 4, 2010)	Previously in US Application 17/072,417
291.	Transcript of Deposition of Doris Weber dated May 13, 2022, in IPR2021- 00881	Previously in US Application 17/072,417
292.	Transcript of Deposition of Dr. Alexander M. Klibanov, Ph.D., dated March 24, 2022, in IPR2021-00880 and IPR2021-00881 - [[REDACTED]]	Previously in US Application 17/072,417
293.	Transcript of Deposition of Dr. David M. Brown, M.D., dated April 26, 2022, in IPR2021-00880 and IPR2021-00881	Previously in US Application 17/072,417
294.	Transcript of Deposition of Dr. Diana V. Do, M.D., dated April 21, 2022, in IPR2021-00881	Previously in US Application 17/072,417
295.	Transcript of Deposition of Dr. Lucian V. Del Priore, M.D., dated April 29, 2022, in IPR2021-00881 - [[REDACTED]]	Previously in US Application 17/072,417
296.	Transcript of Deposition of Dr. Richard Manning, Ph.D., dated May 4, 2022, in IPR2021-00881 - [[REDACTED]]	Previously in US Application 17/072,417
297.	Transcript of Deposition of Ivan Hofmann dated June 23, 2022, in IPR2021- 00880 and IPR2021-00881 - [[REDACTED]]	Previously in US Application 17/072,417
298.	Transcript of Deposition of Mary Gerritsen, Ph.D., dated June 17, 2022, in IPR2021-00880 and IPR2021-00881	Previously in US Application 17/072,417
299.	Transcript of Deposition of Thomas Albini, M.D., dated June 22, 2022, in IPR2021-00880 and IPR2021-00881	Previously in US Application 17/072,417
300.	Transcript of the Teleconference before the United States Patent Trial and Appeal Board dated February 23, 2022, in IPR2021-00881	Previously in US Application 17/072,417
301.	Transcript of the Teleconference before the United States Patent Trial and Appeal Board dated May 19, 2022, in IPR2021-00880 and IPR2021-00881	Previously in US Application 17/072,417
302.	Transcript of the Teleconference before the United States Patent Trial and Appeal Board dated September 8, 2021, in IPR2021-00881	Previously in US Application 17/072,417
303.	U.S. Department of Health and Human Services (ASPE), "Medicare Part B Reimbursement of Prescription Drugs," 6/2014, available at: https://aspe.hhs.gov/sites/default/files/private/pdf/106966/ib_mprpd.pdf (accessed September 26, 2022)	Previously in US Application 17/072,417
304.	United Healthcare, "Ophthalmologic Policy: VEGF Inhibitors," effective January 1, 2022, submitted in IPR2021-00881 as Exhibit 1167	Previously in US Application 17/072,417

EXAMINER	DATE CONSIDERED
EAAWIINEK	DATE CONSIDERED
EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through	augh aitation if not in conformance and not
EXAMPLER: Initial inference considered, whether of not citation is in comornance with MFEF 009. Draw line und	Sugn citation if not in comormance and not
considered. Include conv. of this form with next communication to Applicant	
considered. Include copy of this form with next communication to Applicant.	
*Conject of the listed references are either submitted berewith on ware previously sited by an submitted to the Office in s	maior application Dursuant to 27 CED \$

SUBSTITUTE 1449 INFORMATION DISCLOSURE STATEMENT	ATTY. DOCKET NO.	APPLICATION NO.
	REGN-008CIPCON9	17/350,958
	APPLICANT	
	REGENERON PHARMACEUTICALS	, INC.
	FILING DATE	GROUP
	June 17, 2021	To be assigned

NON-PATENT LITERATURE DOCUMENTS		
	DOCUMENT (Including Author, Title, Date, Pertinent Pages, etc.)	
305.	USC-Brookings, "Medicare Payment for Physician-Administered (Part B) Drugs: The Interim Final Rule and a Better Way Forward," https://www.brookings.edu/blog/usc-brookings-schaeffer-on-health- policy/2021/02/10/medicare-payment-for-physician-administered-part-b-drugs/ (accessed September 26, 2022)	Previously in US Application 17/072,417
306.	Vanderkam, "George Yancopoulos: Doing Well by Trying to Do Good," <i>SCIENTIFIC AMERICAN</i> , https://www.scientificamerican.com/article/george- yancopoulos-westinghouse/ (accessed April 14, 2022), cited in Deposition of Dr. Diana V. Do, M.D., on April 21, 2022	Previously in US Application 17/072,417
307.	Verywell Health, "Macular Degeneration: Timeline of Vision Loss Progression," https://www.verywellhealth.com/macular-degeneration-timeline- 5069947 (accessed March 21, 2021)	Previously in US Application 17/072,417
308.	Vestrum Health, "Pharmaceutical Companies," https://www.vestrumhealth.com/pharma.php (accessed January 3, 2022)	Previously in US Application 17/072,417
309.	Vestum Health, "Homepage," https://www.vestrumhealth.com/index.php (accessed January 3, 2022)	Previously in US Application 17/072,417
310.	Visudyne Label (revised April 2016), https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/021119s027lbl.pdf (accessed September 26, 2022)	Previously in US Application 17/072,417
311.	Volkin <i>et al.</i> , "Alterations in the Structure of Proteins that Cause Their Irreversible Inactivation," <i>Developments in Biological Standardization</i> , 74, pp. 73-81 (1992) (Basel, SI)	Previously in US Application 17/072,417
312.	Weidner <i>et al.</i> , "Observations Regarding the Average Sales Price Reimbursement Methodology," <i>Evidence-Based Oncology</i> , 27(4), pp. 156-160 (2021)	Previously in US Application 17/072,417
313.	Wells <i>et al.</i> , "Aflibercept, Bevacizumab, or Ranibizumab for Diabetic Macular Edema," <i>The New England Journal of Medicine</i> , 372(13), pp. 1193-1203 (2015)	Previously in US Application 17/072,417
314.	Wilhelmus, "The Red Eye, Infectious Conjunctivitis, Keratitis, Endophthalmitis, and Periocular Cellulitis," <i>INFECTIOUS DISEASE CLINICS</i> <i>N. AM.</i> , 2(1), pp. 99-116 (March 1988) (Philadelphia, PA)	Previously in US Application 17/072,417
315.	Wirbelauer, "Management of the Red Eye for the Primary Care Physician," <i>AM. J. MED.</i> , 119(4), pp. 302-306 (April 2006) (online publication)	Previously in US Application 17/072,417
316.	World Health Organization, "Blindness and Vision Impairment Fact Sheet," Press Release, (October 14, 2021) https://www.who.int/news-room/fact- sheets/detail/blindness-and-visual-impairment (accessed September 26, 2022)	Previously in US Application 17/072,417
317.	World Health Organization, "International Nonproprietary Names for Pharmaceutical Substances (INN)," <i>WHO Drug Information</i> , 20, pp. 118-119 (2006), cited in Deposition of Dr. Alexander M. Klibanov, Ph.D., on March 24, 2022	Previously in US Application 17/072,417

EXAMINER	DATE CONSIDERED
EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line three considered. Include copy of this form with next communication to Applicant.	ough citation if not in conformance and not

Page 25 of 25

SUBSTITUTE 1449 <u>INFORMATION DISCLOSURE STATEMENT</u>	ATTY. DOCKET NO.	APPLICATION NO.
	REGN-008CIPCON9	17/350,958
	APPLICANT	
	REGENERON PHARMACEUTICALS	, INC.
	FILING DATE	GROUP
	June 17, 2021	To be assigned

NON-PATENT LITERATURE DOCUMENTS				
	DOCUMENT (Including Author, Title, Date, Pertinent Pages, etc.)	REFERENCE PROVIDED*		
318.	Yahoo Finance, "Beovu Now Publicly Reimbursed in Ontario and New Brunswick for the Treatment of Neovascular Wet AMD," Press Release, (December 17, 2021) https://finance.yahoo.com/news/beovu-brolucizumab- injection-now-publicly-120000109.html (accessed December 30, 2021)	Previously in US Application 17/072,417		
319.	Yang, "Comparison of Binding Characteristics and <i>in vitro</i> Activities of Three Inhibitors of Vascular Endothelial Growth Factor A," <i>Molecular</i> <i>Pharmaceutics</i> , 11(10), pp. 3421-3429 (October 2014), cited in Deposition of Dr. Alexander M. Klibanov, Ph.D., on March 24, 2022	Previously in US Application 17/072,417		
320.	Yorston, "Anti-VEGF Drugs in the Prevention of Blindness," <i>Community Eye</i> <i>Health Journal</i> , 27(87), pp. 44-46 (2014)	Previously in US Application 17/072,417		
321.	Zucchi, "EDGAR: Investors' One-Stop-Shop For Company Filings," <i>YAHOO!LIFE</i> , https://www.yahoo.com/lifestyle/tagged/health/edgar-investors- one-stop-shop-170000800.html (accessed January 20, 2021)	Previously in US Application 17/072,417		

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformation considered. Include copy of this form with next communication to Applicant.	nce and not

EXAMINER

*Copies of the listed references are either submitted herewith or were previously cited by or submitted to, the Office in a prior application. Pursuant to 37 C.F.R. § 1.97(d) and MPEP §609, the indicated reference may have been previously cited by or submitted to, the Office in a prior application, where the prior application is identified by its U.S. Application Number in this Information Disclosure Statement.

DATE CONSIDERED

Electronic Acknowledgement Receipt			
EFS ID:	46891703		
Application Number:	17350958		
International Application Number:			
Confirmation Number:	4833		
Title of Invention:	USE OF A VEGF ANTAGONIST TO TREAT ANGIOGENIC EYE DISORDERS		
First Named Inventor/Applicant Name:	George YANCOPOULOS		
Customer Number:	96387		
Filer:	Karl Bozicevic/Kimberly Zuehlke		
Filer Authorized By:	Karl Bozicevic		
Attorney Docket Number:	REGN-008CIPCON9		
Receipt Date:	25-OCT-2022		
Filing Date:	17-JUN-2021		
Time Stamp:	19:51:38		
Application Type:	Utility under 35 USC 111(a)		

Payment information:

Submitted with Payment no						
File Listing:	:					
Document Number	Document Description		File Name	File Size(Bytes)/ Message Digest	Multi Part /.zip	Pages (if appl.)
				58599		
1	Transmittal Letter	REC	GN-008CIPCON9_2022-10-25 _supp_IDS_trans.pdf	a4f279c474c6e788b107e69530693173a5a 8c334	no	5
Warnings:	APOTEX V. REGENERON IPR2022-01524					

Information	:				
2	Information Disclosure Statement (IDS) Form (SB08)	REGN-008CIPCON9_2022-10-25 _supp_IDS_1449.pdf	261419 e0ee3dcc7d22a1addf8ef3ca9665add2d98 6cf52	no	25
Warnings:	ļ				
Information	:				
This is not an l	JSPTO supplied IDS fillable form				
		Total Files Size (in bytes)	: 32	20018	
characterize	vledgement Receipt evidences receip ed by the applicant, and including pages s described in MPEP 503.	•			
characterize Post Card, a <u>New Applica</u> If a new app	ed by the applicant, and including pay s described in MPEP 503. ations Under 35 U.S.C. 111 lication is being filed and the applica	ge counts, where applicable. tion includes the necessary o	It serves as evidence components for a filin	of receipt s og date (see	imilar to 37 CFR
characterize Post Card, a <u>New Applica</u> If a new app 1.53(b)-(d) a	ed by the applicant, and including pays s described in MPEP 503. ations Under 35 U.S.C. 111 lication is being filed and the applica and MPEP 506), a Filing Receipt (37 CF	ge counts, where applicable. tion includes the necessary of TR 1.54) will be issued in due	It serves as evidence components for a filin	of receipt s og date (see	imilar to 37 CFR
characterize Post Card, a <u>New Applica</u> If a new app 1.53(b)-(d) a Acknowledg <u>National Sta</u> If a timely su U.S.C. 371 a	ed by the applicant, and including pay s described in MPEP 503. ations Under 35 U.S.C. 111 lication is being filed and the applica and MPEP 506), a Filing Receipt (37 CF gement Receipt will establish the filin age of an International Application ur ubmission to enter the national stage nd other applicable requirements a F	ge counts, where applicable. tion includes the necessary of R 1.54) will be issued in due of date of the application. <u>nder 35 U.S.C. 371</u> of an international applicati orm PCT/DO/EO/903 indicati	It serves as evidence components for a filin course and the date s ion is compliant with ing acceptance of the	of receipt s og date (see hown on th the condition application	imilar to 37 CFR is ons of 35
characterize Post Card, a <u>New Applica</u> If a new app 1.53(b)-(d) a Acknowledg <u>National Sta</u> If a timely su U.S.C. 371 a national sta <u>New Interna</u> If a new internati	ed by the applicant, and including pay s described in MPEP 503. Ations Under 35 U.S.C. 111 lication is being filed and the applica and MPEP 506), a Filing Receipt (37 CF gement Receipt will establish the filin age of an International Application un ubmission to enter the national stage	ge counts, where applicable. Thion includes the necessary of TR 1.54) will be issued in due og date of the application. <u>Inder 35 U.S.C. 371</u> of an international application form PCT/DO/EO/903 indication PCT/DO/EO/903 indication PCT as a Receiving Office and the international application of MPEP 1810), a Notification	It serves as evidence components for a filin course and the date s ion is compliant with ing acceptance of the e Filing Receipt, in du ion includes the nece	of receipt s og date (see hown on th the condition application e course. ssary comp Application	imilar 37 CFF is ons of 3 n as a onents Numb

the application.

	Electronically Plica		
	Attorney Docket No.	REGN-008CIPCON9	
	Confirmation No.	4833	
INFORMATION	First Named Inventor	George D. Yancopoulos	
DISCLOSURE STATEMENT	Application Number	17/350,958	
	Filing Date	June 17, 2021	
	Group Art Unit		
Address to:	Examiner Name		
Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450	Title: "Use of a VEGF Antagonist to Treat Angiogenic Eye Disorders"		

Electronically Filed

Sir:

The attention of the Examiner is invited to the documents listed on the attached Substitute 1449.

Copies of the U.S. patents and published applications listed on the attached Substitute 1449 are not submitted herewith, in accordance with the Strategic Plan Final Rule, 69 Fed. Reg. 56481-56547 (September 21, 2004), effective October 21, 2004.

Copies of the foreign publication and non-patent literature documents listed on the attached Substitute 1449 are submitted in parent U.S. Application No. 17/072,417.

It is respectfully requested that the information above be expressly considered during the prosecution of this application, and that the documents be made of record therein and appear among the "References Cited" on any patent to issue therefrom.

No aspect of these submissions constitute admission of prior art status or a disclaimer of claim scope.

Statement under 37 C.F.R. §§1.56 and 1.2

Applicant hereby advises the Examiner of the status of a co-pending application(s) in compliance with the Applicant's duty to disclose under 37 C.F.R. §§1.56 and 1.2 (*see* also M.P.E.P. §2001.06(b)) as discussed in *McKesson Info. Soln. Inc., v. Bridge Medical Inc.*, 487 F.3d 897 (Fed. Cir. 2007).

With respect to this statement under *McKesson*, Applicants wishes to bring to the Examiner's attention U.S. Patent Application No. 13/940,370, filed July 12, 2013, which issued as U.S. Patent No. 9,254,338 on February 9, 2016.

With respect to this statement under *McKesson*, Applicants wishes to bring to the Examiner's attention U.S. Patent Application No. 14/972,560, filed December 17, 2015, which issued as U.S. Patent No. 9,669,069 on June 6, 2017.

With respect to this statement under *McKesson*, Applicants wishes to bring to the Examiner's attention U.S. Patent Application No. 15/471,506, filed March 28, 2017, which issued as U.S. Patent No. 10,130,681 on November 20, 2018.

With respect to this statement under *McKesson*, Applicants wishes to bring to the Examiner's attention U.S. Patent Application No. 16/055,847, filed August 6, 2018, which issued as U.S. Patent No. 10,857,205 on December 8, 2020.

With respect to this statement under *McKesson*, Applicants wishes to bring to the Examiner's attention U.S. Patent Application No. 16/159,282, filed October 12, 2018, which issued as U.S. Patent No. 10,828,345 on November 10, 2020.

With respect to this statement under *McKesson*, Applicants wishes to bring to the Examiner's attention U.S. Patent Application No. 16/397,267, filed April 29, 2019, which issued as U.S. Patent No. 10,888,601 on January 12, 2021.

With respect to this statement under *McKesson*, Applicants wishes to bring to the Examiner's attention U.S. Patent Application No. 17/352,892, filed June 21, 2021, which issued as U.S. Patent No. 11,253,572 on February 22, 2022.

With respect to this statement under *McKesson*, Applicant wishes to bring to the Examiner's attention U.S. Patent Application No. 17/072,417, filed October 16, 2020. No actions have been mailed to date.

With respect to this statement under *McKesson*, Applicant wishes to bring to the Examiner's attention U.S. Patent Application No. 17/112,063, filed December 4, 2020. No actions have been mailed to date.

With respect to this statement under *McKesson*, Applicant wishes to bring to the Examiner's attention U.S. Patent Application No. 17/112,404, filed December 4, 2020. No actions have been mailed to date.

With respect to this statement under *McKesson*, Applicant wishes to bring to the Examiner's attention U.S. Patent Application No. 17/740,744, filed May 10, 2022. A Non-Final Office Action was mailed on July 20, 2022.

With respect to this statement under *McKesson*, Applicant wishes to bring to the Examiner's attention *Inter Partes* Review No. IPR2021-00880 of U.S. Patent No. 9,669,069, filed on May 5, 2021; and IPR2021-00881 of U.S. Patent No. 9,254,338, filed on May 5, 2021. Both of which are currently awaiting final decision from PTAB.

With respect to this statement under *McKesson*, Applicant wishes to bring to the Examiner's attention *Inter Partes* Review No. IPR2022-01225 of U.S. Patent No. 10,130,681, filed on July 1, 2022; and IPR2022-01226 of U.S. Patent No. 10,888,601, filed on July 1, 2022.

With respect to this statement under *McKesson*, Applicant wishes to bring to the Examiner's attention *Inter Partes* Review No. IPR2022-01524 of U.S. Patent No. 11,253,572, filed on September 9, 2022.

These documents and the corresponding file wrappers are available on PAIR or PTAB E2E, and thus are not provided with this communication. Please inform the undersigned if there is any difficulty in obtaining the documents from PAIR or PTAB E2E.

Statements

No statement

PTA Statement under 37 CFR § 1.704(d)(1): Each item of information contained in the information disclosure statement filed herewith:

(i) Was first cited in any communication from a patent office in a counterpart foreign or international application or from the Office, and this communication was not received by any individual designated in § 1.56(c) more than thirty days prior to the filing of the information disclosure statement; or

(ii) Is a communication that was issued by a patent office in a counterpart foreign or international application or by the Office, and this communication was not received by any individual designated in § 1.56(c) more than thirty days prior to the filing of the information disclosure statement.

IDS Statement under 37 CFR § 1.97(e)(1): Each item of information contained in the information disclosure statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of the information disclosure statement; or

IDS Statement under 37 CFR § 1.97(e)(2): No item of information contained in the information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the person signing the certification after making reasonable inquiry, no item of information contained in the information disclosure statement was known to any individual designated in § 1.56(c) more than three months prior to the filing of the information disclosure statement.

Fees

 \square

 \boxtimes No fee is believed to be due.

The appropriate fee set forth in 37 C.F.R. §1.17(p) accompanies this information disclosure statement.

The Commissioner is hereby authorized to charge any underpayment of fees up to a strict limit of \$3,000.00 beyond that authorized on the credit card, but not more than \$3,000.00 in additional fees due with any communication for the above-referenced patent application, including but not limited to any necessary fees for extensions of time, or credit any overpayment of any amount to Deposit Account No. 50-0815, order number REGN-008CIPCON9.

Respectfully submitted, BOZICEVIC, FIELD & FRANCIS LLP

Date: <u>October 25, 2022</u>

By: /Karl Bozicevic, Reg. No. 28,807/ Karl Bozicevic, Reg. No. 28,807

BOZICEVIC, FIELD & FRANCIS LLP 201 Redwood Shores Parkway, Suite 200 Redwood City, CA 94065 Telephone: (650) 327-3400 Facsimile: (650) 327-3231

	ATTY. DOCKET NO.	APPLICATION NO.	
	REGN-008CIPCON9	17/350,948	
SUBSTITUTE 1449	APPLICANT		
INFORMATION DISCLOSURE STATEMENT	REGENERON PHARMACEUTICALS, INC.		
	FILING DATE	GROUP	
	June 17, 2021		

U.S. PATENT DOCUMENTS					
DOCUMENT NUMBER DATE NAME REFERENCE PROVIDED*					REFERENCE PROVIDED*
	1	US 7,087,411 B2	08/08/2006	Daly <i>et al</i> .	not required per 69 Fed. Reg. 56481

FOREIGN PATENT DOCUMENTS						
		DOCUMENT NUMBER	DATE	COUNTRY	TRANSLATION	REFERENCE PROVIDED*

NON-PATENT LITERATURE DOCUMENTS				
	DOCUMENT (Including Author, Title, Date, Pertinent Pages, etc.)	REFERENCE PROVIDED*		
2	Berker <i>et al.</i> , "Surgical treatment of central retinal vein occlusion," <i>Acta Ophthalmol.</i> , 86:245-252 (2008)	Herewith		
3	Byeon <i>et al.</i> , "Short-Term Results of Intravitreal Bevacizumab for Macular Edema with Retinal Vein Obstruction and Diabetic Macular Edema, <i>J.</i> <i>OCULAR PHARMACOLOGY AND THERAPEUTICS</i> , 23(4):387-394 (November 2007)	Herewith		
4	ClinicalTrials.gov, "1997: Congress Passes Law (FDAMA) Requiring Trial Registration," (1997), https://clinicaltrials.gov/ct2/about-site/history, submitted in IPR2023-00099 as Exhibit 1085 (last updated May 2021)	Herewith		
5	Corrections to Kiire <i>et al.</i> , "Managing Retinal Vein Occlusion," <i>BMJ</i> , 344(e2110):1 (2012)	Herewith		
6	Expert Declaration of Dr. Jay M. Stewart in Support of Petition for <i>Inter Partes</i> Review of U.S. Patent No. 10,857,205 B2, dated October 27, 2022, in IPR2023- 00099	Herewith		
7	Expert Declaration of Mary Gerritsen, Ph.D. in Support of Petition for <i>Inter</i> <i>Partes</i> Review of U.S. Patent No. 10,857,205 B2, dated October 27, 2022, in IPR2023-00099	Herewith		
8	Gewaily <i>et al.</i> , "Intravitreal steroids versus observation for macular edema secondary to central retinal vein occlusion," <i>Cochrane Database Syst. Rev.</i> , 1(CD007324):1-31 (2009)	Herewith		

EXAMINER	DATE CONSIDERED
EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line three considered. Include copy of this form with next communication to Applicant.	ough citation if not in conformance and not
*Copies of the listed references are either submitted herewith or were previously cited by or submitted to, the Office in a 1.97(d) and MPEP §609, the indicated reference may have been previously cited by or submitted to, the Office in a prior identified by its U.S. Application Number in this Information Disclosure Statement.	1 11 -

		1481 - 01 1	
	ATTY. DOCKET NO.	APPLICATION NO.	
	REGN-008CIPCON9	17/350,948	
SUBSTITUTE 1449	APPLICANT		
INFORMATION DISCLOSURE STATEMENT	REGENERON PHARMACEUTICALS, INC.		
	FILING DATE	GROUP	
	June 17, 2021		

NON-PATENT LITERATURE DOCUMENTS				
	DOCUMENT (Including Author, Title, Date, Pertinent Pages, etc.)			
9	Golan et al., "Current Treatment of Retinal Vein Occlusion," Eur. Ophthalmic Rev., 5:62-68 (2011)	Herewith		
10	Keane <i>et al.</i> , "Retinal vein occlusion and macular edema – critical evaluation of the clinical value of ranibizumab," <i>Clinical Ophthalmology</i> , 5:771-781 (2011)	Herewith		
11	Kiire <i>et al.</i> , "Managing retinal vein occlusion," <i>BMJ</i> , 344(e499):1-16 (February 2012)	Herewith		
12	Kinge <i>et al.</i> , "Efficacy of Ranibizumab in Patients With Macular Edema Secondary to Central Retinal Vein Occlusion: Results From the Sham- Controlled ROCC Study," <i>American Journal of Ophthalmology</i> , 150(3):310- 314 (2010)	Herewith		
13	Kreatsoulas, "Expanding Therapeutic Options for Retinal Vein Occlusion," <i>Retina Today</i> , pp. 20-21 (July/August 2009)	Herewith		
14	Petition for <i>Inter Partes</i> Review of U.S. Patent No. 10,857,205 B2, dated October 28, 2022, in IPR2023-00099	Herewith		
15	Pieramici, "Intravitreal Ranibizumab for Treatment of Macular Edema Secondary to Retinal Vein Occlusion," <i>Retina Today</i> , 44-46 (March 2009)	Herewith		
16	Regeneron Pharmaceuticals, Inc., "Bayer and Regeneron Extend Development Program for VEGF Trap-Eye to Include Central Retinal Vein Occlusion," Press Release, (Apr. 30, 2009), https://investor.regeneron.com/news-releases/news- release-details/bayer-and-regeneron-extend-development-program-vegf- trap-eye, submitted in IPR2023-00099 as Exhibit 1028 (last accessed November 4, 2022)	Herewith		
17	Regeneron Pharmaceuticals, Inc., "Regeneron and Bayer HealthCare Announce Encouraging 32-Week Follow Up Results from a Phase 2 Study of VEGF Trap- Eye in Age-Related Macular Degeneration," Press Release, (Apr. 28, 2008), http://newsroom.regeneron.com/releasedetail.cfm?releaseid=394066, submitted in IPR2023-00099 as Exhibit 1012 (last accessed November 11, 2022)	Herewith		
18	Regeneron Pharmaceuticals, Inc., "Regeneron Reports Third Quarter 2010 Financial Results and Business Highlights," Press Release (Oct. 28, 2010) https://investor.regeneron.com/news-releases/news-release-details/regeneron- reports-third-quarter-2010-financial-results-and, submitted in IPR2023-00099 as Exhibit 1058 (last accessed November 4, 2022)	Herewith		

EXAMINER	DATE CONSIDERED
EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line thr considered. Include copy of this form with next communication to Applicant.	ough citation if not in conformance and not

		ruge 5 of 1	
	ATTY. DOCKET NO.	APPLICATION NO.	
	REGN-008CIPCON9	17/350,948	
SUBSTITUTE 1449	APPLICANT		
INFORMATION DISCLOSURE STATEMENT	REGENERON PHARMACEUTICALS, INC.		
	FILING DATE	GROUP	
	June 17, 2021		

NON-PATENT LITERATURE DOCUMENTS		
	DOCUMENT (Including Author, Title, Date, Pertinent Pages, etc.)	REFERENCE PROVIDED*
19	Regeneron Pharmaceuticals, Inc., Quarterly Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 (Form 10-Q), submitted in IPR2023-00099 as Exhibit 1021 (Sept. 30, 2009)	Herewith
20	Regeneron Pharmaceuticals, Inc., Quarterly Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 (Form 10-Q), submitted in IPR2023-00099 as Exhibit 1022 (Sept. 30, 2010)	Herewith
21	Shahid <i>et al.</i> , "The Management of Retinal Vein Occlusion: is Interventional Ophthalmology the Way Forward?," <i>Br. J. Ophthalmology</i> , 90:627-639 (2006)	Herewith
22	Sophie <i>et al.</i> , "Aflibercept: a Potent Vascular Endothelial Growth Factor Antagonist for Neovascular Age-Related Macular Degeneration and Other Retinal Vascular Diseases," <i>Biol. Ther.</i> , 2(3):1-22 (2012)	Herewith
23	Wu <i>et al.</i> , "Comparison Of Two Doses Of Intravitreal Bevacizumab (Avastin) For Treatment Of Macular Edema Secondary To Branch Retinal Vein Occlusion," <i>Retina</i> , 28:212-219 (2008)	Herewith

EXAMINER	DATE CONSIDERED
EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line thro considered. Include copy of this form with next communication to Applicant.	ugh citation if not in conformance and not
*Copies of the listed references are either submitted herewith or were previously cited by or submitted to, the Office in a 1.97(d) and MPEP §609, the indicated reference may have been previously cited by or submitted to, the Office in a prior identified by its U.S. Application Number in this Information Disclosure Statement.	

Page 4 of 4

	ATTY. DOCKET NO.	APPLICATION NO.	
	REGN-008CIPCON9	17/350,948	
SUBSTITUTE 1449	APPLICANT		
INFORMATION DISCLOSURE STATEMENT	REGENERON PHARMACEUTICALS, INC.		
	FILING DATE	GROUP	
	June 17, 2021		

NON-PATENT LITERATURE DOCUMENTS - FINAL WRITTEN DECISIONS		
	DOCUMENT (Including Author, Title, Date, Pertinent Pages, etc.)	REFERENCE PROVIDED*
24	Final Written Decision Determining All Challenged Claims Unpatentable Denying Petitioner's Motion to Exclude Evidence Denying in part and Dismissing in Part Patent Owner's Motion to Exclude Evidence dated November 9, 2022, in IPR2021-00880 dated November 9, 2022, for US 9,669,069 B2	Herewith
25	Final Written Decision Determining All Challenged Claims Unpatentable Denying in part and Dismissing in part Petitioners' Motion to Exclude Denying in part and Dismissing in part Denying Patent Owner's Motion to Exclude dated November 9, 2022, in IPR2021-00881 dated November 9, 2022, for US 9,254,338 B2	Herewith

EXAMINER	DATE CONSIDERED	
EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.		
*Copies of the listed references are either submitted herewith or were previously cited by or submitted to, the Office in a	a prior application. Pursuant to 37 C.F.R. §	

Electronic Acknowledgement Receipt			
EFS ID:	47020380		
Application Number:	17350958		
International Application Number:			
Confirmation Number:	4833		
Title of Invention:	USE OF A VEGF ANTAGONIST TO TREAT ANGIOGENIC EYE DISORDERS		
First Named Inventor/Applicant Name:	George YANCOPOULOS		
Customer Number:	96387		
Filer:	Karl Bozicevic/Kimberly Zuehlke		
Filer Authorized By:	Karl Bozicevic		
Attorney Docket Number:	REGN-008CIPCON9		
Receipt Date:	14-NOV-2022		
Filing Date:	17-JUN-2021		
Time Stamp:	17:22:49		
Application Type:	Utility under 35 USC 111(a)		

Payment information:

Submitted with Payment		no				
File Listing:						
Document Number	Document Description		File Name	File Size(Bytes)/ Message Digest	Multi Part /.zip	Pages (if appl.)
				58642		
1	Transmittal Letter	RE	GN-008CIPCON9_2022-11-14 _supp_IDS_trans.pdf	2068f9f90114bc233b0a108f37e35dbd3768 a159	no	5
Warnings:	APOTEX V. REGENERON IPR2022-01524					

Information	:				
2	Information Disclosure Statement (IDS) Form (SB08)	REGN-008CIPCON9_2022-11-14 _Substitute_1449.pdf	46301 e18104ed2621e52c443d82e74b9791e8070 64b94	no	4
Warnings:		<u> </u>	1		1
Information	:				
This is not an l	JSPTO supplied IDS fillable form				
		Total Files Size (in bytes)	: 10	04943	
characterize	vledgement Receipt evidences receip ed by the applicant, and including pages s described in MPEP 503.	•			
characterize Post Card, a <u>New Applica</u> If a new app	d by the applicant, and including pages s described in MPEP 503. Itions Under 35 U.S.C. 111 lication is being filed and the applica	ge counts, where applicable. ition includes the necessary c	It serves as evidence components for a filir	of receipt s ng date (see	similar to 937 CFR
characterize Post Card, a <u>New Applica</u> If a new app 1.53(b)-(d) a	ed by the applicant, and including pages s described in MPEP 503. <u>Ations Under 35 U.S.C. 111</u> lication is being filed and the applica nd MPEP 506), a Filing Receipt (37 CF	ge counts, where applicable. tion includes the necessary c TR 1.54) will be issued in due	It serves as evidence components for a filir	of receipt s ng date (see	similar to 937 CFR
characterize Post Card, a <u>New Applica</u> If a new app 1.53(b)-(d) a Acknowledg	d by the applicant, and including pages s described in MPEP 503. Itions Under 35 U.S.C. 111 lication is being filed and the applica	ge counts, where applicable. Ition includes the necessary of R 1.54) will be issued in due	It serves as evidence components for a filir	of receipt s ng date (see	similar to 937 CFR
characterize Post Card, a <u>New Applica</u> If a new app 1.53(b)-(d) a Acknowledg <u>National Sta</u> If a timely su	ed by the applicant, and including pay s described in MPEP 503. <u>Itions Under 35 U.S.C. 111</u> lication is being filed and the applica nd MPEP 506), a Filing Receipt (37 CF gement Receipt will establish the filin <u>ge of an International Application ur</u> Ibmission to enter the national stage	ge counts, where applicable. Ition includes the necessary of R 1.54) will be issued in due og date of the application. <u>Inder 35 U.S.C. 371</u> of an international applicati	It serves as evidence components for a filir course and the date s ion is compliant with	of receipt s ng date (see shown on tl the conditi	similar to 37 CFR his ons of 35
characterize Post Card, a <u>New Applica</u> If a new app 1.53(b)-(d) a Acknowledg <u>National Sta</u> If a timely su U.S.C. 371 a	ed by the applicant, and including pay s described in MPEP 503. Itions Under 35 U.S.C. 111 lication is being filed and the applica nd MPEP 506), a Filing Receipt (37 CF gement Receipt will establish the filin uge of an International Application ur ubmission to enter the national stage and other applicable requirements a F	ge counts, where applicable. Ition includes the necessary of FR 1.54) will be issued in due og date of the application. Inder 35 U.S.C. 371 of an international applicati form PCT/DO/EO/903 indicati	It serves as evidence components for a filir course and the date s ion is compliant with ing acceptance of the	of receipt s ng date (see shown on th the conditi application	similar to 37 CFR his ons of 35
characterize Post Card, a <u>New Applica</u> If a new app 1.53(b)-(d) a Acknowledg <u>National Sta</u> If a timely su U.S.C. 371 an national sta <u>New Interna</u>	d by the applicant, and including pay s described in MPEP 503. <u>Itions Under 35 U.S.C. 111</u> lication is being filed and the applica nd MPEP 506), a Filing Receipt (37 CF gement Receipt will establish the filin <u>ige of an International Application ur</u> ibmission to enter the national stage nd other applicable requirements a F ge submission under 35 U.S.C. 371 wi tional Application Filed with the USP	ge counts, where applicable. Ition includes the necessary of R 1.54) will be issued in due g date of the application. <u>Inder 35 U.S.C. 371</u> of an international applicati form PCT/DO/EO/903 indicati ill be issued in addition to the <u>PTO as a Receiving Office</u>	It serves as evidence components for a filin course and the date s ion is compliant with ing acceptance of the e Filing Receipt, in du	of receipt s ng date (see shown on th the conditi application le course.	similar to 37 CFR his ons of 35 n as a
characterize Post Card, a <u>New Applica</u> If a new app 1.53(b)-(d) a Acknowledg <u>National Sta</u> If a timely su U.S.C. 371 at national sta <u>New Interna</u> If a new inte	ed by the applicant, and including pages s described in MPEP 503. Initions Under 35 U.S.C. 111 lication is being filed and the applica nd MPEP 506), a Filing Receipt (37 CF gement Receipt will establish the filin uge of an International Application un ubmission to enter the national stage and other applicable requirements a F ge submission under 35 U.S.C. 371 with tional Application Filed with the USP rnational application is being filed an	ge counts, where applicable. Ition includes the necessary of FR 1.54) will be issued in due og date of the application. <u>Inder 35 U.S.C. 371</u> of an international applicati form PCT/DO/EO/903 indicati ill be issued in addition to the <u>PTO as a Receiving Office</u> nd the international applicat	It serves as evidence components for a filir course and the date s ion is compliant with ing acceptance of the e Filing Receipt, in du ion includes the nece	of receipt s ng date (see shown on th the conditi application le course.	e 37 CFR his ons of 35 n as a ponents f
characterize Post Card, a <u>New Applica</u> If a new app 1.53(b)-(d) a Acknowledg <u>National Sta</u> If a timely su U.S.C. 371 an national sta <u>New Interna</u> If a new inte an internatio	d by the applicant, and including pay s described in MPEP 503. <u>Itions Under 35 U.S.C. 111</u> lication is being filed and the applica nd MPEP 506), a Filing Receipt (37 CF gement Receipt will establish the filin <u>ige of an International Application ur</u> ibmission to enter the national stage nd other applicable requirements a F ge submission under 35 U.S.C. 371 wi tional Application Filed with the USP	ge counts, where applicable. Ation includes the necessary of FR 1.54) will be issued in due og date of the application. <u>Inder 35 U.S.C. 371</u> of an international applicati form PCT/DO/EO/903 indicati ill be issued in addition to the <u>PTO as a Receiving Office</u> and the international applicat of MPEP 1810), a Notification	It serves as evidence components for a filir course and the date s ion is compliant with ing acceptance of the e Filing Receipt, in du ion includes the nece of the International	of receipt s ng date (see shown on th the conditi application le course. essary comp Application	e 37 CFR his ons of 35 n as a ponents f n Number

the application.

Exect officarly Filed				
	Attorney Docket No.	REGN-008CIPCON9		
	Confirmation No.	4833		
INFORMATION	First Named Inventor	George D. Yancopoulos		
DISCLOSURE STATEMENT	Application Number	17/350,958		
	Filing Date	June 17, 2021		
	Group Art Unit			
Address to:	Examiner Name			
Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450	Title: "Use of a VEGF . Eye Disorders"	Antagonist to Treat Angiogenic		

Electronically Filed

Sir:

The attention of the Examiner is invited to the documents listed on the attached Substitute 1449.

A copy of the U.S. patent listed on the attached Substitute 1449 is not submitted herewith, in accordance with the Strategic Plan Final Rule, 69 Fed. Reg. 56481-56547 (September 21, 2004), effective October 21, 2004.

Copies of the foreign publication and non-patent literature documents listed on the attached Substitute 1449 are submitted in parent U.S. Application No. 17/072,417.

It is respectfully requested that the information above be expressly considered during the prosecution of this application, and that the documents be made of record therein and appear among the "References Cited" on any patent to issue therefrom.

No aspect of these submissions constitute admission of prior art status or a disclaimer of claim scope.

Statement under 37 C.F.R. §§1.56 and 1.2

Applicant hereby advises the Examiner of the status of a co-pending application(s) in compliance with the Applicant's duty to disclose under 37 C.F.R. §§1.56 and 1.2 (*see* also M.P.E.P. §2001.06(b)) as discussed in *McKesson Info. Soln. Inc., v. Bridge Medical Inc.*, 487 F.3d 897 (Fed. Cir. 2007).

With respect to this statement under *McKesson*, Applicants wishes to bring to the Examiner's attention U.S. Patent Application No. 13/940,370, filed July 12, 2013, which issued as U.S. Patent No. 9,254,338 on February 9, 2016.

With respect to this statement under *McKesson*, Applicants wishes to bring to the Examiner's attention U.S. Patent Application No. 14/972,560, filed December 17, 2015, which issued as U.S. Patent No. 9,669,069 on June 6, 2017.

With respect to this statement under *McKesson*, Applicants wishes to bring to the Examiner's attention U.S. Patent Application No. 15/471,506, filed March 28, 2017, which issued as U.S. Patent No. 10,130,681 on November 20, 2018.

With respect to this statement under *McKesson*, Applicants wishes to bring to the Examiner's attention U.S. Patent Application No. 16/055,847, filed August 6, 2018, which issued as U.S. Patent No. 10,857,205 on December 8, 2020.

With respect to this statement under *McKesson*, Applicants wishes to bring to the Examiner's attention U.S. Patent Application No. 16/159,282, filed October 12, 2018, which issued as U.S. Patent No. 10,828,345 on November 10, 2020.

With respect to this statement under *McKesson*, Applicants wishes to bring to the Examiner's attention U.S. Patent Application No. 16/397,267, filed April 29, 2019, which issued as U.S. Patent No. 10,888,601 on January 12, 2021.

With respect to this statement under *McKesson*, Applicants wishes to bring to the Examiner's attention U.S. Patent Application No. 17/352,892, filed June 21, 2021, which issued as U.S. Patent No. 11,253,572 on February 22, 2022.

With respect to this statement under *McKesson*, Applicant wishes to bring to the Examiner's attention U.S. Patent Application No. 17/072,417, filed October 16, 2020. A Non-Final Office Action issued on October 17, 2022. A response thereto has not yet been filed.

With respect to this statement under *McKesson*, Applicant wishes to bring to the Examiner's attention U.S. Patent Application No. 17/112,063, filed December 4, 2020. A Non-Final Office Action issued on October 11, 2022. A response thereto has not yet been filed.

With respect to this statement under *McKesson*, Applicant wishes to bring to the Examiner's attention U.S. Patent Application No. 17/112,404, filed December 4, 2020. A Non-Final Office Action issued on October 27, 2022. A response thereto has not yet been filed.

With respect to this statement under *McKesson*, Applicant wishes to bring to the Examiner's attention U.S. Patent Application No. 17/740,744, filed May 10, 2022. A Notice of Allowance issued on November 14, 2022. A response thereto has not yet been filed.

With respect to this statement under *McKesson*, Applicant wishes to bring to the Examiner's attention *Inter Partes* Review Application No. IPR2021-00880 of U.S. Patent No. 9,669,069, filed on May 5, 2021. A Final Written Decision dated November 9, 2022, has been issued by PTAB.

With respect to this statement under *McKesson*, Applicant wishes to bring to the Examiner's attention *Inter Partes* Review Application No. IPR2021-00881 of U.S. Patent No. 9,254,338, filed on May 5, 2021. A Final Written Decision dated November 9, 2022, has been issued by PTAB.

With respect to this statement under *McKesson*, Applicant wishes to bring to the Examiner's attention *Inter Partes* Review Application No. IPR2022-01225 of U.S. Patent No. 10,130,681, filed on July 1, 2022; IPR2022-01226 of U.S. Patent No. 10,888,601, filed on July 1, 2022.

With respect to this statement under *McKesson*, Applicant wishes to bring to the Examiner's attention *Inter Partes* Review Application No. IPR2023-00099 of U.S. Patent No. 10,857,205, filed on October 28, 2022.

These documents and the corresponding file wrappers are available on PAIR or PTAB E2E, and thus are not provided with this communication. Please inform the undersigned if there is any difficulty in obtaining the documents from PAIR or PTAB E2E.

Statements

No statement

PTA Statement under 37 CFR § 1.704(d)(1): Each item of information contained in the information disclosure statement filed herewith:

(i) Was first cited in any communication from a patent office in a counterpart foreign or international application or from the Office, and this communication was not received by any individual designated in § 1.56(c) more than thirty days prior to the filing of the information disclosure statement; or

(ii) Is a communication that was issued by a patent office in a counterpart foreign or international application or by the Office, and this communication was not received by any individual designated in § 1.56(c) more than thirty days prior to the filing of the information disclosure statement.

- **IDS Statement under 37 CFR § 1.97(e)(1):** Each item of information contained in the information disclosure statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of the information disclosure statement; or
- **IDS Statement under 37 CFR § 1.97(e)(2):** No item of information contained in the information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the person signing the certification after making reasonable inquiry, no item of information contained in the information disclosure statement was known to any individual designated in § 1.56(c) more than three months prior to the filing of the information disclosure statement.

Fees

 \square

 \boxtimes No fee is believed to be due.

The appropriate fee set forth in 37 C.F.R. §1.17(p) accompanies this information disclosure statement.

The Commissioner is hereby authorized to charge any underpayment of fees up to a strict limit of \$3,000.00 beyond that authorized on the credit card, but not more than \$3,000.00 in additional fees due with any communication for the above-referenced patent application, including but not limited to any necessary fees for extensions of time, or credit any overpayment of any amount to Deposit Account No. 50-0815, order number REGN-008CIPCON9.

Respectfully submitted, BOZICEVIC, FIELD & FRANCIS LLP

Date: <u>14 November 2022</u>

By: /Karl Bozicevic, Reg. No. 28,807/ Karl Bozicevic, Reg. No. 28,807

BOZICEVIC, FIELD & FRANCIS LLP 201 Redwood Shores Parkway, Suite 200 Redwood City, CA 94065 Telephone: (650) 327-3400 Facsimile: (650) 327-3231